item: #1 of 299 id: cord-000050-tfcerilc author: Rao, Srinivas title: Multivalent HA DNA Vaccination Protects against Highly Pathogenic H5N1 Avian Influenza Infection in Chickens and Mice date: 2008-06-18 words: 5614 flesch: 39 summary: A DNA prime-Mycobacterium bovis BCG boost vaccination strategy for cattle induces protection against bovine tuberculosis Immune response in mice and cattle after immunization with a Boophilus microplus DNA vaccine containing bm86 gene Immunization of pigs to prevent disease in humans: construction and protective efficacy of a Salmonella enterica serovar Typhimurium live negative-marker vaccine Humoral response to West Nile virus vaccination in alpacas and llamas Preliminary results of an anticircumsporozoite DNA vaccine trial for protection against avian malaria in captive African black-footed penguins (Spheniscus demersus) Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses Immunization of turkeys with a DNA vaccine expressing either the F or N gene of avian metapneumovirus Protection of turkeys against Chlamydophila psittaci challenge by DNA and rMOMP vaccination and evaluation of the immunomodulating effect of 1 alpha DNA vaccination in the avian Cross-protection among lethal H5N2 influenza viruses induced by DNA vaccine to the hemagglutinin Enhanced protective efficacy of H5 subtype avian influenza DNA vaccine with codon optimized HA gene in a pCAGGS plasmid vector Characterization of H5N1 influenza viruses that continue to circulate in geese in southeastern Control and prevention of avian influenza in an evolving scenario Genesis of pandemic influenza Containing pandemic influenza at the source The next influenza pandemic: can it be predicted viruses and vaccines Scientific barriers to developing vaccines against avian influenza viruses Overview of avian influenza DIVA test strategies Emergence and predominance of an H5N1 influenza variant in China A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates Immunization by avian H5 influenza hemagglutinin mutants with altered receptor binding specificity Protective immunity to lethal challenge of the 1918 pandemic influenza virus by vaccination Crossprotectiveness and immunogenicity of influenza A/Duck/Singapore/3/97(H5) vaccines against infection with A/Vietnam/1203/04(H5N1) virus in ferrets Vesicular stomatitis virus vectors expressing avian influenza H5 HA induce cross-neutralizing antibodies and long-term protection Efficacy of the AGRO-JET MIT-II NEEDLE-LESS JET INJECTOR for Iron Dextran Administration in Piglets Molecular determinants within the surface proteins involved in the pathogenicity of H5N1 influenza viruses in chickens Are we ready for pandemic influenza? For the two 5 plasmid combination groups pCMV/R 8kB-HA Biological features of genetic immunization DNA vaccines DNA vaccines: immunology, application, and optimization Strategies for inducing protection against avian influenza A virus subtypes with DNA vaccines A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice Immunotargeting with CD154 (CD40 ligand) enhances DNA vaccine responses in ducks Development and application of reference antisera against 15 hemagglutinin subtypes of influenza virus by DNA vaccination of chickens Effects of DDA, CpG-ODN, and plasmid-encoded chicken IFN-gamma on protective immunity by a DNA vaccine against IBDV in chickens Principles for vaccine protection in chickens and domestic waterfowl against avian influenza: emphasis on Asian H5N1 high pathogenicity avian influenza Association of serologic and protective responses of avian influenza vaccines in chickens Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates Needle-free injection of DNA vaccines: a brief overview and methodology keywords: animals; avian; chickens; dna; h5n1; immunization; influenza; mice; protection; vaccine; virus; viruses cache: cord-000050-tfcerilc.txt plain text: cord-000050-tfcerilc.txt item: #2 of 299 id: cord-000194-cwzpb8fu author: Haque, Azizul title: Confronting Potential Influenza A (H5N1) Pandemic with Better Vaccines date: 2007-10-17 words: 5247 flesch: 36 summary: Emerg Infect Dis Virus-like particle (VLP) vaccine conferred complete protection against a lethal infl uenza virus challenge Infl uenza A virus with defective M2 ion channel activity as a live vaccine Immunogenicity and effi cacy of Russian live attenuated and US inactivated infl uenza vaccines used alone and in combination in nursing home residents Does infl uenza vaccination exacerbate asthma in children? Safety and immunogenicity of a recombinant of an inactivated subvirion infl uenza A (H5N1) vaccine Safety and immunogenicity of an inactivated split-virion infl uenza A/Vietnam/1194/2004 (H5N1) vaccine: phase 1 randomised trial Infl uenza and the challenge for immunology Construction and immunogenicity of recombinant fowlpox vaccines coexpressing HA of AIV H5N1 and chicken IL18 Cross-reactivity to highly pathogenic avian infl uenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted infl uenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy Establishment of multiple sublineages of H5N1 infl uenza virus in Asia: implications for pandemic control Role of specifi c hemagglutinin amino acids in the immunogenicity and protection of H5N1 infl uenza virus vaccines Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic infl uenza A (H5N1) viruses Protection against multiple infl uenza Live attenuated (cold-adapted) infl uenza vaccines have long been used in Russia, and a similar product has been approved for use in the United States (14) . keywords: h5n1; human; infection; infl; mice; pandemic; protection; response; uenza; vaccine; virus; viruses cache: cord-000194-cwzpb8fu.txt plain text: cord-000194-cwzpb8fu.txt item: #3 of 299 id: cord-000262-4owsb0bg author: Leung, Gabriel M. title: Reflections on Pandemic (H1N1) 2009 and the International Response date: 2010-10-05 words: 4617 flesch: 36 summary: Rapid operations to contain the initial emergence of pandemic influenza The role of the Health Protection Agency in the 'containment' phase during the first wave of pandemic influenza in England Influenza Pandemic: An independent review of the UK response to the 2009 influenza pandemic Influenza (H1N1) 2009 outbreak and school closure Closure of schools during an influenza pandemic Facemasks and hand hygiene to prevent influenza transmission in households: a cluster randomized trial Household transmission of 2009 influenza A (H1N1) virus after a school-based outbreak Household transmission of 2009 pandemic influenza A (H1N1) virus in the United States Surgical mask vs N95 respirator for preventing influenza among health care workers: a randomized trial Antiviral treatment for patients hospitalized with 2009 pandemic influenza A (H1N1) A new decade, a new seasonal influenza: the Council of the European Union Recommendation on seasonal influenza vaccination Estimates of the transmissibility of the 1968 (Hong Kong) influenza pandemic: evidence of increased transmissibility between successive waves Emerging infectious diseases: a 10-year perspective from the National Institute of Allergy and Infectious Diseases Early observational research and registries during the 2009-2010 influenza A pandemic Studies needed to address public health challenges of the 2009 H1N1 influenza pandemic: insights from modeling Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during Spring-Summer 2009: four observational studies from Canada Global pandemic influenza action plan to increase vaccine supply We thank Timothy M. Uyeki of the US Centers for Disease Control and Prevention for substantial discussion and input. keywords: countries; data; h1n1; health; influenza; pandemic; public; transmission; vaccine; virus cache: cord-000262-4owsb0bg.txt plain text: cord-000262-4owsb0bg.txt item: #4 of 299 id: cord-000452-1gd006zy author: Kim, Y. C. title: Delivery Systems for Intradermal Vaccination date: 2011-04-07 words: 12403 flesch: 32 summary: However, some ID delivery devices in development offer additional desirable features such as needle-free delivery or improved ease of administration, which may be drivers for further adoption of ID vaccine delivery even if there is no net immunologic benefit. Other vaccine trials of ID vaccine delivery are planned for other applications including BCG, IPV, varicella zoster virus, H1N1 and yellow fever (PATH 2009). keywords: cells; delivery; device; dna; dose; et al; immunization; influenza; injection; intradermal; methods; microneedles; response; skin; studies; study; use; vaccination; vaccine; virus cache: cord-000452-1gd006zy.txt plain text: cord-000452-1gd006zy.txt item: #5 of 299 id: cord-001260-6krujv2m author: Bremer, Paul T. title: Injection Route and TLR9 Agonist Addition Significantly Impact Heroin Vaccine Efficacy date: 2014-02-11 words: 3633 flesch: 44 summary: Mice treated with CpG ODN 1826 exhibited greatly shifted dose–response curves (10–13-fold vs unvaccinated controls) while non-CpG ODN vaccine groups did not exhibit the same robust effect (2–7-fold shift for ip and combo, 2–3-fold shift for sc). To thoroughly assess vaccine efficacy, full dose–response curves were generated for heroin-induced analgesia in both hot plate and tail immersion tests. keywords: cpg; heroin; mice; odn; plate; tail; titers; vaccine cache: cord-001260-6krujv2m.txt plain text: cord-001260-6krujv2m.txt item: #6 of 299 id: cord-002282-ldfa616a author: Joung, Young Hee title: The Last Ten Years of Advancements in Plant-Derived Recombinant Vaccines against Hepatitis B date: 2016-10-13 words: 8150 flesch: 32 summary: Edible plant vaccines are based on different parts of plants, such as fruits, seeds, and root vegetables. Among these platforms, the use of plant cells has received considerable attention in terms of intrinsic safety, scalability, and appropriate modification of target proteins. keywords: antigen; cell; expression; hbsag; hbv; hepatitis; influenza; level; n.a; plant; production; protein; recombinant; surface; tobacco; transgenic; vaccine; virus cache: cord-002282-ldfa616a.txt plain text: cord-002282-ldfa616a.txt item: #7 of 299 id: cord-002333-90f9vr0a author: Madan, Anuradha title: Immunogenicity and Safety of an AS03-Adjuvanted H7N9 Pandemic Influenza Vaccine in a Randomized Trial in Healthy Adults date: 2016-12-01 words: 4273 flesch: 43 summary: Pain was the most common solicited injection site symptom, as observed in other studies of adjuvanted influenza vaccines [12-17, 19, 31, 32] . The safety analysis was descriptive and was performed on the total vaccinated cohort ( participants who received ≥1 dose of study vaccine or placebo). keywords: as03; groups; h7n9; influenza; participants; response; study; vaccine; virus cache: cord-002333-90f9vr0a.txt plain text: cord-002333-90f9vr0a.txt item: #8 of 299 id: cord-002500-9p2n8tjx author: Lambe, Teresa title: A review of Phase I trials of Ebola virus vaccines: what can we learn from the race to develop novel vaccines? date: 2017-05-26 words: 7337 flesch: 31 summary: key: cord-002500-9p2n8tjx authors: Lambe, Teresa; Bowyer, Georgina; Ewer, Katie J title: A review of Phase I trials of Ebola virus vaccines: what can we learn from the race to develop novel vaccines? date: 2017-05-26 journal: Philos Trans R Soc Lond B Biol Sci DOI: 10.1098/rstb.2016.0295 sha: doc_id: 2500 cord_uid: 9p2n8tjx Sporadic outbreaks of Ebola virus infection have been documented since the mid-Seventies and viral exposure can lead to lethal haemorrhagic fever with case fatalities as high as 90%. We discuss here the different aspects of the immune assays currently used in the Phase I clinical trials for Ebola virus vaccines, and draw comparisons across the immune outputs where possible; various trials have examined both cellular and humoral immunity in European and African cohorts. keywords: antibody; assays; dose; ebola; ebov; evd; immunity; phase; protection; responses; trials; vaccination; vaccine; virus cache: cord-002500-9p2n8tjx.txt plain text: cord-002500-9p2n8tjx.txt item: #9 of 299 id: cord-002842-4evbeijx author: Pandey, Rajan Kumar title: Novel Immunoinformatics Approaches to Design Multi-epitope Subunit Vaccine for Malaria by Investigating Anopheles Salivary Protein date: 2018-01-18 words: 5777 flesch: 41 summary: To enhance the stability of vaccine protein, disulfide engineering was performed in a region of high mobility. The molecular weight of vaccine protein was found to be 58 kDa which will favor the antigenicity of the vaccine construct 23 . keywords: cell; construct; ctl; epitopes; model; prediction; protein; response; salivary; sequence; server; structure; subunit; subunit vaccine; vaccine cache: cord-002842-4evbeijx.txt plain text: cord-002842-4evbeijx.txt item: #10 of 299 id: cord-003403-ypefqm71 author: Roberts, Christine C. title: Assay Challenges for Emerging Infectious Diseases: The Zika Experience date: 2018-10-02 words: 4960 flesch: 33 summary: Here we review emerging infectious disease vaccine clinical assay development and trial execution with a special focus on the state of Zika virus clinical assays and diagnostics. Congenital cerebral malformations and dysfunction in fetuses and newborns following the 2013 to 2014 Zika virus epidemic in French Polynesia Detection and sequencing of Zika virus from amniotic fluid of fetuses with microcephaly in Brazil: A case study Collaborative Study to Evaluate a Candidate World Health Organization International Standard for Zika Virus for Nucleic Acid Amplification Technique (NAT)-Based Assays FDA FDA provides new tools for the development and proper evaluation of tests for detecting Zika virus infection Current status of Zika vaccine development: Zika vaccines advance into clinical evaluation Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: Phase 1, randomised, double-blind, placebo-controlled clinical trials Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: Randomised, open-label, phase 1 clinical trials This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license keywords: assays; clinical; dengue; detection; development; diagnostic; dna; infection; use; vaccine; virus; zika; zikv cache: cord-003403-ypefqm71.txt plain text: cord-003403-ypefqm71.txt item: #11 of 299 id: cord-003567-h8uq5z8b author: Crank, Michelle C title: Preparing for the Next Influenza Pandemic: The Development of a Universal Influenza Vaccine date: 2019-04-15 words: 1559 flesch: 27 summary: Updating the accounts: global mortality of the 1918-1920 Spanish influenza pandemic Influenza vaccines: good, but we can do better Making universal influenza vaccines: lessons from the 1918 pandemic Can we predict the next influenza pandemics? Antibody determinants of influenza immunity The way forward: potentiating protective immunity to novel and pandemic influenza through engagement of memory CD4 T cells Immunodominance and antigenic variation of influenza virus hemagglutinin: implications for design of universal vaccine immunogens Dynamic perspectives on the search for a universal influenza vaccine Universal influenza vaccine approaches employing full-length or head-only HA proteins Universal influenza virus vaccines that target the conserved hemagglutinin stalk and conserved sites in the head domain The role of M2e in the development of universal influenza vaccines Neuraminidase, the forgotten surface antigen, emerges as an influenza vaccine target for broadened protection How live attenuated vaccines can Inform the development of broadly cross-protective influenza vaccines New vaccine design and delivery technologies Influenza immunization in low-and middle-income countries: preparing for next-generation influenza vaccines Novel vaccine technologies: essential components of an adequate response to emerging viral diseases Emerging viral diseases from a vaccinology perspective: preparing for the next pandemic Advances in antiviral vaccine development A universal influenza vaccine: the strategic plan for the National Institute of Allergy and Infectious Diseases Historical estimates of world population On the doctrine of original antigenic sin Pandemic risk: how large are the expected losses? Vaccine development in the twenty-first century: changing paradigms for elusive viruses Improving the characterization of and expanding the reagents for these models would not only benefit influenza vaccine development but would also provide answers to immunological questions relevant to other respiratory virus infections and emerging infectious diseases in general. keywords: immunity; influenza; pandemic; universal; vaccine cache: cord-003567-h8uq5z8b.txt plain text: cord-003567-h8uq5z8b.txt item: #12 of 299 id: cord-003656-7mzsaz7a author: Wium, Martha title: DNA Vaccines Against Mycoplasma Elicit Humoral Immune Responses in Ostriches date: 2019-05-14 words: 5578 flesch: 45 summary: Elsenburg: Western Cape Department of Agriculture Cross-protection among lethal H5N2 influenza viruses induced by DNA vaccine to the hemagglutinin Protective efficacy of DNA vaccines against duck hepatitis B virus infection Turkeys are protected from infection with Chlamydia psittaci by plasmid DNA vaccination against the major outer membrane protein DNA vaccination in the avian A DNA prime-protein boost vaccination strategy targeting turkey coronavirus spike protein fragment containing neutralizing epitope against infectious challenge Protection of chickens against infectious bronchitis virus with a multivalent DNA vaccine and boosting with an inactivated vaccine Induction of a protective response in ducks vaccinated with a DNA vaccine encoding engineered duck circovirus Capsid protein Sequential DNA immunization of chickens with bivalent heterologous vaccines induce highly reactive and cross-specific antibodies against influenza hemagglutinin key: cord-003656-7mzsaz7a authors: Wium, Martha; Jonker, Hester Isabella; Olivier, Adriaan Jacobus; Bellstedt, Dirk Uwe; Botes, Annelise title: DNA Vaccines Against Mycoplasma Elicit Humoral Immune Responses in Ostriches date: 2019-05-14 journal: keywords: antigen; dna; infections; mycoplasma; oppa; ostriches; pci; plasmid; protein; response; trial; vaccination; vaccine; week cache: cord-003656-7mzsaz7a.txt plain text: cord-003656-7mzsaz7a.txt item: #13 of 299 id: cord-003764-141u6ax7 author: Shrestha, Ashish C. title: Cytolytic Perforin as an Adjuvant to Enhance the Immunogenicity of DNA Vaccines date: 2019-04-30 words: 6314 flesch: 34 summary: Emerg Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity Effective humoral immune response from a H1N1 DNA vaccine delivered to the skin by microneedles coated with PLGA-based cationic nanoparticles Differential humoral and cellular immunity induced by vaccination using plasmid DNA and protein recombinant expressing the NS3 protein of dengue virus type 3 Vaccines for emerging infectious diseases: Lessons from MERS coronavirus and Zika virus Clinical applications of DNA vaccines: Current progress DNA Vaccines-How Far From Clinical Use? DNA Vaccines: However, one of the major challenges for the development of DNA vaccines is their poor immunogenicity in humans, which has led to refinements in DNA delivery, dosage in prime/boost regimens and the inclusion of adjuvants to enhance their immunogenicity. keywords: antigen; cells; dcs; dna; encoding; immunogenicity; ns3; prf; protein; responses; vaccine; virus cache: cord-003764-141u6ax7.txt plain text: cord-003764-141u6ax7.txt item: #14 of 299 id: cord-003806-ctass7hz author: Bull, James J. title: Recombinant vector vaccine evolution date: 2019-07-19 words: 8806 flesch: 41 summary: We use mathematical and computational models to study vaccine evolution and immunity. Although the selective basis of vaccine evolution is easy to comprehend, the immunological consequences are not. keywords: adaptive; antigen; evolution; growth; host; host evolution; immunity; inoculum; revertant; vaccine; vaccine evolution cache: cord-003806-ctass7hz.txt plain text: cord-003806-ctass7hz.txt item: #15 of 299 id: cord-003828-bhfghcby author: Zrzavy, Tobias title: Vaccination in Multiple Sclerosis: Friend or Foe? date: 2019-08-07 words: 5607 flesch: 29 summary: Plotkin's Vaccines Vaccine adjuvants: putting innate immunity to work In vivo activation of antigen-specific CD4 T cells Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling Aluminum hydroxide adjuvants activate caspase-1 and induce IL-1beta and IL-18 release Immunological mechanisms of vaccination Vaccine adjuvants: from 1920 to 2015 and beyond Comparative safety of vaccine adjuvants: a summary of current evidence and future needs Adjuvants Safety Project C. Safety of vaccine adjuvants: focus on autoimmunity Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity Cell recruitment and cytokines in skin mice sensitized with the vaccine adjuvants: saponin, incomplete Freund's adjuvant, and monophosphoryl lipid A Human T H 17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation Cellular mechanisms of IL-17-induced blood-brain barrier disruption Induction of lupus autoantibodies by adjuvants Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland Carbohydrate-based immune adjuvants Extrafollicular antibody responses Control systems and decision making for antibody production Rabies vaccine prepared in human cell cultures: progress and perspectives Therefore, vaccination of MS patients is of major interest. keywords: adjuvants; cells; hepatitis; immune; influenza; patients; risk; sclerosis; vaccination; vaccines cache: cord-003828-bhfghcby.txt plain text: cord-003828-bhfghcby.txt item: #16 of 299 id: cord-003926-ycdaw2vh author: Maslow, Joel N. title: Zika Vaccine Development—Current Progress and Challenges for the Future date: 2019-07-14 words: 3768 flesch: 39 summary: Expert Rev Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: Randomised, open-label, phase 1 clinical trials Safety and immunogenicity of an anti-Zika virus DNA vaccine-Preliminary Report In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunization with a prMEnv DNA vaccine Rapid development of a DNA vaccine for Zika virus Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: Phase 1, randomised, double-blind, placebo-controlled clinical trials Vaccine protection against Zika virus from Brazil Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys Modified mRNA vaccines protect against Zika virus infection Purified inactivated Zika vaccine candidates afford protection against lethal challenge in mice A measles virus-based vaccine candidate mediates protection against Zika virus in an allogeneic mouse pregnancy model Animal models of Zika virus infection, pathogenesis, and immunity Zika virus infection during pregnancy in mice causes placental damage and fetal demise Increased hospitalizations for neuropathies as indicators of Zika virus infection, according to Health Information System data Guillain-Barré syndrome, acute disseminated encephalomyelitis and encephalitis associated with Zika virus infection in Brazil: Detection of viral RNA and Isolation of virus during late infection Ethical Considerations for Zika Virus Human Challenge Trials; National Institutes of Health Bystander risk, social value, and ethics of human research Zika vaccines: Role for controlled human infection Starting in mid-2015, Zika virus infection achieved epidemic status, spreading rapidly through South America, Central America, and the Caribbean Islands [5] . keywords: development; human; infection; mice; studies; study; trials; vaccine; virus; zika cache: cord-003926-ycdaw2vh.txt plain text: cord-003926-ycdaw2vh.txt item: #17 of 299 id: cord-004078-d1pd09zj author: Mettu, Ravinder title: Synthetic carbohydrate-based vaccines: challenges and opportunities date: 2020-01-03 words: 11569 flesch: 32 summary: A possible approach to a synthetic carbohydrate vaccine Antitumor immunity provided by a synthetic multiple antigenic glycopeptide displaying a tri-Tn glycotope A fully synthetic immunogen carrying a carcinoma-associated carbohydrate for active specific immunotherapy Linear PADRE T helper epitope and carbohydrate B cell epitope conjugates induce specific high titer IgG antibody responses Synthesis and biological evaluation of a multiantigenic Tn/TF-containing glycopeptide mimic of the tumor-related MUC1 glycoprotein Chemoselective assembly and immunological evaluation of multiepitopic glycoconjugates bearing clustered Tn antigen as synthetic anticancer vaccines A fully synthetic vaccine consisting of a tumor-associated glycopeptide antigen and a T-cell epitope for the induction of a highly specific humoral immune response Fully synthetic vaccines consisting of tumor-associated MUC1 glycopeptides and a lipopeptide ligand of the toll-like receptor 2 A cancer therapeutic vaccine based on clustered Tnantigen mimetics induces strong antibody-mediated protective immunity Immunological response from an entirely carbohydrate antigen: design of synthetic vaccines based on Tn-PS A1 conjugates Sialyl-Tn polysaccharide A1 as an entirely carbohydrate Immunogen: synthesis and immunological evaluation Carbohydrate-monophosphoryl lipid a conjugates are fully synthetic self-adjuvanting cancer vaccines eliciting robust immune responses in the mouse Synthesis and evaluation of monophosphoryl lipid a derivatives as fully synthetic self-adjuvanting glycoconjugate cancer vaccine carriers A fully synthetic self-Adjuvanting Globo H-based vaccine elicited strong T cell-mediated antitumor immunity Synthesis and evaluation of GM2-Monophosphoryl lipid a conjugate as a fully synthetic self-adjuvant Cancer vaccine Robust immune responses elicited by a fully synthetic three-component vaccine Towards a selfadjuvanting multivalent B and T cell epitope containing synthetic glycolipopeptide cancer vaccine Antitumor activity of a self-adjuvanting glyco-lipopeptide vaccine bearing B cell, CD4+ and CD8+ T cell epitopes Synthetic multivalent glycopeptide-lipopeptide antitumor vaccines: impact of the cluster effect on the killing of tumor cells Synthesis and immunological properties of N-modified GM3 antigens as therapeutic cancer vaccines Efficient metabolic engineering of GM3 on tumor cells by N-phenylacetyl-D-mannosamine Improving the antigenicity of sTn antigen by modification of its sialic acid residue for development of glycoconjugate cancer vaccines Synthetic and immunological studies of 5′-N-phenylacetyl sTn to develop carbohydrate-based cancer vaccines and to explore the impacts of linkage between carbohydrate antigens and carrier proteins Synthetic and immunological studies of sTn derivatives carrying 5-N-(p-substituted Phenylacetyl)Sialic acid for the development of effective Cancer vaccines Improvement of the immune efficacy of carbohydrate vaccines by chemical modification on the GM3 antigen Enhancement of the immunogenicity of synthetic carbohydrate vaccines by chemical modifications of STn antigen Synthetic and immunological studies of N-acyl modified S-linked STn derivatives as anticancer vaccine candidates A cancer vaccine based on fluorine-modified sialyl-Tn induces robust immune responses in a murine model Synthesis and evaluation of Glycoconjugates comprising N-acyl-modified Thomsen-Friedenreich antigens as anticancer vaccines Live attenuated vaccines: historical successes and current challenges Protein carriers for Glycoconjugate vaccines: history, selection criteria Entirely carbohydrate-based vaccines: an emerging field for specific and selective immune responses. Compare to biologically isolated vaccines, the advantages of synthetic vaccines include well-defined antigen structure with spacer arm, homogeneity, highly reproducibility, higher purity and better safety profile [35] . keywords: antibodies; antigen; cancer; carbohydrate; carrier; cell; development; fig; glycoconjugate; group; igg; immune; immunogenicity; mice; polysaccharide; protein; stn; studies; synthesis; synthetic; vaccines cache: cord-004078-d1pd09zj.txt plain text: cord-004078-d1pd09zj.txt item: #18 of 299 id: cord-004181-exbs3tz7 author: Pumchan, Ansaya title: Novel Chimeric Multiepitope Vaccine for Streptococcosis Disease in Nile Tilapia (Oreochromis niloticus Linn.) date: 2020-01-17 words: 5774 flesch: 35 summary: Interestingly, the designed chimeric multiepitope DNA vaccine and protein vaccine exhibited effective prevention in Nile tilapia against S. agalactiae, with efficacy similar to that of the whole-cell inactivated vaccine. Herein, the comparative efficacy of both the 45F2 and 42E2 DNA and recombinant protein vaccines indicated that the DNA vaccine provided a higher efficacy than the recombinant protein vaccine. keywords: 42e2; agalactiae; analysis; cell; chimeric; dna; epitopes; expression; fish; multiepitope; protein; serotype; structure; tilapia; vaccine cache: cord-004181-exbs3tz7.txt plain text: cord-004181-exbs3tz7.txt item: #19 of 299 id: cord-004274-cot05vx7 author: Jackson, Nicholas A. C. title: The promise of mRNA vaccines: a biotech and industrial perspective date: 2020-02-04 words: 4261 flesch: 25 summary: key: cord-004274-cot05vx7 authors: Jackson, Nicholas A. C.; Kester, Kent E.; Casimiro, Danilo; Gurunathan, Sanjay; DeRosa, Frank title: The promise of mRNA vaccines: a biotech and industrial perspective date: 2020-02-04 journal: NPJ Vaccines DOI: 10.1038/s41541-020-0159-8 sha: doc_id: 4274 cord_uid: cot05vx7 mRNA technologies have the potential to transform areas of medicine, including the prophylaxis of infectious diseases. Assuming that mRNA vaccines will be proven clinically efficacious and safe, one of the central advantages hinges on rapidity of manufacture. keywords: cap; clinical; delivery; development; expression; human; mrna; novel; phase; self; translation; vaccines cache: cord-004274-cot05vx7.txt plain text: cord-004274-cot05vx7.txt item: #20 of 299 id: cord-004348-4jdn4kw6 author: Chen, Juine-Ruey title: Better influenza vaccines: an industry perspective date: 2020-02-14 words: 6907 flesch: 30 summary: A randomized double-blind placebo-controlled trial Modest waning of influenza vaccine efficacy and antibody titers during the 2007-2008 influenza season Intraseason waning of influenza vaccine protection: evidence from the US influenza vaccine effectiveness network WHO preferred product characteristics for next generation influenza vaccines Two escape mechanisms of influenza a virus to a broadly neutralizing stalk-binding antibody How single mutations affect viral escape from broad and narrow antibodies to H1 influenza hemagglutinin Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations Not applicable. Key Facts About Influenza (Flu) 2019 Available from Antibody response to influenza vaccination in the elderly: a quantitative review Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices-United States Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines Quadrivalent influenza vaccine: a new opportunity to reduce the influenza burden Age Group (Pediatric and Adult), and Route of Administration (Injection and Nasal Spray): Global Opportunity Analysis and Industry Forecast The 2015 global production capacity of seasonal and pandemic influenza vaccine Addendum to the recommended composition of influenza virus vaccines for use in the 2019-2020 northern hemisphere influenza season 2019 Lessons from pandemic influenza a(H1N1): the research-based vaccine industry's perspective Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains Molecular changes associated with adaptation of human influenza a virus in embryonated chicken eggs Evolving complexities of influenza virus and its receptors The role of receptor binding specificity in interspecies transmission of influenza viruses Differences in sialic acid-galactose linkages in the chicken egg amnion and allantois influence human influenza virus receptor specificity and variant selection Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children Live attenuated influenza vaccine in children induces B-cell responses in tonsils Influenza vaccine effectiveness against 2009 pandemic influenza a(H1N1) virus differed by vaccine type during 2013-2014 in the United States Intranasal influenza vaccine: why does Canada have different recommendations from the USA on its use? keywords: antigenic; cell; conserved; egg; h1n1; human; immunity; influenza; protection; response; strains; vaccine; virus; viruses cache: cord-004348-4jdn4kw6.txt plain text: cord-004348-4jdn4kw6.txt item: #21 of 299 id: cord-004435-l66ost6q author: Oli, Angus Nnamdi title: Immunoinformatics and Vaccine Development: An Overview date: 2020-02-26 words: 8948 flesch: 30 summary: mSphere An overview of bioinformatics tools for epitope prediction: implications on vaccine development Bioinformatics tools for identifying class I-restricted epitopes In silico-accelerated identification of conserved and immunogenic variola/vaccinia T-cell epitopes NHLBI-AbDesigner: an online tool for design of peptide-directed antibodies iVAX: an integrated toolkit for the selection and optimization of antigens and the design of epitope-driven vaccines From genome to vaccine: in silico predictions, ex vivo verification Designing string-of-beads vaccines with optimal spacers HIV vaccine development by computer assisted design: the GAIA vaccine NERVE: new Enhanced reverse vaccinology environment Jennerpredict server: prediction of protein vaccine candidates (PVCs) in bacteria based on host-pathogen interactions Genome-wide prediction of vaccine target of human herpes simplex viruses using Vaxign RV VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines VacSol: a high throughput in silico pipeline to predict potential therapeutic targets in prokaryotic pathogens using subtractive reverse vaccinology PanRV: pangenome-reverse vaccinology approach for identifications of potential vaccine candidates in microbial pangenome Understanding Emerging and Re-Emerging Infectious Diseases. Current conventional vaccines came empirically when there were vague or no knowledge of vaccine immune system activation. keywords: antigenic; antigens; approach; cell; data; design; development; diseases; epitope; hla; host; human; immune; immunoinformatics; infection; pathogens; protein; responses; system; vaccine; virus cache: cord-004435-l66ost6q.txt plain text: cord-004435-l66ost6q.txt item: #22 of 299 id: cord-004518-jd1wxobz author: Běláková, Jana title: DNA vaccines: are they still just a powerful tool for the future? date: 2007-12-03 words: 8119 flesch: 34 summary: Efficacious expression of protein from DNA vaccines is dependent on the presence of DNA vaccine in the nucleus. In contrast to plasmid DNA vaccines, virally vectored genetic vaccines induce a specific immune response not only against the expressed transgene, but also against the viral capsid and/or envelope and this response is often effective even after the first immunization. keywords: antigen; cells; delivery; dna; expression; gene; immunization; injection; mhc; mice; plasmid; protein; response; vaccination; vaccines; vectors; virus cache: cord-004518-jd1wxobz.txt plain text: cord-004518-jd1wxobz.txt item: #23 of 299 id: cord-005081-kxrzv16n author: Kiselev, O. I. title: Progress in the development of pandemic influenza vaccines and their production technologies date: 2010-11-12 words: 7266 flesch: 42 summary: The state-of-the-art technologies provide safety not only at the laboratories where vaccine viruses are constructed but also make the production process wholly safe. The main task of protecting the population against influenza pandemics requires state-of-the-art approaches to the construction of influenza vaccines to be based on reassortment and genetic engineering techniques, including the analysis of primary structures of influenza viral genes, synthesis and cloning of the main viral genes, reverse genetics techniques, and banks of plasmids bearing basic viral genes. keywords: antigens; cells; influenza; influenza vaccines; influenza virus; obtaining; pandemic; production; protein; strains; technologies; vaccines; vectors; virus; viruses; years cache: cord-005081-kxrzv16n.txt plain text: cord-005081-kxrzv16n.txt item: #24 of 299 id: cord-005246-cskb0njm author: Ludwig, George V. title: Insect-transmitted vertebrate viruses: Flaviviridae date: 1993 words: 8062 flesch: 33 summary: epidemics and research in the last forty years and prospects for the future Vaecinia virus expression vectors Togavirus morphology and morphogenesis Possible involvement of receptors in the entry of Kunjin virus into vero cells Nucleotide sequence of the virulent SA-14 strain of Japanese encephalitis virus and its attenuated vaccine derivative Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus Preliminary analysis ofmurine cytotoxic T cell responses to the proteins of the flavivirus Kunjin using vaccinia virus expression Recombinant vaccinia virus producing the prM and E proteins of yellow fever virus protects mice from lethal yellow fever encephalitis Persistent infection of vero cells by the flavivirus Murray Valley encephalitis virus Protection of mice against yellow fever virus encephalitis by immunization with a vaccinia virus recombinant encoding the yellow fever virus non-structural proteins, NS1, NS2a, and NS2b Establishment and characterization of St. Louis encephalitis virus persistent infections in Aedes and Culex mosquito cell lines Acidotropic amines inhibit proteolytic processing of flavivirus prM protein Transc~ription of infectious yellow fever RNA from full-length cDNA templates produced by in vitro ligation Structure of the flavivirus genome Humoral immune response to the entire human immunodeficieney virus glycoprotein made in insect cells Chemical and antigenie structure of flaviviruses Distinction of influenza viruses of different host cell origin Replication of Togaviridae and Flaviviridae Studies on yellow fever in Ethiopia. (95) made an infectious clone of the 17D yellow fever vaccine virus in an effort to produce a homogenous population of vaccine virus and to help elucidate the mechanisms for vaccine attenuation. keywords: antigenic; cells; culture; dengue; development; encephalitis; fever; flavivirus; hosts; infection; insect; mosquito; proteins; transmission; vaccine; vertebrate; virus; viruses cache: cord-005246-cskb0njm.txt plain text: cord-005246-cskb0njm.txt item: #25 of 299 id: cord-005400-50lmj4op author: Ada, Gordon title: Overview of vaccines and vaccination date: 2005 words: 7488 flesch: 45 summary: Combining vaccines so that three or more can be administered simultaneously results in considerable savings, therefore there are determined efforts to add other vaccines to longtime successful combinations (diphtheria, acellular pertussis, tetanus [DaPT] and MMR) such as DaPT-hepatitis B-H aemophilus influenzae type b. Live, attenuated agent vaccines have the potential to stimulate strong humoral and cell-mediated immune responses that can be highly effective in preventing or clearing a later infection in most recipients. keywords: agents; antigen; cells; countries; disease; dna; infection; measles; mhc; new; response; vaccination; vaccine; virus cache: cord-005400-50lmj4op.txt plain text: cord-005400-50lmj4op.txt item: #26 of 299 id: cord-006252-cbelsymu author: Gross, Peter A. title: Current Recommendations for the Prevention and Treatment of Influenza in the Older Population date: 2012-11-18 words: 7667 flesch: 45 summary: Experiences in the use and efficacy of inactivated influenza vaccine in nursing homes Impact of epidemic type A influenza in a defined adult population Underestimation of the role of pneumonia and influenza in causing excess mortality Effectiveness of inactivated influenza vaccine among non-institutionalized elderly persons Resistance of influenza A virus to amantadine and rimantadine: results of one decade of surveillance Antibody induced by influenza vaccines in the elderly: a review of the literature Influenza vaccination in community elderly: a controlled trial of postcard reminders Clinical manifestations and consequences of influenza Antimicrobial agents: antiviral agents Immunizations for health care workers and patients in hospitals Survey of underlying conditions of persons hospitalized with acute respiratory disease during influenza epidemics in Houston Lack of effect of influenza vaccine on theophylline levels and warfarin anticoagulation in the elderly The effect of split virus influenza vaccination on theophylline pharmacokinetics Association of in fluenza immunization with reduction in mortality in an elderly References Experiences in the use and efficacy of inactivated influenza vaccine in nursing homes Impact of epidemic type A influenza in a defined adult population Underestimation of the role of pneumonia and influenza in causing excess mortality Effectiveness of inactivated influenza vaccine among non-institutionalized elderly persons Resistance of influenza A virus to amantadine and rimantadine: results of one decade of surveillance Antibody induced by influenza vaccines in the elderly: a review of the literature Influenza vaccination in community elderly: a controlled trial of postcard reminders Clinical manifestations and consequences of influenza Antimicrobial agents: antiviral agents Immunizations for health care workers and patients in hospitals Survey of underlying conditions of persons hospitalized with acute respiratory disease during influenza epidemics in Houston Lack of effect of influenza vaccine on theophylline levels and warfarin anticoagulation in the elderly The effect of split virus influenza vaccination on theophylline pharmacokinetics Association of in fluenza immunization with reduction in mortality in an elderly population: a prospective study Immunization of elderly people with high doses of influenza vaccine Relation of chronic disease and immune response to influenza vaccine in the elderly Immunization of elderly people with two doses of influenza vaccine Effect of influenza vaccine on serum anticonvulsant concentrations And addendum clarification Economical laboratory support system for influenza virus surveillance Prevention and control of influenza: role of vaccine Economic impact of influenza: the individual's perspective Prevention and Treatment of Influenza population: a prospective study Immunization of elderly people with high doses of influenza vaccine Relation of chronic disease and immune response to influenza vaccine in the elderly Immunization of elderly people with two doses of influenza vaccine Effect of influenza vaccine on serum anticonvulsant concentrations Epidemiologic implications of changes in the influenza virus genome T-cell recognition of influenza viral antigens Impact of influenza epidemic on mortality in the United States from Frequency of adverse reactions to influenza vaccine in the elderly Frequency of adverse reactions after influenza vaccine Effects of influenza virus vaccine on hepatic drug metabolism keywords: amantadine; care; influenza; influenza vaccine; influenza virus; persons; risk; vaccine; virus cache: cord-006252-cbelsymu.txt plain text: cord-006252-cbelsymu.txt item: #27 of 299 id: cord-006890-81wv1s33 author: Viret, Jean-Francois title: Development of a SARS vaccine: an industrial perspective on the global race against a global disease date: 2014-01-09 words: 2069 flesch: 31 summary: Thus, the main issues to be critically addressed are dealing with vaccine safety and may be summarized in two questions: how to achieve an acceptable balance between requested speed and safety aspects? However, even if such vaccines prove to be immunogenic they may not be protective, or may even lead to ADE-mediated pathology. keywords: development; disease; safety; sars; vaccine cache: cord-006890-81wv1s33.txt plain text: cord-006890-81wv1s33.txt item: #28 of 299 id: cord-006892-n2ncamqh author: Donaldson, Braeden title: Virus-like particle vaccines: immunology and formulation for clinical translation date: 2018-09-19 words: 9783 flesch: 25 summary: Novelty, adaptability and formulation compatibility may prove invaluable in helping place VLP vaccines at the forefront of vaccination technology. Areas covered: The purpose of this review is to outline the diversity of VLP vaccines, VLP-specific immune responses, and to explore how modern formulation and delivery techniques can enhance the clinical relevance and overall success of VLP vaccines. keywords: administration; antibodies; antigen; cells; delivery; development; expression; formulation; human; immune; influenza; particles; pathways; presentation; production; response; vaccination; vaccine; virus; vlp; vlp vaccines cache: cord-006892-n2ncamqh.txt plain text: cord-006892-n2ncamqh.txt item: #29 of 299 id: cord-007440-7gcpk9x9 author: Koprowski, Hilary title: Vaccines and sera through plant biotechnology() date: 2005-03-07 words: 2113 flesch: 49 summary: However, plant production of vaccines and sera is not a simple procedure with assured success in each undertaking. Codon optimization, careful approaches to harvesting and purifying plant products, use of plant parts such as chloroplasts to increase uptake of the material are but a few potential avenues to help increase the yield of the final product. keywords: antibody; plant; production; rabies; vaccines; virus cache: cord-007440-7gcpk9x9.txt plain text: cord-007440-7gcpk9x9.txt item: #30 of 299 id: cord-007681-vhghhvnu author: Schwartz, Benjamin title: Prioritization of Pandemic Influenza Vaccine: Rationale and Strategy for Decision Making date: 2009-06-15 words: 5049 flesch: 26 summary: The time required to develop, license, and manufacture pandemic influenza vaccine is also an important variable. Because of the uncertainties about the severity and epidemiology of the next pandemic, vaccine supply, and the best approach to using vaccine to reduce health, societal and economic impacts, there is no scientific method to define the optimal use of pandemic influenza vaccine. keywords: groups; influenza; pandemic; population; prioritization; public; risk; vaccination; vaccine cache: cord-007681-vhghhvnu.txt plain text: cord-007681-vhghhvnu.txt item: #31 of 299 id: cord-007710-0u5ot5h4 author: Graham, Barney S. title: Challenges and Opportunities for Respiratory Syncytial Virus Vaccines date: 2013-05-24 words: 4116 flesch: 32 summary: Several technological and conceptual advances have recently occurred that make RSV vaccine development more feasible, and this collected knowledge is intended to help inform and organize the future contributions of funding agencies, scientists, regulatory agencies, and policy makers that will be needed to achieve the goal of a safe, effective, and accessible vaccine to prevent RSV-associated disease. RSV vaccine development may particularly benefit from defining the atomic structure of antigenic sites on the fusion (F) glycoprotein (see chapter by J.S. McLellan et al., this volume). keywords: development; disease; infants; infection; rsv; vaccine; virus; volume cache: cord-007710-0u5ot5h4.txt plain text: cord-007710-0u5ot5h4.txt item: #32 of 299 id: cord-007733-zh8e76w7 author: DiMenna, Lauren J. title: Pandemic Influenza Vaccines date: 2009-06-15 words: 12736 flesch: 35 summary: This is being addressed by attempts to increase the immunogenicity of influenza virus vaccines through novel adjuvants. FM/1/47 strain of influenza A virus in mice by a monoclonal antibody with cross-neutralizing activity among H1 and H2 strains A PCR based method for the identification of equine influenza virus from clinical samples Development and evaluation of an Influenza virus subtype H7N2 vaccine candidate for pandemic preparedness Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children Virus infection activates IL-1 beta and IL-18 production in human macrophages by a caspase-1-dependent pathway The role of alpha/beta and gamma interferons in development of immunity to influenza A virus in mice Development of a recombinant fowlpox virus vector-based vaccine of H5N1 subtype avian influenza Passive transfer of local immunity to influenza virus infection by IgA antibody Vaccines for preventing influenza in the elderly A case-control study of elderly patients with acute respiratory illness: effect of influenza vaccination on admission Healthy human subjects have CD4+ T cells directed against H5N1 influenza virus Partial protection against H5N1 influenza in mice with a single dose of a chimpanzee adenovirus vector expressing nucleoprotein The genesis of a pandemic influenza virus A fused gene of nucleoprotein (NP) and herpes simplex virus genes (VP22) induces highly protective immunity against different subtypes of influenza virus Heterotypic protection against influenza by immunostimulating complexes is associated with the induction of cross-reactive cytotoxic T lymphocytes Immunoprophylactic strategies against respiratory influenza virus infection Lack of antibody production following immunization in old age: association with CD8(+)CD28(−) T cell clonal expansions and an imbalance in the production of Th1 and Th2 cytokines Influenza virus (A/HK/156/97) hemagglutinin expressed by an alphavirus replicon system protects chickens against lethal infection with Hong Kong-origin H5N1 viruses Transient resistance of influenza virus to interferon action attributed to random multiple packaging and activity of NS genes Avian influenza in North and South America Ecology and epidemiology of avian influenza in North and South America Lethal H5N1 influenza viruses escape host anti-viral cytokine responses The NS1 gene of H5N1 influenza viruses circumvents the host anti-viral cytokine responses Generation of an attenuated H5N1 avian influenza virus vaccine with all eight genes from avian viruses Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein A virus obtained from influenza patients Vaccines for preventing influenza in healthy children NK and NK/T cells in human senescence A combination in-ovo vaccine for avian influenza virus and Newcastle disease virus Role of hemagglutinin cleavage for the pathogenicity of influenza virus Crossreactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy Influenza in old age Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics Live, attenuated influenza keywords: antibodies; avian; cd8; cells; challenge; et al; h5n1; human; immunity; infection; influenza; influenza virus; m2e; mice; pandemic; pathogenic; protection; responses; vaccination; vaccine; virus; viruses cache: cord-007733-zh8e76w7.txt plain text: cord-007733-zh8e76w7.txt item: #33 of 299 id: cord-008716-38sqkh9m author: Schmidt, Alexander C title: Current research on respiratory viral infections: Third International Symposium date: 2001-06-01 words: 24777 flesch: 38 summary: I. Isolation, properties and characterization Newly recognized myxoviruses from children with respiratory disease Growth on artificial medium of an agent associated with atypical pneumonia and its identification as PPLO Isolation and characterization of adenovirus 5 from the brain of an infant with fatal cerebral edema Respiratory viruses interfere with bacteriologic response to antibiotic in children with acute otitis media Parainfluenza Viruses Rational design of live-attenuated recombinant vaccine virus for human respiratory syncytial virus by reverse genetics Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5% proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development Recovery of viruses other than cytomegalovirus from bronchoalveolar lavage fluid Immunity to influenza in man Immunization of types four and seven adenoviruses by selective infection of the intestinal tract Respiratory viral infections in immunocompetent and immunocompromised persons Host responses to respiratory virus infection and immunization Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice The molecular basis of pneumococcal infection: a hypothesis Rehospitalization for respiratory illness in infants of less than 32 weeks' gestation Acute respiratory viral infections in ambulatory children of urban northeast Brazil Heparan sulfate glycosaminoglycans are involved in adenovirus type 5 and 2-host cell interactions Comparison of rapid diagnostic techniques for respiratory syncytial and influenza A virus respiratory infections in young children Human parainfluenza virus type 3 (PIV3) expressing the hemagglutinin protein of measles virus provides a potential method for immunization against measles virus and PIV3 in early infancy Prolonged survival of pancreatic islet allografts mediated by adenovirus immunoregulatory transgenes Rapid diagnosis of respiratory syncytial virus infections in immunocompromised adults Mechanism of protective immunity against influenza virus infection in mice without antibodies Efficacy of a Pneumococcal Conjugate Vaccine against Acute Otitis Media. Respiratory virus infections in immunocompromised patients are characterized by persistence of viral infection, prolonged shedding of virus, a high rate of nosocomial acquisition, and a high frequency of pneumonia and death. keywords: adenovirus; adults; age; antibody; cell; children; clinical; day; development; disease; et al; group; human; infants; infected; infection; influenza; influenza virus; mice; pandemic; patients; protein; respiratory; risk; rsv; rsv disease; rsv vaccine; study; syncytial; time; tract; treatment; vaccine; viral; virus; virus infection; viruses; years cache: cord-008716-38sqkh9m.txt plain text: cord-008716-38sqkh9m.txt item: #34 of 299 id: cord-008881-579ronfq author: Nicholson, KarlG title: MULTISITE INTRADERMAL ANTIRABIES VACCINATION: Immune Responses in Man and Protection of Rabbits Against Death from Street Virus by Postexposure Administration of Human Diploid-Cell-Strain Rabies Vaccine date: 1981-10-24 words: 2887 flesch: 40 summary: WHO consultation on cell culture rabies vaccines and their protective effect in man Immunoglobulin IgG and IgM antibody responses to rabies vaccine transformed the management of diabetes and it is now administered to about 4 million diabetics throughout the world. We thank Dr C. Charbonnier and l'lnstitut Merieux for the gift of the vaccine Requests for reprints should be addressed to K. G. N. Successful protection of humans exposed to rabies infection Postexposure treatment with the new human diploid cell rabies vaccine and antirabies serum Post-exposure use of human diploid cell culture rabies vaccine Deitch MW Postexposure trial of a human diploid cell strain rabies vaccine Immunization with a human diploid cell strain of rabies virus vaccine: two year results Studies with human diploid cell strain rabies vaccine and human rabies immunoglobulin in man Human diploid cell strain rabies vaccine rapid prophylactic immunisation of volunteers with small doses Immune responses of humans to a human diploid cell strain of rabies virus vaccine: lymphocyte transformation, production of virus-neutralizing antibody, and induction of interferon L'injecteur sans aiguille Dermo-jet Presse Mé Quantitative assay and potency test of antirabies serum and immunoglobulin MacNaughton MR Enzyme linked immunosorbent assay for detection of antibody in volunteers experimentally infected with human coronavirus 229 E group viruses Purification of human T and B lymphocytes Immunogenicity and acceptability of a human diploid cell culture rabies vaccine in volunteers Rabies prophylaxis simplified Resultats de la vaccination antirabique preventive par le vaccin inactive concentre souche Rabies PM/W138-1503-3M cultivee sur cellules diploides humaines Developments in Biological Standardisation Prophylactic immunization of humans against rabies by intradermal inoculation of human diploid cell culture vaccine A large scale antirabies immunisation study in humans using HDCS vaccine. keywords: antibody; cell; hdcs; human; insulin; rabies; vaccine cache: cord-008881-579ronfq.txt plain text: cord-008881-579ronfq.txt item: #35 of 299 id: cord-009381-q9s38fkh author: Roth, James A. title: Mechanistic Bases for Adverse Vaccine Reactions and Vaccine Failures date: 2007-09-28 words: 5958 flesch: 31 summary: In addition, animal vaccines have improved human health through control of zoonotic diseases such as rabies, brucellosis, and leptospirosis. Indeed, it can be argued that animal vaccines have had a profound impact on modern society. keywords: animals; bovine; canine; disease; immune; live; mlv; reactions; response; vaccination; vaccine; virus cache: cord-009381-q9s38fkh.txt plain text: cord-009381-q9s38fkh.txt item: #36 of 299 id: cord-009383-ozx5u0t3 author: Sheppard, Michael title: Viral Vectors for Veterinary Vaccines date: 2007-09-28 words: 4167 flesch: 22 summary: Publications describing viral vectors for veterinary vaccine delivery can be divided into several groups, which are represented in the following tables: Table II, poxvirus vectors; Table III, adenovirus vectors; Table IV, herpesvirus vectors; and Table V , other virus vectors. Viral vaccine vectors have really developed from a greater technological understanding of viruses at the genetic level, where today they have become a viable alternative strategy as one method for the delivery of vaccines. keywords: delivery; disease; et al; gene; recombinant; type; vaccine; vector; virus cache: cord-009383-ozx5u0t3.txt plain text: cord-009383-ozx5u0t3.txt item: #37 of 299 id: cord-009947-0zz4x8li author: Day, M. J. title: COMPILED BY THE VACCINATION GUIDELINES GROUP (VGG) OF THE WORLD SMALL ANIMAL VETERINARY ASSOCIATION (WSAVA) date: 2007-09-03 words: 4806 flesch: 41 summary: The minimum vaccination protocol in this situation would be a single administration of core vaccines at or before the time of admission to the shelter. It should be emphasised that the considerations given above do not generally apply to killed core vaccines nor to the optional vaccines, and particularly not to vaccines containing bacterial antigens. keywords: age; animal; core; feline; pet; vaccination; vaccines; vgg; weeks cache: cord-009947-0zz4x8li.txt plain text: cord-009947-0zz4x8li.txt item: #38 of 299 id: cord-010266-elhgew3x author: Spier, R.E. title: Ethical aspects of vaccines and vaccination date: 1998-12-02 words: 5155 flesch: 44 summary: key: cord-010266-elhgew3x authors: Spier, R.E. title: Ethical aspects of vaccines and vaccination date: 1998-12-02 journal: Vaccine DOI: 10.1016/s0264-410x(98)00169-8 sha: doc_id: 10266 cord_uid: elhgew3x nan Published by Elsevier Science Ltd. An example of the implications of these changes may be seen in the area of vaccines and vaccination which evinces the pressing need to review traditional ethical positions to take the maximum advantage of the potential for animal and human benefit inherent in this prophylactic approach to healthcare. keywords: agents; cost; ethics; people; society; system; use; vaccination; vaccines; way; world cache: cord-010266-elhgew3x.txt plain text: cord-010266-elhgew3x.txt item: #39 of 299 id: cord-011325-r42hzazp author: Stowe, Julia title: Do Vaccines Trigger Neurological Diseases? Epidemiological Evaluation of Vaccination and Neurological Diseases Using Examples of Multiple Sclerosis, Guillain–Barré Syndrome and Narcolepsy date: 2019-10-01 words: 4777 flesch: 36 summary: In this article, which focusses on the evaluation of the relationship between vaccination and neurological diseases, the statistical approaches to causality assessment are first discussed and their relative merits evaluated, followed by an overview of a selection of vaccine safety studies involving neurological disease with differing conclusions; some of the included studies have shown a small elevated risk, others none, two lack evidence to draw any definitive conclusion and one provides robust evidence of causal association. Cohort studies are feasible for vaccine safety studies when data from a whole country or region can be used. keywords: association; cases; influenza; narcolepsy; risk; safety; study; vaccination; vaccine cache: cord-011325-r42hzazp.txt plain text: cord-011325-r42hzazp.txt item: #40 of 299 id: cord-011370-as2v2c2h author: Wilder-Smith, Annelies title: Dengue vaccine development: status and future date: 2019-11-29 words: 3502 flesch: 38 summary: Epidemic arboviral diseases: priorities for research and public health Evidence-based risk assessment and communication: a new global dengue-risk map for travellers and clinicians Dengue infection in international travellers visiting Bali, Indonesia Imported dengue fever in East London: a 6-year retrospective observational study Camino Verde (The Green Way): evidence-based community mobilisation for dengue control in Nicaragua and Mexico: feasibility study and study protocol for a randomised controlled trial Mitigating diseases transmitted by aedes mosquitoes: a cluster-randomised trial of permethrin-impregnated school uniforms Wolbachia and the near cessation of dengue outbreaks in Northern Australia despite continued dengue importations via travellers The global burden of dengue: an analysis from the Global Burden of Disease Study Symptomatic Dengue in children in 10 asian and latin American countries Participants in the summit on Dengue immune correlates of P. Immune correlates of protection for dengue: state of the art and research agenda Efficacy and long-term safety of a dengue vaccine in regions of endemic disease Evaluation of interferences between dengue vaccine serotypes in a monkey model Effect of dengue serostatus on Dengue vaccine safety and efficacy Deliberations of the strategic advisory group of experts on immunization on the use of CYD-TDV dengue vaccine Vaccine confidence plummets in the Philippines following dengue vaccine scare: why it matters to pandemic preparedness Measles cases hit record high in Europe Measles and human movement in Europe Measles: a global resurgence Pre-vaccination screening strategies for the use of the CYD-TDV dengue vaccine: A meeting report Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines Development of standard clinical endpoints for use in dengue interventional trials: introduction and methodology A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2-17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebocontrolled study Robust and balanced immune responses to all 4 dengue virus serotypesfollowingadministrationofasingledose of a live attenuated tetravalent dengue vaccine to healthy, Flavivirus-naive adults Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD vaccine? key: cord-011370-as2v2c2h authors: Wilder-Smith, Annelies title: Dengue vaccine development: status and future date: 2019-11-29 journal: Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz DOI: 10.1007/s00103-019-03060-3 sha: doc_id: 11370 cord_uid: as2v2c2h Dengue, the most common arbovirus, represents an increasingly significant cause of morbidity worldwide, including in travelers. keywords: cyd; dengue; der; infection; live; phase; tdv; travelers; trials; vaccine cache: cord-011370-as2v2c2h.txt plain text: cord-011370-as2v2c2h.txt item: #41 of 299 id: cord-011486-5osu6hdu author: Lestari, Fajar Budi title: Rotavirus infection in children in Southeast Asia 2008–2018: disease burden, genotype distribution, seasonality, and vaccination date: 2020-05-21 words: 7613 flesch: 43 summary: Inactivated rotavirus vaccine induces protective immunity in gnotobiotic piglets An oral versus intranasal prime/ boost regimen using attenuated human rotavirus or VP2 and VP6 virus-like particles with immunostimulating complexes influences protection and antibody-secreting cell responses to rotavirus in a neonatal gnotobiotic pig model Parenteral administration of RF 8-2/ 6/7 rotavirus-like particles in a one-dose regimen induce protective immunity in mice Safety and immunogenicity of a parenterally administered rotavirus VP8 subunit vaccine in healthy adults Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebocontrolled trial Cost-effectiveness of rotavirus vaccination in Vietnam Cost-effectiveness of rotavirus immunization in Indonesia: taking breastfeeding patterns into account Effectiveness of rotavirus vaccine in preventing severe gastroenteritis in young children according to socioeconomic status Rotavirus vaccines: effectiveness, safety, and future directions Differences of Rotavirus Vaccine Effectiveness by Country: Likely Causes and Contributing Factors Causes of impaired oral vaccine efficacy in developing countries The effect of rotavirus vaccine on diarrhoea mortality Real-world impact of rotavirus vaccination Reduced rotavirus vaccine effectiveness among children born during the rotavirus season: a pooled analysis of 5 case-control studies from the Americas Evaluating the first introduction of rotavirus vaccine in Thailand: moving from evidence to policy Infant rotavirus vaccination may provide indirect protection to older children and adults in the United States Estimating the herd immunity effect of rotavirus vaccine Household catastrophic healthcare expenditure and impoverishment due to rotavirus gastroenteritis requiring hospitalization in Malaysia Religious and community leaders' acceptance of rotavirus vaccine introduction in Yogyakarta, Indonesia: a qualitative study Rotavirus: Govt urged to protect kids with vaccine Rotavirus Disease and Vaccines in Asia Effectiveness of monovalent rotavirus vaccine in the Philippines Health economics of rotavirus immunization in Vietnam: potentials for favorable costeffectiveness in developing countries The decision making process on new vaccines introduction in South Africa Capturing budget impact considerations within economic evaluations: a systematic review of economic evaluations of rotavirus vaccine in low-and middle-income countries and a proposed assessment framework Health and economic impact of rotavirus vaccination in GAVI-eligible countries Costs of vaccine programs across 94 low-and middle-income countries Rotavirus: common, severe, devastating, preventable Economic costs of rotavirus gastroenteritis and cost-effectiveness of vaccination in developing countries Guidelines for estimating costs of introducing new vaccines into the national immunization system Economic evaluation of human rotavirus vaccine in Thailand Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations Global, Regional, and National Estimates of Rotavirus Mortality in Children <5 Years of Age Estimates of the global, regional, and national morbidity, mortality, and aetiologies of diarrhoea in 195 countries: a systematic analysis for the global burden of disease study Rotavirus vaccine efficacy: current status and areas for improvement Pediatric hospitalizations attributable to rotavirus gastroenteritis among Cambodian children: seven years of active surveillance Detection of group a rotavirus strains circulating among children with acute diarrhea in Indonesia Identification of rotavirus strains causing Diarrhoea in children under five years of age in Yogyakarta, Indonesia Risk factors of rotavirus diarrhea in hospitalized children in Sanglah Hospital, Denpasar: a prospective cohort study Association between Severe Dehydration in Rotavirus Diarrhea and Exclusive Breastfeeding among Infants at Dr. Hasan Sadikin General Hospital Prevalence and clinical characteristics of rotavirus diarrhea in Genotyping and clinical factors in pediatric diarrhea caused by rotaviruses: one-year surveillance in Surabaya Identification of the P genotypes of rotavirus in children with acute diarrhea in Pekanbaru, Indonesia Diarrhea among hospitalized children under five: a call for inclusion of rotavirus vaccine to the national immunization program in Indonesia Equine-like G3 rotavirus strains as predominant strains among children in Indonesia in 2015-2016 Molecular characterisation of rotavirus strains detected during a clinical trial of the human neonatal rotavirus vaccine (RV3-BB) in Indonesia. keywords: asia; children; countries; diarrhea; efficacy; gastroenteritis; genotype; human; infection; rotavirus; southeast; strains; vaccination; vaccine; years cache: cord-011486-5osu6hdu.txt plain text: cord-011486-5osu6hdu.txt item: #42 of 299 id: cord-013290-j3assowx author: Guibinga, Ghiabe H. title: Protection against Borreliella burgdorferi infection mediated by a synthetically engineered DNA vaccine date: 2020-08-12 words: 5089 flesch: 43 summary: Ebola GP DNA vaccine is temperature stable and safely demonstrates cellular and humoral immunogenicity advantages in healthy volunteers Safety and immunogenicity of an Anti-Zika virus DNA vaccine -preliminary report Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial Augmentation of cellular and humoral immune responses to HPV16 and HPV18 E6 and E7 antigens by VGX-3100 Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial Identification of a Borrelia burgdorferi OspA T cell epitope that promotes anti-OspA IgG in mice Anti-OspA DNA-encoded monoclonal antibody prevents transmission of spirochetes in tick challenge providing sterilizing immunity in mice Pre-exposure prophylaxis with OspA-specific human monoclonal antibodies protects mice against tick transmission of lyme disease spirochetes Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein CD14 signaling restrains chronic inflammation through induction of p38-MAPK/SOCS-dependent tolerance Signaling through CD14 attenuates the inflammatory response to Borrelia burgdorferi, the agent of lyme disease Borrelia burgdorferi changes its surface antigenic expression in response to host immune responses Rapid and sensitive quantification of Borrelia burgdorferi-infected mouse tissues by continuous fluorescent monitoring of PCR An effective second-generation outer surface protein A-derived Lyme vaccine that eliminates a potentially autoreactive T cell epitope DNA vaccination and gene therapy: optimization and delivery for cancer therapy Lyme borreliosis in laboratory mice Gene expression profiling provides insights into the pathways involved in inflammatory arthritis development: murine model of Lyme disease Characterization of guinea pig T cell responses elicited after EP-assisted delivery of DNA vaccines to the skin Development of an intradermal DNA vaccine delivery strategy to achieve single-dose immunity against respiratory syncytial virus Reactivity with a specific epitope of outer surface protein A predicts protection from infection with the Lyme disease spirochete, Borrelia burgdorferi Protective immunization with plasmid DNA containing the outer surface lipoprotein A gene of Borrelia burgdorferi is independent of an eukaryotic promoter An OspA-based DNA vaccine protects mice against infection with Borrelia burgdorferi DNA vaccines expressing a fusion product of outer surface proteins A and C from Borrelia burgdorferi induce protective antibodies suitable for prophylaxis but Not for resolution of Lyme disease Electroporation delivery of DNA vaccines: prospects for success CpG DNA as a vaccine adjuvant CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases CD4+ T cells promote antibody production but not sustained affinity maturation during Borrelia burgdorferi infection Diversity of the lyme disease spirochetes and its influence on immune responses to infection and vaccination Identification of Borrelia burgdorferi ospC genotypes in canine tissue following tick infestation: implications for Lyme disease vaccine and diagnostic assay design Incomplete protection of hamsters vaccinated with unlipidated OspA from Borrelia burgdorferi infection is associated with low levels of antibody to an epitope defined by mAb LA-2 Monoclonal antibodies specific for the outer surface protein A (OspA) of Borrelia burgdorferi prevent Lyme borreliosis in severe combined immunodeficiency (scid) mice OspA DNA vaccine, pLD1 in combination with CELLECTRA® in vivo delivery technology. keywords: antibody; burgdorferi; disease; dna; guinea; human; lyme; mice; ospa; pld1; protein; responses; vaccine cache: cord-013290-j3assowx.txt plain text: cord-013290-j3assowx.txt item: #43 of 299 id: cord-013326-qsqaimsy author: Hankaniemi, Minna M. title: Structural Insight into CVB3-VLP Non-Adjuvanted Vaccine date: 2020-08-24 words: 6386 flesch: 47 summary: EV-D68 [17] or polyvalent VLP-vaccines against EV-A71, CVA6, CVA10, and CVA16 An atomic-resolution structure of CVB3 virus was resolved by X-ray crystallography 25 years ago [21] , however, similar structures of other CVBs are lacking. keywords: coxsackievirus; cva16; cvb1; cvb3; enterovirus; figure; mice; particles; production; structure; vaccine; virus; vlp; vlps cache: cord-013326-qsqaimsy.txt plain text: cord-013326-qsqaimsy.txt item: #44 of 299 id: cord-014462-11ggaqf1 author: None title: Abstracts of the Papers Presented in the XIX National Conference of Indian Virological Society, “Recent Trends in Viral Disease Problems and Management”, on 18–20 March, 2010, at S.V. University, Tirupati, Andhra Pradesh date: 2011-04-21 words: 35463 flesch: 47 summary: The following virus isolates have been used in the analysis: GTPV-Uttarkashi, P60, vaccine virus; GTPV Mukteswar, P10, Challenge virus; GTPV (Akola), GTPV Bareilly/00, GTPV Ladakh/01 and GTPV Sambalpur/82, field isolates and SPPV Srinagar, P40; SPPV Ranipet, P50; SPPV-RF, P50, vaccine viruses and SPPV Makdhoom/07, SPPV CIRG/08, SPPV Pune/08, SPPV Bareilly, SPPV 183/03 and SPPV 125/02, field isolates. Present paper discusses about virus disease of quarantine importance affecting ornamental and fruit plants such as Chrysanthimum, Dahlia, Dianthus, Rosabengalensis, Cattleya, Cymbidium, Dendrobium, Lilium, Citrus, Vitis etc. keywords: acid; analysis; animals; antibodies; antigen; assay; cases; cells; cloned; control; crop; curl; dengue; detection; development; disease; dna; elisa; expression; field; food; gene; host; india; infection; isolates; leaf; management; methods; molecular; mosaic; mosaic virus; nucleotide; pathogens; patients; pcr; plant; positive; present; primers; production; protein; region; resistance; response; results; rna; samples; sequence; specific; study; symptoms; time; tomato; total; vaccine; vector; viral; virus; virus infection; viruses; world; yellow cache: cord-014462-11ggaqf1.txt plain text: cord-014462-11ggaqf1.txt item: #45 of 299 id: cord-014901-d9szap94 author: Permyakova, N. V. title: State of research in the field of the creation of plant vaccines for veterinary use date: 2015-01-04 words: 8092 flesch: 34 summary: as a feedstuff additive Expression of hemagglutinin protein of rinderpest virus in transgenic tobacco and immunogenicity of plant derived protein in a mouse model Systemic and oral immunogenicity of hemagglutinin protein of rinderpest virus expressed by transgenic peanut plants in a mouse model Expression of hemagglutinin protein of rinderpest virus in trans genic pigeon pea Oral immunogenicity of the plant derived spike protein from swine transmissible gastroenteritis coronavirus Cloning and sequence analysis of the Korean strain of spike gene of porcine epidemic diarrhea virus and expression of its neutraliz ing epitope in plants Successful oral prime immunization with VP60 from rabbit haemorrhagic disease virus pro duced in transgenic plants using different fusion strate gies Mucosal and sys temic immunization elicited by Newcastle disease virus (NDV) transgenic plants as antigens Expres sion of the fusion glycoprotein of Newcastle disease virus in transgenic rice and its immunogenicity in mice Expression of immunogenic S1 glycoprotein of infectious bronchitis virus in trans genic potatoes Transient expression of the ectodomain of matrix protein 2 (M2e) of avian RUSSIAN Immunization with plant expressed hemagglutinin protects chickens from lethal highly pathogenic avian influenza virus H5N1 challenge infection Immunogenicity study of plant made oral subunit vaccine against porcine reproductive and res piratory syndrome virus (PRRSV) Expression of the rabies virus glycoprotein in transgenic tomatoes Immunization against rabies with plant derived antigen Development of an edible rabies vaccine in maize using the Vnukovo strain Induction of a protective immune response to rabies virus in sheep after oral immunization with transgenic maize, expressing the rabies virus glycoprotein Expression of the rabies virus nucleoprotein in plants at high levels and evaluation of immune responses in mice Expression of rabies virus G pro tein in carrots (Daucus carota) Such com panies as SemBioSys Genetics Inc. (Calgary, Can ada), Medicago Inc. (Quebec, Canada), Protalix Bio Therapeutics (Karmiel, Israel), and ORF Genetics (Iceland) proved the possibility of quick establishing of the production of purified plant proteins, which are quite competitive in today's market. keywords: antigen; cells; development; disease; expression; gene; genome; immunization; plant; plant cells; plant vaccines; production; protein; response; system; target; transgenic; use; vaccines; virus cache: cord-014901-d9szap94.txt plain text: cord-014901-d9szap94.txt item: #46 of 299 id: cord-016126-i7z0tdrk author: Dangi, Mehak title: Advanced In Silico Tools for Designing of Antigenic Epitope as Potential Vaccine Candidates Against Coronavirus date: 2018-10-14 words: 3226 flesch: 42 summary: It is basically an empirical method to hunt antigenic proteins. All these limitations are conquered by reverse vaccinology approach utilizing genome sequence information which ultimately is translated into proteins. keywords: approach; epitopes; host; prediction; proteins; vaccine; vaccinology cache: cord-016126-i7z0tdrk.txt plain text: cord-016126-i7z0tdrk.txt item: #47 of 299 id: cord-016178-2ix6c0he author: Rajan, V. title: An Oral Vaccine for TGEV Immunization of Pigs date: 2014-05-28 words: 6058 flesch: 39 summary: Is the bronchus-associated lymphoid tissue (BALT) an integral structure of the lung in normal mammals, including humans? Antigenic modules in the N-terminal S1 region of the transmissible gastroenteritis virus spike protein Porcine coronaviruses Challenges in therapeutic glycoprotein production A continuous epitope from transmissible gastroenteritis virus S protein fused to E. coli heat-labile toxin B subunit expressed by attenuated Salmonella induces serum and secretory immunity Plant-based vaccines: unique advantages Expression, characterization, and biologic activity of recombinant human lactoferrin in rice Immunogenicity of the S protein of transmissible gastroenteritis virus expressed in baculovirus Immunogenicity of porcine transmissible gastroenteritis virus spike protein expressed in plants Development of oral vaccine in plants against transmissible gastroenteritis virus of swine Oral delivery of bioencapsulated coagulation factor IX prevents inhibitor formation and fatal anaphylaxis in hemophilia B mice Oral tolerance: immune mechanisms and treatment of autoimmune diseases Oral tolerance A cysteine protease from maize isolated in a complex with cystatin Pregnant gilts received the following treatments: group A (oral corn vaccine on days À35 to À29 and À14 to À8), group B (oral corn vaccine on days À35 to À33 and À14 to À12), group C (oral corn vaccine on days À35 and À14), group D (oral corn placebo on days À14 to À8), group E (intramuscular live vaccine on days À35 and À14), and group F (oral corn vaccine on days À14 to À8), where the À sign represents days before farrowing. keywords: antibodies; antigen; corn; days; et al; piglets; protein; tgev; vaccine; virus cache: cord-016178-2ix6c0he.txt plain text: cord-016178-2ix6c0he.txt item: #48 of 299 id: cord-016200-zfh20im0 author: Saxena, Jyoti title: Edible Vaccines date: 2013-10-22 words: 7629 flesch: 48 summary: Research in the field of edible vaccines holds immense potential for the future and every advancement made in this direction is bringing the dream of edible vaccine one step closer. Edible vaccines An edible vaccine for malaria using transgenic tomatoes of varying sizes, shapes and colors to carry different antigens Plant derived edible vaccines In vivo analysis of plastid psbA, rbcL and rpl32 UTR elements by chloroplast transformation: tobacco plastid gene expression is controlled by modulation of transcript levels and translation efficiency Control mechanisms of plastid gene expression Production of antibodies in transgenic plants Immunotherapeutic potential of antibodies produced in plants Production of biologically active human interleukin-4 in transgenic tomato and potato Transgenic plants as vaccine production systems Expression of hepatitis B surface antigen in transgenic plants Edible vaccine protects mice against Escherichia coli heat-labile enterotoxin (LT): potatoes expressing a synthetic LT-B gene Edible plant vaccines: applications for prophylactic and therapeutic molecular medicine Edible vaccines: a concept comes of age Plant biotechnology and in vitro biology in the 21st century Production of hepatitis B surface antigen in transgenic plants for oral immunization Human immune responses to a novel Norwalk virus vaccine delivered in transgenic potatoes Immunogenicity in humans of an edible vaccine for hepatitis B Oral immunization with a combination of Plasmodium yoelii merozoite surface protein 1 and 4/5 enhances protection against lethal malarial challenge keywords: antibodies; antigen; diseases; expression; gene; hepatitis; human; immune; plants; potatoes; production; protein; transgenic; vaccine; virus cache: cord-016200-zfh20im0.txt plain text: cord-016200-zfh20im0.txt item: #49 of 299 id: cord-016222-dltsdqcm author: Siegel, Frederic R. title: Lessening the Impacts from Non-Tectonic (Natural) Hazards and Triggered Events date: 2016-06-24 words: 7137 flesch: 52 summary: The threat or onset of infectious disease can be mitigated in several ways. With respect to improved diagnostics (4 above), Nature published a December 2015 supplement in which contributors modeled the impact of new diagnostic and prognostic technologies for lessening the global burden of infectious diseases [ 11 ] . keywords: areas; collapse; disease; earth; health; landslide; people; risk; rocks; slope; stress; subsidence; surface; vaccines; water cache: cord-016222-dltsdqcm.txt plain text: cord-016222-dltsdqcm.txt item: #50 of 299 id: cord-016268-xcx1c0da author: Sahai, Aastha title: Plant Edible Vaccines: A Revolution in Vaccination date: 2013-04-15 words: 11303 flesch: 39 summary: These results suggest a new strategy for the development of plant vaccines. Protein Expression and Purifi cation A plant-derived vaccine against hepatitis B virus Plant based HIV-1 vaccine candidate: Tat protein produced in spinach Synthesis and assembly of anthrax lethal factor cholera toxin B-subunit fusion protein in transgenic potato Current trends in edible vaccine development using transgenic plants Oral immunization with hepatitis B surface antigen expressed in transgenic plants The green revolution: Plants as heterologous expression vectors Foods as production and delivery vehicles for human vaccines Expression of hepatitis B surface antigen in transgenic banana plants Edible vaccines: Current status and future Edible vaccines Accumulation of trehalose within transgenic chloroplasts confers drought tolerance Chloroplast expression of His-tagged GUS-fusions: A general strategy to overproduce and purify foreign proteins using transplastomic plants as bioreactors N-glycoprotein biosynthesis in plants: Recent developments and future trends Pharming and transgenic plants Eukaryotic viral expression systems for polypeptides Development of an edible rabies vaccine in maize using the Vnukovo strain Auto antigens produced in plants for oral tolerance therapy of autoimmune diseases Induction of oral tolerance to prevent diabetes with transgenic plants requires glutamic acid decarboxylase (GAD) and IL-4 Antibody processing and engineering in plants, and new strategies for vaccine production Optimization of human papillomavirus type 16 (HPV-16) L1 expression in plants: Comparison of the suitability of different HPV-16 L1 gene variants and different cell-compartment localization Production of edible vaccines for oral immunization in transgenic plants, current and future prospective Recent advances in plant derived vaccine antigens against human infectious diseases Edible vaccine-vegetables as alternative to needles Transgenic plants as vaccine production systems Expression of hepatitis B surface antigen in transgenic plants Expression of Norwalk virus capsid protein in transgenic tobacco and protein and its oral immunogenicity in mice Edible vaccine protects mice against E. coli heat-labile enterotoxin (LT): Potatoes expressing a synthetic LT-B gene Multiple presentation of foreign peptides on the surface of an RNA-free bacteriophage capsid Generation of transgenic banana ( Musa acuminata ) plants via Agrobacterium -mediated transformation Rapid production of specifi c vaccines for lymphoma by expression of tumor-derived single-chain Fv epitopes in tobacco plants Expression of the rabies virus glycoprotein in transgenic tomatoes Routes of immunization and antigen delivery systems for optimal mucosal immune responses in humans Edible vaccines: keywords: antigen; cells; diseases; et al; expression; gene; hepatitis; human; immunization; mice; mucosal; plant; production; protein; surface; system; tobacco; transformation; transgenic; vaccines; virus cache: cord-016268-xcx1c0da.txt plain text: cord-016268-xcx1c0da.txt item: #51 of 299 id: cord-016371-zkawdcac author: Perrie, Yvonne title: Vaccines date: 2013-10-17 words: 9606 flesch: 33 summary: The widespread use of aluminium salts as vaccine adjuvants is due to a combined ability to (generally speaking) improve vaccine immune responses as well as provide an excellent safety profi le. As with the liposome systems a range of immunostimulatory agents have been considered in the design of niosomes as vaccine adjuvants. keywords: adjuvants; aluminium; antigen; cationic; cells; dda; delivery; et al; immune; infl; liposomes; response; subunit; system; use; vaccines; vesicles cache: cord-016371-zkawdcac.txt plain text: cord-016371-zkawdcac.txt item: #52 of 299 id: cord-016475-7ldxvbpz author: Pleschka, Stephan title: Anti-viral approaches against influenza viruses date: 2006 words: 17141 flesch: 32 summary: Apoptosis is mainly regarded to be a host cell defense against virus viruses (reviewed in: Julkunen et al., 2000; Ludwig et al., 2003; infections since many viruses express anti-apoptotic proteins to prevent this cellular response. The etiological agent of the disease, influenza virus is responsible E. Bogner and A. Holzenburg (eds.) , New Concepts of Antiviral Therapy, 115-167. keywords: activation; activity; anti; apoptosis; cell; disease; et al; human; immunity; induction; infection; influenza; influenza virus; inhibitors; kinase; mek; neuraminidase; oseltamivir; pathway; production; protein; replication; response; strain; treatment; type; vaccine; viral; virus; viruses; zanamivir cache: cord-016475-7ldxvbpz.txt plain text: cord-016475-7ldxvbpz.txt item: #53 of 299 id: cord-016508-39glgeft author: Possas, Cristina title: Vaccines: Biotechnology Market, Coverage, and Regulatory Challenges for Achieving Sustainable Development Goals date: 2019-06-13 words: 6598 flesch: 32 summary: One of the major gaps in vaccine innovation, particularly affecting the development of new vaccines against emerging and neglected diseases, is related to the inability of scientists to explain the diversity of individual immune responses and clinical outcomes to the same vaccine and how this diversity relates to innate and acquired immunity. Pfizer is expected to increase its participation in the market in the next decade due to the success of its pneumococcal vaccine Prevnar 13 and increasing investments in vaccine development. keywords: access; countries; development; diseases; global; goals; health; innovation; market; patent; public; system; vaccine; world cache: cord-016508-39glgeft.txt plain text: cord-016508-39glgeft.txt item: #54 of 299 id: cord-016594-lj0us1dq author: Flower, Darren R. title: Identification of Candidate Vaccine Antigens In Silico date: 2012-09-28 words: 12575 flesch: 33 summary: A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine design Identification and characterization of pathogenicity and other genomic islands using base composition analyses A novel strategy for the identification of genomic islands by comparative analysis of the contents and contexts of tRNA sites in closely related bacteria MobilomeFINDER: web-based tools for in silico and experimental discovery of bacterial genomic islands CpGcluster: a distance-based algorithm for CpG-island detection CpGIF: an algorithm for the identification of CpG islands Identifying CpG islands by different computational techniques CpG_MI: a novel approach for identifying functional CpG islands in mammalian genomes Evaluation of genomic island predictors using a comparative genomics approach IslandPath: aiding detection of genomic islands in prokaryotes Score-based prediction of genomic islands in prokaryotic genomes using hidden Markov models A computational approach for identifying pathogenicity islands in prokaryotic genomes Resolving the structural features of genomic islands: a machine learning approach Detection of genomic islands via segmental genome heterogeneity Prediction of pathogenicity islands in enterohemorrhagic Escherichia coli O157:H7 using genomic barcodes IslandViewer: an integrated interface for computational identification and visualization of genomic islands Towards pathogenomics: a web-based resource for pathogenicity islands Identification and characterization of a novel family of pneumococcal proteins that are protective against sepsis Functional genomics of pathogenic bacteria SYFPEITHI: database for searching and Tcell epitope prediction SYFPEITHI: database for MHC ligands and peptide motifs HIV sequence databases MHCBN 4.0: a database of MHC/TAP binding peptides and T-cell epitopes MHCBN: a comprehensive database of MHC binding and non-binding peptides EPIMHC: a curated database of MHCbinding peptides for customized computational vaccinology AntiJen: a quantitative immunology database integrating functional, thermodynamic, kinetic, biophysical, and cellular data JenPep: a novel computational information resource for immunobiology and vaccinology JenPep: a database of quantitative functional peptide data for immunology The immune epitope database 2.0 AntigenDB: an immunoinformatics database of pathogen antigens VIOLIN: vaccine investigation and online information network Epitopic peptides with low similarity to the host proteome: towards biological therapies without side effects Peptimmunology: immunogenic peptides and sequence redundancy Primer: mechanisms of immunologic tolerance Recent advances in immune modulation Cutting edge: contributions of apoptosis and anergy to systemic T cell tolerance Discriminating antigen and non-antigen using proteome dissimilarity III: tumour and parasite antigens Discriminating antigen and non-antigen using proteome dissimilarity II: viral and fungal antigens Discriminating antigen and non-antigen using proteome dissimilarity: bacterial antigens Gapped BLAST and PSI-BLAST: a new generation of protein database search programs Single proteins might have dual but related functions in intracellular and extracellular microenvironments Locating proteins in the cell using TargetP, SignalP and related tools Improved prediction of signal peptides: SignalP 3.0 A comprehensive assessment of N-terminal signal peptides prediction methods WoLF PSORT: protein localization predictor Secreted protein prediction system combining CJ-SPHMM, TMHMM, and PSORT PSORT-B: improving protein subcellular localization prediction for Gram-negative bacteria PSORT: a program for detecting sorting signals in proteins and predicting their subcellular localization Predicting protein subcellular locations using hierarchical ensemble of Bayesian classifiers based on Markov chains SubLoc: a server/client suite for protein subcellular location based on SOAP Gpos-PLoc: an ensemble classifier for predicting subcellular localization of Gram-positive bacterial proteins Advantages of combined transmembrane topology and signal peptide prediction-the Phobius web server Prediction of lipoprotein signal peptides in Gram-negative bacteria Prediction of twin-arginine signal peptides Validating subcellular localization prediction tools with mycobacterial proteins Toward bacterial protein sub-cellular location prediction: single-class discrimminant models for all gram-and gram+ compartments Multi-class subcellular location prediction for bacterial proteins Alpha helical trans-membrane proteins: enhanced prediction using a Bayesian approach Beta barrel trans-membrane proteins: enhanced prediction using a Bayesian approach A predictor of membrane class: discriminating alpha-helical and beta-barrel membrane proteins from non-membranous proteins TATPred: a Bayesian method for the identification of twin arginine translocation pathway signal sequences LIPPRED: a web server for accurate prediction of lipoprotein signal sequences and cleavage sites Combining algorithms to predict bacterial protein sub-cellular location: parallel versus concurrent implementations Predicting the subcellular localization of viral proteins within a mammalian host cell Virus-PLoc: a fusion classifier for predicting the subcellular localization of viral proteins within host and virus-infected cells Structure and sequence relationships in the lipocalins and related proteins Structural Relationship of Streptavidin to the Calycin Protein Superfamily Analysis of known bacterial protein vaccine antigens reveals biased physical properties and amino acid composition Adaptation of protein surfaces to subcellular location Hierarchical classification of G-protein-coupled receptors with data-driven selection of attributes and classifiers GPCRTree: online hierarchical classification of GPCR function Optimizing amino acid groupings for GPCR classification On the hierarchical classification of G protein-coupled receptors Proteomic applications of automated GPCR classification VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines Identifying candidate subunit vaccines using an alignment-independent method based on principal amino acid properties DNA and peptide sequences and chemical processes multivariately modeled by principal component analysis and partial least-squares projections to latent structures Principal property-values for 6 nonnatural amino-acids and their application to a structure activity relationship for oxytocin peptide analogs Peptide binding to the HLA-DRB1 supertype: a proteochemometrics analysis Proteochemometrics mapping of the interaction space for retroviral proteases and their substrates Proteochemometrics analysis of substrate interactions with dengue virus NS3 proteases Generalized modeling of enzyme-ligand interactions using proteochemometrics and local protein substructures Rough set-based proteochemometrics modeling of G-protein-coupled receptor-ligand interactions Improved approach for proteochemometrics modeling: application to organic compound-amine G protein-coupled receptor interactions Melanocortin receptors: ligands and proteochemometrics modeling Proteochemometrics modeling of the interaction of amine G-protein coupled receptors with a diverse set of ligands Peptide quantitative structureactivity-relationships, a multivariate approach Multivariate parametrization of 55 coded and non-coded amino-acids New chemical descriptors relevant for the design of biologically active peptides. Vaccines based on APCs and peptides are new but unproven strategies; most modern vaccine development relies instead on effective searches for vaccine antigens. keywords: analysis; antigens; approach; binding; candidate; cell; data; database; discovery; epitope; genome; genomic; host; immunogenicity; islands; methods; mhc; peptide; prediction; protein; sequence; system; vaccines; vaccinology cache: cord-016594-lj0us1dq.txt plain text: cord-016594-lj0us1dq.txt item: #55 of 299 id: cord-016713-pw4f8asc author: Goyal, Amit K. title: Nanotechnological Approaches for Genetic Immunization date: 2013-05-24 words: 16058 flesch: 23 summary: Similarly, copolymers of a hydrophilic poly(ethylene glycol) block and a cationic poly(aminoethyl methacrylate) (PAEM) block have been used for DNA vaccine delivery. However, there are several associated concerns for the use of polymers as vaccines delivery systems such as toxicity, irritancy, allergenicity, and biodegradability. keywords: acid; adjuvant; antibody; antigen; cationic; cells; chitosan; delivery; dna; et al; expression; gene; hepatitis; human; immune; immunity; immunization; lipid; liposomes; mucosal; nanoparticles; oral; plasmid; polymers; potential; properties; protein; responses; surface; systems; targeting; transfection; vaccination; vaccine; virus cache: cord-016713-pw4f8asc.txt plain text: cord-016713-pw4f8asc.txt item: #56 of 299 id: cord-016903-z2vqfq98 author: Herndler-Brandstetter, Dietmar title: The Efficacy of Vaccines to Prevent Infectious Diseases in the Elderly date: 2007 words: 6554 flesch: 27 summary: An evolutionary perspective on immunosenescence Lack of antibody produ ction following immunization in old age: association with CD8 +CD28' T-cell clonal expansions and an imbalance in the production of Thl and Th2 cyrokines Restoration of viral immunity in immunodeficient humans by the adoptive transfer ofT-cell clones The epidemiology of pertussis: a comparison of the epidemiology of the disease pertussis with the epidemiology of Bordetella pertussis infection An epidemic of pertussis among elderly people in a religious institution in The Netherlands Vaccination against tetanus in the elderly: do recommended vaccination strategies give sufficient protection No immunity for the elderly A population-based serologic survey of immunity to tetanus in the United States T-cells from elderly persons respond to neoantigenic stimulation with an unimpaired IL-2 production and an enhanced differentiation into effector cells Epidemiology and ecology of TBE relevant to the production of effectivevaccines TBE vaccination and the Austrian experience Vaccine Immunogenicity and safety of a booster vaccination against tick-borne encephalitis more than 3 years following the last immunisation Epidemiology and prevention of hepatitis A in travelers Hepatitis A and hepatitis B: risks compared with other vaccine preventable diseases and immunization recommendations A prospective,randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix-B) in adults Immunogenicity of an inactivated hepatitis A vaccine in Dutch United Nations troops Immunogenicity of combined hepatitis A and B vaccine in elderly persons They display a high immunogenicity and a similar safety profile in elderly persons compared with inactivated influenza vaccines. keywords: adults; age; cell; diseases; efficacy; immunity; infection; influenza; ofthe; people; persons; risk; vaccination; vaccine; virus; years cache: cord-016903-z2vqfq98.txt plain text: cord-016903-z2vqfq98.txt item: #57 of 299 id: cord-017291-bhe34dky author: Cohen, Cheryl title: Influenza date: 2017-05-05 words: 7132 flesch: 36 summary: Adjuvanted formulations of influenza vaccine are licensed for use in individuals aged ≥65 years in the USA but not currently in children [39] . Children aged 6 months through 8 years should receive two influenza doses administered ≥4 weeks apart the first time influenza vaccine is administered. keywords: children; disease; illness; individuals; infection; influenza; risk; treatment; vaccination; vaccine; virus; viruses; years cache: cord-017291-bhe34dky.txt plain text: cord-017291-bhe34dky.txt item: #58 of 299 id: cord-017838-fbotc479 author: Fagone, Paolo title: Electroporation-Mediated DNA Vaccination date: 2010-12-15 words: 5293 flesch: 18 summary: The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? DNA vaccination: antigen presentation and the induction of immunity Heterologous protection against influenza by injection of DNA encoding a viral protein Genetic immunization is a simple method for eliciting an immune response Vaccination with hemagglutinin or neuraminidase DNA protects BALB/c mice against influenza virus infection in presence of maternal antibody In vivo expression of rat insulin after intravenous administration of the liposome-entrapped gene for rat insulin I Increased expression of DNA cointroduced with nuclear protein in adult rat liver Liposome mediated gene transfer Direct introduction of genes into rats and expression of the genes Receptor-mediated gene delivery and expression in vivo Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform spotty business The mechanism of naked DNA uptake and expression Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein Inactivation of the human immunodeficiency virus type 1 inhibitory elements allows Rev-independent expression of Gag and Gag/protease and particle formation Induction of potent Th1-type immune responses from a novel DNA vaccine for West Nile virus New York isolate (WNV-NY1999) Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein Gene therapy progress and prospects: electroporation and other physical methods Electric pulses applied prior to intramuscular DNA vaccination greatly improve the vaccine immunogenicity Increased gene expression and inflammatory cell infiltration caused by electroporation are both important for improving the efficacy of DNA vaccines Recruitment of antigen-presenting cells to the site of inoculation and augmentation of HIV-1 DNA vaccine immunogenicity by in vivo electroporation Electroporation for drug and gene delivery in the clinic: doctors go electric Direct gene transfer into mouse muscle in vivo In vivo gene electroinjection and expression in rat liver Gene transfer into mouse lyoma cells by electroporation in high electric fields High-level protein secretion into blood circulation after electric pulse-mediated gene transfer into skeletal muscle Increased DNA vaccine delivery and immunogenicity by electroporation in vivo Electroporation improves the efficacy of DNA vaccines in large animals Anti-HBV immune responses in rhesus macaques elicited by electroporation mediated DNA vaccination A single DNA immunization in combination with electroporation prolongs the primary immune response and maintains immune memory for six months Enhancement of the effectiveness of electroporation-augmented cutaneous DNA vaccination by a particulate adjuvant Modulation of the immune response induced by gene electrotransfer of a hepatitis C virus DNA vaccine in nonhuman primates High expression of naked plasmid DNA in muscles of young rodents Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses Cutaneous transfection and immune responses to intradermal nucleic acid vaccination are significantly enhanced by in vivo electropermeabilization Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques Early events of electroporation-mediated intramuscular DNA vaccination potentiate Th1-directed immune responses Inflammatory responses following direct injection of plasmid DNA into skeletal muscle DNA immunization with HIV-1 tat mutated in the trans activation domain induces humoral and cellular immune responses against wild-type Tat Specific immune induction following DNA-based immunization through in vivo transfection and activation of macrophages/antigen-presenting cells Facilitated DNA inoculation induces anti-HIV-1 immunity in vivo In vivo electroporation enhances the immunogenicity of hepatitis C virus nonstructural 3/4A DNA by increased local DNA uptake, protein expression, inflammation, and infiltration of CD3+ T cells Translating innate immunity into immunological memory: implications for vaccine development Signaling to NF-kappaB by Toll-like receptors The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4 Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling TLR9â��/â�� and TLR9+/+ mice display similar immune responses to a DNA vaccine Vaccination with plasmid DNA activates dendritic cells via Toll-like receptor 9 (TLR9) but functions in TLR9-deficient mice A Toll-like receptor-independent antiviral response induced by double-stranded B-form DNA Recognition of cytosolic DNA activates an IRF3-dependent innate immune response TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines Recombinant canarypoxvirus vaccine carrying the prM/E genes of West Nile virus protects horses against a West Nile virus-mosquito challenge Efficacy of an infectious hematopoietic necrosis (IHN) virus DNA vaccine in Chinook Oncorhynchus tshawytscha and sockeye O. nerka salmon Clinical Evaluation of Pain and Muscle Damage Induced by Electroporation of Skeletal Muscle in Humans Abstracts from the American Society of Gene Therapy 7th Furthermore, DNA vaccines could potentially induce immunity in newborns in situations that usually neutralize conventional vaccines via the presence of high levels of maternal antibodies [5] . keywords: cells; dna; electroporation; expression; gene; immunogenicity; mice; muscle; responses; vaccination; vaccine; virus; vivo cache: cord-017838-fbotc479.txt plain text: cord-017838-fbotc479.txt item: #59 of 299 id: cord-017841-57rm046y author: Flower, Darren R. title: Immunomic Discovery of Adjuvants, Delivery Systems, and Candidate Subunit Vaccines: A Brief Introduction date: 2012-09-28 words: 4996 flesch: 41 summary: A principal reason is that there are no effective vaccines for either malaria or HIV, two of the WHO's big three diseases; nor is there expectation that such vaccines will appear in the near future, irrespective of the optimism of those working in the area. Such vaccines may offer low-cost, temperaturestable products suitable for pulmonary delivery, with the added advantage that the pulmonary route avoids the use of needles (and their associated risks). keywords: adjuvants; antigens; chap; delivery; development; discovery; diseases; liposomes; systems; vaccines; vaccinology cache: cord-017841-57rm046y.txt plain text: cord-017841-57rm046y.txt item: #60 of 299 id: cord-018018-2yyv8vuy author: Rybicki, Ed title: History and Promise of Plant-Made Vaccines for Animals date: 2018-07-04 words: 9139 flesch: 16 summary: The early historical account of molecular farming for veterinary vaccines given above gives an idea of the array of technologies available and used up to the mid-2000s: transgenic and transplastomic expression of subunit proteins; recombinant plant viruses either used to express whole vaccine candidate genes, or to display chosen peptides fused to their capsid proteins; fusion of vaccine protein genes to carrier proteins to improve immunogenicity, including by inherent adjuvant properties; candidate parenteral and oral vaccines to both viruses and bacteria; therapeutics for animals made in plants; use of plant cell cultures to make antigens. The case for plant-made veterinary immunotherapeutics Protein body induction: a new tool to produce and recover recombinant proteins in plants Optimizing the yield of recombinant pharmaceutical proteins in plants New viral vector for superproduction of epitopes of vaccine proteins in plants Expression of an animal virus antigenic site on the surface of a plant virus particle Expression of Human papillomavirus type 16 major capsid protein in transgenic Nicotiana tabacum cv Optimization of BY-2 cell suspension culture medium for the production of a human antibody using a combination of fractional factorial designs and the response surface method Orally fed seeds producing designer IgAs protect weaned piglets against enterotoxigenic Escherichia coli infection Oral immunogenicity of human papillomavirus-like particles expressed in potato Expression of Bacillus anthracis protective antigen in transgenic chloroplasts of tobacco, a non-food/feed crop Induction of a protective antibody response to foot and mouth disease virus in mice following oral or parenteral immunization with alfalfa transgenic plants expressing the viral structural protein VP1 Protection of mice against challenge with foot and mouth disease virus (FMDV) by immunization with foliar extracts from plants infected with recombinant tobacco mosaic virus expressing the FMDV structural protein VP1 Protective lactogenic immunity conferred by an edible peptide vaccine to bovine rotavirus produced in transgenic plants One-Health: a safe, efficient, dual-use vaccine for humans and animals against middle east respiratory syndrome coronavirus and rabies virus Induction of protective immunity in swine by recombinant bamboo mosaic virus expressing foot-and-mouth disease virus epitopes Expression of the fusion glycoprotein of Newcastle disease virus in transgenic rice and its immunogenicity in mice A plant-based multicomponent vaccine protects mice from enteric diseases Expression in plants and immunogenicity of plant virus-based experimental rabies vaccine Development of a candidate vaccine for Newcastle disease virus by epitope display in the Cucumber mosaic virus capsid protein keywords: animal; benthamiana; candidate; cell; challenge; development; disease; et al; expression; group; human; mice; plant; production; protein; recombinant; tobacco; transgenic; use; vaccines; virus cache: cord-018018-2yyv8vuy.txt plain text: cord-018018-2yyv8vuy.txt item: #61 of 299 id: cord-018040-k0h5ejjt author: Ilyinskii, P. title: Aspects of Microparticle Utilization for Potentiation of Novel Vaccines: Promises and Risks date: 2009 words: 6938 flesch: 39 summary: In: Levine Virus-like particles: passport to immune recognition Virus-like particles-universal molecular toolboxes Hepatitis B vaccine Improved design and intranasal delivery of an M2e-based human influenza A vaccine Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: followup from a randomised control trial Recent Developments in Vaccine Delivery Systems Immunostimulating Reconstituted Influenza Virosomes Proteosome TM Technology for Vaccines and Adjuvants Protollin: a novel adjuvant for intranasal vaccines MF59 Adjuvant Emulsion The perfect mix: recent progress in adjuvant research Vaccine adjuvants revisited A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM vaccines and conventional vaccines Adjuvant potential of aggregateforming polyglutamine domains Different Interactions between Isomeric Tetrakis-(N-Hexadecylpyridiniumyl) Porphyrins and CdS Nanoparticles Targeting dendritic cells with biomaterials: developing the next generation of vaccines Microparticle-based technologies for vaccines Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: formulation of a model vaccine for respiratory syncytial virus Exploiting lymphatic transport and complement activation in nanoparticle vaccines A practical approach to the use of nanoparticles for vaccine delivery Guard against Gardasil Who's afraid of Gardasil? These biodegradable, biocompatible polymers have been approved for use in humans (e.g., as sutures, bone implants, screws and implants for sustained drug delivery) and have been extensively studied for use in the formulation of vaccine antigens. keywords: adjuvant; antigen; cells; delivery; hiv; influenza; nanoparticles; particles; response; use; vaccination; vaccine; virus cache: cord-018040-k0h5ejjt.txt plain text: cord-018040-k0h5ejjt.txt item: #62 of 299 id: cord-018165-afzjx2ci author: Modrow, Susanne title: Vaccines date: 2013-08-12 words: 4014 flesch: 40 summary: It is being attempted to modify well-explored, less pathogenic viruses (e.g. adenoviruses) and vaccine viruses that were used successfully in the past (usually vaccinia viruses) by using genetic engineering methods in such a way that they encode proteins of other viral species, in addition to their own gene products necessary for infection and replication (▶ Sects. Positive marker vaccines are vaccine viruses that are characterized by a unique marker (nucleic acid sequence). keywords: immune; infection; vaccines; virus; viruses cache: cord-018165-afzjx2ci.txt plain text: cord-018165-afzjx2ci.txt item: #63 of 299 id: cord-018265-twp33bb6 author: Becker, Pablo D. title: Community-acquired pneumonia: paving the way towards new vaccination concepts date: 2007 words: 14131 flesch: 32 summary: Furthermore, DNA coding for vaccine antigens appears to induce excellent immunological memory, which can be reawakened by later immunization or exposure to the pathogen. An epidermal DNA-based influenza vaccine, which contained the HA gene from A/Panama/2007/99 delivered by particle-mediated epidermal delivery was also tested in humans by PowderJect keywords: antibodies; antigens; cell; children; delivery; development; disease; dna; efficacy; immunity; immunization; infection; influenza; mucosal; pneumococcal; pneumoniae; protection; protein; recombinant; responses; rsv; sars; studies; vaccination; vaccine; virus cache: cord-018265-twp33bb6.txt plain text: cord-018265-twp33bb6.txt item: #64 of 299 id: cord-018497-oy7hsrpt author: Beutels, Philippe P.A. title: Economic aspects of vaccines and vaccination: a global perspective date: 2005 words: 6373 flesch: 43 summary: The conquest of smallpox An interpretation of the modern rise of population in Europe Economic evaluation of vaccination programmes in humans: a methodological exploration with applications to hepatitis B, varicella-zoster, measles, pertussis, hepatitis A and pneumococcal vaccination Economic epidemiology and infectious disease Infectious diseases of humans -dynamics and control Increase in congenital rubella occurrence after immunisation in Greece: retrospective survey and systematic review Economics of eradication vs control of infectious diseases Lecture at the advanced course in vaccinology, International Vaccine Institute Assessing the economic impact of communicable disease outbreaks: the case of SARS Globalization and Disease: The Case of SARS Methods for the economic evaluation of health care programmes The cost of integrating hepatitis B virus vaccine into national immunization programmes: a case study from Addis Ababa Cost-effectiveness of hepatitis B vaccine in The Gambia Providing health care. This principle also applies to the provision of health care. keywords: analysis; benefits; care; costs; countries; effectiveness; health; life; program; time; vaccination; vaccines cache: cord-018497-oy7hsrpt.txt plain text: cord-018497-oy7hsrpt.txt item: #65 of 299 id: cord-018677-gmitz3gg author: Clemens, John D. title: Sequential stages of clinical trials and overview of issues to be considered date: 2005 words: 6434 flesch: 32 summary: The promulgation of GCP has had several implications for vaccine trials in developing countries. Indeed, a common tactic in older Phase III vaccine trials was to evaluate adverse events only in a small subsample of the total trial population, obviating the possibility of detecting rare but potentially significant side-effects. keywords: countries; iii; licensure; phase; protection; safety; studies; subjects; target; trials; vaccine cache: cord-018677-gmitz3gg.txt plain text: cord-018677-gmitz3gg.txt item: #66 of 299 id: cord-018811-zhwr3h07 author: Oxford, John title: Influenza Vaccines Have a Short but Illustrious History of Dedicated Science Enabling the Rapid Global Production of A/Swine (H1N1) Vaccine in the Current Pandemic date: 2010-06-18 words: 13262 flesch: 44 summary: Immunogenicity and original antigenic sin in humans The specificity of the antihaemagluttinin antibody response induced in man by inactivated vaccines and by natural infection Strain specificity of serum antibody to the haemagglutinin of influenza A (H3N2) viruses in children following immunisation or natural infection Immunisation with influenza virus a vaccines: comparison of intradermal and subcutaneous routes Immunisation with Asian strain influenza vaccineequivalence of the subcutaneous and intradermal routes Effect of dosage and route of inoculation upon antigenicity of inactivated influenza virus vaccine (Hong Kong strain) in man Influenza antibody in human respiratory secretions after subcutaneous or respiratory immunisation with inactivated virus Specificity of respiratory secretion antibody against influenza virus Purified influenza vaccine; clinical and serological response to varying doses and different routes of immunisation Antibody in respiratory secretions following immunisation with influenza virus vaccines Humoral and secretory antibody responses to immunisation with low and high dosage split influenza virus vaccines Neurological illness is a recognized sequel to immunization with a variety of vaccines but had not previously been observed with any frequency after influenza virus vaccines. keywords: antibody; children; dose; h1n1; h3n2; infection; influenza; influenza vaccine; influenza virus; new; pandemic; response; strain; swine; vaccine; virus; virus vaccine; viruses; volunteers; years cache: cord-018811-zhwr3h07.txt plain text: cord-018811-zhwr3h07.txt item: #67 of 299 id: cord-018969-0zrnfaad author: Giese, Matthias title: Types of Recombinant Vaccines date: 2015-09-24 words: 14241 flesch: 44 summary: Vaccine proteins made by the host are natural proteins and contain important posttranslational modifi cations such as the correct glycosylation. By covalent linkage of PRP with T cell dependent protein antigens, a conjugated vaccine was created to overcome the T cell independent characteristics of PRP. keywords: antigen; bacteria; bees; cells; control; dna; expression; feeding; fig; gas; host; immune; infection; mucosal; nov; plague; plasmid; protective; protein; response; shigella; specifi; studies; system; tick; vaccination; vaccine; varroa; virus; viruses; vlps cache: cord-018969-0zrnfaad.txt plain text: cord-018969-0zrnfaad.txt item: #68 of 299 id: cord-021637-f5wwn45z author: Douglas, R. Gordon title: The Vaccine Industry date: 2017-07-17 words: 6460 flesch: 38 summary: A key strategic document that guides the stakeholders in vaccine development is the target product profile (TPP). The first stage of vaccine development involves acceptance of a candidate from a basic research laboratory and development of a small-scale process and formulation to make material for Phase I study, analytical release assays, preclinical toxicology, immunological assays to evaluate clinical responses, an investigational new drug (IND) filing, and well-designed Phase I/IIa studies. keywords: companies; countries; development; industry; manufacturing; market; phase; process; product; r&d; research; studies; vaccine; world cache: cord-021637-f5wwn45z.txt plain text: cord-021637-f5wwn45z.txt item: #69 of 299 id: cord-021937-p9vqpazu author: Tsai, Theodore F. title: Immunization in the Asia-Pacific Region date: 2017-07-17 words: 9483 flesch: 25 summary: In China, vaccine recommendations are made through the National Centers for Disease Control based on recommendations of the Chinese Expert Committee on EPI under the Ministry of Health and Family Welfare; however, provincial or local Centers for Disease Control may issue independent recommendations for specific vaccines or modify the national recommendation for routine vaccines (see Tables 75.1 key: cord-021937-p9vqpazu authors: Tsai, Theodore F.; Rao, Raman D.S.V.; Xu, Zhi Yi title: Immunization in the Asia-Pacific Region date: 2017-07-17 journal: Plotkin's Vaccines DOI: 10.1016/b978-0-323-35761-6.00075-4 sha: doc_id: 21937 cord_uid: p9vqpazu nan and inactivated Vero cell-derived JE vaccines from China, Japan, and Korea, regionally; live attenuated hepatitis A vaccine from China, regionally; live attenuated and inactivated pandemic and seasonal influenza vaccines from India and China, internationally; and oral cholera vaccine from Vietnam, internationally). keywords: asia; cases; china; control; countries; development; disease; health; immunization; india; japan; manufacturers; national; new; public; region; vaccination; vaccine; virus; years cache: cord-021937-p9vqpazu.txt plain text: cord-021937-p9vqpazu.txt item: #70 of 299 id: cord-021966-5m21bsrw author: Shaw, Alan R. title: Vaccines date: 2009-05-15 words: 21179 flesch: 27 summary: 67 n NeW ANTIGeN dISCOVeRy MeThOdS n Historically, vaccine antigens were not discovered in the literal sense. The history of vaccine development is rich with immunologic insights that emerged from careful observations of how diseases spread in populations and how such spread differs in disease-naïve and experienced populations, as well as of how innovative experimental approaches revealed fundamental aspects of immune system function. keywords: adjuvant; antibody; antigens; cell; development; disease; dna; efforts; gene; hiv; host; human; immunity; immunization; individuals; infection; live; number; pathogen; protection; protein; responses; rotavirus; safety; studies; use; vaccination; vaccine; vaccine development; vectors; virus cache: cord-021966-5m21bsrw.txt plain text: cord-021966-5m21bsrw.txt item: #71 of 299 id: cord-022039-y0l943xg author: Gruber, Marion F. title: Regulation and Testing of Vaccines date: 2017-07-17 words: 14886 flesch: 29 summary: Characterization of cell substrates should address certain general issues that might affect the safety and purity of vaccine products. The Vaccine Safety Datalink uses electronic health data from participating sites and conducts vaccine safety studies based on questions or concerns raised from the medical literature and VAERS reports. keywords: act; cber; data; development; disease; drug; efficacy; fda; guidance; health; human; industry; information; licensure; process; product; review; safety; studies; trials; use; vaccines cache: cord-022039-y0l943xg.txt plain text: cord-022039-y0l943xg.txt item: #72 of 299 id: cord-022168-qautse9a author: Liu, Li title: Clinical Use of DNA Vaccines date: 2017-07-25 words: 7126 flesch: 34 summary: Additional insight gained from the success of DNA vaccines in veterinary practice is that the DNA scaling-up might not be a potential hindrance for DNA vaccine being effective in humans. intradermal (i.d.) administration (VRC 011) HIV DNA Vaccine: stepwise improvements make a difference DNA vaccines: developing new strategies against cancer The end or the beginning of the drive to an HIV-preventive vaccine: a view from over 20 years Adjuvanting a DNA vaccine with a TLR9 ligand plus Flt3 ligand results in enhanced cellular immunity against the simian immunodeficiency virus DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials Targeting plasmid-encoded proteins to the antigen presentation pathways Therapeutic HPV DNA vaccines DNA vaccines: an historical perspective and view to the future Prospects for control of emerging infectious diseases with plasmid DNA vaccines HIV therapeutic vaccines: moving towards a functional cure Clinical development of a cytomegalovirus DNA vaccine: from product concept to pivotal phase 3 trial Xenogeneic human p53 DNA vaccination by electroporation breaks immune tolerance to control murine tumors expressing mouse p53 Genetic immunization is a simple method for eliciting an immune response Using plasmids as DNA vaccines for infectious diseases Induction of broadly neutralizing H1N1 influenza antibodies by vaccination Direct gene transfer into mouse muscle in vivo DNA vaccine for cancer immunotherapy ▶ Gene Delivery by Electroporation In Vitro: Mechanisms keywords: antigen; cancer; cells; delivery; dna; immunogenicity; influenza; plasmid; proteins; responses; tumor; vaccine cache: cord-022168-qautse9a.txt plain text: cord-022168-qautse9a.txt item: #73 of 299 id: cord-022349-z8w1wkm8 author: Beeler, Judy A. title: Human and Animal Viruses date: 2007-09-02 words: 4589 flesch: 43 summary: Viruses held to a low number of passages in animals or cell cultures represent a viral population that is similar to that found in nature, and freezing these pools guards against genetic mutations that occur during subsequent passage. The classification of viruses is based on morphological and physiochemical properties. keywords: cell; culture; drying; freeze; freezing; seed; vaccines; virus; viruses cache: cord-022349-z8w1wkm8.txt plain text: cord-022349-z8w1wkm8.txt item: #74 of 299 id: cord-023853-y5g4ceq9 author: Affolder, Rebecca title: Global Immunization Challenge: Progress and Opportunities date: 2009-05-18 words: 7961 flesch: 40 summary: AMCs speed the development of new vaccines by enabling biotech and pharmaceutical companies to successfully invest in vaccine development (IAVI 2005) . A gap in the routine immunization schedules for children in developed and developing countries emerged as new vaccines, including those for hepatitis B, Haemophilus influenzae b (Hib), varicella, pneumococcal, meningococcal, and combination formulations became a routine part of the immunization schedule for children and adolescents in high-income countries (Hardon and Blume 2005) . keywords: access; alliance; children; countries; debt; development; disease; finance; financing; gavi; health; immunization; market; new; vaccines; world cache: cord-023853-y5g4ceq9.txt plain text: cord-023853-y5g4ceq9.txt item: #75 of 299 id: cord-025366-haf542y0 author: Offit, Paul A. title: Vaccine safety date: 2012-11-07 words: 16638 flesch: 42 summary: 51 Because rare reactions, reactions with delayed onset, or reactions in subpopulations may not be detected before vaccines are licensed, postlicensure evaluation of vaccine safety is critical. In contrast with the methodological strengths of prelicensure randomized trials, however, postlicensure observational studies of vaccine safety pose a formidable set of methodological difficulties. keywords: care; cause; cells; children; data; disease; events; following; health; immunization; influenza; information; monitoring; number; parents; people; risk; safety; studies; study; vaccination; vaccine; vaccine safety; vaers cache: cord-025366-haf542y0.txt plain text: cord-025366-haf542y0.txt item: #76 of 299 id: cord-027654-k0uby99n author: Nabel, Gary J. title: The development of gene-based vectors for immunization date: 2020-06-22 words: 6555 flesch: 27 summary: The AIDS Vaccine Clinical Trials Network Potential improvement for poxvirus-based immunizations vehicles Multienvelope HIV vaccine safety and immunogenicity in small animals and chimpanzees Containment of simian immunodefi ciency virus infection in vaccinated macaques: correlation with the magnitude of virus-specifi c pre-and postchallenge CD4+ and CD8+ T cell responses Largescale production and purifi cation of a vaccinia recombinant-derived HIV-1 gp160 and analysis of its immunogenicity Removal of cryptic poxvirus transcription termination signals from the human immunodefi ciency virus type 1 envelope gene enhances expression and immunogenicity of a recombinant vaccinia virus Recombinant virus vaccine-induced SIV-specifi c CD8+ cytotoxic T lymphocytes Immunization with a modifi ed vaccinia virus expressing simian immunodefi ciency virus (SIV) Gag-Pol primes for an anamnestic Gag-specifi c cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge Reduction of simian-human immunodefi ciency virus 89.6P viremia in rhesus monkeys by recombinant modifi ed vaccinia virus Ankara vaccination Enhanced simian immunodefi ciency virusspecifi c immune responses in macaques induced by priming with recombinant Semliki Forest virus and boosting with modifi ed vaccinia virus Ankara Effect of vaccination with recombinant modifi ed vaccinia virus Ankara expressing structural and regulatory genes of SIV(macJ5) on the kinetics of SIV replication in cynomolgus monkeys Induction of simian immunodefi ciency virus (SIV)-specifi c CTL in rhesus macaques by vaccination with modifi ed vaccinia virus Ankara expressing SIV transgenes: infl uence of preexisting anti-vector immunity Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model Immunogenicity and protective effi cacy of a human immunodefi ciency virus type 2 recombinant canarypox (ALVAC) vaccine candidate in cynomolgus monkeys Mature dendritic cells infected with canarypox virus elicit strong anti-human immunodefi ciency virus CD8+ and CD4+ T-cell responses from chronically infected individuals Potentiation of simian immunodefi ciency virus (SIV)-specifi c CD4(+) and CD8(+) T cell responses by a DNA-SIV and NYVAC-SIV prime/boost regimen Cross-protection against mucosal simian immunodefi ciency virus (SIVsm) challenge in human immunodefi ciency virus type 2-vaccinated cynomolgus monkeys Induction of cytotoxic T lymphocytes by recombinant canarypox (ALVAC) and attenuated vaccinia (NYVAC) viruses expressing the HIV-1 envelope glycoprotein Memory cytotoxic T lymphocyte responses in human immunodefi ciency virus type 1 (HIV-1)-negative volunteers immunized with a recombinant canarypox expressing gp 160 of HIV-1 and boosted with a recombinant gp160 Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers Induction of neutralizing antibodies and gag-specifi c cellular immune responses to an R5 primary isolate of human immunodefi ciency virus type 1 in rhesus macaques ALVAC-SIVgag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodefi ciency virus SIVmacinduced immunodefi ciency AAV vectors: is clinical success on the horizon? Venezuelan equine encephalitis virus vectors expressing HIV-1 proteins: vector design strategies for improved vaccine effi cacy Vaccination of macaques against pathogenic simian immunodefi ciency virus with Venezuelan equine encephalitis virus replicon particles Sindbis virus vectors for expression in animal cells Evaluation of recombinant alphaviruses as vectors in gene therapy Replication-defective viruses as vaccines and vaccine vectors An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective effi cacy Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses Priming with plasmid DNAs expressing interleukin-12 and simian immunodefi ciency virus gag enhances the immunogenicity and effi cacy of an experimental AIDS vaccine based on recombinant vesicular stomatitis virus A single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector A live, attenuated recombinant West Nile virus vaccine A single intranasal inoculation with a paramyxovirusvectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge Vaccine cell substrates Cell line issues: historical and future perspectives Points to Consider in the Characterization of Cell Lines Used to Produce Biologicals. In contrast, the gene-based delivery of vaccine vectors can stimulate both humoral and cellular immunity, thus providing greater selective pressure on infectious agents in vaccines. keywords: adenovirus; cell; development; dna; gene; human; immunity; immunodefi; immunogenicity; recombinant; responses; vaccine; vaccinia; vectors; virus cache: cord-027654-k0uby99n.txt plain text: cord-027654-k0uby99n.txt item: #77 of 299 id: cord-032017-h0cj4izx author: Roach, E. Steve title: Child Neglect by Any Other Name date: 2020-09-17 words: 2286 flesch: 50 summary: In 1800, when things were certainly very natural, only 57% of children survived to age five. In recent years, over 95% of children survive to age five years. keywords: child; children; parents; risk; vaccine cache: cord-032017-h0cj4izx.txt plain text: cord-032017-h0cj4izx.txt item: #78 of 299 id: cord-032600-lldbjm77 author: Soni, Dheeraj title: The sixth revolution in pediatric vaccinology: immunoengineering and delivery systems date: 2020-09-14 words: 6668 flesch: 25 summary: 5 Specifically, vaccine delivery systems can now be engineered to mimic the size, shape, and surface chemistry of pathogens, 7 which are often referred to as pathogen-like particles. Recent advances in the nascent field of immunoengineering may allow for the design of vaccine delivery systems that can potentially accelerate the development of novel and effective early life vaccination strategies. keywords: adjuvant; alum; antigen; cell; delivery; formulations; immune; immunity; immunoengineering; infants; nanoparticles; responses; systems; vaccination; vaccine; vaccinology cache: cord-032600-lldbjm77.txt plain text: cord-032600-lldbjm77.txt item: #79 of 299 id: cord-032751-pmclolvh author: Head, Katharine J. title: A National Survey Assessing SARS-CoV-2 Vaccination Intentions: Implications for Future Public Health Communication Efforts date: 2020-09-23 words: 5100 flesch: 38 summary: Of note for communication scholars, these findings suggest that social normative messaging could capitalize on the high level of vaccine intention. Importantly, because vaccine intent and/or need may be different for people who were previously infected with SARS-CoV-2 and perceived threat variables (discussed below) are usually only measured for future threats, only participants who answered no to the question do you believe that you've had COVID-19 are included in the current study (n = 3,159). keywords: covid-19; health; intentions; participants; ref; sars; vaccination; vaccine; variables cache: cord-032751-pmclolvh.txt plain text: cord-032751-pmclolvh.txt item: #80 of 299 id: cord-035016-ipv8npdy author: Torreele, Els title: Business-as-Usual will not Deliver the COVID-19 Vaccines We Need date: 2020-11-09 words: 5575 flesch: 31 summary: The ‘race’ for COVID-19 vaccines is exposing the deficiencies of a business-as-usual medical innovation ecosystem driven by corporate interests, not health outcomes. In April 2020, the World Health Organization (WHO) published a Target Product Profile 4 (TPP) for COVID-19 vaccines with minimal and ideal vaccine characteristics to guide developers. keywords: access; companies; covid-19; efficacy; global; health; public; r&d; technologies; trials; vaccine cache: cord-035016-ipv8npdy.txt plain text: cord-035016-ipv8npdy.txt item: #81 of 299 id: cord-163946-a4vtc7rp author: Awasthi, Raghav title: VacSIM: Learning Effective Strategies for COVID-19 Vaccine Distribution using Reinforcement Learning date: 2020-09-14 words: 4476 flesch: 47 summary: Therefore, we pipelined the ACKTR model with a supervised learning based Contextual Bandits approach where recommendations for vaccine distribution policy were used as training data for the latter. In this paper, we introduce VacSIM, a novel feed-forward reinforcement learning approach for learning effective policy combined with near real-time optimization of vaccine distribution and demonstrate its potential benefit if applied to five States across India. keywords: action; approach; distribution; learning; model; policy; state; vaccine; vacsim cache: cord-163946-a4vtc7rp.txt plain text: cord-163946-a4vtc7rp.txt item: #82 of 299 id: cord-252856-oc0zd11h author: Pagliusi, Sonia title: Quality vaccines for all people(): Report on the 16th annual general meeting of the Developing Countries Vaccine Manufacturers' Network, 05–07th October 2015, Bangkok, Thailand date: 2016-06-30 words: 4471 flesch: 37 summary: Prevention of shortages starts at country level, while PAHO acts regionally to facilitate timely and sufficient supply, and vaccine manufacturers worldwide are essential for assured global supply. The DCVMN 2015 Annual General Meeting gave rich insights into advances in vaccine technologies and development of new vaccines, and provided valuable opportunity for vaccine manufacturers, regulatory authorities and international organisations to have face-to-face interactions. keywords: countries; dcvmn; development; gavi; global; health; immunisation; international; manufacturers; phase; supply; vaccine; world cache: cord-252856-oc0zd11h.txt plain text: cord-252856-oc0zd11h.txt item: #83 of 299 id: cord-254469-7q6xi2xx author: Wang, Fuzhou title: An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development date: 2020-05-05 words: 4743 flesch: 40 summary: Therefore, further in-depth studies are needed to elucidate the structure and corresponding physiological and immunological properties of the S protein and also other structural proteins that have a potential role in vaccine development, including mRNA based vaccines. The spike glycoprotein (S protein) is now a key target for vaccine development, therapeutic antibody generation, and the clinical diagnosis of COVID-19. keywords: ace2; coronavirus; cov-2; covid-19; development; mrna; protein; s protein; sars; vaccine; virus cache: cord-254469-7q6xi2xx.txt plain text: cord-254469-7q6xi2xx.txt item: #84 of 299 id: cord-254513-7d10vd86 author: Phillips, B. C. title: Echo chambers as early warning signals of widespread vaccine refusal in social-epidemiological networks date: 2020-10-20 words: 6217 flesch: 48 summary: The connection between social network activ- 5 ity and health issues in populations has long been exploited by researchers [3] , especially relating to disease spread [4] , with the assertion that firm understanding of social network structure is important to the implementation of effective change is driven primarily by exposure to news sources and contrasting views from neighbours, communities can support the reinforcement of sentiments already held [17] . A measure of polarization on social media networks based on community boundaries On modularity of social network communities: The spectral characterization ACM International Conference on Web Intelligence and Intelligent Agent Technology Clustering coefficients for correlation networks Epidemic dynamics on complex net-550 works The small world yields the most effective information spreading The wisdom of partisan crowds Network dynamics of social influence in the wisdom of crowds Condensed-Matter Physics Theory of early warning signals of disease emergence and leading indicators of elimination Anticipating the emergence of infectious diseases Spatial early warning signals of social 570 and epidemiological tipping points in a coupled behaviour-disease network keywords: echo; ews; fig; license; network; opinion; preprint; social; vaccine cache: cord-254513-7d10vd86.txt plain text: cord-254513-7d10vd86.txt item: #85 of 299 id: cord-254890-4ynsgu6c author: Heldens, J.G.M. title: Veterinary vaccine development from an industrial perspective date: 2008-03-03 words: 9220 flesch: 32 summary: The gathering of all the required information and test results on the vaccine (vaccine development) is usually organised in structured and well phased manner. Later, vaccine development took advantage of new studies of the molecular basis of bacterial pathogenesis. keywords: adjuvants; animals; antigen; cell; development; disease; eec; et al; immunity; infection; manufacturing; parasite; production; quality; systems; use; vaccination; vaccine; veterinary; virus cache: cord-254890-4ynsgu6c.txt plain text: cord-254890-4ynsgu6c.txt item: #86 of 299 id: cord-255549-i2o6rs29 author: Pagliusi, Sonia title: Vaccines: Shaping global health() date: 2017-03-14 words: 4361 flesch: 37 summary: M-P. Kieny reviewed evolving collaborative innovation in vaccine development. Access to funding for vaccine development is also getting increasingly difficult as it takes about 6 years for a vaccine to reach the market, and most investors prefer faster and higher returns. keywords: access; countries; dcvmn; development; health; ipv; manufacturers; market; national; paho; polio; supply; vaccine cache: cord-255549-i2o6rs29.txt plain text: cord-255549-i2o6rs29.txt item: #87 of 299 id: cord-255734-038xu4hq author: Taylor, Deborah R. title: Obstacles and advances in SARS vaccine development date: 2006-02-13 words: 5338 flesch: 42 summary: A novel coronavirus associated with severe acute respiratory syndrome SARS-beginning to understand a new virus Severe acute respiratory syndrome coronavirus phylogeny: toward consensus Identification of a new human coronavirus Coronaviridae: the viruses and their replication Lung pathology of fatal severe acute respiratory syndrome SARS coronavirus-infected cells in lung detected by new in situ hybridization technique Expression of lymphocytes and lymphocyte subsets in patients with severe acute respiratory syndrome Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome Significant changes of peripheral T lymphocyte subsets in patients with severe acute respiratory syndrome SARS-related virus predating SARS outbreak Dissection study on the severe acute respiratory syndrome 3C-like protease reveals the critical role of the extra domain in dimerization of the enzyme: defining the extra domain as a new target for design of highly specific protease inhibitors SARS in newborns and children Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China Role of China in the quest to define and control severe acute respiratory syndrome Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice Mice susceptible to SARS coronavirus Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity Mechanisms of host defense following severe acute respiratory syndromecoronavirus (SARS-CoV) pulmonary infection of mice Resolution of primary severe acute respiratory syndrome-associated coronavirus infection requires Stat1 Virology: SARS virus infection of cats and ferrets Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS Koch's postulates fulfilled for SARS virus Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome Macaque model for severe acute respiratory syndrome Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys Protection of chickens after live and inactivated virus vaccination against challenge with nephropathologenic infectious bronchitis virus Safety and efficacy of a modified-live canine coronavirus vaccine in dogs Antibody-mediated enhancement of disease in feline infectious peritonitis: comparisons with dengue hemorrhagic fever Inactivated hepatitis A vaccine: active and passive immunoprophylaxis in chimpanzees Live attenuated varicella vaccine Highly infectious SARS-CoV pseudotyped virus reveals the cell tropism and its correlation with receptor expression Genetically engineered vaccines: an overview Developing new smallpox vaccines Current status and future trends in vaccine regulation-USA SARS-associated coronavirus quasispecies in individual patients SARS associated coronavirus has a recombinant polymerase and coronaviruses have a history of host-shifting Mosaic evolution of the severe acute respiratory syndrome coronavirus Antibody-dependent enhancement of virus infection and disease The role of IgG subclass of mouse monoclonal antibodies in antibody-dependent enhancement of feline infectious peritonitis virus infection of feline macrophages Localization of antigenic sites of the S glycoprotein of feline infectious peritonitis virus involved in neutralization and antibody-dependent enhancement Antibody-dependent enhancement of feline infectious peritonitis virus infection in feline alveolar macrophages and human monocyte cell line U937 by serum of cats experimentally or naturally infected with feline coronavirus Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus Identification of an antigenie determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies Synthesis and characterization of a native, oligomeric form of recombinant severe acute respiratory syndrome coronavirus spike glycoprotein Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV Subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice Immune responses in Balb/c mice induced by a candidate SARS-CoV inactivated vaccine prepared from F69 strain Assembly of human severe acute respiratory syndrome coronavirus-like particles Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets Effects of a SARS-associated coronavirus vaccine in monkeys Retroviral vectors pseudotyped with severe acute respiratory syndrome coronavirus S protein Induction of SARS-nucleoprotein-specific immune response by use of DNA vaccine DNA vaccine of SARS-CoV S gene induces antibody response in mice A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice Characterization of humoral responses in mice immunized with plasmid DNAs encoding SARS-CoV spike gene fragments Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus SARS CTL vaccine candidates; HLA supertype-, genome-wide scanning and biochemical validation Kanta Subbarao, Edward Tabor, Miriam Darnell, Robin Levis and Hira Nakhasi are gratefully acknowledged for comments on the manuscript. [12] noted that a rapid decline of T-cell subsets in the periphery was observed in patients during the acute phase of SARS infection, but they observed restoration of T cells during recovery. keywords: animal; coronavirus; cov; disease; infection; mice; protein; sars; syndrome; vaccine; virus cache: cord-255734-038xu4hq.txt plain text: cord-255734-038xu4hq.txt item: #88 of 299 id: cord-257027-q2y7fewk author: Lemaire, D. title: Coping with genetic diversity: the contribution of pathogen and human genomics to modern vaccinology date: 2011-10-28 words: 5852 flesch: 24 summary: A 2020 vision for vaccines against HIV, tuberculosis and malaria The Genomes On Line Database (GOLD) in 2009: status of genomic and metagenomic projects and their associated metadata Genome-based vaccines The top five game changers in vaccinology: toward rational and directed vaccine development Whole-genome random sequencing and assembly of Haemophilus influenzae Rd Reverse vaccinology and genomics Comparative analysis of epitope predictions: proposed library of putative vaccine candidates for HIV Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing Epidemiological profile of meningococcal disease in the United States A universal vaccine for serogroup B meningococcus Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates Vaccinology in the genome era HLA supertype-, genome-wide scanning and biochemical validation Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants Utility of the Trypanosoma cruzi sequence database for identification of potential vaccine candidates by in silico and in vitro screening Genome-wide variation and identification of vaccine targets in the Plasmodium falciparum genome Vaccine-induced immunity circumvented by typical Mycobacterium tuberculosis Beijing strains Variation in protection by BCG: implications of and for heterologous immunity Identification of a universal Group B streptococcus vaccine by multiple genome screen The use of genomics in microbial vaccine development Evidence that pneumococcal serotype replacement in Massachusetts following conjugate vaccination is now complete Human genetics of infectious diseases: a unified theory Genome-wide association studies and infectious disease Functional gene discovery using RNA interference-based genomic screens to combat pathogen infection Genetic localization of a locus controlling the intensity of infection by Schistosoma mansoni on chromosome 5q31-q33 Severe hepatic fibrosis in Schistosoma mansoni infection is controlled by a major locus that is closely linked to the interferon-gamma receptor gene An autosomal dominant major gene confers predisposition to pulmonary tuberculosis in adults Genetic susceptibility to tuberculosis in Africans: a genome-wide scan A major susceptibility locus for leprosy in India maps to chromosome 10p13 Chromosome 6q25 is linked to susceptibility to leprosy in a Vietnamese population A major susceptibility locus on chromosome 22q12 plays a critical role in the control of kala-azar Innate immunity genes as candidate genes: searching for relevant natural polymorphisms in databases and assessing family-based association of polymorphisms with human diseases Genetic determination and linkage mapping of Plasmodium falciparum malaria related traits in Senegal Linkage of mild malaria to the major histocompatibility complex in families living in Burkina Faso Genome-wide and fine-resolution association analysis of malaria in West Africa Analysis of the 5q31-q33 locus shows an association between IL13-1055C/T IL-13-591A/G polymorphisms and Schistosoma haematobium infections TNF as a malaria candidate gene: polymorphism-screening and family-based association analysis of mild malaria attack and parasitemia in Burkina Faso Association analyses of NCR3 polymorphisms with P. falciparum mild malaria Susceptibility to leprosy is associated with PARK2 and PACRG A whole-genome association study of major determinants for host control of HIV-1 A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C Genetic variation in IL28B and spontaneous clearance of hepatitis C virus Heterogeneity in vaccine immune response: the role of immunogenetics and the emerging field of vaccinomics Differential genetic determination of immune responsiveness to hepatitis B surface antigen and to hepatitis A virus: a vaccination study in twins Genetic regulation of immune responses to vaccines in early life Host genetic factors and vaccine-induced immunity to hepatitis B virus infection The evolutionary genomics of pathogen recombination Vaccine immunogenetics: bedside to bench to population The lower susceptibility to Plasmodium falciparum malaria of Fulani of Burkina Faso (west Africa) is associated with low frequencies of classic malaria-resistance genes Measles antibody seroprevalence rates among immunized Inuit, Innu and Caucasian subjects BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies Reemergence of invasive Haemophilus influenzae type b disease in a well-vaccinated population in remote Alaska Adversomics: the emerging field of vaccine adverse event immunogenetics A framework for variation discovery and genotyping using next-generation DNA sequencing data A tutorial on statistical methods for population association studies How malaria has affected the human genome and what human genetics can teach us about malaria Prioritizing genes for pathway impact using network analysis Ectopic kidney with varied vasculature: demonstrated by CT angiography The influence of host and bacterial genotype on the development of disseminated disease with Mycobacterium tuberculosis Interactome networks and human disease Gene expression analysis reveals early changes in several molecular pathways in cerebral malaria-susceptible mice versus cerebral malaria-resistant mice Gene-expression profiling discriminates between cerebral malaria (CM)-susceptible mice and CM-resistant mice Assessing the human immune system through blood transcriptomics Transcriptional profiling of mycobacterial antigen-induced responses in infants vaccinated with BCG at birth Curating the innate immunity interactome Systems biology approaches to new vaccine development Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans Systems biology of vaccination for seasonal influenza in humans The heritability of vaccine responses is generally high (44) , reaching 89% for the antibody response against measles vaccine (16) . keywords: antigens; approaches; association; candidate; development; diseases; genes; genome; malaria; pathogen; response; vaccine cache: cord-257027-q2y7fewk.txt plain text: cord-257027-q2y7fewk.txt item: #89 of 299 id: cord-257533-i85dyg8n author: Henn, Wolfram title: Allocation criteria for an initial shortage of a future SARS-CoV-2 vaccine and necessary measures for global immunity date: 2020-06-23 words: 1071 flesch: 30 summary: but anyway relevant-initial shortage of vaccine supply without creating social discomfort or even unrest. After having overcome the expected initial shortage of vaccines, the global community must take appropriate measures to rapidly generate a worldwide herd immunity against SARS-CoV-2 through implementing mandatory vaccination programs encompassing all countries and age groups. keywords: covid-19; sars; shortage; vaccine cache: cord-257533-i85dyg8n.txt plain text: cord-257533-i85dyg8n.txt item: #90 of 299 id: cord-257582-e9306xae author: Day, M. J. title: Recommendations on vaccination for Latin American small animal practitioners: a report of the WSAVA Vaccination Guidelines Group date: 2020-03-30 words: 25495 flesch: 42 summary: Repeatedly on our practice visits, we noted large sign boards above the reception desk in practices that listed individual dog and cat vaccines and their prices. There remains the significant challenge of veterinary vaccines being available directly to owners and breeders out with the veterinary practice. keywords: age; animal; brazil; canine; cats; core; core vaccines; countries; disease; dogs; et al; evidence; feline; felv; guidelines; immune; immunity; infection; latam; non; practice; prevalence; products; puppies; rabies; studies; use; vaccination; vaccines; veterinary; vgg; virus; weeks; wsava cache: cord-257582-e9306xae.txt plain text: cord-257582-e9306xae.txt item: #91 of 299 id: cord-257722-7rmzaau4 author: Rhee, Joon Haeng title: Current and New Approaches for Mucosal Vaccine Delivery date: 2019-10-25 words: 14138 flesch: 26 summary: Recent research into oral vaccine delivery of NPs has been directed toward the incorporation of mucoadhesive polymers. Modifications through quarterization, thiolation, acylation, and grafting resulted in copolymers with higher mucoadhesion strength, increased hydrophobic interactions (advantageous in hydrophobic antigen entrapment), and increased solubility in alkaline pH, higher solubility, and controlled/ extended release profiles, which consequently confer wider application of chitosan derivatives for oral vaccine delivery [140, 141] . keywords: acid; adjuvants; administration; antigens; cationic; cells; chitosan; delivery; immunization; influenza; intranasal; liposomes; microparticles; mucosal; nanogel; nanoparticles; nasal; nps; oral; particles; plga; polymers; protein; responses; surface; systems; vaccination; vaccine; virus cache: cord-257722-7rmzaau4.txt plain text: cord-257722-7rmzaau4.txt item: #92 of 299 id: cord-257899-l866puqk author: Yun, Cheol-Heui title: Nanoparticles to Improve the Efficacy of Vaccines date: 2020-05-02 words: 1846 flesch: 25 summary: With great advancements in the area of material science, a new era of innovative strategies for vaccine design has arrived, enabling the precise delivery of vaccines, the enhanced role of vaccine adjuvants, an increase in the sparing effect, better stabilization, and slow release at the induction site. [11] discussed the possibility of zinc oxide (ZnO)-based nanocomposites as vaccine adjuvants and the application of cancer immunotherapeutics because of their biocompatibility, unique physicochemical properties, cost-effective mass production, intrinsic adjuvant-like properties and immunomodulatory function. keywords: antigen; nanoparticles; nps; responses; vaccines cache: cord-257899-l866puqk.txt plain text: cord-257899-l866puqk.txt item: #93 of 299 id: cord-258353-uw8padla author: Williams, Joshua T.B. title: Caring for the Vaccine Hesitant Family: Evidence-Based Alternatives to Dismissal date: 2020-05-22 words: 2768 flesch: 40 summary: In sum, both parental confidence and physician wellbeing may improve as we work with vaccine hesitant parents via motivational interviewing. As policymakers and public health experts work to address vaccine hesitancy, we believe pediatricians also can play a role in increasing vaccine confidence. keywords: approach; interviewing; parents; physicians; providers; vaccination; vaccine cache: cord-258353-uw8padla.txt plain text: cord-258353-uw8padla.txt item: #94 of 299 id: cord-258624-041cf99j author: Ahmad, Sajjad title: Design of a Novel Multi Epitope-Based Vaccine for Pandemic Coronavirus Disease (COVID-19) by Vaccinomics and Probable Prevention Strategy against Avenging Zoonotics date: 2020-05-23 words: 8231 flesch: 43 summary: The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health — The latest 2019 novel coronavirus outbreak in Wuhan, China Novel Coronavirus (2019-nCoV) Situation Summary | CDC A novel coronavirus outbreak of global health concern ScienceDaily: Your source for the latest research news Database resources of the national center for biotechnology information Exoproteome and secretome derived broad spectrum novel drug and vaccine candidates in Vibrio cholerae targeted by Piper betel derived compounds Combating tigecycline resistant Acinetobacter baumannii: A leap forward towards multi-epitope based vaccine discovery Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes The HMMTOP transmembrane topology prediction server SPAAN: a software program for prediction of adhesins and adhesin-like proteins using neural networks Adhesins as targets for vaccine development The immune epitope database (IEDB): 2018 update Improved method for predicting linear B-cell epitopes BepiPred-2.0: improving sequencebased B-cell epitope prediction using conformational epitopes MHCPred: a server for quantitative prediction of peptide--MHC binding Identification of putative vaccine candidates against Helicobacter pylori exploiting exoproteome and secretome: a reverse vaccinology based approach VirulentPred: a SVM based prediction method for virulent proteins in bacterial pathogens Vaxign: the first web-based vaccine design program for reverse vaccinology and applications for vaccine development AllerTOP-a server for in silico prediction of allergens Multi-epitope vaccines: a promising strategy against tumors and viral infections Peptide vaccine: progress and challenges Development of a multi-epitope peptide vaccine inducing robust T cell responses against brucellosis using immunoinformatics based approaches Exploring dengue genome to construct a multi-epitope based subunit vaccine by utilizing immunoinformatics approach to battle against dengue infection SCRATCH: a protein structure and structural feature prediction server I-TASSER server for protein 3D structure prediction homology modelling of protein structures and complexes others, Galaxy: a platform for interactive large-scale genome analysis GalaxyRefine: protein structure refinement driven by side-chain repacking Disulphide bonds and protein stability Disulfide by Design 2.0: a web-based tool for disulfide engineering in proteins Codon usage: nature's roadmap to expression and folding of proteins JCat: a novel tool to adapt codon usage of a target gene to its potential expression host Novel immunoinformatics approaches to design multi-epitope subunit vaccine for malaria by investigating anopheles salivary protein In-silico design of a multi-epitope vaccine candidate against onchocerciasis and related filarial diseases Computational immunology meets bioinformatics: the use of prediction tools for molecular binding in the simulation of the immune system PATCHDOCK and SymmDock: servers for rigid and symmetric docking FireDock: fast interaction refinement in molecular docking RRDistMaps: a UCSF Chimera tool for viewing and comparing protein distance maps Discovery studio visualizer VMD: visual molecular dynamics A one-pot multicomponent facile synthesis of dihydropyrimidin-2(1: H)-thione derivatives using triphenylgermane as a catalyst and its binding pattern validation Antechamber: an accessory software package for molecular mechanical calculations The FF14SB force field Langevin stabilization of molecular dynamics A fast SHAKE algorithm to solve distance constraint equations for small molecules in molecular dynamics simulations On the Berendsen thermostat CPPTRAJ: software for processing and analysis of molecular dynamics trajectory data UCSF Chimera-Superimposing and Morphing MMPBSA.py: This was significant to evaluate as homology between virus protein (s) to be used in vaccine designing and the host is likely to cause strong autoimmune reactions in the host [58] . keywords: binding; candidates; cell; construct; coronavirus; covid-19; energy; epitopes; glycoprotein; host; human; mepvc; molecular; protein; receptors; score; structure; system; tlr3; tlr4; vaccine cache: cord-258624-041cf99j.txt plain text: cord-258624-041cf99j.txt item: #95 of 299 id: cord-258626-p469ysi8 author: Davis-Wurzler, Gina M. title: 2013 Update on Current Vaccination Strategies in Puppies and Kittens date: 2014-02-26 words: 10941 flesch: 38 summary: Assignment of vaccine products (which are considered biological agents, not drugs, and are therefore assessed and approved under the United States Department of Agriculture [USDA] Animal and Plant Health Inspection Service rather than the Food and Drug Administration) into these categories is based on how the product is created. The goal is to reach the highest level of overall animal health with the minimum number of adverse events, based on scientific and epidemiologic merit. Immunity in the fetus and newborn AAFP Feline Vaccination Advisory Panel report American Animal Hospital Association Canine Vaccination Task Force The defense of the body Cells and their response to antigen AVMA Council on Biologic and Therapeutic Agents' report on cat and dog vaccines Vaccines & vaccinations: guidelines vs. reality Vaccines and vaccinations: the strategic issues Infectious diseases of the dog and cat Vaccines and their production Multicenter case-control study of risk factors associated with development of vaccine-associated sarcomas in cats The use of vaccines Canine viral diseases Canine vaccination Vaccination of puppies born to immune dams with a canine adenovirus-based vaccine protects against a canine distemper virus challenge Vaccination against canine distemper virus infection in infant ferrets with and without maternal antibody protection using recombinant attenuated poxvirus vaccines Quedgeley (Gloucester): British Small Animal Veterinary Association Infectious canine hepatitis and canine acidophil cell hepatitis Infectious diseases of the dog and cat Seroconversion of puppies to canine parvovirus and canine distemper virus: a comparison of two combination vaccines Canine parvovirus (CPV) vaccination: comparison of neutralizing antibody responses in pups after inoculation with CPV2 or CPV2b modified live virus vaccine Evaluation of the efficacy and duration of immunity of a canine combination vaccine against virulent parvovirus, infectious canine hepatitis virus, and distemper virus experimental challenges Duration of serologic response to five viral antigens in dogs National Association of State Public Health Veterinarians. keywords: animal; antibody; canine; cats; disease; feline; infection; kittens; product; puppies; risk; use; vaccination; vaccine; virus; weeks cache: cord-258626-p469ysi8.txt plain text: cord-258626-p469ysi8.txt item: #96 of 299 id: cord-259927-xh9cw9ao author: Papadopoulos, Nikolaos G. title: Promising approaches for the treatment and prevention of viral respiratory illnesses date: 2017-07-21 words: 7351 flesch: 24 summary: A viruses Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies Layer-by-layer nanoparticle vaccines carrying the G protein CX3C motif protect against RSV infection and disease Eleven years of Inflexal V-a virosomal adjuvanted influenza vaccine Human papillomavirus and HPV vaccines: a review AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial M2e-based universal influenza A vaccine Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development Comparison of a novel microcrystalline tyrosine adjuvant with aluminium hydroxide for enhancing vaccination against seasonal influenza Matrix M H5N1 vaccine induces cross-H5 clade humoral immune responses in a randomized clinical trial and provides protection from highly pathogenic influenza challenge in ferrets Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults Chitosan-a versatile semi-synthetic polymer in biomedical applications Genetic immunization is a simple method for eliciting an immune response Development of an intradermal DNA vaccine delivery strategy to achieve single-dose immunity against respiratory syncytial virus Modified mRNA vaccines protect against Zika virus infection DNA and RNA-based vaccines: principles, progress and prospects Replicon RNA viral vectors as vaccines Transforming growth factor-beta promotes rhinovirus replication in bronchial epithelial cells by suppressing the innate immune response Efficacy and safety of high-dose influenza vaccine in elderly adults: a systematic review and meta-analysis Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: a systematic review and meta-analysis A systematic review and meta-analysis of cross-reactivity of antibodies induced by oil-in-water emulsion adjuvanted influenza H5N1 virus monovalent vaccines Preclinical pharmacokinetics of MHAA4549A, a human monoclonal antibody to influenza A virus, and the prediction of its efficacious clinical dose for the treatment of patients hospitalized with influenza A Efficacy and safety of treatment with an anti-m2e monoclonal antibody in experimental human influenza Safety and upper respiratory pharmacokinetics of the hemagglutinin stalk-binding antibody VIS410 support treatment and prophylaxis based on population modeling of seasonal influenza A outbreaks Priming by a novel universal influenza vaccine (Multimeric-001)-a gateway for improving immune response in the elderly population A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adults Evaluation of the immunogenicity and safety of different doses and formulations of a broad spectrum influenza vaccine (FLU-v) developed by SEEK: study protocol for a single-center, randomized, double-blind and placebo-controlled clinical phase IIb trial Caparr os-Wanderley W. Synthetic Influenza vaccine (FLU-v) stimulates cell mediated immunity in a double-blind, randomised, placebo-controlled phase I trial A synthetic influenza virus vaccine induces a cellular immune response that correlates with reduction in symptomatology and virus shedding in a randomized phase Ib live-virus challenge in humans A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP1M1 in adults aged over 50 years A Phase IIA study to assess the safety and efficacy of a new influenza candidate vaccine MVA-NP1M1 in healthy adults-Flu002 Clinical Study Report Evaluating the immunogenicity and safety of a BiondVax-developed universal influenza vaccine (Multimeric-001) either as a standalone vaccine or as a primer to H5N1 influenza vaccine Back to the future: immunization with M-001 prior to trivalent influenza vaccine in 2011/12 enhanced protective immune responses against 2014/15 epidemic strain Safety and immunogenicity of multimeric-001-a novel universal influenza vaccine Implication of respiratory syncytial virus (RSV) F transgene sequence heterogeneity observed in Phase 1 evaluation of MEDI-534, a live attenuated parainfluenza type 3 vectored RSV vaccine Phase-I study MEDI-534, of a live, attenuated intranasal vaccine against respiratory syncytial virus and parainfluenza-3 virus in seropositive children A randomized, blinded, controlled, dose-ranging study of a respiratory syncytial virus recombinant fusion (F) nanoparticle vaccine in healthy women of childbearing age Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial Trivalency of a nanobody specific for the human respiratory syncytial virus fusion glycoprotein drastically enhances virus neutralization and impacts escape mutant selection Efficacy, safety, and pharmacokinetics of a new 10% liquid intravenous immunoglobulin containing high titer neutralizing antibody to RSV and other respiratory viruses in subjects with primary immunodeficiency disease Treatment with novel RSV Ig RI-002 controls viral replication and reduces pulmonary damage in immunocompromised Sigmodon hispidus Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection Highly conserved protective epitopes on influenza B viruses Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses Tackling influenza with broadly neutralizing antibodies Influenza virus vaccine based on the conserved hemagglutinin stalk domain Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies Chimeric hemagglutinin constructs induce broad protection against influenza B virus challenge in the mouse model Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus Influenza vaccine research funded by the European Commission FP7-Health-2013-Innovation-1 project Antibodies to watch in 2017 Protective efficacy and immunogenicity of an adenoviral vector vaccine encoding the codon-optimized F protein of respiratory syncytial virus Immunogenicity of RSV F DNA vaccine in BALB/c Mice RSV fusion (F) protein DNA vaccine provides partial protection against viral infection Chimeric virus-like particles containing a conserved region of the G protein in combination with a single peptide of the M2 protein confer protection against respiratory syncytial virus infection Baculovirus-expressed virus-like particle vaccine in combination with DNA encoding the fusion protein confers protection against respiratory syncytial virus Co-immunization with virus-like particle and DNA vaccines induces protection against respiratory syncytial virus infection and bronchiolitis Respiratory syncytial virus: infection, detection, and new options for prevention and treatment Immunogenicity and efficacy of codon optimized DNA vaccines encoding the F-protein of respiratory syncytial virus Mucosal vaccines against respiratory syncytial virus Prevention of colds by vaccination against a rhinovirus: a report by the scientific committee on common cold vaccines Challenges in developing a cross-serotype rhinovirus vaccine Misdirected antibody responses against an N-terminal epitope on human rhinovirus VP1 as explanation for recurrent RV infections Wide-scale prevention through immunization appears to be within reach for respiratory syncytial virus and promising for influenza virus, whereas additional effort is needed in regard to rhinovirus, as well as other respiratory tract viruses. keywords: antiviral; asthma; human; ifv; immune; infection; influenza; novel; patients; prevention; rhinovirus; rna; rsv; safety; tract; treatment; trial; vaccine; virus; viruses cache: cord-259927-xh9cw9ao.txt plain text: cord-259927-xh9cw9ao.txt item: #97 of 299 id: cord-260956-w6wxsg4p author: Dimitrov, Kiril M. title: Newcastle disease vaccines—A solved problem or a continuous challenge? date: 2017-07-31 words: 10568 flesch: 26 summary: Forty-Second Western Poultry Disease Conference Generation of recombinant lentogenic Newcastle disease virus from cDNA Level of protection of chickens against highly pathogenic H5 avian influenza virus with Newcastle disease virus based live attenuated vector vaccine depends on homology of H5 sequence between vaccine and challenge virus Evolutionary changes affecting rapid diagnostic of 2008 Newcastle disease viruses isolated from double-crested cormorants Adjuvant potential of resiquimod with inactivated Newcastle disease vaccine and its mechanism of action in chicken Phylogenetic and pathotypic characterization of newcastle disease viruses circulating in west Africa and efficacy of a current vaccine Protective dose of a recombinant Newcastle disease LaSota-avian influenza virus H5 vaccine against H5N2 highly pathogenic avian influenza virus and velogenic viscerotropic Newcastle disease virus in broilers with high maternal antibody levels Back to the past: do vector vaccines represent the future? Practical aspects of poultry vaccination Efficacy of Newcastle disease virus recombinant expressing avian influenza virus H6 hemagglutinin against Newcastle disease and low pathogenic avian influenza in chickens and turkeys Autogenous vaccines: current use patterns and end users' needs in the integrated broiler industry Development of an effective polyvalent vaccine against both Marek's and Newcastle diseases based on recombinant Marek's disease virus type 1 in commercial chickens with maternal antibodies Expression of interferon gamma by a highly virulent strain of Newcastle disease virus decreases its pathogenicity in chickens Expression of chicken interleukin-2 by a highly virulent strain of Newcastle disease virus leads to decreased systemic viral load but does not significantly affect mortality in chickens Pathologic characterization of genotypes XIV and XVII Newcastle disease viruses and efficacy of classical vaccination on specific pathogen-free birds Vaccines for List A poultry diseases: emphasis on avian influenza Efficacy of a recombinant fowl pox-based Newcastle disease virus vaccine candidate against velogenic and respiratory challenge Infectious bronchitis virus S2 expressed from recombinant virus confers broad protection against challenge Structural comparison of the cleavage-activation site of the fusion glycoprotein between virulent and avirulent strains of Newcasltle disease virus Effect of lipopolysaccharide on intranasal administration of liposomal Newcastle disease virus vaccine to SPF chickens Avian influenza in Mexico Stimulatory effect of CpG sequences on humoral response in chickens Development of a novel thermostable Newcastle disease virus vaccine vector for expression of a heterologous gene Comparative immune response from vaccinating chickens with lentogenic Newcastle disease virus strains Generation by reverse genetics of an effective, stable, live-attenuated newcastle disease virus vaccine based on a currently circulating, highly virulent Indonesian strain Protection by recombinant Newcastle disease viruses (NDV) expressing the glycoprotein (G) of avian metapneumovirus (aMPV) subtype A or B against challenge with virulent NDV and aMPV Vaccination with Newcastle disease vaccine and CpG oligodeoxynucleotides induces specific immunity and protection against Newcastle disease virus in SPF chicken Enhancement of mucosal immune responses by intranasal co-delivery of Newcastle disease vaccine plus CpG oligonucleotide in SPF chickens in vivo Development of a Newcastle disease virus vector expressing a foreign gene through an internal ribosomal entry site provides direct proof for a sequential transcription mechanism Recombinant Newcastle disease virus as a viral vector: effect of genomic location of foreign gene on gene expression and virus replication Newcastle disease virus (NDV) recombinants expressing infectious laryngotracheitis virus (ILTV) glycoproteins gB and gD protect chickens against ILTV and NDV challenges Synthesis, characterization, and immune efficacy of layered double hydroxide@SiO2 nanoparticles with shell-core structure as a delivery carrier for Newcastle disease virus DNA vaccine P and M gene junction is the optimal insertion site in Newcastle disease virus vaccine vector for foreign gene expression IgA response and protection following nasal vaccination of chickens with Newcastle disease virus DNA vaccine nanoencapsulated with Ag@SiO2 hollow nanoparticles Biological evaluation of N-2-hydroxypropyl trimethyl ammonium chloride chitosan as a carrier for the delivery of live Newcastle disease vaccine The authors gratefully acknowledge David Suarez for his useful comments on the manuscript. Live and inactivated vaccines compared Potency of a recombinant NDV-H5 vaccine against various HPAI H5N1 virus challenges in SPF chickens Field efficacy trial of a novel HVT-IBD vector vaccine for 1-day-old broilers Avian influenza vaccines against H5N1 'bird flu Recombinant infectious bursal disease virus expressing Newcastle disease virus (NDV) neutralizing epitope confers partial protection against virulent NDV challenge in chickens Generation by reverse genetics of an effective attenuated Newcastle disease virus vaccine based on a prevalent highly virulent Chinese strain Newcastle disease outbreaks in recent years in western Europe were caused by an old (VI) and a novel genotype (VII) Lights and shades on an historical vaccine canine distemper virus, the Rockborn strain Assembly and biological and immunological properties of Newcastle disease virus-like particles Control by vaccination Newcastle disease Antigenic differences among Newcastle disease virus strains of different genotypes used in vaccine formulation affect viral shedding after a virulent challenge Comparison of viral shedding following vaccination with inactivated and live Newcastle disease vaccines formulated with wild-type and recombinant viruses Effects of Newcastle disease virus vaccine antibodies on the shedding and transmission of challenge viruses Protection of chickens from Newcastle and Marek's diseases with a recombinant herpesvirus of turkeys vaccine expressing the Newcastle disease virus fusion protein Newcastle disease virus-like particles as a platform for the development of vaccines for human and agricultural pathogens Recombinant Newcastle disease virus as a vaccine vector Newcastle disease. keywords: birds; challenge; chickens; disease; disease virus; et al; gene; live; nd vaccines; ndv; newcastle; newcastle disease; poultry; recombinant; strains; vaccination; vaccines; vector; virulent; virus cache: cord-260956-w6wxsg4p.txt plain text: cord-260956-w6wxsg4p.txt item: #98 of 299 id: cord-261301-8mw2kpmr author: McVey, Scott title: Vaccines in Veterinary Medicine: A Brief Review of History and Technology date: 2010-05-13 words: 4041 flesch: 34 summary: In the mid-1950s, veterinarians were commonly using rabies vaccines of brain tissue origin in dogs. The principal biologic products used in practice at that time were rabies vaccines, 'viabilized' canine distemper/hepatitis virus vaccine and antisera, hog cholera and erysipelas vaccines and antisera, leptospirosis bacterins, and clostridial toxoids (Fig. 1) . keywords: antibody; antigens; development; disease; efficacy; feline; immunity; protection; rabies; use; vaccines cache: cord-261301-8mw2kpmr.txt plain text: cord-261301-8mw2kpmr.txt item: #99 of 299 id: cord-261566-fn08b0y2 author: Mudgal, Rajat title: Prospects for mucosal vaccine: shutting the door on SARS-CoV-2 date: 2020-09-15 words: 7065 flesch: 27 summary: The genes encoding structural proteins, including spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins are present at 3ˊ end of genomic RNA. 7, 8 The S protein of coronaviruses is one of the most important targets for the development of SARS vaccines and therapeutics because it is involved in receptor recognition, as well as virus attachment and entry. key: cord-261566-fn08b0y2 authors: Mudgal, Rajat; Nehul, Sanketkumar; Tomar, Shailly title: Prospects for mucosal vaccine: shutting the door on SARS-CoV-2 date: 2020-09-15 journal: Human vaccines & immunotherapeutics DOI: 10.1080/21645515.2020.1805992 sha: doc_id: 261566 cord_uid: fn08b0y2 The sudden emergence of a highly transmissible and pathogenic coronavirus SARS-CoV-2 in December 2019 from China and its rapid global spread has posed an international health emergency. keywords: antigen; cells; coronavirus; cov; cov-2; development; immune; immunity; infection; mers; mucosal; protein; response; sars; syndrome; vaccine cache: cord-261566-fn08b0y2.txt plain text: cord-261566-fn08b0y2.txt item: #100 of 299 id: cord-261876-7rsc803x author: Kaslow, David C. title: Certainty of success: three critical parameters in coronavirus vaccine development date: 2020-05-25 words: 6468 flesch: 17 summary: As noted by Callow et al. 35 the human challenge data are consistent with the notion that adults have human coronavirus infections on a 2-3 year cyclic pattern and that protective amounts of antibody may have disappeared by 2 years, and that if we had been able to reinoculate the volunteers after a further year, the reinfection rate would have been even higher. In considering the “certainty of success” in development of human coronavirus vaccines, particularly SARS-CoV-2, a third, related critical parameter is proposed—infectious inoculum intensity, at an individual-level, and force of infection, at a population-level. keywords: certainty; coronavirus; cov-2; disease; human; incubation; infection; inoculum; period; response; sars; success; vaccine cache: cord-261876-7rsc803x.txt plain text: cord-261876-7rsc803x.txt item: #101 of 299 id: cord-262282-9xh51cd1 author: Serwer, Philip title: Optimizing Anti-Viral Vaccine Responses: Input from a Non-Specialist date: 2020-05-15 words: 4324 flesch: 54 summary: (1) Although phage uptake into human cells occurs, no evidence exists that phages replicate in human cells Pathogen homolog RNA phage vaccines, on the other hand, would have an a priori and reasonable projection (not certainty) of safety. keywords: antibody; objective; option; phage; sars; strategy; type; vaccine; virus; viruses cache: cord-262282-9xh51cd1.txt plain text: cord-262282-9xh51cd1.txt item: #102 of 299 id: cord-263277-m4too6ob author: Guzmán, Carlos Alberto title: Next Generation Influenza Vaccines: Looking into the Crystal Ball date: 2020-08-21 words: 1924 flesch: 23 summary: Nevertheless, practical considerations, like manufacturing capacity to serve the huge demand for influenza vaccines and considerably higher production costs still represent a bottleneck. The review by Clemens et al. further elaborates on the potential and limitations of harnessing T cells for the development of influenza vaccines [11] . keywords: cells; generation; influenza; vaccination; vaccines cache: cord-263277-m4too6ob.txt plain text: cord-263277-m4too6ob.txt item: #103 of 299 id: cord-263619-p17oomzn author: Moss, William J. title: Measles date: 2009-01-30 words: 9549 flesch: 35 summary: Measles virus can be isolated in tissue culture from white blood cells, respiratory tract secretions, and urine, although the ability to isolate measles virus diminishes quickly after rash onset. These signs and symptoms are a consequence of the host immune response to replicating measles vaccine virus, but do not result in serious morbidity or mortality. keywords: age; antibodies; children; disease; et al; immunity; infection; measles; measles virus; months; mortality; rash; responses; vaccination; vaccine; virus cache: cord-263619-p17oomzn.txt plain text: cord-263619-p17oomzn.txt item: #104 of 299 id: cord-264356-3zu4w0a9 author: Ino, Hiroyasu title: Vaccine mandate in long‐term care facilities date: 2020-10-01 words: 1548 flesch: 50 summary: 11, 12 The elderly are typically given a larger dose of the flu vaccine, so there is a possibility that larger doses of COVID-19 vaccines are required for the elderly. We can apply the discussion of vaccine mandate for immigrants. keywords: covid-19; ltcfs; residents; telehealth; vaccine cache: cord-264356-3zu4w0a9.txt plain text: cord-264356-3zu4w0a9.txt item: #105 of 299 id: cord-264571-rtac6hh2 author: Bhatia, Saurabh title: Chapter 9 Edible Vaccines date: 2015-12-31 words: 2752 flesch: 42 summary: Reported expression rates range from 0.01% to 2% total soluble protein (TSP), which can render edible vaccine proteins less immunogenic. In addition, unlike almost all other cell lines used for production of vaccines, components of plant cells have always been an important part of the normal human diet. keywords: cells; expression; plants; production; protein; transgenic; vaccines cache: cord-264571-rtac6hh2.txt plain text: cord-264571-rtac6hh2.txt item: #106 of 299 id: cord-264814-v4wnmg03 author: Flanagan, Katie L. title: Progress and Pitfalls in the Quest for Effective SARS-CoV-2 (COVID-19) Vaccines date: 2020-10-02 words: 15157 flesch: 34 summary: Med Hypotheses Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells in vitro Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization Monoclonal antibody analysis of neutralization and antibody-dependent enhancement of feline infectious peritonitis virus Monoclonal antibodies to the spike protein of feline infectious peritonitis virus mediate antibody-dependent enhancement of infection of feline macrophages Evaluation of modified vaccinia virus ankara based recombinant SARS vaccine in ferrets Molecular mechanism for antibody-dependent enhancement of coronavirus entry Distinct systems serology features in children, elderly and COVID patients. The standardization of a range of assays to support vaccine studies, such as viral neutralization assays, to enable comparison of different vaccine candidates in different populations will be key to facilitating vaccine development, an issue which represents a current focus of the WHO (43). keywords: cell; challenge; coronavirus; cov-2; covid-19; development; disease; dna; human; immunity; infection; key; nabs; patients; phase; protein; response; safety; sars; studies; table; trials; vaccine; virus cache: cord-264814-v4wnmg03.txt plain text: cord-264814-v4wnmg03.txt item: #107 of 299 id: cord-265472-b1s4stvz author: Guimarães, Luísa Eça title: Vaccines, adjuvants and autoimmunity date: 2015-10-31 words: 14650 flesch: 37 summary: An experimental study in Brown Norway rats Aluminum in the central nervous system (CNS): toxicity in humans and animals, vaccine adjuvants, and autoimmunity Six revolutions in vaccinology From Pasteur to genomics: progress and challenges in infectious diseases Systems vaccinology Vaccinomics, adversomics, and the immune response network theory: individualized vaccinology in the 21st century Studies of twins in vaccinology Vaccinomics current findings, challenges and novel approaches for vaccine development The HLA genomic loci map: expression, interaction, diversity and disease The link between genetic variation and variability in vaccine responses: systematic review and meta-analyses Development of polyarthritis after insertion of silicone breast implants followed by remission after implant removal in 2HLA-identical sisters bearing rheumatoid arthritis susceptibility genes Autoimmune/auto-inflammatory syndrome induced by adjuvants (ASIA) after quadrivalent human papillomavirus vaccination in Colombians: a call for personalised medicine Anticardiolipin and anti-beta(2) glycoprotein I antibodies in sera of 61 apparently healthy children at regular preventive visits Autoimmunity and hepatitis A vaccine in children Bacterial induction of autoantibodies to beta2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome Vaccination-induced systemic autoimmunity in farmed Atlantic salmon Autoimmune response following annual influenza vaccination in 92 apparently healthy adults High non-specific T lymphocyte response to the adjuvanted H1N1 vaccine in comparison with the H1N1/H3N2/B-Brisbane vaccine without adjuvant Short and long-term effects of pandemic unadjuvanted influenza A(H1N1) pdm09 vaccine on clinical manifestations and autoantibody profile in primary Sjögren's syndrome Pneumococcal vaccination of patients with systemic lupus erythematosus: effects on generation of autoantibodies Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study Safety and immunogenicity of the quadrivalent HPV vaccine in female systemic lupus erythematosus patients aged 12 to 26 years Anti-phospholipid antibodies following vaccination with recombinant hepatitis B vaccine Development of autoantibodies before the clinical onset of systemic lupus erythematosus Genetics and autoantibodies Silicone and autoimmunity Platinum in the environment: frequency of reactions to platinum-group elements in patients with dermatitis and urticaria Silicone and scleroderma revisited Rupture of silicone gel breast implants and symptoms of pain and fatigue This suggests that genomics is crucial in inter-individual variations in vaccine immune responses [82] . keywords: adjuvants; aluminum; anti; antibodies; arthritis; asia; autoimmune; autoimmunity; cases; cell; development; disease; hbv; hepatitis; hpv; human; infection; inflammatory; influenza; patients; response; risk; silicone; specific; studies; syndrome; vaccination; vaccine; virus cache: cord-265472-b1s4stvz.txt plain text: cord-265472-b1s4stvz.txt item: #108 of 299 id: cord-265642-7mu530yp author: Syomin, B. V. title: Virus-Like Particles as an Instrument of Vaccine Production date: 2019-06-17 words: 7110 flesch: 38 summary: One of the most important properties of VLPs is mimicking virus particles and the consequent ability to induce a strong immune response to the antigen which they demonstrate irrespective of the source of the monomers which multimerize into VLPs, these being either insect viruses, in particular the gypsy virus THE PRODUCT RANGE A number of VLP vaccines are available on pharmaceutical markets in many countries. keywords: antigen; cells; development; disease; example; expression; hepatitis; human; particles; production; protein; response; surface; system; vaccines; virus; vlps cache: cord-265642-7mu530yp.txt plain text: cord-265642-7mu530yp.txt item: #109 of 299 id: cord-265757-8ces57rn author: Tondella, M. L. title: International Bordetella pertussis assay standardization and harmonization meeting report. Centers for Disease Control and Prevention, Atlanta, Georgia, United States, 19–20 July 2007 date: 2009-02-05 words: 11139 flesch: 36 summary: Possible reasons for the resurgence of reported pertussis are (1) greater awareness of pertussis; (2) waning of vaccine-induced immunity; (3) lessened potency of pertussis vaccines; (4) genetic changes in B. pertussis; and (5) the general availability of better laboratory tests for the diagnosis of pertussis. Since most individuals had been exposed to pertussis vaccine or infection, the study focused on an estimation of the incidence of recent infections, as defined by the presence of IgG anti-PT antibodies above defined thresholds keywords: adults; antigens; assay; bordetella; disease; efficacy; evaluation; igg; infection; laboratory; new; pertussis; reference; sera; serologic; studies; vaccine; years cache: cord-265757-8ces57rn.txt plain text: cord-265757-8ces57rn.txt item: #110 of 299 id: cord-266199-smlq11y9 author: Dhakal, Santosh title: Nanoparticle-based vaccine development and evaluation against viral infections in pigs date: 2019-11-06 words: 7654 flesch: 32 summary: potential and limitations Respiratory nanoparticle-based vaccines and challenges associated with animal models and translation Chitosan nanoparticles act as an adjuvant to promote both Th1 and Th2 immune responses induced by ovalbumin in mice Poly(anhydride) nanoparticles act as active Th1 adjuvants through Toll-like receptor exploitation Liposome-based adjuvants for subunit vaccines: formulation strategies for subunit antigens and immunostimulators Vaccine delivery using nanoparticles Potent antigen-specific immune responses stimulated by codelivery of CpG ODN and antigens in degradable microparticles Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity M-cell targeted biodegradable PLGA nanoparticles for oral immunization against hepatitis B Dendritic cell targeted chitosan nanoparticles for nasal DNA immunization against SARS CoV nucleocapsid protein Rapid endo-lysosomal escape of poly(dl-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery Enhanced and prolonged crosspresentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles Cytotoxic T cell vaccination with PLGA microspheres interferes with influenza A virus replication in the lung and suppresses the infectious disease Entrapment of H1N1 influenza virus derived conserved peptides in PLGA nanoparticles enhances T cell response and vaccine efficacy in pigs Biodegradable nanoparticle delivery of inactivated swine influenza virus vaccine provides heterologous cell-mediated immune response in pigs Induction of potent antigen-specific cytotoxic T cell response by PLGA-nanoparticles containing antigen and TLR agonist Polyanhydride nanovaccine against swine influenza virus in pigs Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development Virus-like particle engineering: from rational design to versatile applications Phagocytic processing of exogenous particulate antigens by macrophages for presentation by class I MHC molecules Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages Major findings and recent advances in virus-like particle (VLP)-based vaccines Development of a porcine reproductive and respiratory Research efforts are ongoing to develop porcine viral vaccines using NPs-based technologies. keywords: adjuvant; antigen; cell; delivery; disease; influenza; mucosal; nps; pigs; plga; porcine; responses; swine; vaccine; virus; vlps cache: cord-266199-smlq11y9.txt plain text: cord-266199-smlq11y9.txt item: #111 of 299 id: cord-266202-3qku90ml author: Billington, John title: Developing Vaccines for SARS-CoV-2 and Future Epidemics and Pandemics: Applying Lessons from Past Outbreaks date: 2020-06-01 words: 4325 flesch: 37 summary: EIDs are a particularly challenging target for global health preparedness, including for vaccine development. Insufficient attention has been given to challenges, lessons learned, and potential solutions to support and sustain vaccine industry engagement in vaccine development for EIDs. keywords: companies; development; ebola; eid; epidemic; global; health; pandemic; vaccine; virus; zika cache: cord-266202-3qku90ml.txt plain text: cord-266202-3qku90ml.txt item: #112 of 299 id: cord-266204-ipa017wz author: Poland, G. A. title: Personalized vaccinology: A review date: 2018-08-28 words: 7241 flesch: 27 summary: Dissecting polyclonal vaccine-induced humoral immunity against HIV using systems serology Cytometry by time-offlight shows combinatorial cytokine expression and virus-specific cell niches within a continuum of CD8 + T cell phenotypes Highresolution myogenic lineage mapping by single-cell mass cytometry Metabolic phenotypes of response to vaccination in humans Heterogeneity in vaccine immune response: the role of immunogenetics and the emerging field of vaccinomics Vaccinomics, adversomics, and the immune response network theory: individualized vaccinology in the 21st century Pharmacology, vaccinomics, and the second golden age of vaccinology A systems biology approach to the effect of aging, immunosenescence and vaccine response Genetics and vaccines in the era of personalized medicine The weight of obesity on the human immune response to vaccination Understanding immunosenescence to improve responses to vaccines Vaccine immunogenetics: bedside to bench to population Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology Vaccine discovery and translation of new vaccine technology Systems vaccinology: learning to compute the behavior of vaccine induced immunity Additive effects of HLA alleles and innate immune genes determine viral outcome in HCV infection Role of HLA, KIR, MICA, and cytokines genes in leprosy Association of variants in BAT1-LTA-TNF-BTNL2 genes within 6p21.3 region show graded risk to leprosy in unrelated cohorts of Indian population Immunogenetics of HIV disease Vaccinomics provides the opportunity to examine not only immune response genes likely to be involved in vaccine response, but also the possibility of identifying the influence of new (uncharacterized) genes on vaccine-induced immunity. keywords: age; cell; development; genes; immunity; immunogenicity; influenza; responses; sex; systems; vaccination; vaccine; vaccinology; vaccinomics; virus cache: cord-266204-ipa017wz.txt plain text: cord-266204-ipa017wz.txt item: #113 of 299 id: cord-266259-0f0guyea author: Chandler, Rebecca E. title: Optimizing safety surveillance for COVID-19 vaccines date: 2020-06-17 words: 1412 flesch: 32 summary: Nat Rev Immunol DOI: 10.1038/s41577-020-0372-8 sha: doc_id: 266259 cord_uid: 0f0guyea Evolution of the current infrastructure for surveillance of vaccine safety will be essential to meet our commitments to the public in the deployment of a vaccine (or vaccines) to COVID-19. Public confidence in vaccination programmes is therefore at high risk if the systems for monitoring vaccine safety do not perform optimally. keywords: health; safety; surveillance; vaccine cache: cord-266259-0f0guyea.txt plain text: cord-266259-0f0guyea.txt item: #114 of 299 id: cord-267012-45tre8rn author: Premanand, Balraj title: Baculovirus Surface Display of Immunogenic Proteins for Vaccine Development date: 2018-05-31 words: 11144 flesch: 27 summary: [41] developed recombinant baculovirus vaccines that showed reduced immune pathological conditions in mice. In a subsequent study, researchers developed recombinant baculovirus vaccines against avian infectious bronchitis virus (IBV), Japanese encephalitis virus (JEV), and bovine herpesvirus-1 (BHV-1) with the GP64 domains (SP, TM, and CTD). keywords: antibodies; baculovirus; cells; challenge; envelope; expression; gp64; immunity; immunization; infection; influenza; mice; mucosal; protection; protein; responses; study; surface; vaccine cache: cord-267012-45tre8rn.txt plain text: cord-267012-45tre8rn.txt item: #115 of 299 id: cord-267666-i7uuf3ck author: Sarkar, Bishajit title: Engineering a Novel Subunit Vaccine against SARS-CoV-2 by Exploring Immunoformatics Approach date: 2020-11-11 words: 1874 flesch: 32 summary: ImmunoTargets 1340 and therapy Recombinant and epitope-based vaccines on the road to the 1343 market and implications for vaccine design and production Physicochemical characterization and functional analysis of 1347 some snake venom toxin proteins and related non-toxin proteins of other chordates cell differentiation and plasticity during visceral leishmaniasis infection. 7, 1352 Another Decade, Another Coronavirus Amino acid neighbours and detailed 1356 conformational analysis of cysteines in proteins ElliPro: a new structure-based tool for the prediction of antibody epitopes More than one reason to rethink the use of 1364 peptides in vaccine design Computational immunology meets 1369 bioinformatics: the use of prediction tools for molecular binding in the simulation of the immune 1370 system Reverse 1376 vaccinology 2.0: Human immunology instructs vaccine antigen design Therapeutic and vaccine 1380 strategies against SARS-CoV-2: past, present and future. keywords: design; epitopes; figure; protein; sars; structure; vaccine cache: cord-267666-i7uuf3ck.txt plain text: cord-267666-i7uuf3ck.txt item: #116 of 299 id: cord-267897-w4pbq2lb author: Lindblad, E. B. title: Chapter 18 Mineral Adjuvants ∗ ∗ The present chapter is an updated version of the chapter “Mineral Adjuvants,” published in Immunopotentiators in Modern Vaccines, p. 217–233. Ed. Virgil Schijns & Derek O'Hagan, Elsevier Science Publishers (2005). date: 2017-12-31 words: 9789 flesch: 34 summary: In human vaccination, aluminum adjuvants have been primarily used in tetanus, diphtheria, pertussis, and poliomyelitis vaccines as part of standard childhood vaccination programs for more than 60 years in many countries. Later, aluminum adjuvants were also introduced in hepatitis A and hepatitis B virus vaccines, as well as in vaccines against human papillomavirus (causing genital warts and cervical cancers), and vaccines against Lyme disease/Borreliose and Japanese encephalitis. keywords: adjuvant; adsorption; aluminum; aluminum adjuvants; aluminum hydroxide; aluminum phosphate; antigen; calcium; calcium phosphate; cells; effect; hydroxide; il-4; mice; mineral; phosphate; response; surface; toxoid; vaccination; vaccines cache: cord-267897-w4pbq2lb.txt plain text: cord-267897-w4pbq2lb.txt item: #117 of 299 id: cord-268501-z4oztgi0 author: Palatnik-de-Sousa, Clarisa B. title: What Would Jenner and Pasteur Have Done About COVID-19 Coronavirus? The Urges of a Vaccinologist date: 2020-08-26 words: 6333 flesch: 36 summary: It was concluded that, the immunopathology of SARS vaccines was a consequence to a Th2 type of response to the antigen and it was avoided in vaccines that drive the response to a Th1 immunity, with or without adjuvants (53) . In fact, inactivated vaccines preserve the intact structure of the antigens and their B-cell epitopes that enable them to interact with the antibody paratopes, and promote the synthesis of neutralizing antibodies. keywords: antibodies; chadox1; cov-2; disease; efficacy; human; inactivated; phase; protein; sars; sinovac; trials; vaccine; virus cache: cord-268501-z4oztgi0.txt plain text: cord-268501-z4oztgi0.txt item: #118 of 299 id: cord-269352-0o3mryu1 author: Dhama, K. title: DNA vaccines and their applications in veterinary practice: current perspectives date: 2008-04-19 words: 6863 flesch: 29 summary: Salient features of DNA vaccines and strategies to improve vaccine efficacy DNA vaccines, generated using plasmids, include a gene encoding target antigen under the transcriptional control of an effective viral/eukaryotic promoter, along with a polyadenylation signal sequence (poly-A) and a bacterial origin of replication ( Fig. 1 ) (Gurunathan et al. 2000) . Sichuan Da Xue Xue Bao Yi Xue Ban Use of attenuated bacteria as delivery vectors for DNA vaccines Immunization of bovines using a DNA vaccine prepared from the Jaboticabal strain of Anaplasma marginale Bm86 antigen induces a protective immune response against Boophilus microplus following DNA and protein vaccination in sheep Immunity and disease resistance strategies in poultry: current and future prospects DNA vaccines and prevention of infectious diseases in bovines: A Review In ovo vaccination with the Eimeria tenella EtMIC2 gene induces protective immunity against coccidiosis Construction of recombinant plasmid with VP1 genes against Asia I FMDV and elementary analysis of its immunological activity CpG motif in ATCGAT hexamer improves DNA-vaccine efficiency against lethal Pseudorabies virus infection in pigs Humoral immune responses to DNA vaccines expressing secreted, membrane bound and non-secreted forms of the Taenia ovis 45W antigen The application of nucleic acid vaccines in veterinary medicine Priming of cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen-presenting cells and evidence for antigen transfer from myocytes Prime-boost immunization with DNA followed by a recombinant vaccinia virus expressing P50 induced protective immunity against Babesia gibsoni infection in dogs Potency of an experimental DNA vaccine against Aujeszky's disease in pigs Stable and long-lasting immune response in horses after DNA vaccination against equine arteritis virus Development of novel strategies to control foot-and-mouth disease: marker vaccines and antivirals Induction of protection against porcine cysticercosis in growing pigs by DNA vaccination Induction of immune responses in cattle with a DNA vaccine encoding glycoprotein C of bovine herpesvirus-1 Cloning of canine parvovirus VP2 gene and its use as DNA vaccine in dogs Immunogenicity of a recombinant plasmid DNA containing glycoprotein gene of rabies virus CVS A DNA vaccine that encodes rabies virus glycoprotein lacking transmembrane domain enhances antibody response but not protection Induction of immune response in mice with a DNA vaccine encoding outer membrane protein (omp31) of Brucella melitensis 16M DNA vaccines: immunology, application, and optimization Comparison of the immunological memory after DNA vaccination and protein vaccination against anthrax in sheep West Nile virus vaccines On the use of DNA vaccines for the prophylaxis of mycobacterial diseases A tumor reducing factor extracted by phenol from papillomatous tissue of cotton tail rabbits Hemagglutinin (H) gene of canine distemper virus cloned in pTargeT mammalian expression vector induces neutralizing antibody response in dogs Nucleic acid immunization protects dogs against challenge with virulent canine parvovirus Novel chitosan derivative nanoparticles enhance the immunogenicity of a DNA vaccine encoding hepatitis B virus core antigen in mice DNA prime followed by protein boost enhances neutralization and Th1 type immunity against FMDV Strategies for inducing protection against avian influenza A virus subtypes with DNA vaccines CpG motifs in bacterial DNA and their immune effects Nucleic acid vaccination of Brucella abortus ribosomal L7/L12 gene elicits immune response Generation of reassortant influenza vaccines by reverse genetics that allows utilization of a DIVA (Differentiating Infected from Vaccinated Animals) strategy for the control of avian influenza Oral DNA vaccination with polyprotein gene of IBDV delivered by attenuated Salmonella elicits protective immune response in chickens A Semliki Forest virus replicon vectored DNA vaccine expressing the E2 glycoprotein of classical swine fever virus protects pigs from lethal challenge Priming with DNA encoding E2 and boosting with E2 protein formulated with CpG oligodeoxynucleotides induces strong immune responses and protection from Bovine viral diarrhea virus in cattle DNA vaccines: a review DNA vaccines: recent developments and future possibilities Suppository-mediated DNA immunization induces mucosal immunity against bovine herpesvirus-1 in cattle Improved protection from velogenic Newcastle disease virus challenge following multiple immunizations with plasmid DNA encoding for F and HN genes Antibody responses to DNA vaccination of horses using the influenza virus hemagglutinin gene Approaches to enhance the efficacy of DNA vaccines Modulation of immune responses to bovine herpesvirus-1 in cattle by immunization with a DNA vaccine encoding glycoprotein D as a fusion protein with bovine CD154 Adjuvant effects of ILl beta, IL-2, IL-8, 1L-15, IFN-alpha, IFN-gamma TGF-beta and lymphotactin in DNA vaccination against Eimeria acervulina Use of DNA and recombinant canarypox viral vectors for equine herpes virus vaccination Efficacy of particle-based DNA delivery for vaccination of sheep against FMDV DNA vaccination against bovine viral diarrhoea virus induces humoral and cellular responses in cattle with evidence for protection against viral challenge DNA immunization of dairy cows with the clumping factor A of Staphylococcus aureus DNA vaccination against influenza viruses: a review with emphasis on equine and swine influenza DNA vaccination in avian Virus neutralizing antibody response in mice and dogs with a bicistronic DNA vaccine encoding rabies virus glycoprotein and canine parvovirus VP2 Electric pulses applied prior to intramuscular DNA vaccination greatly improve the vaccine immunogenicity Development of rabies DNA vaccine using a recombinant plasmid Brucella abortus: immunity, vaccines and prevention strategies based on nucleic acids Immune response in mice and cattle after immunization with a B. microplus DNA vaccine containing bm86 gene Protection of kids against C. parvum infection after immunization of dams with CP15-DNA Immunization with DNA vaccines encoding different mycobacterial antigens elicits a Th1 type immune response in lambs and protects against Mycobacterium avium subspecies paratuberculosis infection Development of DNA vaccine against chicken anemia virus simultaneously using it's VP1 and VP2 proteins The carboxyl-terminal 120-residue polypeptide of IB virus nucleocapsid induces CTLs and protects chickens from acute infection Recent developments in veterinary vaccinology DNA Fragment Encoding Human IL-1β 163-171 Peptide Enhances the Immune Responses Elicited in Mice by DNA Vaccine against Foot-and-Mouth Disease DNA vaccines: future strategies and relevance to intracellular pathogens Laboratory and field evaluation of Schistosoma japonicum DNA vaccines in sheep and water buffalo in China CD virus DNA vaccination induces humoral and cellular immunity and protects against a lethal intracerebral challenge DNA vaccines and adjuvants DNA immunization with a bovine rotavirus VP4 gene induces a Th1-like immune response in mice DNA vaccine using M. bovis Ag85B antigen induces partial protection against experimental infection in BALB/c mice Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells DNA vaccines: recent technological and clinical advances Effect of vaccination route and composition of DNA vaccine on the induction of protective immunity against psuedorabies infection in pigs Immune response to vaccines based upon the VapA protein of the horse pathogen, Rhodococcus equi, in a murine model Protection of turkeys against C. psittaci challenge by parenteral and mucosal inoculations and the effect of turkey interferon-gamma on genetic immunization Enhanced immunogenicity of microparticulated multiepitope DNA vaccine encoding T and B cell epitopes of foot and mouth disease virus in mice Immunomodulatory effect of plasmids co-expressing cytokines in classical swine fever virus subunit gp55/E2-DNA vaccination Direct gene transfer into mouse muscle in vivo A DNA vaccine against FMD elicits an immune response in swine which is enhanced by co-administration with interleukin-2. keywords: antigen; disease; dna; encoding; et al; gene; immunity; immunization; infection; plasmid; protection; protein; responses; vaccination; vaccines; virus cache: cord-269352-0o3mryu1.txt plain text: cord-269352-0o3mryu1.txt item: #119 of 299 id: cord-269448-1jikrn37 author: Borja-Cabrera, G.P. title: Immunogenicity assay of the Leishmune(®) vaccine against canine visceral leishmaniasis in Brazil date: 2008-09-15 words: 4949 flesch: 40 summary: Recently we described the safety analysis of Leishmune ® vaccine performed in a cohort of 600 dogs from Brazilian endemic and epidemic areas of canine and human visceral leishmaniasis. In the present investigation we report the immunogenicity assay of Leishmune ® , monitored in the same dog cohort, confirming the immuno protective potential previously described for the FML-saponin vaccine [17, 18] and disclosing the potential use of Leishmune ® vaccine to interrupt epidemics. keywords: canine; dogs; fml; leishmaniasis; leishmune; saponin; vaccinated; vaccine; visceral; zvl cache: cord-269448-1jikrn37.txt plain text: cord-269448-1jikrn37.txt item: #120 of 299 id: cord-269623-9pxdeva3 author: Nicholson, Karl G title: Influenza date: 2003-11-22 words: 9809 flesch: 36 summary: Of the three types of influenza viruses-A, B, and C-only types A and B cause widespread outbreaks. In southern China, influenza viruses circulate throughout the year. keywords: avian; children; efficacy; h5n1; human; illness; influenza; neuraminidase; oseltamivir; pandemic; people; treatment; vaccination; vaccines; virus; viruses; years; zanamivir cache: cord-269623-9pxdeva3.txt plain text: cord-269623-9pxdeva3.txt item: #121 of 299 id: cord-269992-ruf0vvz4 author: Sohrab, Sayed Sartaj title: An edible vaccine development for coronavirus disease 2019: the concept date: 2020-07-31 words: 2005 flesch: 48 summary: The concept of edible vaccine development has been presented in Fig. 1 . The oral administration of edible vaccines is a preferable route of vaccination for being a simple and safe route of administration; the low production cost allows for local production and minimal plant material processing; natural bio-encapsulation and hence, stability in the gastrointestinal (GI) tract; and protective immunogenicity at the GI mucosa. keywords: cost; development; plant; production; vaccine cache: cord-269992-ruf0vvz4.txt plain text: cord-269992-ruf0vvz4.txt item: #122 of 299 id: cord-270709-jahnjvyk author: Hasford, Joerg title: Large Simple Double-Blind Randomized Trials for the Rapid Assessment of the Effectiveness of COVID-19 Vaccines date: 2020-08-26 words: 968 flesch: 41 summary: Vaccine safety information can be collected by established systems like the Vaccine Safety Datalink in the United States [7] , prescription event monitoring programs (eg, the Drug Surveillance Research Unit in the United Kingdom [8] ), or by direct patient safety reporting on websites, including those accessible with smartphones [9] , which can be specifically designed for vaccine trials. Thus, the sponsors of vaccine trials and the drug regulatory agencies should start the preparatory work now to be ready once an investigational vaccine is ready to be administered on a large scale. Disclaimer. keywords: challenge; trials; vaccine cache: cord-270709-jahnjvyk.txt plain text: cord-270709-jahnjvyk.txt item: #123 of 299 id: cord-270998-1adloi3o author: Cunha, Rafes D. S. title: Comparison of immunity against canine distemper, adenovirus and parvovirus after vaccination with two multivalent canine vaccines date: 2020-04-27 words: 2425 flesch: 45 summary: Although no statistical difference between the two vaccines has been shown, a comparable proportion of animals was protected using vaccine V11 made in Brazil, which reinforces the quality of the product in comparison to the vaccine imported from the United States. Elevencell vaccine titres were not inferior to the imported US vaccine in conferring protective titres against CDV, CPV and CAH, which confirms the efficacy of this product. keywords: animals; canine; dogs; group; study; vaccination; vaccine cache: cord-270998-1adloi3o.txt plain text: cord-270998-1adloi3o.txt item: #124 of 299 id: cord-271153-c0aw6jkz author: Privor-Dumm, Lois title: Archetype analysis of older adult immunization decision-making and implementation in 34 countries date: 2020-05-27 words: 7748 flesch: 41 summary: Many of the countries in this archetype lack a strong NITAG for adult vaccine decisions, but exhibit some elements of the 'disease prevention archetype. Understanding the different approaches countries have taken on adult immunization could help provide future learnings and technical support for adult vaccines within life-course immunization strategies. keywords: adult; archetype; countries; country; data; decision; disease; health; immunization; implementation; making; vaccination; vaccine cache: cord-271153-c0aw6jkz.txt plain text: cord-271153-c0aw6jkz.txt item: #125 of 299 id: cord-271250-ywb26cq6 author: Sarkar, Indranil title: Selection of adjuvants for vaccines targeting specific pathogens date: 2019-04-22 words: 11442 flesch: 35 summary: Vaccines (Basel) Vaccine development for respiratory syncytial virus Adjuvants and the vaccine response to the DS-Cav1-stabilized fusion glycoprotein of respiratory syncytial virus van den Hurk S. Induction of mucosal immunity and protection by intranasal immunization with a respiratory syncytial virus subunit vaccine formulation Mucosal adjuvants: opportunities and challenges What role does the route of immunization play in the generation of protective immunity against mucosal pathogens? Intranasal immunization with H5N1 vaccine plus poly I:poly C12U, a toll-like receptor agonist, protects mice against homologous and heterologous virus challenge TLR3 agonists and proinflammatory antitumor activities Leukotrienes are potent adjuvant during fungal infection: effects on memory T cells Antigenic diversity and immune evasion by malaria parasites Immune mechanisms in malaria: new insights in vaccine development Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations The future of the rts,s/as01 malaria vaccine: an alternative development plan Vaccine adjuvant uses of poly-IC and derivatives Recommendations of the advisory committee on immunization practices for use of herpes zoster vaccines Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice HPV -immune response to infection and vaccination Efficacy of human papillomavirus L1 protein vaccines (Cervarix and Gardasil) in reducing the risk of cervical intraepithelial neoplasia: a meta-analysis Immunobiology of HPV and HPV vaccines Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2-and 3-dose schedules in girls aged 9-14 years: results to month 12 from a randomized trial Adjuvants in tuberculosis vaccine development TB vaccine development and the end tb strategy: importance and current status NOD2 and toll-like receptors are nonredundant recognition systems of mycobacterium tuberculosis Multi-stage subunit vaccines against mycobacterium tuberculosis: an alternative to the BCG vaccine or a BCG-prime boost? Phase 2b controlled trial of M72/AS01E vaccine to prevent tuberculosis Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans Systems biology of vaccination for seasonal influenza in humans Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS, S malaria vaccine Integrated analysis of genetic and proteomic data identifies biomarkers associated with adverse events following smallpox vaccination Molecular signatures of a TLR4 agonist-adjuvanted hiv-1 vaccine candidate in humans Molecular and cellular signatures underlying superior immunity against Bordetella pertussis upon pulmonary vaccination Systems vaccinology identifies an early innate immune signature as a correlate of antibody responses to the ebola vaccine rVSV-ZEBOV Predictive markers of safety and immunogenicity of adjuvanted vaccines MF59 and Pam3CSK4 boost adaptive responses to influenza subunit vaccine through an IFN type I-independent mechanism of action The T helper type 2 response to cysteine proteases requires dendritic cell-basophil cooperation via ROS-mediated signaling Key roles of adjuvants in modern vaccines Systems analysis of protective immune responses to RTS,S malaria vaccination in humans Complex immune correlates of protection in HIV-1 vaccine efficacy trials Identification of immune signatures predictive of clinical protection from malaria Systems vaccinology: enabling rational vaccine design with systems biological approaches New approaches to understanding the immune response to vaccination and infection Vaccine adjuvants: putting innate immunity to work The importance of adjuvant formulation in the development of a tuberculosis vaccine Recent advances of vaccine adjuvants for infectious diseases The authors like to thank all the current and previous members from the laboratory as well as the animal care facility at VIDO-InterVac, University of Saskatchewan, Canada for their contribution. Front Immunol STING-activating adjuvants elicit a Th17 immune response and protect against Mycobacterium tuberculosis infection A liposome-based mycobacterial vaccine induces potent adult and neonatal multifunctional T cells through the exquisite targeting of dendritic cells Intranasal c-di-GMPadjuvanted plant-derived H5 influenza vaccine induces multifunctional Th1 CD4+ cells and strong mucosal and systemic antibody responses in mice Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/ AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection Mechanisms of action of adjuvants Synthetic cationic peptide IDR-1002 provides protection against bacterial infections through chemokine induction and enhanced leukocyte recruitment 11 (TLR11) interacts with flagellin and profilin through disparate mechanisms CpG oligonucleotides as cancer vaccine adjuvants. keywords: action; activation; adjuvants; alum; antibody; antigen; as01; cells; dcs; development; human; ifn; immune; immunity; induction; mf59; mice; mucosal; pathogens; responses; systems; th1; vaccine cache: cord-271250-ywb26cq6.txt plain text: cord-271250-ywb26cq6.txt item: #126 of 299 id: cord-271528-ob4l0bcf author: Bar-Zeev, Naor title: COVID-19 vaccines: early success and remaining challenges date: 2020-09-04 words: 1506 flesch: 46 summary: key: cord-271528-ob4l0bcf authors: Bar-Zeev, Naor; Inglesby, Tom title: COVID-19 vaccines: early success and remaining challenges date: 2020-09-04 journal: Lancet DOI: 10.1016/s0140-6736(20)31867-5 sha: doc_id: 271528 cord_uid: ob4l0bcf nan In The Lancet, Denis Y Logunov and colleagues from the N F Gamaleya Research Institute of Epidemiology and Microbiology in Russia present findings from two phase 1/2, non-randomised, open-label studies of a heterologous, replication-deficient, recombinant adenovirus vector-based vaccine in both frozen and lyophilised formulations. Showing safety will be crucial with COVID-19 vaccines, not only for vaccine acceptance but also for trust in vaccination broadly. keywords: covid-19; safety; studies; vaccine cache: cord-271528-ob4l0bcf.txt plain text: cord-271528-ob4l0bcf.txt item: #127 of 299 id: cord-272241-2fwz8z8n author: Kumar, Amit title: Exploring the SARS-CoV-2 structural proteins for multi-epitope vaccine development: an in-silico approach date: 2020-09-09 words: 4612 flesch: 42 summary: WHO | Coronavirus disease World Health Organization Immunization with SARS Coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus Insights into the immunological properties of intrinsically disordered malaria proteins using proteome scale predictions The authors would like to thank IIT Mandi for research facilities. Microbes Infect Molecular basis of COVID-19 relationships in different species: a one health perspective Structural and evolutionary analysis indicate that the SARS-CoV-2 Mpro is a challenging target for small-molecule inhibitor design Probable molecular mechanism of remdesivir for the treatment of COVID-19: need to know more Preliminary identification of potential vaccine targets for the COVID-19 Coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice This important paper detail about vaccine development Identification of an epitope of SARS-coronavirus nucleocapsid protein Long-lived memory T lymphocyte responses against SARS coronavirus nucleocapsid protein in SARS-recovered patients Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a six-year follow-up study Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection Designing B-and T-cell multi-epitope based subunit vaccine using immunoinformatics approach to control Zika virus infection Strategic development of a next-generation multi-epitope vaccine to prevent nipah virus zoonotic infection In silico/ keywords: cell; complex; construct; coronavirus; cov-2; epitopes; prediction; protein; residues; sars; server; structure; vaccine cache: cord-272241-2fwz8z8n.txt plain text: cord-272241-2fwz8z8n.txt item: #128 of 299 id: cord-272512-gevrlcvy author: Shewen, P.E. title: Challenges in mucosal vaccination of cattle date: 2009-03-15 words: 4852 flesch: 30 summary: Vet Immunol Immunopathol DOI: 10.1016/j.vetimm.2008.10.297 sha: doc_id: 272512 cord_uid: gevrlcvy Recognition of the mucosal portal of entry for many infectious diseases and of the relevance of mucosal immune response to protection has encouraged the development of vaccines administered by mucosal routes, principally oral and intranasal, for stimulation of intestinal and nasopharyngeal lymphoid tissues respectively. I N F O Mucosal immunity Vaccination Mannheimia haemolytica Cattle A B S T R A C T Recognition of the mucosal portal of entry for many infectious diseases and of the relevance of mucosal immune response to protection has encouraged the development of vaccines administered by mucosal routes, principally oral and intranasal, for stimulation of intestinal and nasopharyngeal lymphoid tissues respectively. keywords: antigen; calves; cells; lkt; mucosal; nasal; response; vaccination; vaccines cache: cord-272512-gevrlcvy.txt plain text: cord-272512-gevrlcvy.txt item: #129 of 299 id: cord-273099-zkk5d6gd author: Muzumdar, Jagannath M. title: Vaccine supply, demand, and policy: A primer date: 2016-01-01 words: 7504 flesch: 42 summary: Thus, the dearth of suppliers appears to have affected the stability of vaccine supply. Specifically, we sought to (1) highlight issues faced by vaccine manufacturers that make the vaccine industry a unique segment of the prescription drug industry, (2) provide an overview of the vaccine market with regards to vaccine supply and demand, and (3) provide an overview and critical evaluation of policy options proposed and implemented by various parties to address vaccine supply and demand problems. keywords: act; children; costs; demand; development; fda; health; immunization; market; policy; products; safety; states; supply; united; vaccination; vaccine cache: cord-273099-zkk5d6gd.txt plain text: cord-273099-zkk5d6gd.txt item: #130 of 299 id: cord-273151-1h8c4yq9 author: LOCHT, Camille title: Vaccines against COVID-19 date: 2020-10-20 words: 1519 flesch: 40 summary: Vaccines take usually at least 10 to 15 years to be developed, due to the phasing of vaccine development, from pre-clinical to clinical phases 1, 2 and 3, the latter being the conclusive efficacy trial. Anti-COVID-19 vaccine development has proceeded at an unprecedented pace, as several phases are conducted simultaneously because of massive financial resources poured into vaccine development. keywords: phase; safety; vaccine cache: cord-273151-1h8c4yq9.txt plain text: cord-273151-1h8c4yq9.txt item: #131 of 299 id: cord-273526-ah0dvnxv author: Cao, Weiping title: Nasal delivery of Protollin-adjuvanted H5N1 vaccine induces enhanced systemic as well as mucosal immunity in mice date: 2017-06-05 words: 4409 flesch: 38 summary: Our findings suggest that nasal delivery of H5N1 vaccine with Protollin adjuvant can overcome the poor immunogenicity of H5N1 vaccines, induce both cellular and humoral immune responses, enhance protection against challenge with clade 1 and clade 2 H5N1 viruses and achieve significant antigen dose-sparing. The inherently poor immunogenicity of unadjuvanted H5N1 influenza vaccines warranted efforts to explore novel adjuvants and alternate delivery systems to improve immunogenicity and protective efficacy of H5N1 vaccines. keywords: cells; fig; h5n1; influenza; mice; mucosal; protollin; vaccine; virus cache: cord-273526-ah0dvnxv.txt plain text: cord-273526-ah0dvnxv.txt item: #132 of 299 id: cord-274112-6t0wpiqy author: Webby, RJ title: Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines date: 2004-04-03 words: 4214 flesch: 41 summary: Future influenza vaccines and the use of genetic recombinants Developing vaccines against pandemic influenza The structure of the hemagglutinin, a determinant for the pathogenicity of influenza viruses Proteolytic cleavage of influenza virus hemagglutinins: primary structure of the connecting peptide between HA1 and HA2 determines proteolytic cleavability and pathogenicity of Avian influenza viruses Molecular analyses of the hemagglutinin genes of H5 influenza viruses: origin of a virulent turkey strain Rescue of influenza A virus from recombinant DNA A DNA transfection system for generation of influenza A virus from eight plasmids Generation of influenza A viruses entirely from cloned cDNAs Eight-plasmid system for rapid generation of influenza virus vaccines Plasmid-only rescue of influenza A virus vaccine candidates Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses Preparation of a standardized, efficacious agricultural H5N3 vaccine by reverse genetics Development of a Vero cellderived influenza whole virus vaccine Influvac: a safe Madin Darby Canine Kidney (MDCK) cell culturebased influenza vaccine Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children Generation of High-Yielding Influenza A Viruses in African Green Monkey Kidney (Vero) Cells by reverse genetics Avian influenza The agent must be handled only under conditions of at least biosafety level 3 (BSL3), and it can kill fertilised chicken eggs, the standard medium for the reassortment and Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines propagation of influenza virus before its inactivation and formulation for use in vaccines. keywords: cells; eggs; genetics; h5n1; hong; influenza; pandemic; reverse; vaccine; virus; viruses cache: cord-274112-6t0wpiqy.txt plain text: cord-274112-6t0wpiqy.txt item: #133 of 299 id: cord-274264-s477tw3x author: Shen, M. title: Projected COVID-19 epidemic in the United States in the context of the effectiveness of a potential vaccine and implications for social distancing and face mask use date: 2020-10-30 words: 4127 flesch: 47 summary: key: cord-274264-s477tw3x authors: Shen, M.; Zu, J.; Fairley, C. K.; Pagan, J. A.; An, L.; Du, Z.; Guo, Y.; Rong, L.; Xiao, Y.; Zhuang, G.; Li, Y.; Zhang, L. title: Projected COVID-19 epidemic in the United States in the context of the effectiveness of a potential vaccine and implications for social distancing and face mask use date: 2020-10-30 journal: nan DOI: 10.1101/2020.10.28.20221234 sha: doc_id: 274264 cord_uid: s477tw3x Background: Multiple candidates of COVID-19 vaccines have entered Phase III clinical trials in the United States (US). The findings from this study can inform the planned rollout of COVID-19 vaccines and the continued implementation of non-pharmaceutical interventions such as social distancing and mask use mandates. . keywords: coverage; covid-19; effectiveness; face; mask; vaccine cache: cord-274264-s477tw3x.txt plain text: cord-274264-s477tw3x.txt item: #134 of 299 id: cord-274756-nnm1n09a author: Varadé, Jezabel title: Human immunology and immunotherapy: main achievements and challenges date: 2020-09-02 words: 19166 flesch: 27 summary: Several factors have been involved in these advancements, and the most important ones include the development of thousands of different monoclonal antibodies that allow the identification of a large variety of cell subpopulations and the functional analysis of immune cells. After infection or vaccination, innate immune cells (such as monocytes and macrophages) display long-term functional changes through epigenetic and metabolic reprogramming, including histone acetylation, methylation and modulation of noncoding RNAs [94] keywords: activation; antibodies; antigen; autoimmune; cancer; cells; cytokines; development; diseases; expression; genes; human; immune; immunity; immunotherapy; killer; lymphocytes; lymphoid; memory; molecules; nk cells; pathogens; patients; receptor; regulatory; responses; system; t cells; therapeutic; therapy; tumor; tumor cells; types; use; vaccines cache: cord-274756-nnm1n09a.txt plain text: cord-274756-nnm1n09a.txt item: #135 of 299 id: cord-275031-0y0d4brz author: Häfner, Sophia title: Contagion 2.0() date: 2015-07-02 words: 1984 flesch: 40 summary: Although several experimental vaccines provide some protections against T. cruzi infection, as compared to live attenuated T. cruzi vaccines, these approaches do not provide a strong and long-lasting immunity against T. cruzi infection. Live attenuated vaccines, in particular, miming best the natural infection, hold the advantage of eliciting the most complete and long-lasting immunization, are relatively inexpensive to produce, suitable to be distributed to large populations and do not require adjuvants. keywords: cruzi; disease; infection; vaccination; vaccine cache: cord-275031-0y0d4brz.txt plain text: cord-275031-0y0d4brz.txt item: #136 of 299 id: cord-275033-y9z9l0ji author: Carter-Pokras, O. title: The Role of Epidemiology in Informing United States Childhood Immunization Policy and Practice date: 2020-10-14 words: 8536 flesch: 31 summary: [19] [20] The increased availability and recommendations for more childhood vaccines represent remarkable achievements of the maturing immunization system of the United States to prevent vaccine preventable diseases, but have contributed to growing concerns about vaccine safety acceptability. This led to recommendations for two doses of measles vaccines, one at 12-15 months and a second at 4 to 6 years of age. keywords: care; children; coverage; development; disease; evidence; health; immunization; measles; national; new; policy; public; states; united; vaccination; vaccine cache: cord-275033-y9z9l0ji.txt plain text: cord-275033-y9z9l0ji.txt item: #137 of 299 id: cord-275210-baqaqsli author: DREESEN, DAVID W. title: Animal Vaccines date: 2007-09-05 words: 5277 flesch: 41 summary: In his quest for a means to prevent rabies in humans, Louis Pasteur initiated research into animal rabies vaccine in France in the early 1880s (Bunn, 1991) . The WHO's World Survey of Rabies reported that there are at least 23 countries or territories that reported producing animal rabies vaccines during 1999. keywords: animals; cats; dogs; rabies; strain; usa; use; vaccination; vaccines; virus cache: cord-275210-baqaqsli.txt plain text: cord-275210-baqaqsli.txt item: #138 of 299 id: cord-275538-c44gmu22 author: Davis-Wurzler, Gina M. title: Current Vaccination Strategies in Puppies and Kittens date: 2006-03-24 words: 10386 flesch: 39 summary: There are killed virus vaccines that are efficacious; however, because they contain killed virus, they require an adjuvant to maximize the host's immune response. Assignment of vaccine products (which are considered biologic agents rather than drugs and are therefore assessed and approved by the US Department of Agriculture [USDA] rather than the US Food and Drug Administration keywords: age; animal; antibody; canine; cats; disease; feline; infection; kittens; product; risk; use; vaccination; vaccine; virus; weeks cache: cord-275538-c44gmu22.txt plain text: cord-275538-c44gmu22.txt item: #139 of 299 id: cord-276193-cngz535o author: Volz, A. title: Modified Vaccinia Virus Ankara: History, Value in Basic Research, and Current Perspectives for Vaccine Development date: 2016-08-01 words: 17885 flesch: 25 summary: Recombinant MVA viruses are clonally isolated in repetitive cell culture passages screening for specific selection markers. Complementation of a defect in virus production is a faster and more convenient method to obtain recombinant MVA viruses. keywords: ankara; antibodies; candidate; cells; challenge; efficacy; et al; gene; genome; host; human; immune; immunization; immunogenicity; induction; infection; influenza; mers; mice; mva; protection; protein; recombinant; responses; smallpox; vaccination; vaccine; vaccinia; vaccinia virus; vacv; vector; virus; viruses cache: cord-276193-cngz535o.txt plain text: cord-276193-cngz535o.txt item: #140 of 299 id: cord-276209-5999g9gp author: Poland, Gregory A. title: Tortoises, hares, and vaccines: A cautionary note for SARS-CoV-2 vaccine development date: 2020-06-02 words: 1609 flesch: 49 summary: What does history teach us in regard to vaccine development? In vaccine development, we need only look back a handful of decades to recall failed vaccines against measles and RSV that used inactivated virus approaches. keywords: risk; studies; vaccine; virus cache: cord-276209-5999g9gp.txt plain text: cord-276209-5999g9gp.txt item: #141 of 299 id: cord-276907-b855tj7x author: Giersing, Birgitte K. title: Report from the World Health Organization’s third Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 8–10th June 2016 date: 2019-11-28 words: 12257 flesch: 33 summary: Dr. Jean-Marie Okwo-Bele, director of IVB, opened proceedings with a synopsis of the significant milestones in vaccine development in the nine months since the previous meeting in September 2015: the first dengue and malaria vaccines have been licensed or achieved the equivalent of licensure, respectively, the first RSV vaccine candidate has entered phase III studies in the elderly and pregnant women, the most advanced HIV vaccine candidate has met its endpoints in the interim analysis of a phase II study, and preparations to commence an efficacy study are underway, WHO convened the MERS-Coronavirus R&D community, and a phase I clinical study is now underway (NCT02670187), Ebola virus vaccines are under review and have progressed to the point of consideration for licensure in record time, There are co-ordinated efforts to develop a Zika virus vaccine as expeditiously as possible. In addition to these significant advances in vaccine development, the UK government published in May 2016 the report on 'Tackling Drug-Resistant Infections Globally' that it commissioned in collaboration with the Welcome Trust [2] . keywords: antibiotic; burden; candidates; data; development; disease; efficacy; global; immunization; impact; infection; lmics; pdvac; phase; potential; product; protection; studies; study; use; vaccine; vaccine development cache: cord-276907-b855tj7x.txt plain text: cord-276907-b855tj7x.txt item: #142 of 299 id: cord-278417-ty4wbtkv author: Chugh, Tulsi title: Timelines of COVID-19 Vaccines date: 2020-07-21 words: 1016 flesch: 48 summary: A comprehensive review of a formidable foe and the road ahead Pandemic preparedness: Developing vaccines and therapeutic antibodies for COVID-19 The early landscape of COVID-19 vaccine development in the UK and rest of the world BCG-induced trained immunity: can it offer protection against COVID-19? BCG vaccination enhances the immunogenicity of subsequent influenza vaccination in healthy volunteers: A randomized, placebocontrolled pilot study Improved immunotherapy for pulmonary tuberculosis with Mycobacterium Vaccae Effects of Mycobacterial vaccae vaccine in a mouse model of tuberculosis: protective action and differentially expressed genes Mutations in SARS-CoV-2 viral RNA identified in Eastern India: Some ecological studies do suggest a link between prior BCG vaccine and recorded cases of COVID-19. keywords: bcg; covid-19; vaccine cache: cord-278417-ty4wbtkv.txt plain text: cord-278417-ty4wbtkv.txt item: #143 of 299 id: cord-279026-s3yx62u6 author: Tizard, Ian R. title: Adverse consequences of vaccination date: 2020-07-10 words: 6724 flesch: 44 summary: In New Zealand adverse event reports should be made to the Ministry for Primary Industries Adverse events in humans associated with accidental exposure to the livestock brucellosis vaccine RB51 Human illness associated with use of veterinary vaccines Evaluation of the safety of vaccinating mares against equine viral arteritis during mid or late gestation or during the immediate postpartum period Pharmacovigilance: Suspected adverse events Vaccination and ill-health in dogs: A lack of temporal association and evidence of equivalence Vaccine hypersensitivity-update and overview Adverse reactions to vaccination: From anaphylaxis to autoimmunity Revisiting adverse reactions to vaccines: A critical appraisal of autoimmune syndrome induced by adjuvants (ASIA) Vaccine-induced enhancement of viral infections Rabies vaccine is associated with decreased all-cause mortality in dogs Vaccine-associated adverse events Large-scale survey of adverse reactions to canine non-rabies combined vaccines in Japan Adverse events after vaccine administration in cats: 2,560 cases Adverse events diagnosed within three days of vaccine administration in dogs Adverse vaccinal reactions in dogs and cats A space-time cluster of adverse events associated with canine rabies vaccine AA amyloidosis in vaccinated growing chickens IgE reactivity to vaccine components in dogs that developed immediate-type allergic reactions after vaccination Membranoproliferative glomerulonephritis possibly associated with over-vaccination in a cocker spaniel Fatal adverse pulmonary reaction in calves after inadvertent intravenous vaccination Anaphylaxis in dogs and cats Comparative vaccine-specific and other injectable-specific risks of injection-site sarcomas in cats Immune modulation following immunization with polyvalent vaccines in dogs In the United States, adverse vaccine events should also be reported to the US Department of Agriculture APHIS Center for Veterinary Biologics at 1-800-752-6255. keywords: administration; animals; canine; cause; disease; dogs; events; example; live; reactions; result; vaccination; vaccine; veterinary; virus cache: cord-279026-s3yx62u6.txt plain text: cord-279026-s3yx62u6.txt item: #144 of 299 id: cord-279260-tdvb0fhv author: Lv, Huibin title: COVID‐19 vaccines: knowing the unknown date: 2020-05-21 words: 1480 flesch: 41 summary: Here we discuss areas that need to be addressed for COVID‐19 vaccine development, and what can be learned from examples of vaccine development in the past. The current status of COVID-19 vaccine development and factors that need to be considered are discussed. keywords: cov-2; development; sars; vaccine cache: cord-279260-tdvb0fhv.txt plain text: cord-279260-tdvb0fhv.txt item: #145 of 299 id: cord-279629-t1xjy12y author: Nazneen Akhand, Mst Rubaiat title: Genome based Evolutionary study of SARS-CoV-2 towards the Prediction of Epitope Based Chimeric Vaccine date: 2020-04-15 words: 6731 flesch: 37 summary: ( Figure 10E ) indicated low chance of deformation of vaccine protein V3. Protein sequence of the spike, envelope, membrane and nucleocapsid were also retrieved from the corresponding genome sequences found in NCBI (Supplementary File 1). keywords: analysis; cell; coronavirus; covid-19; different; epitopes; et al; figure; novel; prediction; protein; sars; server; spike; study; table; vaccine cache: cord-279629-t1xjy12y.txt plain text: cord-279629-t1xjy12y.txt item: #146 of 299 id: cord-280172-6o1gqe8v author: Sanami, Samira title: Design of a Multi-epitope Vaccine against SARS-CoV-2 using Immunoinformatics approach date: 2020-07-15 words: 5871 flesch: 50 summary: The study of vaccine structure in this complex showed high RMSF in most of its amino acids. KK and GPGPG linkers joined the screened T and B-cell epitopes in a structure of multi-epitope vaccine, respectively. keywords: amino; cell; epitopes; fig; hla; model; protein; sars; server; simulation; structure; vaccine cache: cord-280172-6o1gqe8v.txt plain text: cord-280172-6o1gqe8v.txt item: #147 of 299 id: cord-280459-y0tbvs3t author: Ramvikas, M. title: Nasal Vaccine Delivery date: 2016-10-07 words: 7335 flesch: 29 summary: Invitro cellular models for nasal drug absorption studies The isoenzyme pattern of lactate-dehydrogenase in nasal secretions Review on nasal drug delivery system The nose and paranasal sinuses physiology and anatomy Enhanced bioavailability of drugs via intranasal drug delivery system Advances in nasal trans-mucosal drug delivery Nasal drug delivery: an approach of drug delivery through nasal route Nasal drug delivery: possibilities, problems & solutions Review: clinical opportunities provided by the nasal administration of peptides Mucosal vaccines: the promise and the challenge NALT-versus Peyer's-patch-mediated mucosal immunity Recent progress in mucosal vaccine development: potential and limitations The microbial ecology and immunology of the adenoid: implications for otitis media Collaboration of epithelial cells with organized mucosal lymphoid tissues Advantages of intranasal vaccination and considerations on device selection Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system Strong cellular and humoral anti-HIV Env immune responses induced by a heterologous rhabdoviral prime-boost approach Intranasal immunization with a plant virus expressing a peptide from HIV-1gp41 stimulates better mucosal and systemic HIV-1 specific IgA and IgG than oral immunization Immunogenicity of an HIV-1 gag DNA vaccine carried by attenuated Shigella Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes Vaccination with a Shigella DNA vaccine vector induces antigen-specific CD8+ T cells and antiviral protective immunity The use of natural and synthetic phospholipids as pharmaceutical excipients Liposomes as vaccine delivery systems: a review of the recent advances Liposomes act as stronger sub-unit vaccine adjuvants when compared to microspheres Adjuvant activity of monophosphoryl lipid A for nasal and oral immunization with soluble or liposome-associated antigen Adjuvant activity of monophosphoryl lipid A for nasal and oral immunization with soluble or liposome-associated antigen Humans immunized with Streptococcus mutans antigens by mucosal routes Intranasal immunization with proteoliposomes protects against influenza Mucosal immunoadjuvant activity of liposomes: role of alveolar macrophages Surface modified liposomes for nasal delivery of DNA vaccine Intranasal delivery of nanoparticles encapsulating BPI3V proteins induces an early humoral immune response in mice Adjuvanted poly(lactic-coglycolic) acid nanoparticle-entrapped inactivated porcine reproductive and respiratory syndrome virus vaccine elicits cross-protective immune response in pigs Immunization with biodegradable nanoparticles efficiently induces cellular immunity and protects against influenza virus infection Preventative vaccine-loaded mannosylated chitosan nanoparticles intended for nasal mucosal delivery enhance immune responses and potent tumor immunity Development and characterization of bipolymer based nanoparticulate carrier system as vaccine adjuvant for effective immunization Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally Evaluation of mucoadhesive nanoparticle based nasal vaccine Chitosan nanoparticle encapsulated hemagglutinin-split influenza virus mucosal vaccine Induction of protective immunity against chlamydia trachomatis genital infection by a vaccine based on major outer membrane protein-lipophilic immune response-stimulating complexes Intranasal immunisation with influenza-ISCOM induces strong mucosal as well as systemic antibody and cytotoxic T-lymphocyte responses ISCOM is an efficient mucosal delivery system for mycoplasma mycoides subsp. Yet developing vaccine delivery systems that induce humoral and cell-mediated response with mucosal immunity has been challenging to date. keywords: administration; antigen; cavity; cells; delivery; drug; immune; immunity; immunization; intranasal; mucosal; nasal; responses; route; system; vaccine; virus cache: cord-280459-y0tbvs3t.txt plain text: cord-280459-y0tbvs3t.txt item: #148 of 299 id: cord-282158-08u3x1z4 author: Yang, William H. title: Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: An observer-blind, randomized trial() date: 2013-09-13 words: 5330 flesch: 42 summary: The World Health Organization (WHO) encouraged the development and use of adjuvanted influenza A(H1N1)pdm09 vaccines [9, 10] , with the aim of dose-reduction, antigen-sparing and to potentially provide broader vaccine efficacy against drifted strains through cross-reactive immunity [11] . Based on the experience of developing a pre-pandemic A/H5N1 influenza vaccine utilizing AS03 (an ␣-tocopherol oil-in-water emulsion based Adjuvant System) keywords: a(h1n1)pdm09; age; as03; group; influenza; study; subjects; vaccine; years cache: cord-282158-08u3x1z4.txt plain text: cord-282158-08u3x1z4.txt item: #149 of 299 id: cord-282246-wyanwvxa author: Sen, Adrish title: Chapter 40 The Role of Innate Immunity in Regulating Rotavirus Replication, Pathogenesis, and Host Range Restriction and the Implications for Live Rotaviral Vaccine Development date: 2020-12-31 words: 7586 flesch: 29 summary: Natural RV infection efficiently protects against severe reinfection, and for this reason, a variety of experimental and licensed live attenuated RV vaccines have been developed or proposed. The other strategy that has proven highly successful for the reproducible attenuation of the RVs used in live attenuated RV vaccines has been to take advantage of the HRR (see above) of heterologous (nonhuman origin) RVs as vaccine candidates for humans [82] . keywords: activation; cells; host; human; ifn; ifns; infection; interferon; nsp1; protein; replication; response; rotavirus; vaccines cache: cord-282246-wyanwvxa.txt plain text: cord-282246-wyanwvxa.txt item: #150 of 299 id: cord-282360-byqhzyzi author: Zhang, Dingmei title: Enterovirus 71 vaccine: close but still far date: 2010-04-18 words: 4412 flesch: 33 summary: We reviewed publications on the development of EV71 vaccines in order to provide an overview of the field. To develop EV71 vaccines with a high protection efficacy, strategies such as the use of adjuvant, strong promoters, tissue-specific promoters, and addition of mucosal immune adjuvant should be considered. keywords: cell; development; enterovirus; ev71; infection; mice; oral; protein; vaccine; vp1 cache: cord-282360-byqhzyzi.txt plain text: cord-282360-byqhzyzi.txt item: #151 of 299 id: cord-282507-swxs5pr1 author: Lacaille-Dubois, Marie-Aleth title: Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: A review date: 2019-07-31 words: 8462 flesch: 32 summary: Vaccines MAGE-A3 immunotherapeutic as ajuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double blind, randomized, placebo-controlled Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor >1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial MAGE-A3: an immunogenic target used in clinical practice Design, synthesis and evaluation of optimized saponin variants derived from the vaccine adjuvant QS-21 Development of a minimal saponin vaccine adjuvant bsed on QS-21 Development of improved vaccine adjuvants based on the saponin natural product QS-21 through chemical synthesis From discovery to licensure, the adjuvant system story GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives Understanding Modern Vaccines: Perspectives in Vaccinology 1 The perfect mix: recent progress in adjuvant research Safetey and immunogenicity of an adjuvanted protein therapeutic HIV-1 vaccine in subjects with HIV-1 infection: a randomized placebo-controlled study Long-term follow-up of HIV-1-infected adults who received the F4/AS01B HIV-1 vaccine candidate in two randomized controlled trials Long term extensions of randomized vaccination trials of ACC-001 and QS-21 in mild to moderate Alzheimer's disease Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine when given as a booster to BCG in Gambian infants: an open-label randomized controlled trial System analysis of protective immune responses to RTS,S malaria vaccination in humans Saponins as vaccine adjuvants Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex Randomized, doubleblind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01 B and RTS,S/AS02 A in malaria-naïve adults: safety, efficacy, and immunologic associates of protection A review of the biological and pharmacological activities of saponins Bioactive saponins from plants: an update New perspectives for natural triterpene glycosides as potential adjuvants Saponins as immunoadjuvants and immunostimulants Bioactive saponins with cancer related and immunomodulatory activity: recent developments Efficacy of an adjuvanted Herpes Zoster subunit vaccine in older adults Recent advances of vaccine adjuvants for infectious diseases Evaluation of the immune response to RTS,S/AS01 and RTS,S/AS02 adjuvanted vaccines Immunogenicity and safety of a booster dose of an investigantional adjuvanted polyprotein HIV-1 vaccine in healthy adults and effect of administered chloroquine Improved CD4 + T cell responses to Mycobacterium tuberculosis in PPD negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial Strong and persistent CD4 + T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp 120, Nef and Tat antigens formulated in three adjuvant systems A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein E subunit vaccine candidate in young and older adults Vaccine potentiation by combination adjuvants Amphiphilic nature of saponins and their effects on artificial and biological membranes and potential consequences for red blood and cancer cells Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity Elucidating the mechanisms of action of saponin-derived adjuvants Identification of QS-21 as an inflammasome-activating molecular component of saponin adjuvants Characterization of T-cell immune responses in clinical trials of the candidate RTS,S malaria vaccine Efficacy of RTS,S/AS01 E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomized controlled trial Two phase 2 multiple ascending dose studies of vanutide cridificar (ACC-001) and QS-21 adjuvant in mild-to-moderate Alzheimer's disease The vaccine study team, 2015. A phase II trial in adults > 60 years of age evaluating different formulations (containing 25, 50, or 100 μg gE combined with AS01) and different schedules showed that all formulations elicited robust humoral and CD4 + T cell immune responses that persisted for at least 3 years after vaccination. keywords: adjuvant; adults; as01; cd4; cell; et al; immune; malaria; phase; qs-21; responses; rts; safety; vaccine cache: cord-282507-swxs5pr1.txt plain text: cord-282507-swxs5pr1.txt item: #152 of 299 id: cord-283405-aozxvxxs author: Vermillion, Meghan S. title: Pregnancy and infection: using disease pathogenesis to inform vaccine strategy date: 2018-02-01 words: 8432 flesch: 21 summary: This enables production of a vaccine strain with maximum efficacy and safety, and represents another promising alternative to conventional attenuated or killed virus vaccines. Recombinant virus vaccines, however, warrant careful consideration of the safety of the vector itself, especially in pregnant women. keywords: antibody; congenital; disease; immunity; immunization; infection; influenza; maternal; pregnancy; protection; risk; safety; transmission; vaccination; vaccine; virus; women cache: cord-283405-aozxvxxs.txt plain text: cord-283405-aozxvxxs.txt item: #153 of 299 id: cord-283475-28900qlr author: Yu, Wenzhou title: Vaccine-preventable disease control in the People’s Republic of China: 1949–2016 date: 2018-12-18 words: 5048 flesch: 38 summary: China's experience with hepatitis B vaccine is an interesting case study on use of cost-sharing to finance the introduction of new vaccines that may be of relevance to middle-income countries ineligible for GAVI support. Farm collectives and the RCMS were dismantled, and while EPI vaccines were still provided for free, funding for vaccine delivery switched to fee-for-service, usually 1-2 RMB paid by parents to the village or township doctor for each dose administered. keywords: china; coverage; delivery; health; hepatitis; immunization; measles; national; people; vaccination; vaccine cache: cord-283475-28900qlr.txt plain text: cord-283475-28900qlr.txt item: #154 of 299 id: cord-285128-48l1w65p author: Custers, Jerome title: Vaccines based on replication incompetent Ad26 viral vectors: standardized template with key considerations for a risk/benefit assessment date: 2020-10-03 words: 4758 flesch: 29 summary: In the unlikely event that recombination occurs between vaccine vector and wild-type adenoviruses, the virulence can maximally be 22 equal to the wild-type adenovirus already present in the tissue. The vector genome (linear ds-DNA) travels to the nucleus of the host cell where antigen expression occurs, in the absence of vaccine vector replication. keywords: ad26; adenovirus; cell; human; replication; responses; safety; studies; type; vaccine; vector cache: cord-285128-48l1w65p.txt plain text: cord-285128-48l1w65p.txt item: #155 of 299 id: cord-285613-hbd44euq author: Søborg, Christian title: Vaccines in a hurry date: 2009-05-26 words: 3805 flesch: 39 summary: In the present discussion paper, we propose mechanisms to facilitate development of emergency vaccines in Europe by focusing on public–private scientific partnerships, fast-track approval of emergency vaccine by regulatory agencies and proposing incentives for emergency vaccine production in private vaccine companies. In the present discussion paper, we address mechanisms to facilitate development of emergency vaccines in Europe by focusing on regulatory aspects and proposing incentives for emergency vaccine production in private vaccine companies. keywords: approval; development; disease; emergency; health; production; public; safety; vaccine cache: cord-285613-hbd44euq.txt plain text: cord-285613-hbd44euq.txt item: #156 of 299 id: cord-285691-pceenwb6 author: Falo, Louis D. title: Advances in skin science enable the development of a COVID-19 Vaccine date: 2020-05-30 words: 181 flesch: 12 summary: Taken together, these and studies by others demonstrate the potential for the development of cutaneous immune engineering strategies to control systemic immune responses including the potential for developing novel vaccine strategies and immunotherapies, and even negative immunization strategies to treat systemic allergy and autoimmune diseases. The immunological anatomy of the skin Antigen-Presenting cells in the skin Microneedles for drug and vaccine delivery Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development Improved cutaneous genetic immunization by microneedle array delivery of an adjuvanted adenovirus vaccine keywords: skin cache: cord-285691-pceenwb6.txt plain text: cord-285691-pceenwb6.txt item: #157 of 299 id: cord-285760-y37ji92k author: Connell, Anna R. title: Mumps Outbreaks in Vaccinated Populations—Is It Time to Re-assess the Clinical Efficacy of Vaccines? date: 2020-09-18 words: 13114 flesch: 26 summary: In contrast, other studies appear to contradict, these findings, showing no link between mumps protection and time elapsed following administration of mumps vaccine (138, 148, 149, 184, 185) . I. Incidence and severity of mumps in vaccinated and control groups Preparation of mumps vaccines and immunization of monkeys against experimental mumps infection European Centre for Disease Prevention and Control. keywords: antibodies; antibody; cell; efficacy; failure; immunity; immunization; individuals; infection; measles; mmr; mumps; mumps vaccine; muv; outbreaks; protection; response; rubella; specific; strain; vaccination; vaccine; virus; years cache: cord-285760-y37ji92k.txt plain text: cord-285760-y37ji92k.txt item: #158 of 299 id: cord-285883-rlliacex author: Kremer, Eric J. title: Pros and Cons of Adenovirus-Based SARS-CoV-2 Vaccines date: 2020-10-09 words: 1490 flesch: 49 summary: An example is the evolution and checkered history of vaccines based on adenoviruses (Ads). Many of the first replication-defective Ad vectors in the early 1980s were vaccines. keywords: cells; cov-2; vaccine cache: cord-285883-rlliacex.txt plain text: cord-285883-rlliacex.txt item: #159 of 299 id: cord-285982-1a5u7uux author: Moss, Ronald B title: Prospects for control of emerging infectious diseases with plasmid DNA vaccines date: 2009-09-07 words: 4229 flesch: 37 summary: These and other attributes make DNA vaccines ideal for development against emerging pathogens. The rapid manufacturing capabilities of DNA vaccines may be particularly important for emerging infectious diseases including the current novel H1N1 Influenza A pandemic, where pre-existing immunity is limited. keywords: cells; colleagues; dna; immune; influenza; plasmid; responses; vaccination; vaccines; virus cache: cord-285982-1a5u7uux.txt plain text: cord-285982-1a5u7uux.txt item: #160 of 299 id: cord-287067-rrsgl377 author: Beutels, Philippe title: Funding of drugs: do vaccines warrant a different approach? date: 2008-11-30 words: 5436 flesch: 40 summary: These impacts have the potential to change decisions, for instance on rotavirus vaccine. In high-income countries, the main benefi t of rotavirus vaccines is the prevention of parental care and productivity losses in virtually all households with infants or toddlers. keywords: benefi; care; cost; countries; ectiveness; ects; eff; health; time; vaccination; vaccines cache: cord-287067-rrsgl377.txt plain text: cord-287067-rrsgl377.txt item: #161 of 299 id: cord-287410-boxxlopy author: Devi, Arpita title: In silico designing of multi-epitope vaccine construct against human coronavirus infections date: 2020-08-10 words: 7221 flesch: 55 summary: The antigenicity of the epitopes and vaccine constructs was predicted using Vaxigen v2.0 (Doytchinova & Flower, 2007) webserver. The allergenicity of the epitopes and vaccine construct was predicted using AllerTOP v2.0 (Dimitrov et al., 2014) webserver. keywords: binding; cell; construct; coronavirus; cov; epitopes; level; protein; sars; score; server; structure; vaccine cache: cord-287410-boxxlopy.txt plain text: cord-287410-boxxlopy.txt item: #162 of 299 id: cord-287824-zg5akivn author: Chan, Yinghan title: Advanced drug delivery systems can assist in managing influenza virus infection: A hypothesis date: 2020-09-24 words: 1159 flesch: -1 summary: Vaccine Anti-455 bacterial activity of inorganic nanomaterials and their antimicrobial peptide conjugates 456 against resistant and non-resistant pathogens Perspectives and 459 advancements in the design of nanomaterials for targeted cancer theranostics Microparticles as Vaccine Adjuvants and Delivery Systems Investigation of 465 tunable acetalated dextran microparticle platform to optimize M2e-based influenza 466 vaccine efficacy Molecular assembly and application of biomimetic microcapsules Hybrid inorganic-organic capsules for eficient intracellular delivery of novel siRNAs 472 against influenza A (H1N1) virus infection Biodegradable Polyelectrolyte/Silica Composite Microcapsules as Carriers for Small 476 Application of dendrimers for the treatment of 479 infectious diseases Nanoparticle vaccines against infectious diseases Delivery Vehicles for Active Phytoconstituents Emerging Trends 492 in Nanomedicine for Topical Delivery in Skin Disorders: Current and Translational 493 Oligonucleotide 495 therapy: An emerging focus area for drug delivery in chronic inflammatory respiratory 496 diseases Emerging trends in 498 the novel drug delivery approaches for the treatment of lung cancer Interactions 501 with the macrophages: An emerging targeted approach using novel drug delivery 502 systems in respiratory diseases Gene Delivery by PAMAM Dendrimer 505 Conjugated with the Nuclear Localization Signal Peptide Derived from Influenza B 506 Identification of biomarkers and genetic approaches toward chronic obstructive 510 pulmonary disease Inhibition of influenza A virus infection in vitro by saliphenylhalamide-loaded 513 porous silicon nanoparticles Enhanced inhibition of influenza virus infection 516 by peptide-noble-metal nanoparticle conjugates Development of an adjuvanted nanoparticle vaccine against influenza virus, an 520 in vitro study Pulmonary surfactant-biomimetic 523 nanoparticles potentiate heterosubtypic influenza immunity Protein Nanoparticle Immunization Induces Broad Cross-Protection against 527 Different Influenza Viruses in Mice Virus-mimetic polymer 530 nanoparticles displaying hemagglutinin as an adjuvant-free influenza vaccine Porous gold nanoparticles for 533 attenuating infectivity of influenza A virus Inhibition of H1N1 influenza virus infection by zinc oxide nanoparticles: 537 Another emerging application of nanomedicine Phase 3 Pivotal Trial of NanoFlu TM in Older Adults Editorial: Advances and challenges in nanomedicine Nanoethics: From utopian dreams and apocalyptic nightmares towards a 543 more balanced view The authors declare no conflict of interest, financial or otherwise. Single-371 dose mucosal immunization with a candidate universal influenza vaccine provides 372 rapid protection from virulent H5N1, H3N2 and H1N1 viruses Exploiting Nanotechnology to Target Viruses Universal influenza vaccines: from viruses to 378 nanoparticles Nanotherapeutic Anti-influenza Solutions: Current Knowledge and Future Challenges Influenza antivirals and resistance: The next 10 384 years? keywords: delivery; drug; influenza; vaccine; virus cache: cord-287824-zg5akivn.txt plain text: cord-287824-zg5akivn.txt item: #163 of 299 id: cord-287853-cob7ur35 author: Sharma, Vaneet Kumar title: The expanding role of mass spectrometry in the field of vaccine development date: 2018-05-31 words: 3758 flesch: 12 summary: The glycan shield of HIV is predominantly oligomannose independently of production system or viral clade Structural constraints determine the glycosylation of HIV-1 envelope trimers Ion mobility mass spectrometry for extracting spectra of N-glycans directly from incubation mixtures following glycan release: application to glycans from engineered glycoforms of intact, folded HIV gp120 MALDI-MS/MS with traveling wave ion mobility for the structural analysis of N-linked glycans Ion mobility mass spectrometry for ion recovery and clean-up of MS and MS/MS spectra obtained from low abundance viral samples Global Nglycan site occupancy of HIV-1 gp120 by metabolic engineering and high-resolution intact mass spectrometry Structural principles controlling HIV envelope glycosylation Global site-specific Nglycosylation analysis of HIV envelope glycoprotein Comprehensive characterization of reference standard lots of HIV-1 subtype C Gp120 proteins for clinical trials in Southern African regions Cell culture as a substrate for the production of influenza vaccines: memorandum from a WHO meeting Current and emerging cell culture manufacturing technologies for influenza vaccines Critical review of current and emerging quantification methods for the development of influenza vaccine candidates Influenza vaccine: the challenge of antigenic drift Confronting the next pandemic-workshop on lessons learned from potency testing of pandemic (H1N1) 2009 influenza vaccines and considerations for future potency tests Application of deglycosylation and electrophoresis to the quantification of influenza viral hemagglutinins facilitating the production of 2009 pandemic influenza (H1N1) vaccines at multiple manufacturing sites in China Quantification of influenza virus hemagglutinins in complex mixtures using isotope dilution tandem mass spectrometry Optimization of digestion parameters for protein quantification Simultaneous quantification of hemagglutinin and neuraminidase of influenza virus using isotope dilution mass spectrometry Quantification of viral proteins of the avian H7 subtype of influenza virus: an isotope dilution mass spectrometry method applicable for producing more rapid vaccines in the case of an influenza pandemic Development of influenza A (H7N9) candidate vaccine viruses with improved hemagglutinin antigen yield in eggs Quantification of immunoreactive viral influenza proteins by immunoaffinity capture and isotope-dilution liquid chromatography-tandem mass spectrometry Immunocapture isotope dilution mass spectrometry in response to a pandemic influenza threat Quantification of influenza neuraminidase activity by ultra-high performance liquid chromatography and isotope dilution mass spectrometry Label-free mass spectrometry-based quantification of hemagglutinin and neuraminidase in influenza virus preparations and vaccines Quantification of proteins by label-free LC-MSE Absolute quantification of proteins by LCMS E a virtue of parallel MS acquisition Selective and quantitative detection of influenza virus proteins in commercial vaccines using two-dimensional high-performance liquid chromatography and fluorescence detection Approach to the profiling and characterization of influenza vaccine constituents by the combined use of size-exclusion chromatography, gel electrophoresis and mass spectrometry Strain identification of commercial influenza vaccines by mass spectrometry Simultaneous quantification of the viral antigens hemagglutinin and neuraminidase in influenza vaccines by LC-MS E Fast and highly selective determination of hemagglutinin content in quadrivalent influenza vaccine by reversed-phase high-performance liquid chromatography method Advancing dengue vaccine development Site-specific characterization of envelope protein N-glycosylation on Sanofi Pasteur's tetravalent CYD dengue vaccine Absolute quantification of dengue virus serotype 4 chimera vaccine candidate in Vero cell culture by targeted mass spectrometry After Ebola in West Africaunpredictable risks, preventable epidemics Identification of N-glycans from Ebola virus glycoproteins by matrix-assisted laser desorption/ ionisation time-of-flight and negative ion electrospray tandem mass spectrometry Comparison of N-and O-linked glycosylation patterns of ebolavirus glycoproteins Development of a liquid chromatography high resolution mass spectrometry method for the quantitation of viral envelope glycoprotein in Ebola virus-like particle vaccine preparations Chikungunya virus: pathophysiology, mechanism, and modeling Development and application of a reversed-phase high-performance liquid chromatographic method for quantitation and characterization of a Chikungunya virus-like particle vaccine Characterization of Nglycosylation profiles from mammalian and insect cell derived chikungunya VLP Label-free quantitative mass spectrometry for analysis of protein antigens in a meningococcal group B outer membrane vesicle vaccine Physicochemical characterisation of glycoconjugate vaccines for prevention of meningococcal diseases Defined conjugation of glycans to the lysines of CRM 197 guided by their reactivity mapping Quantification by LC-MS E of outer membrane vesicle proteins of the Bexsero ® vaccine The dual role of lipids of the lipoproteins in Trumenba, a self-adjuvanting vaccine against meningococcal meningitis B disease Robust manufacturing and comprehensive characterization of recombinant hepatitis E viruslike particles in Hecolin ® Hepatitis E virus: a renewed hope with Hecolin Molecular and structural characterization of the L1 virus-like particles that are used as vaccine antigens in Cervarix™, the AS04-adjuvanted HPV-16 and-18 cervical cancer vaccine Viruslike particles in vaccine development Virus-like particle-based human vaccines: quality assessment based on structural and functional properties Status of vaccine research and development of vaccines for Nipah virus Proteomic composition of Nipah virus-like particles Production of immunogenic West Nile virus-like particles using a herpes simplex virus 1 recombinant vector Characterization of human enterovirus71 virus-like particles used for vaccine antigens Mass spectrometric characterization of the glycosylation pattern of HIV-gp120 expressed in CHO cells Glycan profiles of the 27 N-glycosylation sites of the HIV envelope protein CN54gp140 Comparative analysis of the glycosylation profiles of membrane-anchored HIV-1 envelope glycoprotein trimers and soluble gp140 Mapping the complete glycoproteome of virion-derived HIV-1 gp120 provides insights into broadly neutralizing antibody binding Haemagglutinin quantification and identification of influenza A&B strains propagated in PER. 77 Label-free MS-based methods have also been reported for the simultaneous identification and quantification of HA and NA in influenza vaccine with samples analyzed by LC-MS E on a Waters Synapt G2 mass spectrometer. keywords: analysis; characterization; development; envelope; glycosylation; influenza; mass; quantification; spectrometry; vaccine; virus cache: cord-287853-cob7ur35.txt plain text: cord-287853-cob7ur35.txt item: #164 of 299 id: cord-288868-qfdxri93 author: Wack, Andreas title: Vaccinology at the beginning of the 21st century date: 2005-06-13 words: 5085 flesch: 35 summary: This is a promising example of how molecular approaches are employed for the rational design of new vaccines. (d) DCs matured and loaded with antigen in vitro are efficient vaccines [41 ,42,43] . keywords: antigen; cells; dcs; dna; immune; response; vaccination; vaccine; virus cache: cord-288868-qfdxri93.txt plain text: cord-288868-qfdxri93.txt item: #165 of 299 id: cord-289360-h6wvx7gw author: Imperiale, Michael J. title: The Importance of Virology at a Time of Great Need and Great Jeopardy date: 2015-03-10 words: 1291 flesch: 46 summary: We are in the middle of our annual encounter with influenza virus, never knowing when the next strain to which there is little or no preexisting immunity will arise. In 2014-2015, a mismatch between the H3N2 strain in the influenza vaccine and the circulating virus has led to a poorly protective vaccine, which highlights the need for new vaccines. keywords: research; virology; viruses cache: cord-289360-h6wvx7gw.txt plain text: cord-289360-h6wvx7gw.txt item: #166 of 299 id: cord-289535-srrfr1es author: Tregoning, J. S. title: Vaccines for COVID‐19 date: 2020-10-18 words: 14346 flesch: 38 summary: Identity of blood and tissue leukocytes supporting in vitro infection New insights into the immunopathology and control of dengue virus infection Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection Molecular mechanism for antibodydependent enhancement of coronavirus entry A perspective on potential antibody-dependent enhancement of SARS-CoV-2 Is there an ideal animal model for SARS? Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase Caution urged on SARS vaccines Aged BALB/c mice as a model for increased severity of severe acute respiratory syndrome in elderly humans Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus Development of animal models against emerging coronaviruses: from SARS to MERS coronavirus Blocking transmission of Middle East respiratory syndrome coronavirus (MERS-CoV) in llamas by vaccination with a recombinant spike protein Humoral immunogenicity and efficacy of a single dose of ChAdOx1 MERS vaccine candidate in dromedary camels The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice SARS-CoV-2 infection in farmed minks, the Netherlands Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2 Reinfection could not occur in SARS-CoV-2 infected rhesus macaques Ethical guidelines for deliberately infecting volunteers with COVID-19 Human challenge studies to accelerate coronavirus vaccine licensure SARS-CoV-2 controlled human infection models: ethics, challenge agent production and regulatory issues Effect of dexamethasone in hospitalized patients with COVID-19 Criner GJet al, for the GSUSI. Clinical vaccine trials conventionally undergo four broad Phases, from early safety in small numbers of volunteers (Phase I) to wide-scale post-licensure monitoring (Phase IV). keywords: antibodies; antibody; cell; challenge; coronavirus; cov-2; covid-19; development; disease; dna; human; immune; immunity; infection; mers; mice; phase; protein; responses; rna; sars; spike; studies; syndrome; trials; vaccination; vaccine; virus cache: cord-289535-srrfr1es.txt plain text: cord-289535-srrfr1es.txt item: #167 of 299 id: cord-289599-7vsynfgn author: Kostoff, Ronald N. title: COVID-19 vaccine safety date: 2020-09-18 words: 2715 flesch: 35 summary: Questions have been raised as to whether an accelerated vaccine development can be accomplished safely, preventing potential adverse vaccine effects not only in the short-term, but also in the mid-and long-term (https://smartech.gatech.edu/handle/1853/63710). Regulatory Affairs Professionals Society Towards effective cOVId-19 vaccines: Updates, perspectives and challenges (Review) keywords: covid-19; effects; mid; population; potential; term; vaccine cache: cord-289599-7vsynfgn.txt plain text: cord-289599-7vsynfgn.txt item: #168 of 299 id: cord-289763-jek2pd31 author: Fisher, Kimberly A. title: Attitudes Toward a Potential SARS-CoV-2 Vaccine: A Survey of U.S. Adults date: 2020-09-04 words: 4711 flesch: 40 summary: Evidence that these characteristics are predictive of vaccine hesitancy could be useful in targeting vaccine messaging and outreach to populations at risk for not being vaccinated. Our findings suggest that a multipronged approach may be needed in which trusted physicians promote vaccine uptake against a backdrop of innovative approaches and channels to combat vaccine misinformation, consistent with the body of literature of strategies to address vaccine hesitancy (39). keywords: characteristics; coronavirus; covid-19; health; influenza; intent; participants; vaccination; vaccine cache: cord-289763-jek2pd31.txt plain text: cord-289763-jek2pd31.txt item: #169 of 299 id: cord-289961-7q2wkwrf author: Chattopadhyay, Saborni title: Nanoparticle Vaccines Adopting Virus-like Features for Enhanced Immune Potentiation date: 2017-06-09 words: 10547 flesch: 26 summary: As a result, mechanisms behind the benefits of nanoparticle vaccines can often find analogue to the interaction dynamics between the immune system and viruses. As understanding of human immunity and vaccine mechanisms continue to evolve, recognizing the fundamental semblance between synthetic nanoparticles and viruses may offer an explanation for the superiority of nanoparticle vaccines over conventional vaccines and may spur new design rationales for future vaccine research. keywords: adjuvant; antigen; cells; delivery; dna; gold; immune; influenza; liposomes; lymph; nanoparticles; node; protein; responses; size; study; surface; system; vaccine; virus; viruses cache: cord-289961-7q2wkwrf.txt plain text: cord-289961-7q2wkwrf.txt item: #170 of 299 id: cord-290004-v3ruj5bq author: Madsen, Anders title: Prospects and Challenges in the Development of Universal Influenza Vaccines date: 2020-07-06 words: 4407 flesch: 33 summary: The future of influenza vaccines: A historical and clinical perspective Development of a universal influenza vaccine A universal influenza vaccine: The strategic plan for the national institute of allergy and infectious diseases The Compelling Need for Game-Changing Influenza Vaccines an Analysis of the Influenza Vaccine Enterpris The role of Fc-FcγR interactions in IgG-mediated microbial neutralization Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection Highly conserved protective epitopes on influenza B viruses Natural T cell-mediated protection against seasonal and pandemic influenza. Vaccines Immunother Efforts to improve the seasonal influenza vaccine Safety, efficacy, and immunogenicity of Flublok in the prevention of seasonal influenza in adults Adjuvanted influenza vaccines. keywords: cell; development; influenza; protection; universal; vaccines; virus; viruses cache: cord-290004-v3ruj5bq.txt plain text: cord-290004-v3ruj5bq.txt item: #171 of 299 id: cord-290031-vffa1bu0 author: Richmond, Heather title: Seasonal influenza vaccination during a pandemic date: 2020-07-31 words: 1687 flesch: 30 summary: Several policies, such as vaccination strategies to accommodate physical distancing measures, change population recommendations, and timing and location of vaccination have been implemented to increase influenza vaccine uptake during the pandemic. Policy changes in Australia, together with strong communication from public health agencies and media reporting about the risk of coinfection and importance of influenza vaccination, generated significant demand for influenza vaccines early in the season. keywords: influenza; season; vaccination; vaccine cache: cord-290031-vffa1bu0.txt plain text: cord-290031-vffa1bu0.txt item: #172 of 299 id: cord-290705-7xkt6u73 author: Petrini, Stefano title: Evaluation of Passive Immunity Induced by Immunisation Using Two Inactivated gE-deleted Marker Vaccines against Infectious Bovine Rhinotracheitis (IBR) in Calves date: 2020-01-04 words: 4293 flesch: 46 summary: Other European Union states have implemented compulsory eradication programmes combining test-and-removal with vaccination using marker vaccines, conversely to vaccination strategies used in the USA, where non-marker vaccines are used [3] . Marker vaccines are derived from the deletion of one or more genes responsible for the synthesis of glycoproteins or enzymes keywords: animals; bohv-1; bovine; calves; cattle; marker; samples; vaccines cache: cord-290705-7xkt6u73.txt plain text: cord-290705-7xkt6u73.txt item: #173 of 299 id: cord-291315-y40s45iv author: Logunov, Denis Y title: Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia date: 2020-09-04 words: 5736 flesch: 45 summary: Thus, the presence of a pre-existing immune response to the components of vaccine vectors rAd26 and rAd5 does not affect the titre of RBD-specific antibodies in the serum of participants. [30] The incidence of adverse events in our studies was slightly lower than in other work; a comparative clinical study with other vaccines is needed to confirm these findings. keywords: cov-2; covid-19; days; participants; phase; rad26; rad5; sars; study; vaccination; vaccine; volunteers cache: cord-291315-y40s45iv.txt plain text: cord-291315-y40s45iv.txt item: #174 of 299 id: cord-292528-8kdhf123 author: Lau, Yuk-Fai title: A TLR3 ligand that exhibits potent inhibition of influenza virus replication and has strong adjuvant activity has the potential for dual applications in an influenza pandemic date: 2009-02-25 words: 6915 flesch: 46 summary: There is an accumulating body of data showing that H5N1 virus vaccines are generally poorly immunogenic. The 2006-2007 South Hemisphere seasonal influenza vaccine, Fluvax, was from CSL Ptd Ltd. (Victoria, Australia). keywords: adjuvant; antibody; cells; dose; fig; group; h5n1; influenza; mice; pika; reduction; titer; vaccine; virus cache: cord-292528-8kdhf123.txt plain text: cord-292528-8kdhf123.txt item: #175 of 299 id: cord-293234-ouykx6g5 author: Puig-Barberà, J. title: Effectiveness of the 2010–2011 seasonal influenza vaccine in preventing confirmed influenza hospitalizations in adults: A case–case comparison, case-control study date: 2012-08-24 words: 4424 flesch: 38 summary: As a consequence of antigenic drift, influenza vaccines are to be a produced every year [3] . Information related to the administration of the 2009-2010 seasonal influenza vaccine, the A(H1N1) pandemic vaccine and previous 23-valent polysaccharide plain pneumococcal vaccinations was obtained from the Vaccine Information System. keywords: age; case; conditions; controls; effectiveness; influenza; pcr; risk; study; vaccine; years cache: cord-293234-ouykx6g5.txt plain text: cord-293234-ouykx6g5.txt item: #176 of 299 id: cord-293559-c78wcr8m author: Rego, Gabriel N. A. title: Current Clinical Trials Protocols and the Global Effort for Immunization against SARS-CoV-2 date: 2020-08-25 words: 9763 flesch: 53 summary: The current landscape of COVID-19 vaccine development shows that most CTPs are being developed in Asia (Table A1 ). Based on 50 current studies selected from the main clinical trial databases, this systematic review summarizes the global race for vaccine development against COVID-19. keywords: cov-2; covid-19; ctps; development; figure; iii; immunogenicity; mrna; phase; protein; safety; sars; study; trial; vaccine cache: cord-293559-c78wcr8m.txt plain text: cord-293559-c78wcr8m.txt item: #177 of 299 id: cord-294108-uvnh0s9r author: Dube, Taru title: Repurposed Drugs, Molecular Vaccines, Immune‐Modulators, and Nanotherapeutics to Treat and Prevent COVID‐19 Associated with SARS‐CoV‐2, a Deadly Nanovector date: 2020-10-25 words: 13897 flesch: 38 summary: COVID-19 patients seeking intensive care unit (ICU) are particularly older and more likely to carry pre-existing comorbid conditions like hypertension and related heart diseases followed by diabetes. To date, apart from the emergency use approval of the antiviral drug favilavir in China, India, Russia, and parts of the Middle East and the emergency use approval of remdesivir by the US-FDA and Japan in COVID-19 patients, there are no approved therapeutic molecules to treat the COVID-19 pandemic. keywords: care; cells; cov-2; covid-19; covid-19 patients; disease; dose; drug; efficacy; host; human; iii; infection; patients; phase; potential; protein; response; rna; safety; sars; therapeutics; treatment; trial; use; vaccine; virus cache: cord-294108-uvnh0s9r.txt plain text: cord-294108-uvnh0s9r.txt item: #178 of 299 id: cord-294347-axkdf5vu author: Kim, Shin-Hee title: Newcastle Disease Virus as a Vaccine Vector for Development of Human and Veterinary Vaccines date: 2016-07-04 words: 7197 flesch: 43 summary: Consequently, NDV vaccine virus provided protection from RSV challenge. Live attenuated NDV vaccines are widely used all over the world. keywords: avian; disease; gene; ndv; newcastle; protein; responses; strains; vaccine; vector; virus cache: cord-294347-axkdf5vu.txt plain text: cord-294347-axkdf5vu.txt item: #179 of 299 id: cord-294366-swwz4kzd author: Bramwell, Vincent W. title: The rational design of vaccines date: 2005-11-15 words: 4882 flesch: 27 summary: In this complex but increasingly focussed environment of vaccine development, are there opportunities for new solutions for vaccine design? This review provides an insight into the various opportunities for vaccine intervention, analysis of strategies for vaccine development, vaccine ability to modulate immune responses and resultant rational vaccine design. keywords: antibody; antigens; cancer; cells; design; development; diseases; hiv; infection; responses; tuberculosis; vaccine; virus cache: cord-294366-swwz4kzd.txt plain text: cord-294366-swwz4kzd.txt item: #180 of 299 id: cord-294789-07hto8qn author: Schoch-Spana, Monica title: The public’s role in COVID-19 vaccination: human-centered recommendations to enhance pandemic vaccine awareness, access, and acceptance in the United States date: 2020-10-29 words: 5812 flesch: 33 summary: A combination of literature reviews on vaccination, pandemic planning, and health crisis communication; an assessment of current news and social media trends regarding COVID-19 vaccines; and key informant interviews with each working group member focusing on their respective expertise formed the basis of the research presented in this article. In the case of SARS-CoV-2 vaccination, for instance, while an NIH Funding Opportunity Award that could support research on human factors related to vaccine acceptance was made possible in June 2020, the earliest project start date is September 2021, a full nine months after Operation Warp Speed plans for COVID-19 vaccines to become available [21] . keywords: communication; community; cov-2; covid-19; group; health; human; pandemic; populations; public; research; safety; sars; vaccination; vaccine cache: cord-294789-07hto8qn.txt plain text: cord-294789-07hto8qn.txt item: #181 of 299 id: cord-294856-eeh2a0t8 author: Lambert, Paul-Henri title: Consensus Summary Report for CEPI/BC March 12-13, 2020 Meeting: Assessment of Risk of Disease Enhancement with COVID-19 Vaccines date: 2020-05-25 words: 5249 flesch: 32 summary: Virology Intratracheal exposure of common marmosets to MERS-CoV Jordan-n3/2012 or MERS-CoV EMC/2012 isolates does not result in lethal disease Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH-and cysteine protease-independent FcgammaR pathway Antibody-dependent infection of human macrophages by severe acute respiratory syndrome coronavirus A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants Successful vaccination strategies that protect aged mice from lethal challenge from influenza virus and heterologous severe acute respiratory syndrome coronavirus Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets Animal models and antibody assays for evaluating candidate SARS vaccines: summary of a technical meeting 25-26 Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus A Highly Immunogenic, Protective, and Safe Adenovirus-Based Vaccine Expressing Middle East Respiratory Syndrome Coronavirus S1-CD40L Fusion Protein in a Transgenic Human Dipeptidyl Peptidase 4 Mouse Model Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates Correction: Immunodominant SARS Coronavirus Epitopes in Humans Elicited Both Enhancing and Neutralizing Effects on Infection in Non-human Primates Immunogenicity and protective efficacy in monkeys of purified inactivated Verocell SARS vaccine. In murine models, evidence for vaccine related disease enhancement has been demonstrated for inactivated whole vaccine (with and without alum), vectored vaccine expressing N protein (but not seen with vectored vaccine expressing S protein in same report), a replicon particle platform expressing S protein, and a vectored vaccine expressing S proteins. keywords: animal; challenge; coronavirus; cov-2; disease; enhancement; mice; models; response; sars; vaccine; virus cache: cord-294856-eeh2a0t8.txt plain text: cord-294856-eeh2a0t8.txt item: #182 of 299 id: cord-296469-h0ma163u author: Gellin, Bruce G. title: Preparing for the unpredictable: The continuing need for pandemic influenza preparedness date: 2016-10-26 words: 1502 flesch: 39 summary: While this event is advertised as a programme review, in reality as an examination of the progress achieved during the decade, it should also serve to direct the global community on the path forward for the work that remains to achieve global pandemic influenza vaccine and vaccination preparedness. [14] , and WHO's restructuring of its approach to global health emergencies The Global Action Plan for Influenza Vaccines was structured around three broad objectives that underpin pandemic influenza vaccine and vaccination preparedness: -evidence-based increase in seasonal influenza vaccine use; -increase in influenza vaccine production capacity and regulatory capacity; -research and development for improved influenza vaccines. keywords: global; influenza; pandemic; vaccine cache: cord-296469-h0ma163u.txt plain text: cord-296469-h0ma163u.txt item: #183 of 299 id: cord-296831-wdpatr2z author: Matoo, Javaid Jeelani title: Resiquimod enhances mucosal and systemic immunity against avian infectious bronchitis virus vaccine in the chicken date: 2018-04-07 words: 5023 flesch: 50 summary: Further, the combination of R-848 withinactivated IBV vaccine showed higher antibody response than the vaccine alone group. Interestingly, it potentiated the IgA responses in the tear and intestinal secretions when used with both live and inactivated IBV vaccines. keywords: dpi; group; ibv; iga; inactivated; live; r-848; response; vaccine; virus cache: cord-296831-wdpatr2z.txt plain text: cord-296831-wdpatr2z.txt item: #184 of 299 id: cord-296839-b6bm8do1 author: Bernasconi, Valentina title: Developing vaccines against epidemic-prone emerging infectious diseases date: 2019-11-27 words: 4709 flesch: 33 summary: Its efforts are in mapping the needs around the development of diagnostic tools, without which CEPI vaccine candidates cannot be advanced. To support and accelerate vaccine development, CEPI will also support science projects related to the development of biological standards and assays, animal models, epidemiological studies, and diagnostics, as well as build capacities for future clinical trials in risk-prone contexts. keywords: animal; cepi; clinical; development; diseases; eids; epidemic; lassa; outbreak; trials; vaccine cache: cord-296839-b6bm8do1.txt plain text: cord-296839-b6bm8do1.txt item: #185 of 299 id: cord-296886-0bma2749 author: Xu, Yingying title: Intranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives date: 2014-07-10 words: 13105 flesch: 31 summary: With the success of DNA vaccines in various animal models, several phase I & II clinical trials on DNA vaccine against influenza have been being carried out. The two open reading frames of the 22k mRNA of human respiratory syncytial virus: Sequence comparison of antigenic subgroups A and B and expression in vitro Respiratory syncytial virus infection in elderly and high-risk adults Combining DNA and protein vaccines for early life immunization against respiratory syncytial virus in mice The fusion glycoproteins of human respiratory syncytial virus of subgroups A and B: Sequence conservation provides a structural basis for antigenic relatedness Protection against respiratory syncytial virus infection by DNA immunization Immunogenicity and efficacy of codon optimized DNA vaccines encoding the F-protein of respiratory syncytial virus Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate Resistance to respiratory syncytial virus (RSV) challenge induced by infection with a vaccinia virus recombinant expressing the RSV M2 protein (Vac-M2) is mediated by CD8 + T cells, while that induced by Vac-F or Vac-G recombinants is mediated by antibodies Enhanced delivery and expression of a nanoencapsulated DNA vaccine vector for respiratory syncytial virus Nano-encapsulated DNA and/or protein boost immunizations increase efficiency of DNA vaccine protection against RSV Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice DNA vaccines: Protective immunizations by parenteral, mucosal, and gene-gun inoculations Gene gun-based nucleic acid immunization: Elicitation of humoral and cytotoxic T lymphocyte responses following epidermal delivery of nanogram quantities of DNA Advantage of gene gun-mediated over intramuscular inoculation of plasmid DNA vaccine in reproducible induction of specific immune responses Immunobiology of dendritic cells Dendritic cells: Specialized and regulated antigen processing machines Dendritic cells in vivo: A key target for a new vaccine science Targeting vaccines to dendritic cells A versatile bifunctional dendritic cell targeting vaccine vector Dendritic cell targeted HIV gag protein vaccine provides help to a DNA vaccine including mobilization of protective CD8 + T cells Dendritic cell targeted chitosan nanoparticles for nasal DNA immunization against SARS CoV nucleocapsid protein The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement Improving vaccines by targeting antigens to dendritic cells Hematologic effects of flt3 ligand in vivo in mice Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified Modulating dendritic cells to optimize mucosal immunization protocols Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand Nasal Flt3 ligand cDNA elicits CD11c + CD8 + dendritic cells for enhanced mucosal immunity The nasal dendritic cell-targeting Flt3 ligand as a safe adjuvant elicits effective protection against fatal pneumococcal pneumonia Uptake and transport of copolymer biodegradable microspheres by rabbit Peyer's patch M cells Poly (lactide-co-glycolide) particles of different physicochemical properties and their uptake by Peyer's patches in mice M-cell targeted biodegradable PLGA nanoparticles for oral immunization against hepatitis B Claudin 4-targeted protein incorporated into PLGA nanoparticles can mediate M cell targeted delivery Pharmaceutical aspects of intranasal delivery of vaccines using particulate systems Exploiting lymphatic transport and complement activation in nanoparticle vaccines Enhanced mucosal and systemic immune response with intranasal immunization of mice with HIV peptides entrapped in PLG microparticles in combination with Ulex Europaeus-I lectin as M cell target Intestinal M cells: A pathway for entry of reovirus into the host Salmonella typhimurium initiates murine infection by penetrating and destroying the specialized epithelial M cells of the Peyer's patches The M cell as a portal of entry to the lung for the bacterial pathogen Mycobacterium tuberculosis Novel vaccine development strategies for inducing mucosal immunity The M cell-targeting ligand promotes antigen delivery and induces antigen-specific immune responses in mucosal vaccination M cell targeting by a Claudin 4-targeting peptide can enhance mucosal IgA responses A novel M cell-specific carbohydrate-targeted mucosal vaccine effectively induces antigen-specific immune responses Low-dose tolerance is mediated by the microfold cell ligand, reovirus protein sigma1 A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: Polyethylenimine Intranasal immunization with plasmid DNA encoding spike protein of SARS-coronavirus/polyethylenimine nanoparticles elicits antigen-specific humoral and cellular immune responses Intranasal DNA vaccination induces potent mucosal and systemic immune responses and cross-protective immunity against influenza viruses Pulmonary delivery of DNA vaccine constructs using deacylated PEI elicits immune responses and protects against viral challenge infection Application of chitosan microspheres for nasal delivery of vaccines Chitosan-based formulations for delivery of DNA and siRNA Nasal vaccination: A non-invasive vaccine delivery method that holds great promise for the future Chitosan and the mucosal delivery of biotechnology drugs Biomedical applications of amino acid-modified chitosans: A review Immune stimulating activity of two new chitosan containing adjuvant formulations Intranasal gene transfer by chitosan-DNA nanospheres protects BALB/c mice against acute respiratory syncytial virus infection Nasal delivery of chitosan-DNA plasmid expressing epitopes of respiratory syncytial virus (RSV) induces protective CTL responses in BALB/c mice Thiolated chitosans Thiolated chitosan/DNA nanocomplexes exhibit enhanced and sustained gene delivery Biodegradable nanoparticles for drug and gene delivery to cells and tissue PLGA-PEI nanoparticles for gene delivery to pulmonary epithelium Chitosan-coated PLGA nanoparticles for DNA/RNA delivery: Effect of the formulation parameters on complexation and transfection of antisense oligonucleotides Characterization of plasmid DNA location within Chitosan/PLGA/pDNA nanoparticle complexes designed for gene delivery Establishing chitosan coated PLGA nanosphere platform loaded with wide variety of nucleic acid by complexation with cationic compound for gene delivery Cationic microparticles consisting of poly(lactide-co-glycolide) and polyethylenimine as carriers systems for parental DNA vaccination Intranasal delivery of cationic PLGA nano/microparticles-loaded FMDV DNA vaccine encoding IL-6 elicited protective immunity against FMDV challenge Preparation and characterization of cationic PLGA nanospheres as DNA carriers Co-delivery of IL-2 or liposomes augment the responses of mice to a DNA vaccine for pseudorabies virus IE180 Modulation of cellular immune response against hepatitis C virus nonstructural protein 3 by cationic liposome encapsulated DNA immunization Augmentation of antigen-specific immune responses using DNA-fusogenic liposome vaccine Vaccine adjuvant formulations: A pharmaceutical perspective Delivery of plasmid DNA into mammalian cell lines using pH-sensitive liposomes: Comparison with cationic liposomes Surface modified liposomes for nasal delivery of DNA vaccine Cationic lipid/DNA complexes (JVRS-100) combined with influenza vaccine (Fluzone) increases antibody response, cellular immunity, and antigenically drifted protection Improved tuberculosis DNA vaccines by formulation in cationic lipids Protection against tuberculosis by a single intranasal administration of DNA-hsp65 vaccine complexed with cationic liposomes DNA vaccination against respiratory influenza virus infection Intranasal immunization with liposome-encapsulated plasmid DNA encoding influenza virus hemagglutinin elicits mucosal, cellular and humoral immune responses Glycol chitosan improves the efficacy of intranasally administrated replication defective human adenovirus type 5 expressing glycoprotein D of bovine herpesvirus 1 Dendritic cell-targeting DNA-based mucosal adjuvants for the development of mucosal vaccines Improving vaccines by incorporating immunological coadjuvants Mucosal adjuvants and delivery systems for protein-, DNA-and RNA-based vaccines Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: Differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells Intranasal immunization with pneumococcal polysaccharide conjugate vaccines with nontoxic mutants of Escherichia coli heat-labile enterotoxins as adjuvants protects mice against invasive pneumococcal infections Genetically detoxified mutants of heat-labile enterotoxin from Escherichia coli are effective adjuvants for induction of cytotoxic T-cell responses against HIV-1 gag-p55 A dilemma for mucosal vaccination: Efficacy versus toxicity using enterotoxin-based adjuvants Mucosal vaccines: Non toxic derivatives of LT and CT as mucosal adjuvants Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland Heat-labile enterotoxins as adjuvants or anti-inflammatory agents Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. keywords: adjuvants; administration; antigen; cells; chitosan; delivery; dna; dna vaccines; encoding; human; immunity; immunization; influenza; intranasal; mice; mucosal; plasmid; protection; protein; responses; system; vaccination; vaccine; virus cache: cord-296886-0bma2749.txt plain text: cord-296886-0bma2749.txt item: #186 of 299 id: cord-296967-qiil3gqk author: Tatlow, Dean title: A novel concept for treatment and vaccination against Covid‐19 with an inhaled chitosan‐coated DNA vaccine encoding a secreted spike protein portion date: 2020-08-08 words: 2264 flesch: 46 summary: Many studies have proven DNA vaccines to be safe and well tolerated. These antigenic proteins expressed and secreted by plasmid DNA vaccines access both the exogenous and endogenous pathways in the activation of both humoral and cellular mediated immune responses. keywords: coronavirus; dna; plasmid; protein; spike; vaccine cache: cord-296967-qiil3gqk.txt plain text: cord-296967-qiil3gqk.txt item: #187 of 299 id: cord-296998-ep46lzeo author: Pawelec, Graham title: Recent advances in influenza vaccines date: 2020-04-28 words: 3691 flesch: 34 summary: Efforts to improve the effectiveness of influenza vaccines include developing universal vaccines independent of the circulating strains in any particular season and stimulating cellular as well as humoral responses, especially in the elderly. And, unlike the SARS-1 epidemic and, we hope, the SARS-CoV-2 pandemic, influenza will not be eliminated and thus efforts to improve influenza vaccines will remain of crucial importance. keywords: cells; infection; influenza; responses; strains; text; vaccination; vaccines cache: cord-296998-ep46lzeo.txt plain text: cord-296998-ep46lzeo.txt item: #188 of 299 id: cord-297131-3a9vjpvn author: Charlton Hume, Hayley K. title: Synthetic biology for bioengineering virus‐like particle vaccines date: 2018-12-31 words: 6842 flesch: 12 summary: The authors acknowledge the support from Australian Research Sensitivity of immune response quality to influenza helix 190 antigen structure displayed on a modular viruslike particle AntigenDB: An immunoinformatics database of pathogen antigens Expression and purification of virus-like particles for vaccination Chimeric hepatitis B core antigen virus-like particles displaying the envelope domain III of dengue virus type 2 Virus-like particles displaying envelope domain III of dengue virus type 2 induce virus-specific antibody response in mice Designing the next generation of vaccines for global public health GAVI and the vaccine Fund-A boon for immunization in the developing world The use of genomics in microbial vaccine development Plant-produced hepatitis B core protein chimera carrying anthrax protective antigen domain-4 Rotavirus-like particles primary recovery from insect cells in aqueous two-phase systems Progress towards a universal influenza vaccine Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: Implications for vaccine design High-throughput process development for biopharmaceutical drug substances Immune regulation: Immune cell social networks The global threat of Zika virus to pregnancy: Epidemiology, clinical perspectives, mechanisms, and impact A chimaeric plant virus vaccine protects mice against a bacterial infection Plug-and-display: Decoration of virus-like particles via isopeptide bonds for modular immunization Escherichia colibased cell-free synthesis of virus-like particles A monolith purification process for virus-like particles from yeast homogenate A DNA inducing VLP vaccine designed for HIV and tested in mice Design and characterization of a computationally optimized broadly reactive hemagglutinin vaccine for H1N1 influenza viruses Purification of influenza virus-like particles using sulfated cellulose membrane adsorbers Bioorthogonal strategy for bioprocessing of specific-site-functionalized enveloped influenzavirus-like particles U R E 2 Application of synthetic biology to VLP vaccine platforms. keywords: antigens; biology; cell; design; development; epitopes; et al; immunogenicity; influenza; particles; platform; production; protein; system; vaccine; virus; vlp; vlps cache: cord-297131-3a9vjpvn.txt plain text: cord-297131-3a9vjpvn.txt item: #189 of 299 id: cord-297203-f3f31h4r author: Afrough, B. title: Emerging viruses and current strategies for vaccine intervention date: 2019-04-16 words: 5915 flesch: 30 summary: The ease of direct manipulation of viral genomes together with a growing understanding of their biology has led to the development of attenuated virus vaccines with increased safety and immunogenicity. For live attenuated RNA virus vaccines which incorporate error-prone polymerases, reversion to virulence is a distinct possibility after multiple rounds of replication. keywords: approach; development; disease; dna; fever; human; pathogens; replication; safety; vaccination; vaccines; vectors; virus; viruses cache: cord-297203-f3f31h4r.txt plain text: cord-297203-f3f31h4r.txt item: #190 of 299 id: cord-299315-s43gw24k author: Capps, Benjamin title: One Health, Vaccines and Ebola: The Opportunities for Shared Benefits date: 2015-09-16 words: 10084 flesch: 43 summary: We argue that, along with efforts to test Ebola vaccines in humans, existing vaccines that have been proven safe and efficacious in primates should already be deployed in order to protect both species. Currently, several types of Ebola vaccines have been proven effective and safe in primates, but none has been approved in humans yet (see below). keywords: animals; approach; benefit; ebola; et al; health; human; immunity; populations; primates; research; risk; species; trials; vaccine; virus cache: cord-299315-s43gw24k.txt plain text: cord-299315-s43gw24k.txt item: #191 of 299 id: cord-301577-3qc56c7d author: Lamson, Daryl M. title: An unusual case of influenza-like illness after yellow fever vaccination date: 2014-05-31 words: 1808 flesch: 43 summary: To the best of our knowledge, this is the first report finding replicating YF vaccine in the respiratory sample of a post inoculated individual. To the best of our knowledge, this is the first report finding replicating YF vaccine in the respiratory sample of a post inoculated individual. keywords: cell; culture; influenza; vaccine; virus cache: cord-301577-3qc56c7d.txt plain text: cord-301577-3qc56c7d.txt item: #192 of 299 id: cord-301876-d2j9wpqk author: Kalita, Parismita title: Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2 date: 2020-05-04 words: 3458 flesch: 45 summary: Few groups have designed subunit vaccines against SARS-CoV-2; however, their workflow involved either use of single protein for vaccine design [24, 25] or used only CTL epitopes without considering the importance of B-cell or HTL epitopes [26] . Our subsequent analysis of the changes in the Rg for the vaccine-TLR3 complex during the simulation was also determined, and the average Rg was found to be 1.47 nm, demonstrating the compactness of the TLR3 receptor with vaccine subunit during the simulations ( Figure 4C ). keywords: cell; coronavirus; covid-19; epitopes; protein; receptor; sars; subunit; vaccine cache: cord-301876-d2j9wpqk.txt plain text: cord-301876-d2j9wpqk.txt item: #193 of 299 id: cord-302082-aaokc182 author: Stanberry, Lawrence R. title: Vaccines of the future date: 2011-08-31 words: 7739 flesch: 33 summary: The amino acid sequence of the viral envelope glycoprotein gp120 shows 25e35% divergence between clades and up to 20% divergence within any given clade, which constitutes a formidable hurdle to vaccine development. The future of vaccine development can build on the knowledge and experience gained over the last 200 years, and at the same time can take advantage of the most cutting-edge technologies and 194 UNDERSTANDING MODERN VACCINES research. keywords: adjuvants; antigen; candidate; cell; development; diseases; hiv; infection; influenza; responses; specific; table; vaccination; vaccine; vector; women cache: cord-302082-aaokc182.txt plain text: cord-302082-aaokc182.txt item: #194 of 299 id: cord-302155-hksmt48i author: McLean, Rebecca K. title: Vaccine Development for Nipah Virus Infection in Pigs date: 2019-02-04 words: 4169 flesch: 36 summary: Final rule Can Ebola virus vaccines have universal immune correlates of protection? The sporadic nature of NiV outbreaks means that the commercial development of NiV vaccines for use in pigs (other livestock or humans) is limited and animal health companies are of the opinion that NiV vaccines will have limited marketability. keywords: animal; disease; human; infection; malaysia; nipah; niv; outbreak; pigs; vaccine; virus cache: cord-302155-hksmt48i.txt plain text: cord-302155-hksmt48i.txt item: #195 of 299 id: cord-302222-9ad0fw6z author: Monath, Thomas P. title: Vaccines against diseases transmitted from animals to humans: A one health paradigm date: 2013-11-04 words: 15731 flesch: 35 summary: The complexity, timeline, and cost of development of animal vaccines and the regulatory hurdles for product approval are far less than for human vaccines. As mentioned above, the regulatory pathway for animal vaccines is considerably simpler than for human vaccines [201] . keywords: animals; control; development; disease; encephalitis; equine; fever; health; horses; human; immunization; infection; live; livestock; lyme; nile; oral; rabies; rift; transmission; use; vaccination; vaccine; valley; valley fever; veterinary; virus; west; wild; zoonotic cache: cord-302222-9ad0fw6z.txt plain text: cord-302222-9ad0fw6z.txt item: #196 of 299 id: cord-302247-moor7dfc author: Richards, James title: Feline Vaccination Guidelines date: 2001-05-31 words: 4811 flesch: 31 summary: IlFeLV testing is recommended before vaccination; infected cats do not derive any benefit from vaccination. The disease is self-limiting; however, infected cats may develop chronic oculonasal disease. keywords: age; cats; disease; feline; infection; kittens; use; vaccination; vaccines; virus cache: cord-302247-moor7dfc.txt plain text: cord-302247-moor7dfc.txt item: #197 of 299 id: cord-302268-dmb0293x author: Lee, Sujin title: Recent Advances of Vaccine Adjuvants for Infectious Diseases date: 2015-04-23 words: 3741 flesch: 36 summary: XVII-XXIV (How) do aluminium adjuvants work? Aluminium adjuvants--in retrospect and prospect The antigenic effect of intravenous injection of diphtheria toxin Antigen depot is not required for alum adjuvanticity Mechanisms of action of adjuvants Towards an understanding of the adjuvant action of aluminium New horizons in adjuvants for vaccine development Aluminum compounds as vaccine adjuvants The mechanism of action of MF59 -an innately attractive adjuvant formulation The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine Impact of prior or concomitant seasonal influenza vaccination on MF59-adjuvanted H1N1v vaccine (Focetria) in adult and elderly subjects Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes The history of MF59(®) adjuvant: a phoenix that arose from the ashes Adjuvant System AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity Designing and building the next generation of improved vaccine adjuvants Formation of virosomes from influenza subunits and liposomes Influenza virosomes as a combined vaccine carrier and adjuvant system for prophylactic and therapeutic immunizations Applications of influenza virosomes as a delivery system Toll-like receptors and innate immunity Vaccine adjuvants: putting innate immunity to work Bacterial cell wall products as adjuvants: early interferon gamma as a marker for adjuvants that enhance protective immunity GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients AS04, an aluminum salt-and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity Therapeutic potential of Toll-like receptor 9 activation The potential of 1018 ISS adjuvant in hepatitis B vaccines: HEPLISAV review Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses Use of defined TLR ligands as adjuvants within human vaccines Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses An overview of adjuvant formulations and delivery systems ISCOM technology-based Matrix M TM adjuvant: success in future vaccines relies on formulation Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma Immunomodulatory properties of the vaccine adjuvant alum Alum adjuvanticity: unraveling a century old mystery Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles Development and evaluation of AS03, an Adjuvant System containing alpha-tocopherol and squalene in an oil-in-water emulsion Adjuvants for pandemic influenza vaccines Liposomes as vaccine delivery systems: a review of the recent advances Influenza virosomes as vaccine adjuvant and carrier system Role of AS04 in human papillomavirus vaccine: mode of action and clinical profile A new class of effective vaccine adjuvant is based on the TLR pathway. keywords: adjuvants; alum; antigen; immune; immunity; influenza; responses; type; vaccines cache: cord-302268-dmb0293x.txt plain text: cord-302268-dmb0293x.txt item: #198 of 299 id: cord-303368-tzgql225 author: Masset, N. title: Effectiveness of two intranasal vaccines for the control of bovine respiratory disease in newborn beef calves: A randomized non-inferiority multicentre field trial date: 2020-08-19 words: 4095 flesch: 46 summary: The efficacy of BRSV intranasal vaccines has been proven in many challenge trials under controlled conditions even when vaccinations are performed in the presence of MDA (Ellis, 2017; Osman et al., 2018) . Data from challenge studies or from dairy calf field studies cannot be extrapolated to beef calves. keywords: brd; brsv; calves; intranasal; study; vaccine cache: cord-303368-tzgql225.txt plain text: cord-303368-tzgql225.txt item: #199 of 299 id: cord-303447-3a7jxl34 author: Cohn, Amanda C. title: Immunizations in the United States: A Rite of Passage date: 2005-05-28 words: 7979 flesch: 36 summary: The cost of immunizing a child through 6 years of age in 2003 was $436 per child for all vaccines, not including influenza vaccine [12] . Influenza vaccines are developed yearly based on antigenic drifts. keywords: adolescents; children; disease; health; hepatitis; immunization; infants; influenza; pertussis; states; united; vaccination; vaccine; years cache: cord-303447-3a7jxl34.txt plain text: cord-303447-3a7jxl34.txt item: #200 of 299 id: cord-303674-0xo2fiop author: Criscuolo, E. title: Alternative Methods of Vaccine Delivery: An Overview of Edible and Intradermal Vaccines date: 2019-03-04 words: 7459 flesch: 27 summary: To date, vaccine antigens have been transformed into many edible species including lettuce, tomato, potato, papaya, carrot, quinoa, and tobacco [32] . In this regard, recent work has been focused on vaccine delivery systems, as an alternative to injectable vaccines, to increase antigen stability and improve overall immunogenicity. keywords: antigen; cells; delivery; development; expression; immunogenicity; influenza; intradermal; mucosal; plant; production; response; studies; system; vaccination; vaccine; virus cache: cord-303674-0xo2fiop.txt plain text: cord-303674-0xo2fiop.txt item: #201 of 299 id: cord-303880-zv4nbz9p author: Tsikala Vafea, Maria title: Emerging Technologies for Use in the Study, Diagnosis, and Treatment of Patients with COVID-19 date: 2020-06-24 words: 5492 flesch: 39 summary: 19 Re-cently, deep learning models, the core algorithms of AI, have been used to develop a thoracic CT image analysis system, which can automatically detect COVID-19 patients and quantify the disease burden. Frontline healthcare practitioners, including CT and MRI technicians, are at high risk for contracting the virus given their frequent exposure to COVID-19 patients. keywords: coronavirus; covid-19; data; development; disease; health; learning; models; pandemic; patients; sars; use; vaccine; virus cache: cord-303880-zv4nbz9p.txt plain text: cord-303880-zv4nbz9p.txt item: #202 of 299 id: cord-304188-1nm1tbig author: Moody, M. Anthony title: Modulation of HIV-1 immunity by adjuvants date: 2014-04-10 words: 5163 flesch: 37 summary: The role of cytokine DNAs as vaccine adjuvants for optimizing cellular immune responses Vaccine adjuvants: putting innate immunity to work This is an excellent review of adjuvants and the role of PRRs in triggering the immune system. This review will highlight recent work in adjuvant development for HIV-1 vaccines with particular emphasis on antibody responses. keywords: adjuvant; antibody; cell; dna; hiv-1; human; immunization; mucosal; responses; studies; vaccine; virus cache: cord-304188-1nm1tbig.txt plain text: cord-304188-1nm1tbig.txt item: #203 of 299 id: cord-304472-mi5v6512 author: Wilder-Smith, Annelies title: Dengue vaccine development by the year 2020: challenges and prospects date: 2020-10-18 words: 4721 flesch: 37 summary: Evaluation of several ELISA and rapid diagnostic assays for determining prior dengue infection Evaluation of rapid diagnostic tests and conventional enzymelinked immunosorbent assays to determine prior dengue infection Pre-vaccination screening strategies for the use of the CYD-TDV dengue vaccine: a meeting report Use of pre-travel vaccine-preventable disease serology as a screening tool to identify patients in need of pre-travel vaccination: a retrospective audit A: Serostatus-dependent performance of the first licensed dengue vaccine: implications for travellers Timing of administration of dengue vaccine in travellers with a recent confirmed dengue infection Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines A: Evaluation of a tetravalent dengue vaccine by serostatus and serotype A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2-17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study Immunogenicity and safety of lyophilized and liquid dengue tetravalent vaccine candidate formulations in healthy adults: a randomized, phase 2 clinical trial Characterization of the type-specific and crossreactive B cell responses elicited by a live-attenuated tetravalent dengue vaccine Long-term safety and immunogenicity of a tetravalent dengue vaccine candidate in children and adults: a randomized, placebo-controlled, phase 2 study Efficacy of a tetravalent dengue vaccine in healthy children and adolescents Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial Robust and balanced immune responses to all 4 Dengue virus serotypes following administration of a single dose of a live attenuated tetravalent dengue vaccine to healthy, Flavivirus-naive adults Human CD4+ T cell responses to an attenuated tetravalent dengue vaccine parallel those induced by natural infection in magnitude, HLA restriction, and antigen specificity The human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes A 12-month-interval dosing study in adults indicates that a single dose of the national institute of allergy and infectious diseases tetravalent dengue vaccine induces a robust neutralizing antibody response Paediatric Dengue Fever diagnosed through parents' epidemiologic report and preventive strategy during the acute phase of infection Dengue in peace corps volunteers Travel vaccine preventable diseases-updated logarithmic scale with monthly incidence rates What proportion of international travellers acquire a travel-related illness? Another strategy to overcome viral interference for tetravalent dengue vaccines would be to use a heterologous prime-boost strategy. keywords: cyd; dengue; phase; responses; serotypes; tdv; tetravalent; travel; vaccination; vaccine; virus cache: cord-304472-mi5v6512.txt plain text: cord-304472-mi5v6512.txt item: #204 of 299 id: cord-305175-1wg0wodr author: Dolzhikova, I. V. title: Preclinical Studies of Immunogenity, Protectivity, and Safety of the Combined Vector Vaccine for Prevention of the Middle East Respiratory Syndrome date: 2020 words: 4501 flesch: 42 summary: To date, several candidate vaccine preparations based on a protective antigen, MERS-CoV S glycoprotein and its derivatives (S1 subunit, receptor-binding domain), are known: vector vaccines (based on recombinant adenoviruses and vaccinia virus), a DNA vaccine based on plasmid DNA, as well as vaccines based on recombinant proteins and virus-like particles [8] [9] [10] [11] [12] Since the formation of a humoral and cellular immune response is important to protect against MERS-CoV, the use of recombinant viral vectors for antigen delivery seems promising for the development of anti-MERS vaccines. keywords: animals; cov; glycoprotein; immune; immunization; mers; mice; vaccination; vaccine; virus cache: cord-305175-1wg0wodr.txt plain text: cord-305175-1wg0wodr.txt item: #205 of 299 id: cord-305488-vk59ghjm author: Choi, Kang-Seuk title: Newcastle disease virus vectored vaccines as bivalent or antigen delivery vaccines date: 2017-07-26 words: 4853 flesch: 43 summary: Therapeutic potential of oncolytic Newcastle disease virus: a critical review Newcastle disease: evolution of genotypes and the related diagnostic challenges Newcastle disease virus as a vaccine vector for development of human and veterinary vaccines Newcastle disease virus: current status and our understanding Genome replication of Newcastle disease virus: involvement of the rule-of-six Newcastle disease virus V protein is a determinant of host range restriction Recombinant Newcastle disease virus as a vaccine vector Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence Generation of recombinant lentogenic Newcastle disease virus from cDNA High-level expression of a foreign gene from the most 3'-proximal locus of a recombinant Newcastle disease virus Optimization of human immunodeficiency virus Gag expression by Newcastle disease virus vectors for the induction of potent immune responses P and M gene junction is the optimal insertion site in Newcastle disease virus vaccine vector for foreign gene expression Newcastle disease and related avian paramyxoviruses Immunization of cattle with recombinant Newcastle disease virus expressing bovine herpesvirus-1 (BHV-1) To control ND, poultry flocks are subjected to prophylactic vaccination with live attenuated and/or killed NDV vaccines [5] . keywords: chickens; disease; human; live; ndv; newcastle; poultry; protein; vaccines; vector; virus cache: cord-305488-vk59ghjm.txt plain text: cord-305488-vk59ghjm.txt item: #206 of 299 id: cord-305807-n3fs7533 author: Ferreira, T B title: Use of adenoviral vectors as veterinary vaccines date: 2005-10-18 words: 8480 flesch: 31 summary: Applications of pox virus vectors to vaccination: an update Risk of aseptic meningitis after measles, mumps, and rubella vaccine in UK children Laboratory tests for live attenuated poliovirus vaccines Recombinant viral vector vaccines for the veterinary use The application of nucleic acid vaccines in veterinary medicine DNA-antiviral vaccines: new developments and approaches -a review Novel viral vaccines for livestock Bacterial ghosts as vaccine candidates for veterinary applications SV40 in adenovirus vaccines and adenovirus-SV40 recombinants Characteristics of a human cell line transformed by DNA from human adenovirus type 5 The Vaccine Book Recombinant adenoviruses as vaccines Cytotoxic T-lymphocyte target proteins and their major histocompatibility complex class I restriction in response to adenovirus vectors delivered to mouse liver Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs Detailed analysis of the CD8+ T-cell response following adenovirus vaccination Update on adenovirus and its vectors Adenoviruses as vectors for delivering vaccines to mucosal surfaces Adenovirus vectors as recombinant viral vaccines Packaging capacity and stability of human adenovirus type 5 vectors Frequency and stability of chromosomal integration of adenovirus vectors Production of first generation adenovirus vectors: a review Development and optimization of an adenovirus production process A single short stretch of homology between adenoviral vector and packaging cell line can give rise to cytopathic effect-inducing, helper-dependent E1-positive particles Adenoviral vectors for gene transfer and therapy Mucosal immunization with recombinant adenoviruses: induction of immunity and protection of cotton rats against respiratory bovine herpesvirus type 1 infection Vaccination of puppies born to immune dams with a canine adenovirus-based vaccine protects against a canine distemper virus challenge The effect of pre-existing adenovirus-specific immunity on immune responses induced by recombinant adenovirus expressing glycoprotein D of bovine herpesvirus type 1 The immunogenicity and efficacy of replicationdefective and replication-competent bovine adenovirus-3 expressing bovine herpesvirus-1 glycoprotein gD in cattle Canine adenovirus type 2 attachment and internalization: coxsackievirus-adenovirus receptor, alternative receptors, and an RGD-independent pathway Fowl adenovirus recombinant expressing VP2 of infectious bursal disease virus induces protective immunity against bursal disease Vaccination of pigs with a recombinant porcine adenovirus expressing the gD gene from pseudorabies virus A recombinant E1-deleted porcine adenovirus-3 as an expression vector A proposal for a new (third) genus within the family Adenoviridae FIV vaccine development and its importance to veterinary and human medicine: a review FIV vaccine 2002 update and review Immunization trial of cats with a replicationdefective adenovirus type 5 expressing the ENV gene of feline immunodeficiency virus Morbillivirus infections, with special emphasis on morbilliviruses of carnivores Cytotoxic T-lymphocyte activity specific for hemagglutinin (H) protein of canine distemper virus in dogs Immunogenicity of an E1-deleted recombinant human adenovirus against rabies by different routes of administration A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier Adult dogs receiving a rabies booster dose with a recombinant adenovirus expressing rabies virus glycoprotein develop high titers of neutralizing antibodies The use of an E1-deleted, replication-defective adenovirus recombinant expressing the rabies virus glycoprotein for early vaccination of mice against rabies virus A recombinant fowl adenovirus expressing the S1 gene of infectious bronchitis virus protects against challenge with infectious bronchitis virus Research on infectious bursal disease -the past, the present and the future Classical swine fever -an Vaccination against AJD is widely practised with live attenuated or killed whole virus vaccines. keywords: adenovirus; animal; cell; disease; human; pigs; production; protein; recombinant; replication; response; swine; type; use; vaccination; vaccines; vectors; virus cache: cord-305807-n3fs7533.txt plain text: cord-305807-n3fs7533.txt item: #207 of 299 id: cord-306733-df36w6l7 author: Rosales-Mendoza, Sergio title: What Does Plant-Based Vaccine Technology Offer to the Fight against COVID-19? date: 2020-04-14 words: 8607 flesch: 34 summary: Another approach to express heterologous protein in plants relies on the use of viral-based vectors, which exploit the efficient promoters, UTRs, and DNA/RNA replication mechanisms found in plant viruses. A recent review revealed that at least 97 vaccine candidates have been developed based on plant viruses covering infectious agents, cancer, and autoimmune disorders [78] . keywords: antigen; approach; cells; coronavirus; cov-1; covid-19; development; expression; immune; mice; plant; production; protein; sars; vaccines; virus; vlps cache: cord-306733-df36w6l7.txt plain text: cord-306733-df36w6l7.txt item: #208 of 299 id: cord-307899-427a7i3h author: BITTLE, JAMES L. title: Vaccines Produced by Conventional Means to Control Major Infectious Diseases of Man and Animals date: 1989-12-31 words: 17484 flesch: 47 summary: This stems from concern over possible persistence and oncogenicity of vaccine viruses. A large number of different attenuated live-virus HC vaccines with different characteristics have been used over the years, but residual pathogenicity, shedding, and spread of vaccine viruses have remained problems. keywords: animals; antibodies; antibody; bacterium; bovine; canine; cattle; cause; cell; control; culture; disease; dogs; et al; formalin; humans; immunity; immunization; infection; live; man; protection; species; strain; swine; type; vaccine; virus; virus vaccines; viruses cache: cord-307899-427a7i3h.txt plain text: cord-307899-427a7i3h.txt item: #209 of 299 id: cord-309083-ew9cwiw0 author: Su, Hang title: Cyprinid viral diseases and vaccine development date: 2018-09-07 words: 11170 flesch: 39 summary: In the late 1990s, the commercialization of fish vaccines developed rapidly and as a result, there are 38 global approvals in 2003, over 100 in 2006, and over 140 in 2012 according to incomplete statistics [7] . In the following decades, many researchers make extensive explorations of the preparation of fish vaccines to prevent the sudden emergence of fish diseases that are difficult to control with drugs. keywords: aquaculture; carp; carp virus; cyprinid; detection; development; disease; dna; fish; gcrv; gene; goldfish; grass; grass carp; herpesvirus; immune; infection; khv; koi; necrosis; pcr; spring; svcv; vaccine; virus cache: cord-309083-ew9cwiw0.txt plain text: cord-309083-ew9cwiw0.txt item: #210 of 299 id: cord-309555-1ksahg3o author: Cresswell, E. title: A questionnaire-based survey on the uptake and use of cattle vaccines in the UK date: 2014-07-11 words: 4280 flesch: 41 summary: key: cord-309555-1ksahg3o authors: Cresswell, E.; Brennan, M. L.; Barkema, H. W.; Wapenaar, W. title: A questionnaire-based survey on the uptake and use of cattle vaccines in the UK date: 2014-07-11 journal: Vet Rec Open DOI: 10.1136/vropen-2014-000042 sha: doc_id: 309555 cord_uid: 1ksahg3o BACKGROUND: Vaccination is a widely used strategy for disease control in cattle in the UK and abroad. However, there has been limited research describing the uptake and use of cattle vaccines on UK farms. keywords: cattle; cent; farmers; respondents; study; vaccination; vaccines; veterinary cache: cord-309555-1ksahg3o.txt plain text: cord-309555-1ksahg3o.txt item: #211 of 299 id: cord-309999-izdl0f2i author: Qin, Ede title: Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine date: 2006-02-13 words: 3947 flesch: 43 summary: The purity of SARS vaccine was 97.6% by HPLC identification and reacted with convalescent sera of SARS patients. HPLC analysis showed that the purity of SARS vaccine was 97.6%. keywords: antibody; control; cov; group; immunization; levels; monkeys; sars; vaccine cache: cord-309999-izdl0f2i.txt plain text: cord-309999-izdl0f2i.txt item: #212 of 299 id: cord-311112-cg7wqc0q author: Rappuoli, Rino title: Vaccines, emerging viruses, and how to avoid disaster date: 2014-11-29 words: 1122 flesch: 65 summary: key: cord-311112-cg7wqc0q authors: Rappuoli, Rino title: Vaccines, emerging viruses, and how to avoid disaster date: 2014-11-29 journal: BMC Biol DOI: 10.1186/s12915-014-0100-6 sha: doc_id: 311112 cord_uid: cg7wqc0q Rino Rappuoli is a graduate of Siena University, where he also earned his PhD before moving to the Sclavo Research Center, the Italian vaccine institute, also in Siena. I know that there are 'flu vaccines, but are there licensed vaccines for any of the others? keywords: time; vaccine cache: cord-311112-cg7wqc0q.txt plain text: cord-311112-cg7wqc0q.txt item: #213 of 299 id: cord-311331-l7dehit8 author: Diaz-Arévalo, Diana title: Nanoparticle-based vaccines: opportunities and limitations date: 2020-01-17 words: 5069 flesch: 36 summary: Another study designed a unique structure composed of inter-bilayer-crosslinked multilamellar vesicles (ICMVs), which is stable in the extracellular environment but rapidly released in endosomes/lysosomes, thereby enhancing vaccine immune responses. This mixture amplified vaccine responses and upregulated the costimulatory cells on splenic and bone marrow DCs. keywords: antigen; cells; delivery; dna; drug; immune; liposomes; nanoparticles; nps; plga; responses; study; vaccine cache: cord-311331-l7dehit8.txt plain text: cord-311331-l7dehit8.txt item: #214 of 299 id: cord-313911-lfn9ggg3 author: Kenner, Julie title: LC16m8: An attenuated smallpox vaccine date: 2006-11-17 words: 7968 flesch: 38 summary: The frequency of moderate to severe adverse reactions associated with smallpox vaccines currently stockpiled in the US, and the continued threat of bioterrorism have prompted the development of effective vaccines with improved safety profiles. This discovery has further fueled the drive to identify smallpox vaccines with improved safety profiles. keywords: b5r; cell; challenge; dryvax; efficacy; lc16m8; lister; mice; smallpox; strain; studies; vaccination; vaccine; vaccinia; virus cache: cord-313911-lfn9ggg3.txt plain text: cord-313911-lfn9ggg3.txt item: #215 of 299 id: cord-314009-7t1bzc7f author: Barclay, T. title: Vaccine Adjuvant Nanotechnologies date: 2016-10-07 words: 7666 flesch: 27 summary: Given the high expression of lectins on APCs, decorating the surface of vaccine or adjuvant particles with sugar groups can assist vaccine particle targeting to APCs. key: cord-314009-7t1bzc7f authors: Barclay, T.; Petrovsky, N. title: Vaccine Adjuvant Nanotechnologies date: 2016-10-07 journal: Micro and Nanotechnology in Vaccine Development DOI: 10.1016/b978-0-323-39981-4.00007-5 sha: doc_id: 314009 cord_uid: 7t1bzc7f The increasing sophistication of vaccine adjuvant design has been driven by improved understanding of the importance of nanoscale features of adjuvants to their immunological function. keywords: adjuvant; antigen; cell; delivery; emulsion; immune; immunogenicity; influenza; inulin; nanoparticles; oil; particles; responses; self; size; surface; system; vaccine cache: cord-314009-7t1bzc7f.txt plain text: cord-314009-7t1bzc7f.txt item: #216 of 299 id: cord-315131-4yb2b70g author: Hammerschmidt, Sven title: Threat of infection: Microbes of high pathogenic potential – strategies for detection, control and eradication date: 2005-06-28 words: 7181 flesch: 33 summary: The endothelium is affected in two ways: directly by virus infection leading to activation and lytic replication and indirectly by a mediator-induced inflammatory response. A landmark of infectious diseases research is the chemical synthesis of genomes, a major new field of research referred to as “synthetic biology”, that to date has resulted in the chemical synthesis of the poliovirus and of phage φX174 genomes and their expression as infectious viruses. keywords: cells; countries; diseases; eradication; et al; fever; gene; human; poliovirus; shiga; toxin; transport; type; vaccination; vaccine; virus; viruses cache: cord-315131-4yb2b70g.txt plain text: cord-315131-4yb2b70g.txt item: #217 of 299 id: cord-315293-kng4z4kf author: Quesenberry, Katherine E. title: Basic Approach to Veterinary Care of Ferrets date: 2020-05-29 words: 9070 flesch: 47 summary: key: cord-315293-kng4z4kf authors: Quesenberry, Katherine E.; de Matos, Ricardo title: Basic Approach to Veterinary Care of Ferrets date: 2020-05-29 journal: Ferrets, Rabbits, and Rodents DOI: 10.1016/b978-0-323-48435-0.00002-2 sha: doc_id: 315293 cord_uid: kng4z4kf The approach to preventive medicine and basic veterinary care in ferrets is very similar to that used in dogs and cats. National association of state public health veterinarians Acetaminophen UDP-glucuronosyltransferase in ferrets: species and gender differences, and sequence analysis of ferret UGT1A6 Rabbit and ferret hemostasis First survey of endoparasites in pet ferrets in Italy Epidural anesthesia and analgesia in ferrets Urine specific gravity values in clinically healthy young pet ferrets (Mustelo furo) keywords: animals; blood; body; canine; catheter; cats; chapter; disease; distemper; ferrets; needle; pet; pressure; rabies; technique; use; vaccination; vaccine; virus cache: cord-315293-kng4z4kf.txt plain text: cord-315293-kng4z4kf.txt item: #218 of 299 id: cord-315339-dcui85lw author: Broadbent, Andrew J. title: Respiratory Virus Vaccines date: 2015-03-13 words: 28291 flesch: 26 summary: Type I interferons keep activated T cells alive A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a phase I clinical trial Antigenic structure of the human respiratory syncytial virus G glycoprotein and relevance of hypermutation events for the generation of antigenic variants The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta Subcellular localization of Toll-like receptor 3 in human dendritic cells The functional heterogeneity of type 1 effector T cells in response to infection is related to the potential for IFNgamma production AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people Regulation of IgA synthesis and immune response by T cells and interleukins Innate immune control and regulation of influenza virus infections IL-15 trans-presentation by pulmonary dendritic cells promotes effector CD8 T cell survival during influenza virus infection Host DNA released in response to aluminum adjuvant enhances MHC class II-mediated antigen presentation and prolongs CD4 T-cell interactions with dendritic cells Memory CD4 + T cells protect against influenza through multiple synergizing mechanisms Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes The human cytotoxic T cell response to influenza A vaccination Adaptive strategies of the influenza virus polymerase for replication in humans Live attenuated influenza vaccine induces cross-reactive antibody responses in children against an a/Fujian/411/2002-like H3N2 antigenic variant strain Immunoglobulin A (IgA): molecular and cellular interactions involved in IgA biosynthesis and immune response Intestinal IgA: novel views on its function in the defence of the largest mucosal surface The influence of HIV infection on antibody responses to a two-dose regimen of influenza vaccine Human genetic factors and respiratory syncytial virus disease severity Oral immunization with influenza virus in biodegradable microspheres Human immune responses to influenza virus vaccines administered by systemic or mucosal routes Respiratory syncytial virus synergizes with Th2 cytokines to induce optimal levels of TARC/CCL17 Comparative efficacy of inactivated and live attenuated influenza vaccines Naive CD4(+) T cell frequency varies for different epitopes and predicts repertoire diversity and response magnitude ISCOM, a delivery system for parenteral and mucosal vaccination Adjuvant system AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity H5N1 influenza vaccine formulated with AS03 A induces strong crossreactive and polyfunctional CD4 T-cell responses Roles of CD4 + T-cell-independent and -dependent antibody responses in the control of influenza virus infection: evidence for noncognate CD4 + T-cell activities that enhance the therapeutic activity of antiviral antibodies Antigenicity and immunogenicity of equine influenza vaccines containing a carbomer adjuvant The molecular basis of the pathogenicity of the Dutch highly pathogenic human influenza A H7N7 viruses Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity Association of serum anti-neuraminidase antibody with resistance to influenza in man Pathological study of archival lung tissues from five fatal cases of avian H5N1 influenza in Vietnam Systems biology of vaccination for seasonal influenza in humans Alum-adjuvanted H5N1 whole virion inactivated vaccine (WIV) induced IgG1 and IgG4 antibody responses in young children Mucosal vaccines: the promise and the challenge Influenza virus-infected epithelial cells present viral antigens to antigen-specific CD8 + cytotoxic T lymphocytes Gamma interferon is not required for mucosal cytotoxic T-lymphocyte responses or heterosubtypic immunity to influenza A virus infection in mice Heterosubtypic immunity to influenza A virus infection requires B cells but not CD8 + cytotoxic T lymphocytes Heterosubtypic immunity to influenza A virus infection requires a properly diversified antibody repertoire A novel M cell-specific carbohydrate-targeted mucosal vaccine effectively induces antigenspecific immune responses A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells Endogenous naive CD8 + T cell precursor frequency regulates primary and memory responses to infection Vaccination strategies for mucosal immune responses Recent developments in adjuvants for vaccines against infectious diseases Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines Prevention of symptomatic seasonal influenza in 2005-2006 by inactivated and live attenuated vaccines Caspase-1, caspase-8, and calpain are dispensable for IL-33 release by macrophages A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains Protection against the mouse-adapted A/FM/1/47 strain of influenza A virus in mice by a monoclonal antibody with cross-neutralizing activity among H1 and H2 strains Efficacy and effectiveness of influenza vaccines: a systematic review and metaanalysis Effect of priming with H1N1 influenza viruses of variable antigenic distances on challenge with 2009 pandemic H1N1 virus Orthomyxoviridae: the viruses and their replication The majority of studies evaluating respiratory virus vaccines measure serum antibody responses, because, although both cellular and humoral responses contribute to the clearance of a primary infection, neutralizing antibodies are known to protect against secondary infection. keywords: addition; antibodies; antibody; antibody responses; antigen; cd4; cd8; cell responses; cells; challenge; children; disease; et al; host; human; iga; immune; immunity; infection; influenza; influenza infection; influenza vaccines; influenza virus; live; mice; mucosal; protection; protein; replication; responses; rsv; sars; serum; specific; syncytial; t cells; tract; type; vaccination; vaccine; virus; virus infection; virus vaccine; viruses cache: cord-315339-dcui85lw.txt plain text: cord-315339-dcui85lw.txt item: #219 of 299 id: cord-315570-khm1veuv author: González-Mora, Alejandro title: Bacteriophage-Based Vaccines: A Potent Approach for Antigen Delivery date: 2020-09-04 words: 9972 flesch: 36 summary: Until now, phage display vaccines have been used for preventing or treating several diseases including cancer, viral, parasitic and fungal infection as well as their use in immunocontraception and drug abuse, among others [2, [15] [16] Until now, phage display vaccines have been used for preventing or treating several diseases including cancer, viral, parasitic and fungal infection as well as their use in immunocontraception and drug abuse, among others [2, [15] [16] keywords: antigen; bacteriophage; cells; development; display; dna; expression; identification; particles; peptides; phage; phage display; protein; response; systems; use; vaccines cache: cord-315570-khm1veuv.txt plain text: cord-315570-khm1veuv.txt item: #220 of 299 id: cord-316534-ep7ezoko author: Gamble, Lena J title: Current progress in the development of a prophylactic vaccine for HIV-1 date: 2010-12-22 words: 11976 flesch: 31 summary: 148, 253 In an effort to develop HIV-1 vaccines, researchers within this same group generated combinatorial libraries of HRV capsid-incorporated HIV-1 gp41 epitope. 149 Commercial and clinical Ad development of HIV-1 vaccines have progressed preferentially more than vector systems such as HRV because the flexibility of Ad generally exceeds current rhinovirus systems. keywords: ad5; adenovirus; aids; cell; development; dna; gene; hiv; human; immunity; immunodeficiency; infection; mucosal; protection; protein; recombinant; response; type; use; vaccination; vaccine; vectors; virus cache: cord-316534-ep7ezoko.txt plain text: cord-316534-ep7ezoko.txt item: #221 of 299 id: cord-316893-jwjr67po author: Mantel, Carsten title: New immunization strategies: adapting to global challenges date: 2019-12-04 words: 5214 flesch: 31 summary: In spite of their relatively higher gross national income (GNI)/capita, middleincome countries (MICs) that have been excluded from Gavi support or are about to lose this support, increasingly recognize inequities in vaccine coverage as a se- Bundesgesundheitsbl 2020 · 63:25-31 https://doi.org/10.1007/s00103-019-03066-x © Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature 2019 Immunization has made an enormous contribution to global health. An additional 1.5 million deaths could be avoided if global immunization coverage improves [14] . keywords: children; countries; coverage; disease; global; health; immunization; services; strategies; use; vaccination; vaccine cache: cord-316893-jwjr67po.txt plain text: cord-316893-jwjr67po.txt item: #222 of 299 id: cord-317739-2wojtboi author: Abo, Stéphanie M.C. title: Modelling the daily risk of ebola in the presence and absence of a potential vaccine date: 2020-10-15 words: 5065 flesch: 47 summary: The Lancet Early Epidemic Dynamics of the West African 2014 Ebola Outbreak: Estimates Derived with a Simple Two-Parameter Model Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: Final results from the Guinea ring vaccination, open-label, cluster-randomised trial An overview of Ebola virus disease Global cardiovascular risk in patients with HIV infection: concordance and differences in estimates according to three risk equations (Framingham, SCORE, and PROCAM) Understanding the dynamics of Ebola epidemics Ebola and Marburg haemorrhagic fever viruses: Major scientific advances, but a relatively minor public health threat for Africa Dynamics and control of Ebola virus transmission in Montserrado, Liberia: a mathematical modelling analysis Modeling the role of public health education in Ebola virus disease outbreaks in Sudan Vesicular Stomatitis Virus-Based Ebola Vaccines With Improved Cross-Protective Efficacy Vesicular Stomatitis Virus-Based Vaccines for Prophylaxis and Treatment of Filovirus Infections Immunomonitoring of human responses to the rVSV-ZEBOV Ebola vaccine. Learning From the Ebola Crisis The basic reproductive number of Ebola and the effects of public health measures: the cases of Congo and Uganda Transmission dynamics and control of Ebola virus disease (EVD): A review The Ebola outbreak, 2013-2016: old lessons for new epidemics Modeling the Spread of Ebola. keywords: contact; ebola; people; protection; risk; vaccine cache: cord-317739-2wojtboi.txt plain text: cord-317739-2wojtboi.txt item: #223 of 299 id: cord-318272-spt0oea0 author: Bhardwaj, Prateek title: Advancements in prophylactic and therapeutic nanovaccines date: 2020-04-05 words: 14598 flesch: 27 summary: A brief review of computer-assisted approaches to rational design of peptide vaccines Peptide vaccine: progress and challenges Principles of vaccine design-lessons from nature Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles Advances and opportunities in nanoparticle-and nanomaterial-based vaccines against bacterial infections Protein and peptide biomaterials for engineered subunit vaccines and immunotherapeutic applications Immunological mechanisms of vaccination Micro and nanoparticle-based delivery systems for vaccine immunotherapy: an immunological and materials perspective Towards tailored vaccine delivery: needs, challenges and perspectives CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery Innate and adaptive immune cells in the tumor microenvironment Trained innate immunity as underlying mechanism for the long-term, nonspecific effects of vaccines Pathogen-associated molecular patterns on biomaterials: a paradigm for engineering new vaccines Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns Engineering nanoparticles to overcome barriers to immunotherapy Poly(lactide-co-glycolide)-rifampicin nanoparticles efficiently clear Mycobacterium bovis BCG infection in macrophages and remain membrane-bound in phago-lysosomes A therapeutic microparticle-based tumor lysate vaccine reduces spontaneous metastases in murine breast cancer Enantiospecific adjuvant activity of cationic lipid DOTAP in cancer vaccine Dendritic cell-based nanovaccines for cancer immunotherapy Adoptive immunotherapy for cancer: harnessing the T cell response Skwarczynski , Multiantigenic peptide-polymer conjugates as therapeutic vaccines against cervical cancer PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine Dendritic cells and other innate determinants of T helper cell polarisation Rosenberg , Cancer immunotherapy based on mutation-specific CD4 + T cells in a patient with epithelial cancer How regulatory T cells work Human memory B cells originate from three distinct germinal center-dependent and -independent maturation pathways Rituximab specifically depletes short-lived autoreactive plasma cells in a mouse model of inflammatory arthritis The cell biology of antigen processing Quantitative review of antibody response to inactivated seasonal influenza vaccines, Influenza Other Respir Single-injection vaccines: progress, challenges, and opportunities Switched memory B cells maintain specific memory independently of serum antibodies: the hepatitis B example Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype Polymeric particles in vaccine delivery Exploiting lymphatic transport and complement activation in nanoparticle vaccines Memory antibody response from antigen loaded polymer particles and the effect of antigen release kinetics Applications of nanotechnology for immunology Vaccine adjuvants: mode of action Mechanisms of action of adjuvants Toll-like receptor signaling pathways Unleashing the potential of NOD-and Toll-like agonists as vaccine adjuvants Activation with CpG-A and CpG-B oligonucleotides reveals two distinct regulatory pathways of type I IFN synthesis in human plasmacytoid dendritic cells Vaccine delivery using nanoparticles Design of a protective single-dose intranasal nanoparticle-based vaccine platform for respiratory infectious diseases Carbohydrate-functionalized nanovaccines preserve HIV-1 antigen stability and activate antigen presenting cells Polyglutamic acid-trimethyl chitosan-based intranasal peptide nano-vaccine induces potent immune responses against group A streptococcus Applications of nanomaterials as vaccine adjuvants Nanovaccines and their mode of action A novel lipid nanoparticle adjuvant significantly enhances B cell and T cell responses to sub-unit vaccine antigens Curdlan sulfate-O-linked quaternized chitosan nanoparticles: potential adjuvants to improve the immunogenicity of exogenous antigens via intranasal vaccination Green synthesis and evaluation of silver nanoparticles as adjuvant in rabies veterinary vaccine Lipid-derived nanoparticles for immunostimulatory RNA adjuvant delivery Artificial bacterial biomimetic nanoparticles synergize pathogen-associated molecular patterns for vaccine efficacy Coated protein nanoclusters from influenza H7N9 HA are highly immunogenic and induce robust protective immunity Viruslike Particles Encapsidating Respiratory Syncytial Virus M and M2 Proteins Induce Robust T Cell Responses Viral-mimicking protein nanoparticle vaccine for eliciting anti-tumor responses Intranasal nanovaccine confers homo-and hetero-subtypic influenza protection Encapsulins: microbial nanocompartments with applications in biomedicine, nanobiotechnology and materials science Biomimetic protein nanoparticles facilitate enhanced dendritic cell activation and cross-presentation Vault particles: a new generation of delivery nanodevices A protective vaccine against chlamydia genital infection using vault nanoparticles without an added adjuvant A supramolecular vaccine platform based on alpha-helical peptide nanofibers Self-assembled peptide nanofibers raising durable antibody responses against a malaria epitope Nanoscale peptide self-assemblies boost BCG-primed cellular immunity against mycobacterium tuberculosis Titrating T-cell epitopes within self-assembled vaccines optimizes CD4 + helper T cell and antibody outputs Intranasal delivery of adjuvant-free peptide nanofibers elicits resident CD8( + ) T cell-dependent anti-tumor immunity in mice De Berardinis , Vectorized delivery of alpha-galactosylceramide and tumor antigen on filamentous bacteriophage fd induces protective immunity by enhancing tumor-specific T Cell response Targeting mutated plus germline epitopes confers pre-clinical efficacy of an instantly formulated cancer nano-vaccine Heat shock protein-peptide and HSP-based immunotherapies for the treatment of cancer Pre-clinical development of Listeria-based nanovaccines as immunotherapies for solid tumours: insights from melanoma Antitumor humoral and T Cell responses by Mucin-1 conjugates of bacteriophage Qbeta in wild-type mice Intradermal delivery of vaccine nanoparticles using hollow microneedle array generates enhanced and balanced immune response Effect of TLR ligands co-encapsulated with multiepitopic antigen in nanoliposomes targeted to human DCs via Fc receptor for cancer vaccines Tumor growth inhibition by mSTEAP peptide nanovaccine inducing augmented CD8( + ) keywords: activation; adjuvants; antibody; antigen; cancer; cd8; cells; delivery; hiv; immune; immunity; immunization; influenza; malaria; membrane; memory; mice; nanoparticles; nanovaccines; peptide; potential; prophylactic; protein; responses; surface; therapeutic; tumor; vaccine; virus cache: cord-318272-spt0oea0.txt plain text: cord-318272-spt0oea0.txt item: #224 of 299 id: cord-318593-ni84gzg5 author: Wolf, Jayanthi title: Applying lessons from the Ebola vaccine experience for SARS-CoV-2 and other epidemic pathogens date: 2020-06-15 words: 4095 flesch: 32 summary: This report outlines the main lessons learned by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (MSD) during development of an Ebola Zaire vaccine (ERVEBO®) and looks ahead to critical lessons beyond vaccine development. These vaccine candidates were not taken into clinical development prior to the West African outbreak for several reasons, which included the inability to demonstrate clinical efficacy in the absence of an ongoing outbreak and lack of interest by the public health and vaccine development community to invest in the lengthy and costly process of vaccine development without a clear demand for an Ebola vaccine 2 . keywords: african; countries; data; development; ebola; health; manufacturing; outbreak; trials; vaccine cache: cord-318593-ni84gzg5.txt plain text: cord-318593-ni84gzg5.txt item: #225 of 299 id: cord-318683-1yxurnev author: Green, Manfred S title: Confronting the threat of bioterrorism: realities, challenges, and defensive strategies date: 2018-10-16 words: 8027 flesch: 32 summary: Since the west African Ebola virus epidemic, new Ebola virus vaccines that have been long under development are being used successfully in the 2018 epidemic in the Democratic Republic of the Congo. Currently, the vaccines that would most likely be used for pre-exposure or post-exposure prophylaxis are the smallpox and anthrax vaccines. keywords: agents; anthrax; bioterrorism; disease; ebola; exposure; health; outbreak; preparedness; public; response; risk; smallpox; surveillance; treatment; vaccination; vaccine; virus cache: cord-318683-1yxurnev.txt plain text: cord-318683-1yxurnev.txt item: #226 of 299 id: cord-318983-rmvqf6s9 author: SCHMIDT, HARALD title: Vaccine Rationing and the Urgency of Social Justice in the Covid‐19 Response date: 2020-05-28 words: 2885 flesch: 51 summary: 5 Along with other data at the national level indicating that low-income communities and communities of color are at higher risk of serious illness if infected, 6 these disparities bear out that historically and structurally disadvantaged populations incur a far larger share of the morbidity and mortality burden while being far less able to absorb financial and other costs. So They Brave the Subway Association of County-Level Socioeconomic and Political Characteristics with Engagement in Social Distancing for COVID-19 Variation in COVID-19 Hospitalizations and Deaths across New York City Boroughs Most NYC Coronavirus Testing Done in Whitest and Wealthiest ZIP Codes Low-Income and Communities of Color at Higher Risk of Serious Illness if Infected with Coronavirus The Black Plague Interim Updated Planning Guidance on Allocating and Targeting Pandemic Influenza Vaccine during an Influenza Pandemic Fair Allocation of Scarce Medical Resources in the Time of Covid-19 University of Wisconsin School of Medicine Public Health, Department of Medicine University of Wisconsin School of Medicine Public Health, Department of Medicine. keywords: covid-19; groups; health; people; percent; vaccine; years cache: cord-318983-rmvqf6s9.txt plain text: cord-318983-rmvqf6s9.txt item: #227 of 299 id: cord-319226-yvgvyif0 author: French, Jeff title: Key Guidelines in Developing a Pre-Emptive COVID-19 Vaccination Uptake Promotion Strategy date: 2020-08-13 words: 6356 flesch: 36 summary: Since the beginning of the COVID-19 pandemic there has been a tsunami of misinformation and conspiracy theories that have the potential to reduce vaccine uptake. Since the beginning of the COVID-19 pandemic, we have witnessed a tsunami of misinformation and conspiracy theories that have the potential to reduce vaccine uptake. keywords: authorities; covid-19; governments; health; hesitancy; key; media; need; people; public; strategy; uptake; vaccination; vaccine cache: cord-319226-yvgvyif0.txt plain text: cord-319226-yvgvyif0.txt item: #228 of 299 id: cord-321901-zpi7uis1 author: Roberts, Anjeanette title: Animal models and antibody assays for evaluating candidate SARS vaccines: Summary of a technical meeting 25–26 August 2005, London, UK date: 2006-11-30 words: 6604 flesch: 36 summary: Severe acute respiratory syndrome WHO investigates China's fall in SARS cases WHO says SARS outbreak is over, but fight should go on Summary of probable SARS cases with onset of illness from 1 Identification of a novel coronavirus in patients with severe acute respiratory syndrome Coronavirus as a possible cause of severe acute respiratory syndrome Characterization of a novel coronavirus associated with severe acute respiratory syndrome Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage The Genome sequence of the SARS-associated coronavirus SARS coronavirus: a new challenge for prevention and therapy Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China The aetiology, origins, and diagnosis of severe acute respiratory syndrome Structure of SARS coronavirus spike receptor-binding domain complexed with receptor Adaptation of SARS coronavirus to humans Bats are natural reservoirs of SARS-like coronaviruses Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus SARS immunity and vaccination Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice Aged BALB/c mice as a model for increased severity of severe acute respiratory syndrome in elderly humans Virology: SARS virus infection of cats and ferrets Severe acute respiratory syndrome coronavirus infection of golden Syrian hamsters Koch's postulates fulfilled for SARS virus Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome Effects of a SARS-associated coronavirus vaccine in monkeys Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys Macaque model for severe acute respiratory syndrome An animal model of SARS produced by infection of Macaca mulatta with SARS coronavirus An exposed domain in the severe acute respiratory syndrome coronavirus spike protein induces neutralizing antibodies Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS Adenoviral expression of a truncated S1 subunit of SARS-CoV spike protein results in specific humoral immune responses against SARS-CoV in rats Identification of the membrane-active regions of the severe acute respiratory syndrome coronavirus spike membrane glycoprotein using a 16/18-mer peptide scan: implications for the viral fusion mechanism Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice Symptoms of infection caused by SARS coronavirus in laboratory mice and guinea pigs Civets are equally susceptible to experimental infection by two different severe acute respiratory syndrome coronavirus isolates Infection of SARS-CoV on juvenile and adult Brandt's vole Microtus brandtii Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus Therapy with a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine Severe acute respiratory syndrome coronavirus nucleocapsid protein expressed by an adenovirus vector is phosphorylated and immunogenic in mice Characterization of humoral responses in mice immunized with plasmid DNAs encoding SARS-CoV spike gene fragments A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice Immunogenicity of SARS inactivated vaccine in BALB/c mice Augmentation of immune responses to SARS coronavirus by a combination of DNA and whole killed virus vaccines Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses Antibody-dependent enhancement of virus infection and disease Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications Intracellular transport of recombinant coronavirus spike proteins: implications for virus assembly Localization of antigenic sites of the S glycoprotein of feline infectious peritonitis virus involved in neutralization and antibody-dependent enhancement Monoclonal antibody analysis of neutralization and antibody-dependent enhancement of feline infectious peritonitis virus Laboratory Biosafety Manual WHO biosafety guidelines for handling of SARS specimens Caution urged on SARS vaccines The authors thank Dr. Marc P. Girard and Dr. Marie-Paule Kieny for their invaluable assistance in preparing the manuscript. keywords: animal; antibody; assays; coronavirus; cov; disease; human; infection; mice; models; sars; studies; syndrome; vaccines cache: cord-321901-zpi7uis1.txt plain text: cord-321901-zpi7uis1.txt item: #229 of 299 id: cord-322913-sq9mq6f1 author: Ciabattini, Annalisa title: Shelter from the cytokine storm: pitfalls and prospects in the development of SARS-CoV-2 vaccines for an elderly population date: 2020-11-06 words: 8078 flesch: 24 summary: The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50-80 years Study of the effectiveness of influenza vaccination in the elderly in the epidemic of 1989-90 using a general practice database Effectiveness of influenza vaccine in the community-dwelling elderly Effect of influenza vaccine status on winter mortality in Spanish community-dwelling elderly people during 2002-2005 influenza periods Efficacy and costeffectiveness of influenza vaccination of the elderly in a densely populated and unvaccinated community Systems analysis of sex differences reveals an immunosuppressive role for testosterone in the response to influenza vaccination A single dose of unadjuvanted novel 2009 H1N1 vaccine is immunogenic and well tolerated in young and elderly adults Immune response following H1N1pdm09 vaccination: differences in antibody repertoire and avidity in young adults and elderly populations stratified by age and gender Role of the microbiota in the modulation of vaccine immune responses The influence of the intestinal microbiome on vaccine responses Antibiotics-driven gut microbiome perturbation alters immunity to vaccines in humans Recent advances in systems biology integrating clinical, immunologic, and omics data can help to identify stable and robust markers of vaccine response and move towards a better understanding of SARS-CoV-2 vaccine responses in the elderly. keywords: age; aging; cells; cov-2; covid-19; development; disease; gut; infection; influenza; microbiota; patients; population; responses; sars; vaccination; vaccine cache: cord-322913-sq9mq6f1.txt plain text: cord-322913-sq9mq6f1.txt item: #230 of 299 id: cord-322955-7dw32xby author: Kathwate, Gunderao H title: In Silico design and characterization of multi-epitopes vaccine for SARS-CoV2 from its spike proteins date: 2020-06-12 words: 5732 flesch: 41 summary: nature I-TASSER: a unified platform for automated protein structure and function prediction In silico analysis of epitope-based vaccine candidates against hepatitis B virus polymerase protein Improving the physical realism and structural accuracy of protein models by a two-step atomic-level energy minimization GalaxyWEB server for protein structure prediction and refinement. In conclusion, predicted vaccine is a good antigen, probable no allergen and has potential to induce cellular and humoral immunity. keywords: cell; cov2; covid-19; development; epitopes; prediction; protein; response; sars; score; sequence; server; structure; tools; vaccine; web cache: cord-322955-7dw32xby.txt plain text: cord-322955-7dw32xby.txt item: #231 of 299 id: cord-323540-7b2mt1a8 author: García, Leidy Y. title: Contingent assessment of the COVID-19 vaccine date: 2020-06-25 words: 4015 flesch: 46 summary: The Keywords: COVID-19; SARS-CoV-2; vaccine; acceptance; health economics; contingent valuation The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a pandemic coronavirus disease 2019 (COVID- 19) has had a negative impact on people's health and life and on economies around the world. The vaccine is expected to be available free of charge to at least the poorest people with financing from the governments of each country, while the richest people could voluntarily seek vaccines in private clinics. keywords: covid-19; covid-19 vaccine; health; individual; vaccine; value; wtp cache: cord-323540-7b2mt1a8.txt plain text: cord-323540-7b2mt1a8.txt item: #232 of 299 id: cord-323710-cmbg0ty8 author: Mühlebach, Michael D. title: Development of Recombinant Measles Virus-Based Vaccines date: 2016-11-26 words: 4318 flesch: 41 summary: Sixty-Third World Health Assembly Rescue of measles viruses from cloned DNA Measles virus spread and pathogenesis in genetically modified mice A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-inman trial A vectored measles virus induces hepatitis B surface antigen antibodies while protecting macaques against measles virus challenge Protective anti-hepatitis B virus responses in rhesus monkeys primed with a vectored measles virus and boosted with a single dose of hepatitis B surface antigen A recombinant measles virus expressing hepatitis B virus surface antigen induces humoral immune responses in genetically modified mice Attenuated measles virus as a vaccine vector Recombinant measles viruses expressing heterologous antigens of mumps and simian immunodeficiency viruses Recombinant measles virus incorporating heterologous viral membrane proteins for use as vaccines Measles vaccine expressing the secreted form of West Nile virus envelope glycoprotein induces protective immunity in squirrel monkeys, a new model of West Nile virus infection Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis Live attenuated measles vaccine expressing HIV-1 Gag virus like particles covered with gp160DeltaV1V2 is strongly immunogenic Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine Immunogenicity of a recombinant measles HIV-1 subtype C vaccine Toxicology, biodistribution and shedding profile of a recombinant measles vaccine vector expressing HIV-1 antigens, in cynomolgus macaques A recombinant live attenuated measles vaccine vector primes effective HLA-A0201-restricted cytotoxic T lymphocytes and broadly neutralizing antibodies against HIV-1 conserved epitopes Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses The successful induction of T-cell and antibody responses by a recombinant measles virusvectored tetravalent dengue vaccine provides partial protection against dengue-2 infection Immunogenic subviral particles displaying domain III of dengue 2 envelope protein vectored by measles virus Pediatric measles vaccine expressing a dengue antigen induces durable serotypespecific neutralizing antibodies to dengue virus Pediatric measles vaccine expressing a dengue tetravalent antigen elicits neutralizing antibodies against all four dengue viruses Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein Recombinant measles virus exp ressing single or multiple antigens of human immunodeficiency virus (HIV-1) in duce cellular and humoral immune responses Immunogenicity of next-generation HPV vaccines in non-human primates: measles-vectored HPV vaccine versus Pichia pastoris recombinant protein vaccine Recombinant measles virus-HPV vaccine candidates for prevention of cervical carcinoma Evaluation of a recombinant measles virus expressing hepatitis C virus envelope proteins by infection of human PBL-NOD/Scid/ Jak3null mouse Broadly neutralizing immune responses against hepatitis C virus induced by vectored measles viruses and a recombinant envelope protein booster Immunogenicity of attenuated measles virus engineered to express Helicobacter pylori neutrophilactivating protein AIK-C measles vaccine expressing fusion protein of respiratory syncytial virus induces protective antibodies in cotton rats Recombinant measles viruses expressing respiratory syncytial virus proteins induced virus-specific CTL responses in cotton rats Evaluation of measles vaccine virus as a vector to deliver respiratory syncytial virus fusion protein or Epstein-Barr virus glycoprotein gp350 A highly immunogenic and protective middle east respiratory syndrome coronavirus vaccine based on a recombinant measles virus vaccine platform Study of pathogenicity of Nipah virus and its vaccine development Recombinant measles AIK-C vaccine strain expressing the prM-E antigen of Japanese encephalitis virus Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter Toward developing a preventive MERS-CoV vaccine-report from a workshop organized by the Saudi Arabia Ministry of Health and the International Vaccine Institute A roadmap for MERS-CoV research and product development: report from a World Health Organization consultation Rescue of measles virus using a replication-deficient vaccinia-T7 vector RNA polymerase II-controlled expression of antigenomic RNA enhances the rescue efficacies of two different members of the Mononegavirales independently of the site of viral genome replication The rule of six, a basic feature for efficient replication of Sendai virus defective interfering RNA Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche key: cord-323710-cmbg0ty8 authors: Mühlebach, Michael D.; Hutzler, Stefan title: Development of Recombinant Measles Virus-Based Vaccines date: 2016-11-26 journal: Recombinant Virus Vaccines DOI: 10.1007/978-1-4939-6869-5_9 sha: doc_id: 323710 cord_uid: cmbg0ty8 This chapter describes the development of recombinant measles virus (MV)-based vaccines starting from plasmid DNA. keywords: antigen; cells; measles; plasmids; recombinant; rescue; responses; vaccine; virus; viruses cache: cord-323710-cmbg0ty8.txt plain text: cord-323710-cmbg0ty8.txt item: #233 of 299 id: cord-323794-p3zjxo1h author: Malik, A. A. title: Determinants of COVID-19 Vaccine Acceptance in the U.S. date: 2020-05-24 words: 3692 flesch: 46 summary: There were notable geographic differences in COVID-19 vaccine acceptance with DHHS Region 8-Denver having an acceptance rate of over 75% (total sample in region, N = 20; number of participants within sample that would accept COVID-19 vaccine, n = 16) while Region 2-New York (N = 51; n = 22), and Region 5-Chicago (N = 23; n = 9) had an acceptance rate of less than 50% (figure 2a). The purpose of our study is to describe the current vaccine acceptance landscape with aims to 1) predict COVID-19 vaccine acceptance using regularly available demographic information, 2) identify the most vulnerable populations, and 3) provide information for public health officials and politicians to develop messaging for all Americans, while targeting communities most in need. keywords: acceptance; covid-19; license; participants; preprint; vaccine cache: cord-323794-p3zjxo1h.txt plain text: cord-323794-p3zjxo1h.txt item: #234 of 299 id: cord-324001-m7ys95z7 author: Kobinger, Gary P. title: Assessment of the Efficacy of Commercially Available and Candidate Vaccines against a Pandemic H1N1 2009 Virus date: 2010-04-01 words: 3590 flesch: 33 summary: FluSure or pH1N1inact did not generate detectable HAI antibody titers against the seasonal H1N1 strain A/Brisbane/59/2007 included in conventional seasonal influenza vaccines, such as Fluviral or FluMist. H5N1 virus challenge in mice and ferrets Antibody-mediated growth of influenza A NWS virus in macrophagelike cell line P388D1 Infection enhancement of influenza A NWS virus in primary murine macrophages by anti-hemagglutinin monoclonal antibody Subtype cross-reactive, infectionenhancing antibody responses to influenza A viruses The immune response and maternal antibody interference to a heterologous H1N1 swine influenza virus infection following vaccination Immunosuppression during acute infection with foot-and-mouth disease virus in swine is mediated by IL-10 Alveolar macrophages are indispensable for controlling influenza viruses in lungs of pigs keywords: animals; day; flumist; h1n1; influenza; response; vaccine; virus cache: cord-324001-m7ys95z7.txt plain text: cord-324001-m7ys95z7.txt item: #235 of 299 id: cord-324219-z1nigtb5 author: Bradbury, Jane title: Custom-made vaccines at speed date: 2003-06-15 words: 978 flesch: 50 summary: Other experts agree -the use of reverse genetics to make recombinant SARS vaccine could ultimately be the most effective and adaptable system for vaccine development, but will require considerable research set-up time. 'Even 10 years ago,' says Rappuoli, 'genetics was used minimally in vaccine development. keywords: genetics; sars; vaccine cache: cord-324219-z1nigtb5.txt plain text: cord-324219-z1nigtb5.txt item: #236 of 299 id: cord-324349-26uuczmi author: Kidokoro, Minoru title: Vaccinia Virus LC16m8∆ as a Vaccine Vector for Clinical Applications date: 2014-10-17 words: 5262 flesch: 37 summary: Existing vaccine stockpiles have not been updated since the 1970s; because these early vaccines are lymph-derived vaccines produced by propagating vaccine viruses in the skin of animals (i.e., first-generation vaccines ( Table 1 )), they do not meet good manufacturing practice (GMP) standards Multistate outbreak of monkeypox-Illinois, indiana, and wisconsin Vaccinia virus vaccines: Past, present and future Vaccinia viruses: Vaccines against smallpox and vectors against infectious diseases and tumors A vaccinia virus renaissance: New vaccine and immunotherapeutic uses after smallpox eradication Adverse events associated with smallpox vaccination in the United States Neurologic adverse events associated with smallpox vaccination in the united states Adventitious agents and smallpox vaccine in strategic national stockpile Clonal vaccinia virus grown in cell culture as a new smallpox vaccine Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax ® in healthy vaccinia-naive adults Acam2000 clonal vero cell culture vaccinia virus (New York city board of health strain)-A second-generation smallpox vaccine for biological defense Safety and immunogenicity of new cell-cultured smallpox vaccine compared with calf-lymph derived vaccine: A blind, single-centre, randomised controlled trial Modified vaccinia virus ankara protects macaques against respiratory challenge with monkeypox virus MVA vaccination against smallpox: Clinical tests with an attenuated live vaccinia virus strain (MVA) (in German) keywords: cell; gag; gene; lc16m8; mice; mva; smallpox; strain; vaccine; vaccinia; virus cache: cord-324349-26uuczmi.txt plain text: cord-324349-26uuczmi.txt item: #237 of 299 id: cord-324690-82qsirnk author: Dieffenbach, Carl W title: The search for an HIV vaccine, the journey continues date: 2020-05-16 words: 1470 flesch: 42 summary: As we reflect upon the status of HIV vaccine research, we would be remiss if we did not mention the current global pandemic caused by SARS-CoV-2. The authors thank the trial participants, community members, activists and researchers who have so willingly participated in the challenging work of HIV vaccine discovery and development. keywords: hiv; rv144; studies; trial; vaccine cache: cord-324690-82qsirnk.txt plain text: cord-324690-82qsirnk.txt item: #238 of 299 id: cord-324829-0nz0qioh author: Carabineiro, Sónia Alexandra Correia title: Applications of Gold Nanoparticles in Nanomedicine: Recent Advances in Vaccines † date: 2017-05-22 words: 7662 flesch: 32 summary: Recent advances toward clinical applications Polymeric nanoparticles Potent vectors for vaccine delivery targeting cancer and infectious diseases Tracking Targeted Bimodal Nanovaccines: Immune Responses and Routing in Cells, Tissue, and Whole Organism Protection of non-human primates against glanders with a gold nanoparticle glycoconjugate vaccine Synthesis of tumor-associated MUC1-glycopeptides and their multivalent presentation by functionalized gold colloids Metal Based Frameworks for Drug Delivery Systems Gold Nanoparticles: Recent Advances in the Biomedical Applications Additives for vaccine storage to improve thermal stability of adenoviruses from hours to months Assessment of gold nanoparticles as a size-dependent vaccine carrier for enhancing the antibody response against synthetic foot-and-mouth disease virus peptide Structure function attributes of gold nanoparticle vaccine association: Effect of particle size and association temperature Intracellular accumulation and immunological properties of fluorescent gold nanoclusters in human dendritic cells Different-Sized Gold Nanoparticle Activator/Antigen Increases Dendritic Cells Accumulation in Liver-Draining Lymph Nodes and CD8+T Cell Responses Yeast-Expressed Bacteriophage-Like Particles for the Packaging of Nanomaterials Polyelectrolyte Multilayers Assembled Entirely from Immune Signals on Gold Nanoparticle Templates Promote Antigen-Specific T Cell Response Impact of dose, route, and composition on the immunogenicity of immune polyelectrolyte multilayers delivered on gold templates Construction and Immunological Evaluation of CpG-Au@HBc Virus-Like Nanoparticles as a Potential Vaccine Ultrasmall Graphene Oxide Supported Gold Nanoparticles as Adjuvants Improve Humoral and Cellular Immunity in Mice Engineered CpG-Antigen Conjugates Protected Gold Nanoclusters as Smart Self-Vaccines for Enhanced Immune Response and Cell Imaging Endotoxin Nanovesicles: Hydrophilic Gold Nanodots Control Supramolecular Lipopolysaccharide Assembly for Modulating Immunological Responses Epidermal powder immunization induces both cytotoxic T-lymphocyte and antibody responses to protein antigens of influenza and hepatitis B viruses Powder and particle-mediated approaches for delivery of DNA and protein vaccines into the epidermis Recent advances in Hepatitis B vaccination Nanoparticulate mediated transcutaneous immunization: Myth or reality A Solid-in-Oil Dispersion of Gold Nanorods Can Enhance Transdermal Protein Delivery and Skin Vaccination A microarray MEMS device for biolistic delivery of vaccine and drug powders Cancer: Gold nanoparticles were coated with the F1-antigen of Yersinia pestis (bacterium responsible for the plague), using N-hydroxysuccinimide and N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide A recent study showed that animals immunized with a transmissible gastroenteritis virus, conjugated with colloidal gold nanoparticles, produced antibodies with a higher titer than those produced in response to the native virus keywords: adjuvant; antigen; cancer; cells; delivery; gold; hiv; mice; nanoparticles; peptide; protein; response; tumor; vaccine; virus cache: cord-324829-0nz0qioh.txt plain text: cord-324829-0nz0qioh.txt item: #239 of 299 id: cord-324911-6s7ubbxl author: Drury, Georgina title: Process mapping of vaccines: Understanding the limitations in current response to emerging epidemic threats date: 2019-04-17 words: 5387 flesch: 35 summary: As part of their work, the network commissioned the creation of a Vaccine Development Tool (http://www.vaccinedevelopment.org.uk/) to serve as a guide to the key stages in vaccine development. WG3: To understand the challenges in vaccine development and the key rate limiting steps for any given vaccine in development. keywords: animal; bottlenecks; development; ebola; manufacturing; outbreak; process; research; tool; trial; vaccine cache: cord-324911-6s7ubbxl.txt plain text: cord-324911-6s7ubbxl.txt item: #240 of 299 id: cord-325010-7qrht7uq author: Van der Zeijst, Bernard A.M. title: Infectious diseases know no borders: A plea for more collaboration between researchers in human and veterinary vaccines date: 2008-04-11 words: 1003 flesch: 43 summary: Essential for good teamwork and synchronous working is that both parties understand the complete process of vaccine development. A paper published in this issue of The Veterinary Journal by Jacco Heldens and his colleagues does an excellent job in explaining this process (Heldens et al., 2008) and should be required reading for every academic researcher who ventures into vaccine development. keywords: development; vaccine; veterinary cache: cord-325010-7qrht7uq.txt plain text: cord-325010-7qrht7uq.txt item: #241 of 299 id: cord-325052-7vlxa0i7 author: Williamson, E. D. title: Vaccines for emerging pathogens: prospects for licensure date: 2019-04-11 words: 6218 flesch: 37 summary: An alternative is to develop such vaccines to request US Emergency Use Authorization (EUA), or equivalent status in the United States, Canada and the European Union, making use of a considerable number of regulatory mechanisms that are available prior to licensing. An alternative is to develop such vaccines to request US Emergency Use Authorization (EUA), or an alternative status in the United States, Canada and European Union (EU) making use of a considerable number of alternative regulatory mechanisms that are available prior to licensing, so that the products are deployable at the first indications of a disease outbreak. keywords: animal; conditions; development; disease; efficacy; fever; human; pathogens; phase; plague; safety; trial; use; vaccine; virus cache: cord-325052-7vlxa0i7.txt plain text: cord-325052-7vlxa0i7.txt item: #242 of 299 id: cord-325141-x3txhjkr author: Grech, Victor title: Vaccine hesitancy among Maltese Healthcare workers toward influenza and novel COVID-19 vaccination date: 2020-10-01 words: 3682 flesch: 44 summary: Discussion The increased uptake of influenza vaccine is probably due to increased awareness of respiratory viral illness. The increased uptake of influenza vaccine is probably due to increased awareness of respiratory viral illness. keywords: covid-19; healthcare; hesitancy; influenza; uptake; vaccination; vaccine; workers cache: cord-325141-x3txhjkr.txt plain text: cord-325141-x3txhjkr.txt item: #243 of 299 id: cord-325300-wawui0fd author: Tulchinsky, Theodore H. title: 4 Communicable Diseases date: 2000-12-31 words: 31283 flesch: 46 summary: EIS officers are assigned to state health departments, other public health units, and research centers as part of their training, carrying out epidemic investigation and special tasks in disease control. In disease control, individual immunity may also protect another individual. keywords: acute; animals; areas; blood; care; cases; cause; children; contact; control; countries; coverage; deaths; disease; disease control; epidemic; eradication; fever; food; health; hiv; immunization; infection; malaria; new; organism; persons; population; potential; prevention; program; public; risk; spread; states; transmission; treatment; united; vaccination; vaccine; vector; virus; water; world; year cache: cord-325300-wawui0fd.txt plain text: cord-325300-wawui0fd.txt item: #244 of 299 id: cord-325966-0g7a9s5z author: Shih, Hsin-I. title: Fighting COVID-19: a quick review of diagnoses, therapies, and vaccines date: 2020-05-30 words: 7334 flesch: 33 summary: For COVID-19 patients, fever and cough are the two most common symptoms, and some patients might also suffer from sputum production, sore throat, headache, myalgia/arthralgia, rhinorrhea, and diarrhea An earlier study demonstrated that hydroxychloroquine was significantly associated with viral load reduction/disappearance in COVID-19 patients and its effect was strengthened by azithromycin [25] . keywords: antibodies; bcg; cells; coronavirus; cov-2; covid-19; immunity; infection; patients; protein; rna; sars; syndrome; treatment; vaccination; vaccine; virus cache: cord-325966-0g7a9s5z.txt plain text: cord-325966-0g7a9s5z.txt item: #245 of 299 id: cord-326614-cik3ino6 author: Corder, Brigette N. title: A Decade in Review: A Systematic Review of Universal Influenza Vaccines in Clinical Trials during the 2010 Decade date: 2020-10-20 words: 7556 flesch: 40 summary: Influenza Other Respir Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices-United States Deaths averted by influenza vaccination in the U.S. during the seasons 2005/06 through 2013/14 Seasonal Flu Vaccine Effectiveness Studies Immune History and Influenza Vaccine Effectiveness A Study to Assess the Safety and Immunogenicity of a New Influenza Vaccine Candidate MVA-NP+M1 in Healthy Adults Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1 Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses A T cell-inducing influenza vaccine for the elderly: Safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans A Study to Assess the Safety and Efficacy of a New Influenza Candidate Vaccine MVA-NP+M1 In Healthy Adults University of Oxford. Vaccine Safety and Immunogenicity Of A Recombinant H5N1 Vaccine In Adults Safety and immunogenicity of a plant-produced recombinant hemagglutinin-based influenza vaccine (HAI-05) derived from A/Indonesia/05/2005 (H5N1) influenza virus: A phase 1 randomized, double-blind, placebo-controlled, dose-escalation study in healthy adults Study of Single Dose GHB16L2 Trivalent Influenza Vaccine in Healthy Adults Muster, T. Phase I/II trial of a replication-deficient trivalent influenza virus vaccine lacking NS1 Protein Sciences Corporation. keywords: immune; immunogenicity; influenza; np+m1; participants; phase; response; safety; study; trials; vaccination; vaccine; virus cache: cord-326614-cik3ino6.txt plain text: cord-326614-cik3ino6.txt item: #246 of 299 id: cord-326960-9phlylce author: Felberbaum, Rachael S. title: The baculovirus expression vector system: A commercial manufacturing platform for viral vaccines and gene therapy vectors date: 2015-03-20 words: 7296 flesch: 38 summary: Recombinant protein vaccines produced in insect cells Vaccines for viral and parasitic diseases produced with baculovirus vectors Commercial production in insect cells. The advantages of recombinant BEVS vaccines for pandemic influenza are especially important. keywords: baculovirus; bevs; cells; expression; gene; influenza; insect; manufacturing; platform; production; products; protein; recombinant; therapy; vaccine; virus cache: cord-326960-9phlylce.txt plain text: cord-326960-9phlylce.txt item: #247 of 299 id: cord-327650-6afsk8ix author: Ward, Jeremy K. title: The French public's attitudes to a future COVID-19 vaccine: The politicization of a public health issue date: 2020-10-06 words: 4349 flesch: 45 summary: Presses universitaires de Rennes More Americans now see 'very high' preventive health benefits from measles vaccine Beliefs about childhood vaccination in the United States: political ideology, false consensus, and the illusion of uniqueness Psychosocial and demographic characteristics relating to vaccine attitudes in Australia Factors in vaccination intention against the pandemic influenza A/H1N1 Majority acceptance of vaccination and mandates across the political spectrum in Australia De la gestion des risques à la production de la sécurité Rethinking the antivaccine movement concept: a case study of public criticism of the swine flu vaccine's safety in France Vaccine hesitancy and coercion: all eyes on France New Yahoo News/YouGov poll shows coronavirus conspiracy theories spreading on the right may hamper vaccine efforts Ensuring global access to COVID-19 vaccines This work was supported by grants from the Agence Nationale de la Recheche (ANR-20-COVI-0035-01) and the CNRS (Momentum, to JKW). In countries where vaccine hesitancy was widespread before the COVID-19 epidemic, will it affect the coronavirus vaccination campaign? keywords: attitudes; covid-19; future; people; right; vaccination; vaccine cache: cord-327650-6afsk8ix.txt plain text: cord-327650-6afsk8ix.txt item: #248 of 299 id: cord-328557-f6o1aynz author: Samad, Abdus title: Designing a multi-epitope vaccine against SARS-CoV-2: an immunoinformatics approach date: 2020-07-17 words: 7599 flesch: 42 summary: The current world situation is releasing the necessity of an implausible and effectiveness of different anti-viral drugs or vaccine candidates against the SARS-CoV-2. In this study, the RMSD value was used to determine the significant flexibility and departure of vaccine candidates from the receptor structure, where the RMSF of the complex structure was determined to measure the displacement of our particular vaccine candidate's atom relative to the receptor structure. keywords: binding; cells; construct; coronavirus; cov-2; covid-19; ctl; epitopes; et al; figure; host; protein; receptor; sars; score; server; structure; vaccine cache: cord-328557-f6o1aynz.txt plain text: cord-328557-f6o1aynz.txt item: #249 of 299 id: cord-328698-eeg1k5a6 author: Detoc, Maëlle title: Intention to participate in a COVID-19 vaccine clinical trial and to get vaccinated against COVID-19 in France during the pandemic date: 2020-09-17 words: 2525 flesch: 44 summary: Vaccine hesitancy may also have an impact on recruitment in COVID-19 vaccine clinical trial [7] . The impact of the current pandemic on the intention to participate in a COVID-19 vaccine clinical trial and on the intention to get vaccinated against COVID-19 vaccine is not obvious. keywords: covid-19; healthcare; hesitancy; trial; vaccine cache: cord-328698-eeg1k5a6.txt plain text: cord-328698-eeg1k5a6.txt item: #250 of 299 id: cord-328935-mn8r972x author: Hodgins, Douglas C. title: Mucosal Veterinary Vaccines: Comparative Vaccinology date: 2015-03-13 words: 16353 flesch: 27 summary: The gnotobiotic piglet as a model for studies of disease pathogenesis and immunity to human rotaviruses Comparative studies of the pathogenesis, antibody immune responses, and homologous protection to porcine and human rotaviruses in gnotobiotic piglets Gut microbiota and probiotics in modulation of epithelium and gut-associated lymphoid tissue function Prevention of human rotavirus-induced diarrhea in gnotobiotic piglets using bovine antibody Influence of maternal antibodies on vaccine responses: inhibition of antibody but not T cell responses allows successful early prime-boost strategies in mice Canine parvovirus type 2 vaccine protects against virulent challenge with type 2c virus Boosting of secretory IgA antibody responses in man by parenteral cholera vaccination Cleavage of proteins of reproductive secretions by extracellular proteinases of Tritrichomonas foetus Differential production of proinflammatory cytokines: in vitro PRRSV and Mycoplasma hyopneumoniae co-infection model Veterinary Immunology, An Introduction Serum and intestinal isotype antibody responses and correlates of protective immunity to human rotavirus in a gnotobiotic pig model of disease Toll-like receptor 2 and 9 are expressed and functional in gut-associated lymphoid tissues of presuckling newborn swine Efficacy of a recombinant equine influenza vaccine against challenge with an American lineage H3N8 influenza virus responsible for the 2003 outbreak in the United Kingdom Efficacy of a cold-adapted, intranasal equine influenza vaccine: challenge trials Dendritic cell-targeted protein vaccines: a novel approach to induce T-cell immunity Failure of passive transfer in foals: incidence and outcome on four studs in New South Wales Protective immunity in macaques vaccinated with live attenuated, recombinant, and subunit measles vaccines in the presence of passively acquired antibodies Contribution of antibody-secreting cells induced in mucosal lymphoid tissues of pigs inoculated with respiratory or enteric strains of coronavirus to immunity against enteric coronavirus challenge Isotype-specific antibody-secreting cells to transmissible gastroenteritis virus and porcine respiratory coronavirus in gut-and bronchus-associated lymphoid tissues of suckling pigs Effects of various vaccination protocols on passive and active immunity to Pasteurella haemolytica and Haemophilus somnus in beef calves Development of an experimental inactivated PRRSV vaccine that induces virus-neutralizing antibodies Nanobodies ® : new ammunition to battle viruses Maternal antibodies against equine influenza virus in foals and their interference with vaccination Egg yolk IgY: protection against rotavirus induced diarrhea and modulatory effect on the systemic and mucosal antibody responses in newborn calves Cholera toxin improves the F4(K88)-specific immune response following oral immunization of pigs with recombinant FaeG A field trial to evaluate the efficacy of a combined rotaviruscoronavirus/Escherichia coli vaccine in dairy cattle Inactivated rotavirus vaccine induces protective immunity in gnotobiotic piglets Possible mechanisms of protection elicited by candidate rotavirus vaccines as determined with the adult mouse model Rotavirus vaccines: how they work or don't work Role of maternally derived circulating antibodies in protection of neonatal swine against porcine group Because PRRSV infection rapidly subverts the host immune responses, an effective adjuvant must overcome immunosuppression caused by vaccine virus and simultaneously potentiate virus-specific adaptive immunity. keywords: animals; antibodies; antibody; cells; diarrhea; disease; efficacy; enteric; et al; iga; immune; immunity; infection; influenza; mucosal; oral; pigs; porcine; protection; prrsv; reproductive; responses; rotavirus; saif; serum; studies; vaccination; vaccines; virus cache: cord-328935-mn8r972x.txt plain text: cord-328935-mn8r972x.txt item: #251 of 299 id: cord-330342-i55czo8a author: Johnson, Alton R. title: In Pursuit of a SARS-CoV-2 Vaccine date: 2020-10-28 words: 1118 flesch: 33 summary: This operation is unusual, in that the traditional process for vaccine development typically takes >70 months to complete; however, this mission's accelerated process aims to reduce the timeline to a duration of just 14 months (2). Like new drugs, new vaccines are developed through a process that entails a number of distinct phases [https://www.cdc.gov/vaccines/basics/test-approve.html]. keywords: covid-19; doses; phase; vaccine cache: cord-330342-i55czo8a.txt plain text: cord-330342-i55czo8a.txt item: #252 of 299 id: cord-330496-p3o6zkhf author: Tizard, Ian R. title: Feline vaccines date: 2020-07-10 words: 4986 flesch: 45 summary: As with other such vaccines the MLV vaccines induce protection rapidly, probably because of interferon release. Because of the great diversity in FeLV vaccines, the question of relative effectiveness is often asked. keywords: antibodies; cats; cell; feline; immunity; injection; sarcomas; vaccination; vaccines; virus cache: cord-330496-p3o6zkhf.txt plain text: cord-330496-p3o6zkhf.txt item: #253 of 299 id: cord-331217-uup16bhm author: Murphy, Frederick A. title: Adventitious Agents and Smallpox Vaccine in Strategic National Stockpile date: 2005-07-17 words: 2283 flesch: 38 summary: First, adventitious agent testing for viruses in vaccine virus seeds and product intermediates is complicated and might give ambiguous results. However, for old smallpox vaccine stocks, it is enough to question whether any of the infectious agents specifically cited in FDA and European Commission regulations, recommendations, and guidelines are present. keywords: agents; smallpox; stocks; testing; vaccine; viruses cache: cord-331217-uup16bhm.txt plain text: cord-331217-uup16bhm.txt item: #254 of 299 id: cord-332358-0t4uxmj2 author: Lamphear, Barry J. title: A corn-based delivery system for animal vaccines: an oral transmissible gastroenteritis virus vaccine boosts lactogenic immunity in swine date: 2004-06-23 words: 3131 flesch: 41 summary: However, replacing subsequent injections of the modified live TGEV vaccine with oral corn vaccine boosters would clearly save considerable time and effort. Cereals are particularly well-suited expression vehicles since the expressed proteins can be stored at relatively high concentrations for extended periods of time without degradation and dry seed can be formulated into oral vaccines suitable for commercial applications. keywords: corn; farrowing; gilts; groups; tgev; vaccine; virus cache: cord-332358-0t4uxmj2.txt plain text: cord-332358-0t4uxmj2.txt item: #255 of 299 id: cord-335948-qkfxfmxb author: Ampofo, William K. title: Improving influenza vaccine virus selectionReport of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14–16 June 2010 date: 2011-08-08 words: 10007 flesch: 18 summary: key: cord-335948-qkfxfmxb authors: Ampofo, William K.; Baylor, Norman; Cobey, Sarah; Cox, Nancy J.; Daves, Sharon; Edwards, Steven; Ferguson, Neil; Grohmann, Gary; Hay, Alan; Katz, Jacqueline; Kullabutr, Kornnika; Lambert, Linda; Levandowski, Roland; Mishra, A. C.; Monto, Arnold; Siqueira, Marilda; Tashiro, Masato; Waddell, Anthony L.; Wairagkar, Niteen; Wood, John; Zambon, Maria; Zhang, Wenqing title: Improving influenza vaccine virus selectionReport of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14–16 June 2010 date: 2011-08-08 journal: The expanded and enhanced role of the GISRS following the adoption of the International Health Regulations (2005), recognition of the continuing threat posed by avian H5N1 and the aftermath of the 2009 H1N1 pandemic provide an opportune time to critically review the process by which influenza vaccine viruses are selected. keywords: antigenic; data; development; gisrs; global; human; influenza; influenza vaccine; influenza viruses; pandemic; selection; vaccine; vaccine virus; virus selection; viruses cache: cord-335948-qkfxfmxb.txt plain text: cord-335948-qkfxfmxb.txt item: #256 of 299 id: cord-335960-biwnqa3f author: Luke, Anthony title: Prevention of Infectious Diseases in Athletes date: 2007-07-31 words: 6817 flesch: 42 summary: key: cord-335960-biwnqa3f authors: Luke, Anthony; d'Hemecourt, Pierre title: Prevention of Infectious Diseases in Athletes date: 2007-07-31 journal: Clinics in Sports Medicine DOI: 10.1016/j.csm.2007.04.006 sha: doc_id: 335960 cord_uid: biwnqa3f The sports medicine physician may face challenging issues regarding infectious diseases when dealing with teams or highly competitive athletes who have difficulties taking time off to recover. This article reviews preventive strategies for infectious disease in athletes, including immunization recommendations and prophylaxis guidelines, improvements in personal hygiene and prevention of spread of infectious organisms by direct contact, insect-borne disease precautions, and prevention of sexually transmitted diseases. keywords: athletes; contact; disease; immunization; infection; influenza; pertussis; prevention; risk; sports; tick; use; vaccination; vaccine; virus; years cache: cord-335960-biwnqa3f.txt plain text: cord-335960-biwnqa3f.txt item: #257 of 299 id: cord-336730-hqgwj8vs author: Fehr, Daniela title: Placebo-controlled evaluation of a modified life virus vaccine against feline infectious peritonitis: safety and efficacy under field conditions date: 1997-07-31 words: 4309 flesch: 52 summary: However, if the incidence of FIP cases during the first 150 days after vaccination were compared in vaccinated vs placebo cats, there is absolutely no difference in that 12 cats in the vaccine group and 11 cats in the placebo group died during this time. Under experimental conditions, vaccination of FCoV naive cats was also found to reduce the incidence and the severity of infections with the low virulent viruses called FECV38. keywords: cats; fcov; feline; fip; group; placebo; vaccination; vaccine cache: cord-336730-hqgwj8vs.txt plain text: cord-336730-hqgwj8vs.txt item: #258 of 299 id: cord-337577-dqikrmk7 author: Greenberg, Harry B. title: Vaccination against Viruses date: 2016-05-09 words: 4793 flesch: 19 summary: Influenza vaccines must change composition on an almost annual basis to track antigenic drift or shift, and the vaccine varies considerably in effectiveness from year to year depending in part on the accuracy of the antigenic match between the vaccine and circulating strains. Even absent the ability to suffice as the primary basis for influenza vaccines, conserved targets of T cell effectors may prove useful supplements to increase the breadth of coverage by vaccines that also include targets of more potently protective, strain-specific humoral immunity (Antrobus et al., 2014) . keywords: antibody; cell; development; et al; immunity; immunization; influenza; protection; response; vaccine; virus cache: cord-337577-dqikrmk7.txt plain text: cord-337577-dqikrmk7.txt item: #259 of 299 id: cord-339091-3xk2w0d2 author: Flower, Darren R title: Computer aided selection of candidate vaccine antigens date: 2010-11-03 words: 10671 flesch: 37 summary: However, rather than look at nucleic acid sequences, or at protein sequences directly, a new approach, based upon alignment-free techniques, has been developed which shows significant potential; we examine this next. In attempting to overcome the limitations imposed by alignment-dependent sequence similarity methods, we have implemented a novel alignment-independent method for antigen identification based on auto cross covariance (ACC) transformation of protein sequences into uniform equal-length vectors. keywords: antigens; approach; binding; cell; database; epitopes; host; identification; immunogenicity; location; methods; mhc; peptides; prediction; properties; protein; sequence; similarity; system; vaccines cache: cord-339091-3xk2w0d2.txt plain text: cord-339091-3xk2w0d2.txt item: #260 of 299 id: cord-339152-wfakzb6w author: Trovato, Maria title: Viral Emerging Diseases: Challenges in Developing Vaccination Strategies date: 2020-09-03 words: 12011 flesch: 23 summary: United States patent US 20120141520 Advanced oxidation technology for the development of a next-generation inactivated West Nile virus vaccine Replication-defective West Nile virus with NS1 deletion as a new vaccine platform for flavivirus Zika virus associated with microcephaly A single-dose live-attenuated vaccine prevents Zika virus pregnancy transmission and testis damage A live-attenuated Zika virus vaccine candidate induces sterilizing immunity in mouse models A vaccine based on a modified vaccinia virus Ankara vector expressing Zika virus structural proteins controls Zika virus replication in mice Construction and evaluation of novel rhesus monkey adenovirus vaccine vectors Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys Preventative vaccines for Zika virus outbreak: preliminary evaluation Recent advances in Zika virus vaccines Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials Comparison of the virulent Asibi strain of yellow fever virus with the 17D vaccine strain derived from it Live attenuated yellow fever 17D vaccine: a legacy vaccine still controlling outbreaks in modern day Development of Sanofi Pasteur tetravalent dengue vaccine From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine Pathogenesis of dengue: challenges to molecular biology Antibody-dependent enhancement of severe dengue disease in humans Dengue: status of current and under-development vaccines Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial Recent progress in vaccine development against Chikungunya virus Effective vaccine for lassa fever Vaccine platforms for the prevention of Lassa fever Vaccines inducing immunity to Lassa virus glycoprotein and nucleoprotein protect macaques after a single shot Isolation of marburg-like virus from a case of haemorrhagic fever in Zaire Vaccines against Ebola virus A review of Phase I trials of Ebola virus vaccines: what can we learn from the race to develop novel vaccines Viruslike particle vaccination protects nonhuman primates from lethal aerosol exposure with marburgvirus (VLP Vaccination Protects Macaques against Aerosol Challenges) Studies for the development of a safer vaccine are still ongoing, and candidate vaccines include a tetravalent Dengue purified inactivated virus vaccine, currently in phase I/II clinical trial (NCT02421367), and two live attenuated tetravalent chimeric TDV (DENVax), and keywords: antibodies; antibody; cell; coronavirus; cov-2; dengue; development; diseases; human; immunity; infection; influenza; mers; new; outbreak; protein; receptor; recombinant; responses; sars; vaccination; vaccine; vector; virus; viruses cache: cord-339152-wfakzb6w.txt plain text: cord-339152-wfakzb6w.txt item: #261 of 299 id: cord-339726-eg0hajzl author: Jamrozik, Euzebiusz title: Coronavirus Human Infection Challenge Studies: Assessing Potential Benefits and Risks date: 2020-08-25 words: 3648 flesch: 24 summary: Modelling will be particularly useful in (i) comparing potential benefits and risks of HCS with those of vaccine field trials under different epidemiological conditions and (ii) estimating marginal risks to HCS participants in light of the background probabilities of infection in their local community. Vaccine field trials for SARS-CoV-2 might be more difficult (and onerous) than usual because of requirements for intensive testing for asymptomatic infection among participants, although study designs incorporating such testing have been proposed (Kahn et al. 2019) . keywords: challenge; field; hcs; infection; studies; vaccine cache: cord-339726-eg0hajzl.txt plain text: cord-339726-eg0hajzl.txt item: #262 of 299 id: cord-340042-intxyu46 author: Chaudhry, Sundas Nasir title: New insight on possible vaccine development against SARS-CoV-2 date: 2020-09-11 words: 5470 flesch: 31 summary: A pneumonia outbreak associated with a new coronavirus of probable bat origin Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic Coronavirus infections and immune responses SARS and MERS: recent insights into emerging coronaviruses Coronavirus endoribonuclease activity in porcine epidemic diarrhea virus suppresses type I and type III interferon responses The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases The race for coronavirus vaccines: a graphical guide The socio-economic implications of the coronavirus and COVID-19 pandemic: a review SARS-CoV-2 vaccines: status report Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen COVID-19 vaccine development pipeline gears up SARS-CoV-2/COVID-19: Viral genomics, epidemiology, vaccines, and therapeutic interventions The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection Development of an inactivated vaccine candidate for SARS-CoV-2 A preliminary study on serological assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital patients Vaccination strategies to combat novel corona virus SARS-CoV-2 The ORF7b protein of severe acute respiratory syndrome coronavirus (SARS-CoV) is expressed in virus-infected cells and incorporated into SARS-CoV particles Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices-United States, 2019-20 influenza season An oral live attenuated vaccine strategy against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/2019-nCoV) Evolution and containment of transmissible recombinant vector vaccines Progress and prospects on vaccine development against SARS-CoV-2, Vaccines Potential of live pathogen vaccines for defeating the COVID-19 pandemic: history and mechanism mRNA as a transformative technology for vaccine development to control infectious diseases Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines Race for a Coronavirus Vaccine: Thanks in part to institutional support Moderna Therapeutics, and other developers are exploring diverse approaches against SARS-CoV-2 SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness Leveraging mRNAs sequences to express SARS-CoV-2 antigens in vivo The novel coronavirus originating in Wuhan, China: challenges for global health governance Pre-fusion structure of a human coronavirus spike protein A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice Characterization and preclinical evaluation of the cGMP grade DNA based vaccine, AV-1959D to enter the first-in-human clinical trials Engineering DNA vaccines against infectious diseases DNA vaccine protection against SARS-CoV-2 in rhesus macaques Immunogenicity of a DNA vaccine candidate for COVID-19 Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, doseescalation trial Design of a heterosubtypic epitope-based peptide vaccine fused with hemokinin-1 against influenza viruses The role of the proteasome in generating cytotoxic T-cell epitopes: insights obtained from improved predictions of proteasomal cleavage A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster Design of an Epitope-Based Peptide Vaccine against the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): A Vaccine Informatics Approach Application of in-silico reverse vaccinology for designing multiepitope vaccine against Coronavirus Multi-epitope vaccine design using an immunoinformatics approach for 2019 novel coronavirus in China (SARS-CoV-2), bioRxiv The latest advancements in Zika virus vaccine development The Potency of an Anti-MERS Coronavirus Subunit Vaccine Depends on a Unique Combinatorial Adjuvant Formulation The SARS-CoV-2 vaccine pipeline: an overview, Current tropical medicine reports Clover initiates development of recombinant subunit-trimer vaccine for wuhan coronavirus A translatable subunit nanovaccine for COVID-19 Design of a peptide-based subunit vaccine Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig Protection of Rhesus Macaque from SARS-Coronavirus challenge by recombinant adenovirus vaccine Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19 Potential rapid diagnostics, vaccine and therapeutics for 2019 novel coronavirus (2019-nCoV): a systematic review A decade after SARS: strategies for controlling emerging coronaviruses New vaccine technologies to combat outbreak situations Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia Based on these points, the potential parts of S protein, which are used as antigens in immunization improvement, integrate the entire extent of this protein and vaccine development [57] . keywords: cell; coronavirus; cov-2; covid-19; development; immune; novel; protein; receptor; response; sars; spike; vaccine cache: cord-340042-intxyu46.txt plain text: cord-340042-intxyu46.txt item: #263 of 299 id: cord-340516-9dfaqsv7 author: Moore, Anne C. title: Pre-clinical studies of a recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 infection date: 2020-09-06 words: 6704 flesch: 40 summary: We are developing oral vaccines for multiple indications, including influenza and noroviruses, delivered in a tablet form for people. We and others 17 have observed that transgene expression by vaccine vectors orally administered to mice can be suppressed in their intestinal environment, so immunogenicity was assessed following intranasal (i.n.) keywords: antibodies; antibody; antigen; cells; cov-2; iga; immunogenicity; infection; protein; rad; responses; sars; vaccine; virus cache: cord-340516-9dfaqsv7.txt plain text: cord-340516-9dfaqsv7.txt item: #264 of 299 id: cord-340900-f2iuy9e1 author: Wehling, Martin title: Calling for an exponential escalation scheme in vaccine development for COVID-19 date: 2020-06-16 words: 1034 flesch: 47 summary: key: cord-340900-f2iuy9e1 authors: Wehling, Martin title: Calling for an exponential escalation scheme in vaccine development for COVID-19 date: 2020-06-16 journal: Eur J Clin Pharmacol DOI: 10.1007/s00228-020-02933-w sha: doc_id: 340900 cord_uid: f2iuy9e1 PURPOSE: COVID-19 as a pandemic calls for rapid development of vaccines. Here a proposal of a seamless, adaptive, phase 1–3 trial for accelerated vaccine development is described. keywords: people; vaccine; weeks cache: cord-340900-f2iuy9e1.txt plain text: cord-340900-f2iuy9e1.txt item: #265 of 299 id: cord-340994-m7vazpq9 author: Barello, Serena title: ‘Vaccine hesitancy’ among university students in Italy during the COVID-19 pandemic date: 2020-08-06 words: 1710 flesch: 28 summary: Italy's response to vaccine hesitancy: an innovative and cost effective National Immunization Plan based on scientific evidence Quantifying population preferences around vaccination against severe but rare diseases: a conjoint analysis among French university students An observational study of university students of healthcare area: knowledge, attitudes and behaviour towards vaccinations Understanding influenza vaccine perspectives and hesitancy in university students to promote increased vaccine uptake Uptake of influenza vaccination, awareness and its associated barriers among medical students of a University Hospital in Central Saudi Arabia Influenza vaccination of healthcare workers and vaccine allocation for healthcare workers during vaccine shortages Factors associated with 2009 pandemic influenza A (H1N1) vaccination acceptance among university students from India during the post-pandemic phase Using social and behavioural science to support COVID-19 pandemic response Teaching vaccine safety communication to medical students and health professionals Clinical prevention and population health: curriculum framework for health professions Prevention for the 21st century: setting the context through undergraduate medical education Improvement in vaccination knowledge among health students following an integrated extra curricular intervention, an explorative study in the University of Palermo Improvement in attitudes toward influenza vaccination in medical students following an integrated curricular intervention Mandatory influenza vaccination of health care workers: translating policy to practice Missed opportunities? key: cord-340994-m7vazpq9 authors: Barello, Serena; Nania, Tiziana; Dellafiore, Federica; Graffigna, Guendalina; Caruso, Rosario title: ‘Vaccine hesitancy’ among university students in Italy during the COVID-19 pandemic date: 2020-08-06 journal: keywords: health; students; university; vaccine cache: cord-340994-m7vazpq9.txt plain text: cord-340994-m7vazpq9.txt item: #266 of 299 id: cord-342800-62jklwiy author: Xu, Shuqin title: mRNA Vaccine Era—Mechanisms, Drug Platform and Clinical Prospection date: 2020-09-09 words: 13604 flesch: 36 summary: Self-adjuvanting properties of mRNA have both advantages and disadvantages in mRNA vaccine applications, therefore, it is necessary to form mRNA immunogenic regulations according to different medical demands, which in return would effectively improve the application efficacy of mRNA vaccines. The extraordinary advantages associated with mRNA vaccines, including their high efficacy, a relatively low severity of side effects, and low attainment costs, have enabled them to become prevalent in pre-clinical and clinical trials against various infectious diseases and cancers. keywords: antigen; cancer; cap; cationic; cells; clinical; delivery; efficiency; encoding; expression; ifn; immune; mice; mrna; mrna vaccines; protein; responses; self; sequence; specific; translation; vaccines; virus; vitro; vivo cache: cord-342800-62jklwiy.txt plain text: cord-342800-62jklwiy.txt item: #267 of 299 id: cord-342819-p8wp6yvo author: De Groot, Anne S title: Making vaccines “on demand”: A potential solution for emerging pathogens and biodefense? date: 2013-09-01 words: 5668 flesch: 32 summary: An Informatics Perspective of the Immunone Immunoinformatics: The next step in vaccine design From immunome to vaccine: epitope mapping and vaccine design tools How the SARS vaccine effort can learn from HIV-speeding towards the future, learning from the past Immunoinformatic comparison of T-cell epitopes contained in novel swine-origin influenza A (H1N1) virus with epitopes in 2008-2009 conventional influenza vaccine DNA-prime, peptideboost multi-T-cell epitope poxvirus vaccine, induces protective immunity against vaccinia infection by T cell response alone Rapid determination of HLA B*07 ligands from the West Nile virus NY99 genome Analysis of ChimeriVax Japanese Encephalitis Virus envelope for T-cell epitopes and comparison to circulating strain sequences HelicoVax: epitope-based therapeutic Helicobacter pylori vaccination in a mouse model Low immunogenicity predicted for emerging avian-origin H7N9: Implication for influenza vaccine design A consensus epitope prediction approach identifies the breadth of murine T(CD8+)-cell responses to vaccinia virus Putting immunoinformatics to the test Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism Enhanced priming of multispecific, murine CD8+ T cell responses by DNA vaccines expressing stress protein-binding polytope peptides Technologies for enhanced efficacy of DNA vaccines A subdominant CD8(+) cytotoxic T lymphocyte (CTL) epitope from the Plasmodium yoelii circumsporozoite protein induces CTLs that eliminate infected hepatocytes from culture CTL epitopes identified with a defective recombinant adenovirus expressing measles virus nucleoprotein and evaluation of their protective capacity in mice Immunization with a LEAPS heteroconjugate containing a CTL epitope and a peptide from beta-2-microglobulin elicits a protective and DTH response to herpes simplex virus type 1 Recombinant Sindbis viruses expressing a cytotoxic T-lymphocyte epitope of a malaria parasite or of influenza virus elicit protection against the corresponding pathogen in mice Vaccine-induced cytotoxic T lymphocytes protect against retroviral challenge West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays Immunoinformatic comparison of T-cell epitopes contained in novel swine-origin influenza A (H1N1) virus with epitopes in 2008-2009 conventional influenza vaccine Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population Coupling sensitive in vitro and in silico techniques to assess crossreactive CD4(+) T cells against the swine-origin H1N1 influenza virus Low immunogenicity predicted for emerging avian-origin H7N9: Implication for influenza vaccine design T-cell-inducing vaccines -what's the future Structure of the Lassa virus nucleoprotein reveals a dsRNA-specific 3' to 5' exonuclease activity essential for immune suppression Vaccines against Lyme disease: What happened and what lessons can we learn? T cell vaccines for microbial infections A dominant CD4(+) T-cell response to Helicobacter pylori reduces risk for gastric disease in humans Identification of Class I HLA T Cell Control Epitopes for West Nile Virus Development of Burkholderia mallei and pseudomallei vaccines Signatures of T cells as correlates of immunity to Francisella tularensis DNA-prime, peptideboost multi-T-cell epitope poxvirus vaccine, induces protective immunity against vaccinia infection by T cell response alone Epitope-based therapeutic H. pylori vaccination in a mouse model of gastric cancer The two-faced T cell epitope: T cell epitope vaccine responses may be enhanced through genetic immunization. keywords: cell; delivery; design; development; dna; epitopes; influenza; pathogens; process; production; response; use; vaccine; virus cache: cord-342819-p8wp6yvo.txt plain text: cord-342819-p8wp6yvo.txt item: #268 of 299 id: cord-342831-4qfe8kok author: Xia, Yufei title: Chitosan-based mucosal adjuvants: Sunrise on the ocean date: 2015-11-04 words: 7879 flesch: 31 summary: In vitro permeability across Caco-2 Cells (Colonic) can predict in vivo (small intestinal) absorption in man-fact or myth Transport properties are not altered across Caco-2 cells with heightened TEER despite underlying physiological and ultrastructural changes Oral delivery of peptide drugs using nanoparticles self-assembled by poly(gamma-glutamic acid) and a chitosan derivative functionalized by trimethylation Mechanism and consequence of chitosan-mediated reversible epithelial tight junction opening Elucidating the signaling mechanism of an epithelial tight-junction opening induced by chitosan Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice Preparation and evaluation of chitosan nanoparticles containing Diphtheria toxoid as new carriers for nasal vaccine delivery in mice N-Trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model The potential of mannosylated chitosan microspheres to target macrophage mannose receptors in an adjuvant-delivery system for intranasal immunization Diphtheria toxoid-containing microparticulate powder formulations for pulmonary vaccination: preparation, characterization and evaluation in guinea pigs Dendritic cell targeted chitosan nanoparticles for nasal DNA immunization against SARS CoV nucleocapsid protein Mechanistic study of the adjuvant effect of biodegradable nanoparticles in mucosal vaccination Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles Development and characterization of chitosan coated poly-(varepsilon-caprolactone) nanoparticulate system for effective immunization against influenza In vitro and in vivo study of N-trimethyl chitosan nanoparticles for oral protein delivery Covalently stabilized trimethyl chitosan-hyaluronic acid nanoparticles for nasal and intradermal vaccination Co-delivery of viral proteins and a TLR7 agonist from polysaccharide nanocapsules: a needle-free vaccination strategy Development and characterization of surface modified PLGA nanoparticles for nasal vaccine delivery: effect of mucoadhesive coating on antigen uptake and immune adjuvant activity Evaluation of the immune response following a short oral vaccination schedule with hepatitis B antigen encapsulated into alginate-coated chitosan nanoparticles A single immunization with a dry powder anthrax vaccine protects rabbits against lethal aerosol challenge Fully embeddable chitosan microneedles as a sustained release depot for intradermal vaccination First in vivo evaluation of particulate nasal dry powder vaccine formulations containing ovalbumin in mice Novel thermal-sensitive hydrogel enhances both humoral and cell-mediated immune responses by intranasal vaccine delivery Chitosan microparticles for oral vaccination: preparation, characterization and preliminary in vivo uptake studies in murine Peyer's patches Transport of chitosan microparticles for mucosal vaccine delivery in a human intestinal M-cell model Chitosan microparticles for mucosal vaccination against diphtheria: oral and nasal efficacy studies in mice Chitosan chemistry and pharmaceutical perspectives Evaluation of Eudragit-coated chitosan microparticles as an oral immune delivery system pH-sensitive and mucoadhesive thiolated Eudragit-coated chitosan microspheres Formulation, characterization and optimization of Hepatitis B surface antigen (HBsAg)-loaded chitosan microspheres for oral delivery Bioadhesive-based dosage forms: the next generation Chitosan as a novel nasal delivery system for vaccines Induction of protective immunity against H1N1 influenza A(H1N1)pdm09 with spray-dried and electron-beam sterilised vaccines in non-human primates Biodistribution and lymph node retention of polysaccharide-based immunostimulating nanocapsules Chitosan GRAS notice Protective levels of diphtheria-neutralizing antibody induced in healthy volunteers by unilateral priming-boosting intranasal immunization associated with restricted ipsilateral mucosal secretory immunoglobulin A Human susceptibility and resistance to Norwalk virus infection Characterisation of a GII-4 norovirus variant-specific surface-exposed site involved in antibody binding Immunogenicity and specificity of norovirus consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues Norovirus vaccine against experimental human Norwalk virus illness Intranasal vaccination with an adjuvanted Norwalk virus-like particle vaccine elicits antigen-specific B memory responses in human adult volunteers The significance of mucosal immunity and its potential for improving global health has inspired research demonstrating that mucosal vaccines could be an attractive alternative to parenteral administration [6, 7] . keywords: activation; adjuvant; administration; antigen; cells; chitosan; delivery; immunity; intranasal; mucosal; nanoparticles; nasal; oral; responses; system; vaccination; vaccine cache: cord-342831-4qfe8kok.txt plain text: cord-342831-4qfe8kok.txt item: #269 of 299 id: cord-343347-guciupc8 author: Hajj Hussein, Inaya title: Vaccines Through Centuries: Major Cornerstones of Global Health date: 2015-11-26 words: 12286 flesch: 44 summary: In 2012, the FDA approved several vaccines: HibMenCY a new combination of meningococcal and Hib vaccine for infants; Flucelvax, which is the first seasonal influenza vaccine, manufactured using cell culture technology and a quadrivalent formulation of Fluarix (26) . This has led to a suboptimal effectiveness of influenza vaccines, which are only successful against strains included in the vaccine formulation or strains of homogenous subtype. keywords: children; disease; efficacy; health; hepatitis; history; human; immune; immunization; influenza; live; measles; pasteur; polio; response; smallpox; u.s; vaccination; vaccine; virus; world; years cache: cord-343347-guciupc8.txt plain text: cord-343347-guciupc8.txt item: #270 of 299 id: cord-343365-4y9fedcr author: Chang, Christopher title: Unmet Needs in Respiratory Diseases: “You Can’t Know Where You Are Going Until You Know Where You Have Been”—Anonymous date: 2013-11-30 words: 7303 flesch: 45 summary: key: cord-343365-4y9fedcr authors: Chang, Christopher title: Unmet Needs in Respiratory Diseases: “You Can’t Know Where You Are Going Until You Know Where You Have Been”—Anonymous date: 2013-11-30 journal: Clin Rev Allergy Immunol DOI: 10.1007/s12016-013-8399-2 sha: doc_id: 343365 cord_uid: 4y9fedcr The care of patients with respiratory diseases has improved vastly in the past 50 years. keywords: asthma; biomarkers; development; disease; fibrosis; gene; patients; pertussis; rsv; therapy; treatment; tuberculosis; vaccine; virus; years cache: cord-343365-4y9fedcr.txt plain text: cord-343365-4y9fedcr.txt item: #271 of 299 id: cord-343421-k1dqe4lk author: Hoelzer, Karin title: Vaccines as alternatives to antibiotics for food producing animals. Part 2: new approaches and potential solutions date: 2018-07-31 words: 9645 flesch: 30 summary: Underneath the mucus layer, a single layer of intestinal epithelial cells prevents uncontrolled access of the luminal content to the underlying intestinal tissues, further restricting uptake of oral vaccine antigens. This often results in a low immunogenicity of oral vaccines and requires innovative strategies to deliver the vaccine antigens to the intestinal immune system as well as the inclusion of adjuvants that promote innate and adaptive immunity [5] . keywords: antibiotics; antigens; cells; chickens; delivery; development; disease; eimeria; enteritis; immune; necrotic; ovo; perfringens; protection; spores; strains; toxin; use; vaccination; vaccines cache: cord-343421-k1dqe4lk.txt plain text: cord-343421-k1dqe4lk.txt item: #272 of 299 id: cord-343448-xhm97wy2 author: Rinaldi, Andrea title: RNA to the rescue: RNA is one of the most promising targets for drug development given its wide variety of uses date: 2020-06-26 words: 2940 flesch: 41 summary: Moreover, RNA vaccines may be able to elicit a stronger and broader immune response since they stimulate both the adaptive and innate immune systems. In addition, RNA vaccines are cell-free, non-infectious, and not-integrating, thus eliminating the risks of infection and insertional mutagenesis that comes with viral vectors. keywords: cancer; covid-19; gene; mrna; phase; protein; rna; vaccines cache: cord-343448-xhm97wy2.txt plain text: cord-343448-xhm97wy2.txt item: #273 of 299 id: cord-344006-0iq9s94n author: Atzrodt, Cassandra L. title: A Guide to COVID‐19: a global pandemic caused by the novel coronavirus SARS‐CoV‐2 date: 2020-05-23 words: 7289 flesch: 47 summary: Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the Race to find COVID-19 treatments accelerates Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase Accepted Article RNA-Dependent RNA Polymerase by Remdesivir 120 Gilead Sciences Gilead Announces Results From Phase 3 Trial of Investigational Antiviral Remdesivir in Patients With Severe COVID-19 Some FDA Approved drugs exhibit binding affinity as high as kcal/mol against COVID-19 Main Protease (Mpro): A Molecular Docking Study IndiaRxiv Major ongoing clinical trials for COVID-19 treatment and studies currently being conducted or scheduled in Japan. CNN Kamisar B Oxford scientist says its vaccine is making headway, could show efficacy by WSJ News Exclusive | Drugmaker Moderna Delivers First Experimental Coronavirus Vaccine for Human Testing Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine Live bacterial vaccines -a review and identification of potential hazards. keywords: article; cell; copyright; coronavirus; cov-2; covid-19; disease; drugs; human; patients; rights; rna; sars; symptoms; testing; vaccine; virus cache: cord-344006-0iq9s94n.txt plain text: cord-344006-0iq9s94n.txt item: #274 of 299 id: cord-344062-8xxu0orq author: Bozkurt, Hayrunnisa Bekis title: Is the impact of childhood vaccines on coronavirus disease 2019, which is moderate in pediatric patients, possible? date: 2020-07-31 words: 151 flesch: 36 summary: Measles, immune suppression and vaccination: direct and indirect nonspecific vaccine benefits Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein Nonspecific effects of vaccines and the reduction of mortality in children key: cord-344062-8xxu0orq authors: Bozkurt, Hayrunnisa Bekis title: Is the impact of childhood vaccines on coronavirus disease 2019, which is moderate in pediatric patients, possible? date: 2020-07-31 journal: keywords: pediatric cache: cord-344062-8xxu0orq.txt plain text: cord-344062-8xxu0orq.txt item: #275 of 299 id: cord-344162-8gbe6qo7 author: Loomba, S. title: Measuring the Impact of Exposure to COVID-19 Vaccine Misinformation on Vaccine Intent in the UK and US date: 2020-10-26 words: 8786 flesch: 43 summary: A final set of five pieces of misinformation comprising non-overlapping messaging and themes were selected to represent the diverse messaging found in COVID-19 vaccine misinformation (such as information questioning the importance or safety of a vaccine, see Figure 1 ). This analysis provides a platform to help us test and understand how more effective public health communication strategies can be designed and on whom these strategies would have the most positive impact in countering COVID-19 vaccine misinformation. keywords: covid-19; exposure; intent; media; medrxiv; misinformation; perpetuity; preprint; respondents; review; vaccination; vaccine cache: cord-344162-8gbe6qo7.txt plain text: cord-344162-8gbe6qo7.txt item: #276 of 299 id: cord-344563-bjuvxpkc author: Neustroev, M. P. title: Developmental Results of a Vaccine against Salmonella-Induced Equine Abortion date: 2020-11-04 words: 2394 flesch: 43 summary: Complex immunization through live vaccines was suggested to prevent rhinovirus pneumonia and salmonella-induced abortion [11] [12] It should be noted that the previous surveys have determined that the use of live vaccines against salmonella-induced abortion and pneumonia caused by rhinoviruses is not reasonable because of the extreme climate environments for stud horses kept in Yakutia. keywords: abortion; animals; bac; salmonella; strain; vaccine cache: cord-344563-bjuvxpkc.txt plain text: cord-344563-bjuvxpkc.txt item: #277 of 299 id: cord-344576-upsc9cf8 author: Taylor-Robinson, Andrew W title: A vaccine effective against Zika virus is theoretically possible but may not be delivered anytime soon date: 2016-07-05 words: 2605 flesch: 43 summary: The global spread of Zika virus: is public and media concern justified in regions currently unaffected? Probable non-vector-borne transmission of Zika virus Potential sexual transmission of Zika virus Zika virus: your questions answered Possible Association Between Zika Virus Infection and Microcephaly -Brazil Detection and sequencing of Zika virus from amniotic fluid of fetuses with microcephaly in Brazil: a case study Novel vaccine strategies against emerging viruses A systems biology approach for diagnostic and vaccine antigen discovery in tropical infectious diseases Temporal and spatial analysis of the 2014-2015 Ebola virus outbreak in West Africa Mosquitoes and their control Local transmission of Zika virus infection is possible in Australia but should be contained by current vector control measures Introducing new vaccines in developing countries A review of successful flavivirus vaccines and the problems with those flaviviruses for which vaccines are not yet available The Guardian BBC News key: cord-344576-upsc9cf8 authors: Taylor-Robinson, Andrew W title: A vaccine effective against Zika virus is theoretically possible but may not be delivered anytime soon date: 2016-07-05 journal: Res Rep Trop Med DOI: 10.2147/rrtm.s108992 sha: doc_id: 344576 cord_uid: upsc9cf8 Following the first report in May 2015 of the unexpected emergence of Zika in north east Brazil, there has been an explosive epidemic of this infection across Latin America. keywords: disease; health; infection; microcephaly; vaccine; virus; zika cache: cord-344576-upsc9cf8.txt plain text: cord-344576-upsc9cf8.txt item: #278 of 299 id: cord-344669-hw57silv author: Hilton, Shona title: Newsprint media representations of the introduction of the HPV vaccination programme for cervical cancer prevention in the UK (2005–2008) date: 2010-03-17 words: 7528 flesch: 42 summary: The tone was employed primarily to assess whether, from a public health perspective, HPV vaccine was being supported or advocated. Just under half reported that promiscuity increased the risk of contracting an HPV infection (47.7%) and reported on safety and efficacy of HPV vaccines (47.7%). keywords: articles; cancer; girls; health; hpv; hpv vaccination; infection; media; newspapers; programme; tabloid; vaccination; vaccine; women cache: cord-344669-hw57silv.txt plain text: cord-344669-hw57silv.txt item: #279 of 299 id: cord-344750-b9tndbg1 author: Neumann-Böhme, Sebastian title: Once we have it, will we use it? A European survey on willingness to be vaccinated against COVID-19 date: 2020-06-26 words: 2774 flesch: 46 summary: To view a copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/. Compliance with anti-H1N1 vaccine among healthcare workers and general population Anti-vaccine activists, Web 2.0, and the postmodern paradigm-an overview of tactics and tropes used online by the anti-vaccination movement Luxembourg: Publications Office of the European Union Countering COVID-19: A European survey on acceptability and commitment to preventive measures World Health Organization: Draft of the landscape of COVID-19 candidate vaccines The race for coronavirus vaccines How can we develop a COVID-19 vaccine quickly? Game-theoretical reflections on communicating herd immunity in vaccine advocacy Social nudging: the effect of social feedback interventions on vaccine uptake s/VCP_The-State -of-Vacci ne-Confi dence _2015 Don't rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees Listen, understand, engage Can the world find a good covid-19 vaccine quickly enough ? keywords: covid-19; herd; immunity; population; vaccination; vaccine cache: cord-344750-b9tndbg1.txt plain text: cord-344750-b9tndbg1.txt item: #280 of 299 id: cord-345191-nabxpyw3 author: Bell, Sadie title: Parents’ and guardians’ views on the acceptability of a future COVID-19 vaccine: a multi-methods study in England date: 2020-10-19 words: 1958 flesch: 37 summary: To prevent inequalities in uptake, it is crucial to understand and address factors that may affect COVID-19 vaccine acceptability in ethnic minority and lower-income groups who are disproportionately affected by COVID-19. The following reasons were given for COVID-19 vaccine acceptance for self and for 253 child/children, in order of how often they were mentioned by survey participants and 254 importance to interviewees. keywords: child; covid-19; participants; vaccine; views cache: cord-345191-nabxpyw3.txt plain text: cord-345191-nabxpyw3.txt item: #281 of 299 id: cord-345689-5ns1onkw author: Kusters, Inca C. title: Manufacturing Vaccines for an Emerging Viral Infection–Specific Issues Associated with the Development of a Prototype SARS Vaccine date: 2009-01-30 words: 6221 flesch: 39 summary: In particular, SARS vaccine development is hindered by relatively little information about human CoVs in general. Aetiology: Koch's postulates fulfilled for SARS virus Protection of chickens after live and inactivated virus vaccination against challenge with nephropathogenic infectious bronchitis virus PA/Wolgemuth/98 Virology: SARS virus infection of cats and ferrets Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys Infectious diseases. keywords: animal; cells; cov; decontamination; development; experience; inactivation; phase; sars; vaccine; vero; virus; viruses cache: cord-345689-5ns1onkw.txt plain text: cord-345689-5ns1onkw.txt item: #282 of 299 id: cord-348144-t0chpsuh author: Lucas, Alexander H. title: Carbohydrate Moieties as Vaccine Candidates date: 2005-09-01 words: 5574 flesch: 24 summary: PS antigens, by nature of their multivalent, repeating glycotope structure, engage a sufficient number of B cell receptors that result in B cell activation and maturation to antibody secretion. It is likely that bacteria, purified PS, and glycoconjugate vaccines address overlapping as well as distinct subsets of B cells. keywords: antibody; antigens; capsular; carbohydrate; cells; conjugate; glycotopes; polysaccharide; protein; response; type; vaccine cache: cord-348144-t0chpsuh.txt plain text: cord-348144-t0chpsuh.txt item: #283 of 299 id: cord-348283-7xorq5ce author: Naz, Anam title: Designing Multi-Epitope Vaccines to Combat Emerging Coronavirus Disease 2019 (COVID-19) by Employing Immuno-Informatics Approach date: 2020-07-10 words: 8223 flesch: 52 summary: Conservation analysis revealed the high similarity between the prioritized epitopes of the SARS-CoV-2 spike protein with MERS and SARS spike protein epitopes ( Table 2 ). This step was executed to better understand the structures of predicted vaccines. keywords: binding; cell; domain; epitopes; haddock; models; protein; receptor; sars; score; spike; structures; vaccine cache: cord-348283-7xorq5ce.txt plain text: cord-348283-7xorq5ce.txt item: #284 of 299 id: cord-348409-oxjd263z author: Stern, Zachariah title: The development of inovirus-associated vector vaccines using phage-display technologies date: 2019-09-08 words: 6052 flesch: 35 summary: X-ray diffraction studies of filamentous bacteriophage M13 at 7 A resolution Chemical modification of the coat protein in bacteriophage fd and orientation of the virion during assembly and disassembly Bacteriophage f1 infection: fate of the parental major coat protein The fate of the protein component of bacteriophage fd during infection Detection of prokaryotic signal peptidase in an Escherichia coli membrane fraction: endoproteolytic cleavage of nascent f1 pre-coat protein Isolation of mutants in M13 coat protein that affect its synthesis, processing, and assembly into phage Conserved residues of the leader peptide are essential for cleavage by leader peptidase Filamentous phage are released from the bacterial membrane by a two-step mechanism involving a short C-terminal fragment of pIII Architectural insight into inovirus-associated vectors (IAVs) and development of IAV-based vaccines inducing humoral and cellular responses: implications in HIV-1 vaccines A detailed review of the architecture of inoviruses and major inovirus-associated vectors (IAVs) and related vaccines Libraries of peptides and proteins displayed on filamentous phage Phage Display • An early overview of the phage-display and its applications Eliminating helper phage from phage display Identification of peroxisomal proteins by using M13 phage protein VI phage display: molecular evidence that mammalian peroxisomes contain a 2,4-dienoyl-CoA reductase Phage display of cDNA repertoires: the pVI display system and its applications for the selection of immunogenic ligands Surface expression and ligand-based selection of cDNAs fused to filamentous phage gene VI Multivalent display system on filamentous bacteriophage pVII minor coat protein Membrane insertion and assembly of epitopetagged gp9 at the tip of the M13 phage Next generation phage display by use of pVII and pIX as display scaffolds Phage display: concept, innovations, applications and future Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies Identification and characterization of protective epitope of Trichinella spiralis paramyosin Mimotopes selected with neutralizing antibodies against multiple subtypes of influenza A Induction of humoral immune response against Plasmodium falciparum sporozoites by immunization with a synthetic peptide mimotope whose sequence was derived from screening a filamentous phage epitope library High-molecular-weight melanoma-associated antigen mimotope immunizations induce antibodies recognizing melanoma cells Differential immunogenicity of two peptides isolated by high molecular weight-melanoma-associated antigen-specific monoclonal antibodies with different affinities Vaccination with a human high molecular weight melanoma-associated antigen mimotope induces a humoral response inhibiting melanoma cell growth in vitro Targeting melanoma cells with human high molecular weight-melanoma associated antigen-specific antibodies elicited by a peptide mimotope: functional effects Specificity of mimotopeinduced anti-high molecular weight-melanoma associated antigen (HMW-MAA) antibodies does not ensure biological activity A mimotope peptide-based anti-cancer vaccine selected by BAT monoclonal antibody Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune response Mimotope vaccination for epitope-specific induction of anti-VEGF antibodies Peptide mimics of the group B meningococcal capsule induce bactericidal and protective antibodies after immunization Peptides selected from a phage display library with an HIV-neutralizing antibody elicit antibodies to HIV gp120 in rabbits, but not to the same epitope Protective immune responses induced by the immunization of mice with a recombinant bacteriophage displaying an epitope of the human respiratory syncytial virus Immunisation with phage displaying peptides representing single epitopes of the glycoprotein G can give rise to partial protective immunity to HSV-2 Characterization of murine coronavirus neutralization epitopes with phage-displayed peptides Prophylactic vaccination with phagedisplayed epitope of C. albicans elicits protective immune responses against systemic candidiasis in C57BL/6 mice Protective immune responses against systemic candidiasis mediated by phage-displayed specific epitope of Candida albicans heat shock protein 90 in C57BL/6J mice Recombinant bacteriophage-based multiepitope vaccine against Taenia solium pig cysticercosis Schistosoma japonicum: isolation and identification of peptides mimicking ferritin epitopes from phage display library Protective immunity induced by phage displayed mitochondrial related peptides of Schistosoma japonicum Induction of immunity in sheep to Fasciola hepatica with mimotopes of cathepsin L selected from a phage display library Trichinella spiralis: characterization of phagedisplayed specific epitopes and their protective immunity in BALB/ c mice Identification of HIV vaccine candidate peptides by screening random phage epitope libraries Identification and characterization of a peptide that specifically binds the human, broadly neutralizing anti-human immunodeficiency virus type 1 antibody b12 Immunogenicity of HIV type 1 gp120 CD4 binding site phage mimotopes A peptide inhibitor of HIV-1 neutralizing antibody 2G12 is not a structural mimic of the natural carbohydrate epitope on gp120 Constrained peptide models from phage display libraries highlighting the cognate epitope-specific potential of the anti-HIV-1 mAb 2F5 Selection of HIV-specific immunogenic epitopes by screening random peptide libraries with HIV-1-positive sera Collection of phage-peptide probes for HIV-1 immunodominant loop-epitope Mimotopes selected with antibodies from HIV-1-neutralizing long-term non-progressor plasma HIV-1 V3 loop crown epitope-focused mimotope selection by patient serum from random phage display libraries: implications for the epitope structural features Protection of rhesus macaques against disease progression from pathogenic SHIV-89.6PD by vaccination with phage-displayed HIV-1 epitopes Variable epitope library-based vaccines: shooting moving targets Variable epitope libraries: new vaccine immunogens capable of inducing broad human immunodeficiency virus type 1-neutralizing antibody response A general strategy to identify mimotopes of pathological antigens using only random peptide libraries and human sera Induction of hepatitis B virus-specific cytotoxic T lymphocytes response in vivo by filamentous phage display vaccine Phage display for sitespecific immunization and characterization of high-risk human papillomavirus specific E7 monoclonal antibodies Peptide mimotopes of rabies virus glycoprotein with immunogenic activity Immunogenicity and epitope mapping of foreign sequences via genetically engineered filamentous phage Multiple display of foreign peptides on a filamentous bacteriophage. Peptides from plasmodium falciparum circumsporozoite protein as antigens Random-peptide libraries and antigenfragment libraries for epitope mapping and the development of vaccines and diagnostics Developing strategies to enhance and focus humoral immune responses using filamentous phage as a model antigen Phage display of peptide epitopes from HIV-1 elicits strong cytolytic responses Inexpensive anticysticercosis vaccine: s3Pvac expressed in heat inactivated M13 filamentous phage proves effective against naturally acquired Taenia solium porcine cysticercosis The potential of phage display virions expressing malignant tumor specific antigen MAGE-A1 epitope in murine model Phage display particles expressing tumor-specific antigens induce preventive and therapeutic antitumor immunity in murine p815 model A filamentous bacteriophage targeted to carcinoembryonic antigen induces tumor regression in mouse models of colorectal cancer Active immunization against Alzheimer's beta-amyloid peptide using phage display technology Immunization against Alzheimer's beta -amyloid plaques via EFRH phage administration Reduction of betaamyloid plaques in brain of transgenic mouse model of Alzheimer's disease by EFRH-phage immunization EFRH-phage immunization of Alzheimer's disease animal model improves behavioral performance in Morris water maze trials HIV-1 vaccine strategies utilizing viral vectors including antigen-displayed inoviral vectors HIV-1 neutralizing antibodies: understanding nature's pathways Antibodies in HIV-1 vaccine development and therapy Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine Immune clearance of highly pathogenic SIV infection Inducing cross-clade neutralizing antibodies against HIV-1 by immunofocusing Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes Specific phospholipid recognition by human immunodeficiency virus type-1 neutralizing anti-gp41 2F5 antibody The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1->2 mannose residues on the outer face of gp120 Antibody polyspecificity and neutralization of HIV-1: a hypothesis Immunocontraception: filamentous bacteriophage as a platform for vaccine development The Nobel Prize in chemistry keywords: antibodies; development; diseases; display; epitope; iavs; inovirus; peptide; phage; proteins; studies; vaccines; viruses cache: cord-348409-oxjd263z.txt plain text: cord-348409-oxjd263z.txt item: #285 of 299 id: cord-349249-jwvz1ux2 author: Singh, Gagandeep title: A Minimally Replicative Vaccine Protects Vaccinated Piglets Against Challenge With the Porcine Epidemic Diarrhea Virus date: 2019-10-22 words: 6560 flesch: 39 summary: The objective of this study was to evaluate the heat and RNAse treated PEDV vaccine for its safety, immunogenicity and ability to reduce viremia in a weanling piglet model, with the ultimate goal of developing a process which can potentially reduce lead vaccine development time, is safe and be easily applied to newly emerging strains. At DPC 3 and 7, challenge viral RNA was not detected in any of the pigs vaccinated with the heat and RNAse treated PEDV vaccine (Figure 4) , while 4 of the 6 pigs administered the irradiated vaccine were positive by RT-qPCR on DPC3. keywords: challenge; diarrhea; epidemic; heat; pedv; piglets; pigs; porcine; protein; rnase; spike; vaccine; virus cache: cord-349249-jwvz1ux2.txt plain text: cord-349249-jwvz1ux2.txt item: #286 of 299 id: cord-349309-7xsbpid7 author: Condit, Richard C title: The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines date: 2020-09-06 words: 2058 flesch: 36 summary: The Brighton Collaboration Benefit-Risk Assessment of Vaccines by Technology (BRAVATO, formerly the Viral Vector Vaccine Safety Working Group, V3SWG) working group has prepared a standardized template to describe the key considerations for the benefit-risk assessment of viral vector vaccines. Pursuant to this goal, the V3SWG developed a standardized template that the Coalition for Epidemic Preparedness Innovations (CEPI) and other key stakeholders could use to evaluate and communicate key considerations for the benefit-risk assessment of viral vectors and viral vector vaccines. keywords: template; vaccine; vector; virus cache: cord-349309-7xsbpid7.txt plain text: cord-349309-7xsbpid7.txt item: #287 of 299 id: cord-350565-mejd7blb author: Lewnard, Joseph A title: Emerging Challenges and Opportunities in Infectious Disease Epidemiology date: 2019-03-16 words: 6619 flesch: 10 summary: The impact of past vaccination coverage and immunity on pertussis resurgence Direct and indirect effects in vaccine efficacy and effectiveness Population biology of infectious diseases: Part I Population biology of infectious diseases: Part II Modeling infectious disease dynamics in the complex landscape of global health BEAST 2: a software platform for Bayesian evolutionary analysis Supersize me: how whole-genome sequencing and big data are transforming epidemiology The surveillance of communicable diseases of national importance Completeness of notifiable infectious disease reporting in the United States: an analytical literature review US Centers for Disease Control and Prevention and its partners' contributions to global health security Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study US Agency for International Development Uncovering Earth's virome The Global Virome Project Pandemics: spend on surveillance, not prediction Global trends in emerging infectious diseases Towards a genomics-informed, realtime, global pathogen surveillance system Ebola virus disease: 11,323 deaths later, how far have we come? Simulation-guided design further presents the opportunity for applying adaptive trial methods (115) in the context of infectious disease outbreaks, where dynamic trends in incidence may highlight the benefits of such approaches. keywords: data; disease; ebola; epidemiology; health; influenza; methods; models; pathogens; resistance; studies; surveillance; transmission; trial; vaccination; vaccine; virus cache: cord-350565-mejd7blb.txt plain text: cord-350565-mejd7blb.txt item: #288 of 299 id: cord-351190-sq6zsqqi author: Zaheer, Tean title: Topical Review On Nano-vaccinology: Biochemical Promises and Key Challenges date: 2020-09-28 words: 2718 flesch: 24 summary: Nano vaccines have been widely experimented as prophylaxis of important diseases such as: bacterial (E. coli, Helicobacter sp.), viral (HIV, HPV, influenza), cancers (primary and metastatic), parasitic (malaria, toxoplasmosis, coccidiosis) and auto-immune disorders [7] [8] [9] . Nano vaccines have brought a revolution in the science of small by evading cellular pathways and efficient absorption up to blood vessels [15] . keywords: antigen; diseases; immune; nano; nanoparticles; potential; response; vaccines; virus cache: cord-351190-sq6zsqqi.txt plain text: cord-351190-sq6zsqqi.txt item: #289 of 299 id: cord-351649-87g7g5au author: Haagmans, Bart L. title: SARS date: 2009-01-30 words: 6742 flesch: 27 summary: Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets Antibody-mediated enhancement of disease in feline infectious peritonitis: comparisons with dengue hemorrhagic fever Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome Modulation of the immune response to the severe acute respiratory syndrome spike glycoprotein by gene-based and inactivated virus immunization Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats Chemokine up-regulation in SARS-coronavirus-infected, monocyte-derived human dendritic cells Structure of SARS coronavirus spike receptor-binding domain complexed with receptor Significant changes of peripheral T lymphocyte subsets in patients with severe acute respiratory syndrome Long-term persistence of robust antibody and cytotoxic T cell responses in recovered patients infected with SARS coronavirus Bats are natural reservoirs of SARS-like coronaviruses Laboratory diagnosis of four recent sporadic cases of community-acquired SARS, Guangdong province Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine Monoclonal antibodies targeting the HR2 domain and the region immediately upstream of the HR2 of the S protein neutralize in vitro infection of severe acute respiratory syndrome coronavirus Natural mutations in the receptor binding domain of spike glycoprotein determine the reactivity of cross-neutralization between palm civet coronavirus and severe acute respiratory syndrome coronavirus Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study Virology: SARS virus infection of cats and ferrets Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys SARS in newborns and children Lung pathology of fatal severe acute respiratory syndrome Severe acute respiratory syndrome Coronavirus as a possible cause of severe acute respiratory syndrome Long-lived memory T lymphocyte responses against SARS coronavirus nucleocapsid protein in SARS-recovered patients Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine Long-lived effector/central memory T-cell responses to severe acute respiratory syndrome coronavirus (SARS-CoV) S antigen in recovered SARS patients A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses Rewiring the severe acute respiratory syndrome coronavirus (SARS-CoV) transcription circuit: engineering a recombination-resistant genome Severe acute respiratory syndrome coronavirus group-specific open reading frames encode nonessential functions for replication in cell cultures and mice Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies Antibody responses against SARS coronavirus are correlated with disease outcome of infected individuals Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys Prognostic factors for severe acute respiratory syndrome: a clinical analysis of 165 cases Coronavirus nonstructural protein 1 is a major pathogenicity factor: implications for the rational design of coronavirus vaccines In addition, two Chinese groups have demonstrated protective efficacy of inactivated SARS vaccines in rhesus monkeys ( Qin et al., 2006 ; Zhou et al., 2005 ) . keywords: acute; antibodies; antibody; coronavirus; cov; et al; mice; protein; sars; syndrome; vaccines; virus cache: cord-351649-87g7g5au.txt plain text: cord-351649-87g7g5au.txt item: #290 of 299 id: cord-352088-9k01ej6l author: Saiz, Juan-Carlos title: Vaccines against RNA Viruses date: 2020-08-27 words: 2344 flesch: 32 summary: Artificial anti-HIV-1 immunogen comprising epitopes of broadly neutralizing antibodies 2F5, 10E8, and a peptide mimic of VRC01 discontinuous epitope Parenterally administered P24-VP8* nanoparticle vaccine conferred strong protection against rotavirus diarrhea and virus shedding in gnotobiotic pigs Hepatitis C virus vaccine: Challenges and prospects Broad protection of pigs against heterologous PRRSV strains by a GP5-mosaic DNA vaccine prime/GP5-mosaic rVaccinia (VACV) vaccine boost Significant interference with porcine epidemic diarrhea virus pandemic and classical strain replication in small-intestine epithelial cells using an shRNA expression vector A single dose of dendrimer B 2 T peptide vaccine partially protects pigs against foot-and-mouth disease virus infection MVA vectored vaccines encoding rift valley fever virus glycoproteins protect mice against lethal challenge in the absence of neutralizing antibody responses Differential immune transcriptome and modulated signalling pathways in rainbow trout infected with Viral Haemorrhagic Septicaemia Virus (VHSV) and its Derivative Non-Virion (NV) gene deleted. [6] deepen their many years of previous research with peptides as vaccine candidates against foot-and mouth disease virus (FMDV). keywords: pigs; response; rna; vaccines; vhsv; virus; viruses cache: cord-352088-9k01ej6l.txt plain text: cord-352088-9k01ej6l.txt item: #291 of 299 id: cord-353730-owcapg8h author: Dietrich, Jes title: Inducing Dose Sparing with Inactivated Polio Virus Formulated in Adjuvant CAF01 date: 2014-06-23 words: 7899 flesch: 48 summary: Manufacturing of both the CAF01 adjuvants, IPV vaccines and IPV-CAF01 vaccines was performed in LAF units. Monovalent IPV showed a slightly negative zeta potential (2 13 mV), whereas the adjuvanted IPV-CAF01 vaccine showed a positive zeta potential of 54 mV. Therefore, in IPV vaccines formulated with CAF01, a binding between antigen and adjuvant is electrostatically favorable. keywords: administration; antibody; caf01; fig; group; immunity; ipv; polio; poliovirus; response; titers; vaccine; virus cache: cord-353730-owcapg8h.txt plain text: cord-353730-owcapg8h.txt item: #292 of 299 id: cord-353911-hp6s6ebh author: Petráš, Marek title: Early immune response in mice immunized with a semi-split inactivated vaccine against SARS-CoV-2 containing S protein-free particles and subunit S protein date: 2020-11-03 words: 2122 flesch: 42 summary: Vaccine Preparation, characterization and 505 preliminary in vivo studies of inactivated SARS-CoV vaccine Immunization with SARS coronavirus vaccines leads to 510 pulmonary immunopathology on challenge with the SARS virus RNA-Based COVID-19 Vaccine 518 BNT162b2 Selected for a Pivotal Efficacy Study. Design of a Multiepitope-Based Peptide Vaccine 370 against the E Protein of Human COVID-19: An Immunoinformatics Approach Guidelines for the use of flow cytometry and cell sorting in 375 immunological studies (second edition) Inactivated virus vaccines from 378 chemistry to prophylaxis: merits, risks and challenges Safety and immunogenicity of the ChAdOx1 nCoV-386 19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, 387 randomised controlled trial Development of an inactivated vaccine candidate for SARS-CoV-2 An in-silico 397 approach to develop of a multi-epitope vaccine candidate against SARS-CoV-2 398 envelope (E) protein. keywords: antibodies; mice; protein; sars; vaccine; virus cache: cord-353911-hp6s6ebh.txt plain text: cord-353911-hp6s6ebh.txt item: #293 of 299 id: cord-354030-8tfg881h author: Dong, Rong title: Contriving Multi-Epitope Subunit of Vaccine for COVID-19: Immunoinformatics Approaches date: 2020-07-28 words: 7986 flesch: 46 summary: The pdb file of vaccine protein and receptor complex (TLR3, MHC-I, and MHC-II) were used to start the molecular dynamic (MD) simulations. The sequence homology of final vaccine protein to human protein sequence shown that there were no significant alignments ( Figure S4 ). keywords: amino; binding; cell; cell epitopes; complex; cov-2; epitopes; figure; immunoinformatics; mhc; model; prediction; protein; sars; sequence; server; structure; table; vaccine; virus cache: cord-354030-8tfg881h.txt plain text: cord-354030-8tfg881h.txt item: #294 of 299 id: cord-354068-4qlk6y7h author: Friedrich, Brian M. title: Potential Vaccines and Post-Exposure Treatments for Filovirus Infections date: 2012-09-21 words: 10618 flesch: 39 summary: (green monkey disease) Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental ebola virus infections Neutralizing antibody fails to impact the course of ebola virus infection in monkeys Protective efficacy of neutralizing antibodies against ebola virus infection Antibody-dependent enhancement of marburg virus infection Epitopes required for antibody-dependent enhancement of ebola virus infection Antibody-dependent enhancement of ebola virus infection Recombinant human monoclonal antibodies to ebola virus Pre-and postexposure prophylaxis of ebola virus infection in an animal model by passive transfer of a neutralizing human antibody Epitopes involved in antibody-mediated protection from ebola virus Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of ebola hemorrhagic fever Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies Enhanced potency of a fucose-free monoclonal antibody being developed as an ebola virus immunoprotectant Characterization of zaire ebolavirus glycoprotein-specific monoclonal antibodies Neutralizing ebolavirus: Structural insights into the envelope glycoprotein and antibodies targeted against it A DNA vaccine for ebola virus is safe and immunogenic in a phase i clinical trial Immune protection of nonhuman primates against ebola virus with single low-dose adenovirus vectors encoding modified gps Development of a preventive vaccine for ebola virus infection in primates A replication defective recombinant ad5 vaccine expressing ebola virus gp is safe and immunogenic in healthy adults Vaccine to confer to nonhuman primates complete protection against multistrain ebola and marburg virus infections Protection of nonhuman primates against two species of ebola virus infection with a single complex adenovirus vector Enhanced protection against ebola virus mediated by an improved adenovirusbased vaccine A single sublingual dose of an adenovirus-based vaccine protects against lethal ebola challenge in mice and guinea pigs Recombinant adenovirus serotype 26 (ad26) and ad35 vaccine vectors bypass immunity to ad5 and protect nonhuman primates against ebolavirus challenge Rhabdoviridae: The Viruses and Their Replication Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus Cross-protection against marburg virus strains by using a live, attenuated recombinant vaccine Recombinant vesicular stomatitis virus vector mediates postexposure protection against sudan ebola hemorrhagic fever in nonhuman primates Effective post-exposure treatment of ebola infection Inactivated or liveattenuated bivalent vaccines that confer protection against rabies and ebola viruses Replicon-helper systems from attenuated venezuelan equine encephalitis virus: Expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo Recombinant rna replicons derived from attenuated venezuelan equine encephalitis virus protect guinea pigs and mice from ebola hemorrhagic fever virus Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates Vaccine potential of ebola virus vp24, vp30, vp35, and vp40 proteins Protective cytotoxic t-cell responses induced by venezuelan equine encephalitis virus replicons expressing ebola virus proteins A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose ebola virus challenge Successful topical respiratory tract immunization of primates against ebola virus Parainfluenza viruses Mucosal parainfluenza virus-vectored vaccine against ebola virus replicates in the respiratory tract of vector-immune monkeys and is immunogenic Recombinant newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of h5n1 highly pathogenic avian influenza virus protect against virus challenge in monkeys Respiratory tract immunization of non-human primates with a newcastle disease virus-vectored vaccine candidate against ebola virus elicits a neutralizing antibody response Ebola virus vp40-induced particle formation and association with the lipid bilayer Contribution of ebola virus glycoprotein, nucleoprotein, and vp24 to budding of vp40 virus-like particles Ebola virus-like particle-based vaccine protects nonhuman primates against lethal ebola virus challenge Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple marburg viruses Filovirus-like particles produced in insect cells: Immunogenicity and protection in rodents Ebola virus vp40-induced particle formation and association with the lipid bilayer Ebola virus vp40 drives the formation of virus-like filamentous particles along with gp Immunogenicity and protective efficacy of rotavirus 2/6-virus-like particles produced by a dual baculovirus expression vector and administered intramuscularly, intranasally, or orally to mice Expression and self-assembly of empty virus-like particles of hepatitis e virus Enhanced mucosal and systemic immune responses following intravaginal immunization with human papillomavirus 16 l1 virus-like particle vaccine in thermosensitive mucoadhesive delivery systems Intranasal immunization with siv virus-like particles (vlps) elicits systemic and mucosal immunity Protection against lethal challenge by ebola virus-like particles produced in insect cells Ebola virus-like particles produced in insect cells exhibit dendritic cell stimulating activity and induce neutralizing antibodies Immunogenicity of the outer domain of a hiv-1 clade c gp120 Increased potency of fc-receptor-targeted antigens Cross-reactive hiv-1-neutralizing activity of serum igg from a rabbit immunized with gp41 fused to igg1 fc: Possible role of the prolonged half-life of the immunogen Ebola virus glycoprotein fc fusion protein confers protection against lethal challenge in vaccinated mice Transgenic plants as protein factories Monoclonal antibody manufacturing in transgenic plants--myths and realities High-level rapid production of full-size monoclonal antibodies in plants by a single-vector DNA replicon system Recombinant pharmaceuticals from plants: The plant endomembrane system as bioreactor Expression of an immunogenic ebola immune complex in nicotiana benthamiana A replicating cytomegalovirus-based vaccine encoding a single ebola virus nucleoprotein ctl epitope confers protection against ebola virus Effector memory t cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge Broadly targeted human cytomegalovirus-specific cd4+ and cd8+ t cells dominate the memory compartments of exposed subjects Human cytomegalovirus tropism for endothelial cells: Not all endothelial cells are created equal Profound early control of highly pathogenic siv by an effector memory t-cell vaccine Chimeric human parainfluenza virus bearing the ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against ebola virus challenge Disseminated intravascular coagulation ( dic) Coli septic shock is prevented by blocking tissue factor with monoclonal antibody Treatment of ebola virus infection with a recombinant inhibitor of factor viia/tissue factor: A study in rhesus monkeys Dose-response study of recombinant factor viia/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement Recombinant nematode anticoagulant protein c2, an inhibitor of the tissue factor/factor viia complex, in patients undergoing elective coronary angioplasty Marburg virus angola infection of rhesus macaques: Pathogenesis and treatment with recombinant nematode anticoagulant protein c2 Cell penetrating peptide conjugates of steric block oligonucleotides keywords: antibody; cells; challenge; ebola; ebov; exposure; filovirus; human; immune; immunity; infection; lethal; marv; mice; nhps; potential; protection; protein; recombinant; treatment; vaccine; vector; virus cache: cord-354068-4qlk6y7h.txt plain text: cord-354068-4qlk6y7h.txt item: #295 of 299 id: cord-354972-nc496v6s author: Margolin, Emmanuel title: Prospects for SARS-CoV-2 diagnostics, therapeutics and vaccines in Africa date: 2020-09-10 words: 10934 flesch: 27 summary: The host immune response in respiratory virus infection: balancing virus clearance and immunopathology Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection Disappearance of antibodies to SARS-associated coronavirus after recovery Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome Positive RT-PCR test results in patients recovered from COVID-19 Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus Immunization with inactivated Middle East respiratory syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge Molecular mechanism for antibodydependent enhancement of coronavirus entry Medical countermeasures analysis of 2019-nCoV and vaccine risks for antibody-dependent enhancement (ADE) Several strategies may improve the magnitude and durability of vaccine responses in individuals infected with HIV-1, such as higher doses, booster immunizations and/or the use of adjuvants 127 . keywords: africa; cases; coronavirus; countries; cov-2; covid-19; development; disease; individuals; infection; pandemic; patients; responses; risk; sars; south; spike; testing; trial; tuberculosis; vaccine; virus cache: cord-354972-nc496v6s.txt plain text: cord-354972-nc496v6s.txt item: #296 of 299 id: cord-355541-5sctqkwr author: Alcamí, José title: Current situation in the development of a preventive HIV vaccine date: 2005-07-31 words: 7265 flesch: 32 summary: Finally, social, economic and healthcare aspects of research into HIV vaccines and current controversies regarding the development of clinical trials are discussed. HIV vaccine trial justified A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA primemodified vaccinia virus ankara boost vaccination regimen Why an HIV vaccine is not currently within our grasp. keywords: aids; antibodies; cells; development; escape; hiv; infection; patients; phase; proteins; replication; response; trials; vaccine; virus cache: cord-355541-5sctqkwr.txt plain text: cord-355541-5sctqkwr.txt item: #297 of 299 id: cord-355618-7kfxc2w1 author: McAteer, John title: The VACCINES Act, Deciphering Vaccine Hesitancy in the Time of COVID19 date: 2020-04-13 words: 1894 flesch: 41 summary: Despite remarkable advances in vaccine science, vaccine hesitancy has now become a recognized public health threat with potentially disastrous complications. To address vaccine hesitancy, we need to reframe our approach and focus on understanding the root causes of this complicated problem. keywords: hesitancy; immunization; states; vaccine cache: cord-355618-7kfxc2w1.txt plain text: cord-355618-7kfxc2w1.txt item: #298 of 299 id: cord-355689-mo4mvwch author: Huang, Jiechen title: Role of vaccine efficacy in the vaccination behavior under myopic update rule on complex networks date: 2019-09-06 words: 5092 flesch: 43 summary: Price elasticity of demand for influenza vaccination among the elderly in japan Impacts of subsidy policies on vaccination decisions in contact networks Simulation analysis of vaccination subsidy with ABM approach Preferential imitation can invalidate targeted subsidy policies on seasonal-influenza diseases Subsidy strategy based on history information can stimulate voluntary vaccination behaviors on seasonal diseases Effects of behavioral response and vaccination policy on epidemic spreading -an approach based on evolutionary-game dynamics A susceptible-infected epidemic model with voluntary vaccinations Group interest versus self-interest in smallpox vaccination policy Imitation dynamics predict vaccinating behavior Impact of committed individuals on vaccination behavior The impact of imitation on vaccination behavior in social contact networks The influence of social norms on the dynamics of vaccinating behavior for paediatric infectious diseases Risk assessment for infectious disease and its impact on voluntary vaccination behavior in social networks Can influenza epidemics be prevented by voluntary vaccination? keywords: cost; epidemic; individuals; rate; vaccination; vaccine cache: cord-355689-mo4mvwch.txt plain text: cord-355689-mo4mvwch.txt item: #299 of 299 id: cord-355906-yeaw9nr8 author: Nedjadi, Taoufik title: Tackling dengue fever: Current status and challenges date: 2015-12-09 words: 6825 flesch: 40 summary: Development, characterization and application of monoclonal antibodies against Brazilian dengue virus isolates A simple one-step real-time RT-PCR for diagnosis of dengue virus infection Current advances in dengue diagnosis Reliable classifier to differentiate primary and secondary acute dengue infection based on IgG ELISA Human genetic susceptibility to intracellular pathogens Host genetic susceptibility to severe dengue infection Impact of dengue virus infection on feeding behavior of Aedes aegypti Dengue virus infection of the Aedes aegypti salivary gland and chemosensory apparatus induces genes that modulate infection and blood-feeding behavior A novel amino acid substitution in a voltage gated sodium channel is associated with knockdown resistance to permethrin in Aedes aegypti Widespread distribution of newly found point mutation in voltage-gated sodium channel in pyrethroid-resistant Aedes aegypti populations in Vietnam Detection of the V1016G mutation in the voltage-gated sodium channel gene of Aedes aegypti (Diptera: Culicidae) by allele-specific PCR assay, and its distribution and effect on deltamethrin resistance in Thailand Race: A risk factor for dengue hemorrhagic fever Asymptomatic dengue infection in a Cuban population confirms the protective role of the RR variant of the FcgammaRIIa polymorphism A variant in the CD209 promoter is associated with severity of the disease Dengue and dengue haemorrhagic fever: Implications of host genetics Polymorphisms of the TAP 1 and 2 gene may influence clinical outcome of primary dengue viral infection All serotypes of dengue virus induce HLA-A2 major histocompatibility complex class I promoter activity in human liver cells Two putative subunits of a peptide pump encoded in the human major histocompatibility complex class II region Polymorphisms in the oligoadenylate synthetase gene cluster and its association with clinical outcomes of dengue virus infection Cell type specificity and host genetic polymorphisms influence antibodydependent enhancement of dengue virus infection The 1a, 25-dihydroxy-vitamin D3 reduces dengue virus infection in human myelomonocyte (U937) and hepatic (Huh-7) cell lines and cytokine production in the infected monocytes Association of vitamin D receptor gene polymorphisms with clinical outcomes of dengue virus infection Genome-wide association study identifies susceptibility loci for dengue shock syndrome at MICB and PLCE1 Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family Natural killer cell activation enhances immune pathology and promotes chronic infection by limiting CD8+ T-cell immunity Genetic variants of MICB and PLCE1 and associations with non-severe dengue Host gene expression profiling of dengue virus infection in cell lines and patients Common variants of chemokine receptor gene CXCR3 and its ligands CXCL10 and CXCL11 associated with vascular permeability of dengue infection in peninsular Malaysia Early enhanced expression of interferon-inducible protein-10 (CXCL-10) and other chemokines predicts adverse outcome in severe acute respiratory syndrome Two other compounds have also been shown to qualify as potent inhibitors of dengue virus infection are imino-sugars deoxynojirimycin and castanospermine keywords: aegypti; cases; cells; control; dengue; denv; development; disease; fever; genes; host; infection; phase; tetravalent; trial; vaccine; virus cache: cord-355906-yeaw9nr8.txt plain text: cord-355906-yeaw9nr8.txt